0001834494-23-000060.txt : 20230502 0001834494-23-000060.hdr.sgml : 20230502 20230502163631 ACCESSION NUMBER: 0001834494-23-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230502 DATE AS OF CHANGE: 20230502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MeridianLink, Inc. CENTRAL INDEX KEY: 0001834494 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 824844620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40680 FILM NUMBER: 23879726 BUSINESS ADDRESS: STREET 1: 3560 HYLAND AVE STE 200 CITY: COSTA MESA STATE: CA ZIP: 92626 BUSINESS PHONE: 866-417-3274 MAIL ADDRESS: STREET 1: 3560 HYLAND AVE STE 200 CITY: COSTA MESA STATE: CA ZIP: 92626 FORMER COMPANY: FORMER CONFORMED NAME: Project Angel Parent, LLC DATE OF NAME CHANGE: 20201202 10-Q 1 mlnk-20230331.htm 10-Q mlnk-20230331
2023Q1false000183449412/3100018344942023-01-012023-03-3100018344942023-04-26xbrli:shares00018344942023-03-31iso4217:USD00018344942022-12-31iso4217:USDxbrli:shares00018344942022-01-012022-03-310001834494us-gaap:CommonStockMember2022-12-310001834494us-gaap:AdditionalPaidInCapitalMember2022-12-310001834494us-gaap:RetainedEarningsMember2022-12-310001834494us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2023-01-012023-03-310001834494us-gaap:RestrictedStockMember2023-01-012023-03-310001834494us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001834494us-gaap:CommonStockMember2023-01-012023-03-310001834494us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001834494us-gaap:RetainedEarningsMember2023-01-012023-03-310001834494us-gaap:CommonStockMember2023-03-310001834494us-gaap:AdditionalPaidInCapitalMember2023-03-310001834494us-gaap:RetainedEarningsMember2023-03-310001834494us-gaap:CommonStockMember2021-12-310001834494us-gaap:AdditionalPaidInCapitalMember2021-12-310001834494us-gaap:RetainedEarningsMember2021-12-3100018344942021-12-310001834494us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2022-01-012022-03-310001834494us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001834494us-gaap:CommonStockMember2022-01-012022-03-310001834494us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001834494us-gaap:RetainedEarningsMember2022-01-012022-03-310001834494us-gaap:CommonStockMember2022-03-310001834494us-gaap:AdditionalPaidInCapitalMember2022-03-310001834494us-gaap:RetainedEarningsMember2022-03-3100018344942022-03-31mlnk:Segment0001834494mlnk:LendingSoftwareSolutionsMember2023-01-012023-03-310001834494mlnk:LendingSoftwareSolutionsMember2022-01-012022-03-310001834494mlnk:DataVerificationSoftwareSolutionsMember2023-01-012023-03-310001834494mlnk:DataVerificationSoftwareSolutionsMember2022-01-012022-03-310001834494mlnk:LendingSoftwareSolutionsMember2023-01-012023-03-31xbrli:pure0001834494mlnk:LendingSoftwareSolutionsMember2022-01-012022-03-310001834494mlnk:DataVerificationSoftwareSolutionsMember2023-01-012023-03-310001834494mlnk:DataVerificationSoftwareSolutionsMember2022-01-012022-03-310001834494mlnk:SubscriptionFeesMember2023-01-012023-03-310001834494mlnk:SubscriptionFeesMember2022-01-012022-03-310001834494mlnk:ProfessionalServicesMember2023-01-012023-03-310001834494mlnk:ProfessionalServicesMember2022-01-012022-03-310001834494us-gaap:ServiceOtherMember2023-01-012023-03-310001834494us-gaap:ServiceOtherMember2022-01-012022-03-310001834494srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate201613Member2022-12-310001834494srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccountingStandardsUpdate201613Member2022-12-310001834494us-gaap:ComputerEquipmentMember2023-03-310001834494us-gaap:ComputerEquipmentMember2022-12-310001834494us-gaap:LeaseholdImprovementsMember2023-03-310001834494us-gaap:LeaseholdImprovementsMember2022-12-310001834494us-gaap:OfficeEquipmentMember2023-03-310001834494us-gaap:OfficeEquipmentMember2022-12-310001834494us-gaap:OfficeEquipmentMember2022-01-012022-03-310001834494us-gaap:OfficeEquipmentMember2023-01-012023-03-310001834494us-gaap:CustomerRelationshipsMember2023-03-310001834494us-gaap:DevelopedTechnologyRightsMember2023-03-310001834494us-gaap:TrademarksMember2023-03-310001834494us-gaap:NoncompeteAgreementsMember2023-03-310001834494us-gaap:CustomerRelationshipsMember2022-12-310001834494us-gaap:DevelopedTechnologyRightsMember2022-12-310001834494us-gaap:TrademarksMember2022-12-310001834494us-gaap:NoncompeteAgreementsMember2022-12-310001834494us-gaap:CustomerRelationshipsMember2023-01-012023-03-310001834494us-gaap:DevelopedTechnologyRightsMember2023-01-012023-03-310001834494us-gaap:TrademarksMember2023-01-012023-03-310001834494us-gaap:NoncompeteAgreementsMember2023-01-012023-03-310001834494mlnk:CapitalizedSoftwareMember2023-01-012023-03-310001834494us-gaap:CostOfSalesMember2023-01-012023-03-310001834494us-gaap:CostOfSalesMember2022-01-012022-03-310001834494us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001834494us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001834494mlnk:A2021TermLoanMemberus-gaap:SecuredDebtMember2023-03-310001834494mlnk:A2021TermLoanMemberus-gaap:SecuredDebtMember2022-12-310001834494mlnk:A2021TermLoanMemberus-gaap:SecuredDebtMember2021-11-100001834494us-gaap:LineOfCreditMembermlnk:A2021RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-100001834494mlnk:A2021RevolvingCreditFacilityMemberus-gaap:LetterOfCreditMember2021-11-100001834494mlnk:VariableRateComponentTwoMembermlnk:AdjustedEurocurrencyRateMembermlnk:A2021TermLoanMember2023-01-012023-03-310001834494mlnk:VariableRateComponentOneMembermlnk:A2021TermLoanMemberus-gaap:BaseRateMember2023-01-012023-03-310001834494mlnk:A2021TermLoanMember2023-03-310001834494mlnk:A2021TermLoanMember2021-11-100001834494mlnk:FirstLienMember2021-11-100001834494mlnk:A2021TermLoanMember2023-01-012023-03-310001834494mlnk:A2021TermLoanMember2022-01-012022-03-310001834494mlnk:A2021RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-100001834494mlnk:A2021RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-03-310001834494us-gaap:LineOfCreditMembermlnk:A2021RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-03-3100018344942022-05-310001834494mlnk:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2021-07-260001834494mlnk:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2021-07-262021-07-2600018344942022-01-012022-12-310001834494us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001834494us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001834494us-gaap:RestrictedStockMember2022-01-012022-03-310001834494us-gaap:CapitalUnitClassBMember2023-03-310001834494us-gaap:CapitalUnitClassBMember2022-03-310001834494us-gaap:CapitalUnitClassBMember2023-01-012023-03-310001834494us-gaap:CapitalUnitClassBMember2022-01-012022-03-310001834494us-gaap:RestrictedStockUnitsRSUMember2022-12-310001834494us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001834494us-gaap:RestrictedStockUnitsRSUMember2023-03-310001834494us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001834494us-gaap:EmployeeStockMember2023-03-310001834494us-gaap:EmployeeStockMember2023-01-012023-03-310001834494us-gaap:EmployeeStockMember2022-01-012022-03-310001834494us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001834494us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001834494us-gaap:SellingAndMarketingExpenseMember2023-01-012023-03-310001834494us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001834494us-gaap:RestructuringChargesMember2023-01-012023-03-310001834494us-gaap:RestructuringChargesMember2022-01-012022-03-310001834494srt:AffiliatedEntityMember2023-01-012023-03-310001834494srt:AffiliatedEntityMember2022-01-012022-03-310001834494srt:AffiliatedEntityMember2023-03-310001834494srt:AffiliatedEntityMember2022-12-310001834494mlnk:RestrictedStockAwardsUnvestedMember2023-01-012023-03-310001834494mlnk:RestrictedStockAwardsUnvestedMember2022-01-012022-03-310001834494mlnk:RestrictedStockUnitsUnvestedMember2023-01-012023-03-310001834494mlnk:RestrictedStockUnitsUnvestedMember2022-01-012022-03-310001834494mlnk:OptionsToPurchaseCommonStockOutstandingUnexercisedMember2023-01-012023-03-310001834494mlnk:OptionsToPurchaseCommonStockOutstandingUnexercisedMember2022-01-012022-03-310001834494mlnk:RestrictedStockUnitsUnvestedMember2023-01-012023-03-310001834494mlnk:RestrictedStockUnitsUnvestedMember2022-01-012022-03-310001834494mlnk:ThePlanMember2023-02-242023-02-240001834494mlnk:ThePlanMembersrt:MinimumMember2023-02-240001834494mlnk:ThePlanMembersrt:MaximumMember2023-02-240001834494us-gaap:EmployeeSeveranceMember2023-01-012023-03-310001834494us-gaap:OneTimeTerminationBenefitsMember2023-01-012023-03-310001834494us-gaap:EmployeeSeveranceMember2023-03-310001834494mlnk:BeanstalkNetworksLLCMember2022-11-042022-11-040001834494mlnk:BeanstalkNetworksLLCMember2022-01-012022-03-310001834494mlnk:StreetSharesMember2022-04-012022-04-010001834494mlnk:StreetSharesMember2022-04-010001834494mlnk:StreetSharesMember2023-01-012023-03-310001834494us-gaap:SubsequentEventMemberus-gaap:RestrictedStockUnitsRSUMember2023-04-012023-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to_______
Commission file number: 001-40680
____________________________
MeridianLink, Inc.
(Exact Name of Registrant as Specified in its Charter)
______________________________
Delaware82-4844620
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
3560 Hyland Avenue, Suite 200, Costa Mesa, CA
92626
(Address of Principal Executive Offices)(Zip Code)
(714708-6950
(Registrant’s Telephone Number, Including Area Code)
______________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.001 per shareMLNKThe New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  x    No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  x    No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filerx
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes  o    No  x
As of April 26, 2023 there were 80,645,366 shares of the registrant’s common stock, par value $0.001 per share, outstanding.



MeridianLink, Inc.
Table of Contents
Page
PART I. FINANCIAL INFORMATION
Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022
Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2023 and 2022
PART II. OTHER INFORMATION



PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
MERIDIANLINK, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except share and per share data)
As of
March 31, 2023
December 31, 2022
Assets
Current assets:
Cash and cash equivalents
$77,796$55,780
Accounts receivable, net
37,40132,905
Prepaid expenses and other current assets
10,7989,447
Escrow deposit30,00030,000
Total current assets
155,995128,132
Property and equipment, net3,8914,245
Right of use assets1,9292,185
Intangible assets, net285,412297,475
Deferred tax assets, net14,89313,939
Goodwill608,902608,657
Other assets4,7844,524
Total assets
$1,075,806 $1,059,157
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$3,986$1,249
Accrued liabilities
34,10232,500
Deferred revenue
34,09016,945
Current portion of long-term debt, net of debt issuance costs
3,5063,505
Total current liabilities
75,68454,199
Long-term debt, net of debt issuance costs422,526423,404
Long-term deferred revenue9921,141
Other long-term liabilities1,1651,322
Total liabilities
500,367480,066
Commitments and contingencies (Note 5)
Stockholders’ Equity
Preferred stock, $0.001 par value; 50,000,000 shares authorized; zero shares issued and outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.001 par value; 600,000,000 shares authorized, 80,636,894 and 80,644,452 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
132128
Additional paid-in capital626,905621,396
Accumulated deficit(51,598)(42,433)
Total stockholders’ equity575,439579,091
Total liabilities and stockholders’ equity$1,075,806$1,059,157
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
3


MERIDIANLINK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except share and per share data)
Three Months Ended March 31,
20232022
Revenues, net$77,135 $72,754 
Cost of revenues:
Subscription and services
23,501 21,104 
Amortization of developed technology
4,454 3,434 
Total cost of revenues27,955 24,538 
Gross profit
49,180 48,216 
Operating expenses:
General and administrative
22,555 18,187 
Research and development
13,812 8,409 
Sales and marketing
8,213 4,743 
Acquisition related costs 2,283 
Restructuring related costs2,904  
Total operating expenses47,484 33,622 
Operating (loss) income1,696 14,594 
Other (income) expense, net:
Other income(470)(163)
Interest expense, net
9,031 4,358 
Total other expense, net8,561 4,195 
(Loss) income before (benefit from) provision for income taxes(6,865)10,399 
(Benefit from) provision for income taxes(1,199)2,920 
Net (loss) income$(5,666)$7,479 
Net (loss) income per share:
Basic$(0.07)$0.09 
Diluted$(0.07)$0.09 
Weighted average common stock outstanding:
Basic80,659,978 79,974,071 
Diluted80,659,978 82,228,936 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
4


MERIDIANLINK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands, except share data)
Common StockAdditional Paid-in CapitalAccumulated DeficitStockholders’ Equity
SharesAmount
Balance at December 31, 202280,644,452 $128$621,396 $(42,433)$579,091 
Vesting of restricted stock awards59,558 4— — 4 
Vesting of restricted stock units65,770 — — — 
Issuance of common stock due to exercise of stock options97,412 594 — 594 
Shares withheld related to net share settlement of restricted stock units(1,769)(24)— (24)
Repurchases of common stock(228,529)— (3,499)(3,499)
Share-based compensation expense— 4,939 — 4,939 
Net loss— — (5,666)(5,666)
Balance at March 31, 202380,636,894 $132$626,905 $(51,598)$575,439
5


MERIDIANLINK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands, except share data)
Common StockAdditional Paid-in CapitalAccumulated DeficitStockholders’ Equity
SharesAmount
Balance at December 31, 202179,734,984$88$596,542$(40,352)$556,278
Vesting of restricted stock awards484,40132— 32
Vesting of restricted stock units76,937
Issuance of common stock due to exercise of stock options28,909179179
Share-based compensation expense3,8873,887
Net income7,4797,479
Balance at March 31, 202280,325,231$120$600,608$(32,873)$567,855
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
6


MERIDIANLINK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
Three Months Ended March 31,
20232022
Cash flows from operating activities:
Net (loss) income$(5,666)$7,479
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization
14,53112,905
Provision for expected credit losses532
Amortization of debt issuance costs
235484
Share-based compensation expense4,8913,808
Loss on disposal of fixed assets135
Deferred income taxes
(1,198)2,679
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
(5,028)(7,248)
Prepaid expenses and other assets
(1,636)(460)
Accounts payable
2,717301
Accrued liabilities
1,706194
Deferred revenue
16,99714,586
Net cash provided by operating activities28,08134,863
Cash flows from investing activities:
Capitalized software additions
(1,924)(1,522)
Purchases of property and equipment
(134)(419)
Net cash used in investing activities(2,058)(1,941)
Cash flows from financing activities:
Repurchases of common stock(3,490)
Proceeds from exercise of stock options594179
Taxes paid related to net share settlement of RSUs(24)
Principal payments of long-term debt(1,087)
Net cash (used in) provided by financing activities(4,007)179
Net increase in cash and cash equivalents22,01633,101
Cash and cash equivalents, beginning of period55,780113,645
Cash and cash equivalents, end of period$77,796$146,746
Supplemental disclosures of cash flow information:
Cash paid for interest
$9,019$3,869
Cash paid for income taxes
5044
Non-cash investing and financing activities:
Purchase price allocation adjustment related to income tax effects for StreetShares acquisition245
Purchases of property and equipment included in accounts payable and accrued expenses79
Share-based compensation expense capitalized to software additions4879
Excise taxes payable included in repurchases of common stock9
Vesting of RSAs and RSUs432
Initial recognition of operating lease liability3,372
Initial recognition of operating lease right-of-use asset2,627
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
7

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1 – Organization and Description of Business
MeridianLink, Inc., and its wholly-owned subsidiaries, (collectively the “Company”), provides secure, cloud-based digital solutions that transform the ways in which traditional and emerging financial services providers engage with account holders and end users. The Company sells its solutions to financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. The Company delivers its solutions to the substantial majority of its customers using a software-as-a-service (“SaaS”) model under which its customers pay subscription fees for the use of the Company’s solutions. The Company is controlled by its majority stockholder, which is represented by various investment funds of Thoma Bravo UGP, LLC and its affiliates (“Thoma Bravo”). The Company is headquartered in Costa Mesa, California.
Note 2 – Significant Accounting Policies
Basis of Presentation
The unaudited condensed consolidated financial statements of the Company have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or the consolidated balance sheets.

The interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations, stockholders’ equity, and cash flows for the three months ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of March 31, 2023, and its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three months ended March 31, 2023 and 2022, are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 9, 2023.
Operating and Reportable Segment
The Company operates and manages its business and financial information on a consolidated basis for the purposes of evaluating financial performance and the allocation of resources. The Company's management determined that it operates in one operating and reportable segment that is focused exclusively on providing cloud-based digital solutions in the United States. In reaching this conclusion, management considers the definition of the chief operating decision maker (“CODM”), how the business is defined by the CODM, the nature of the information provided to the CODM and how that information is used to make operating decisions, allocate resources, and assess performance. The Company's CODM is the chief executive officer. The results of operations provided to and analyzed by the CODM are at the consolidated level, and accordingly, key resource decisions and assessment of performance are performed at the consolidated level. The Company assesses its determination of operating segments at least annually.
8

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Use of Estimates
The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses. Significant items subject to such estimates include revenue recognition including determining the nature and timing of satisfaction of performance obligations and variable consideration; allowance for credit losses; share-based compensation; the fair value of acquired intangibles; the capitalization of software development costs; the useful lives of long-lived intangible assets; impairment of goodwill and long-lived assets; and income taxes. In accordance with GAAP, management bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from those estimates.
Significant Accounting Policies
The Company’s significant accounting policies are discussed in Note 2, “Significant Accounting Policies” in the Company’s Annual Report. There have been no changes to the Company’s significant accounting policies described in the Company’s Annual Report that have had a material impact on its condensed consolidated financial statements and related notes, except for updates resulting from the adoption of ASU 2016-13, “Financial InstrumentsCredit Losses (Topic 326)” which is discussed in more detail within Note 3, “Revenue Recognition.”
Accounting Pronouncements Recently Adopted
The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies.
ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.”
Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted this guidance effective January 1, 2023, and the adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and disclosures.
Recent Accounting Pronouncements Not Yet Adopted
ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”
ASU 2020-04 provides optional guidance for a limited time to ease the potential accounting burden associated with transitioning away from reference rates, such as the London Inter-Bank Offered Rate (LIBOR), which regulators in the United Kingdom are currently phasing out. The expedients and exceptions provided by ASU 2020-04 are for the application of U.S. GAAP to contracts, hedging relationships, and other transactions affected by the rate reform. Companies can apply the ASU immediately, however, the guidance will only be available for a limited time. In December 2022, the FASB issued ASU 2022-06 which deferred the sunset date from December 31, 2022 to December 31, 2024, after which companies will no longer be permitted to apply the transition relief. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.
9

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Note 3 – Revenue Recognition
Disaggregation of Revenue
The following table disaggregates the Company’s net revenues by solution type (in thousands):
Three Months Ended March 31,
20232022
Lending Software Solutions
$58,001 $49,167 
Data Verification Software Solutions
19,134 23,587 
Total$77,135 $72,754 
Lending Software Solutions accounted for 75%, and 68% of total revenues for the three months ended March 31, 2023 and 2022, respectively. Data Verification Software Solutions accounted for 25% and 32% of total revenues for the three months ended March 31, 2023 and 2022 respectively.
The following table disaggregates the Company’s net revenues by major source (in thousands):
Three Months Ended March 31,
20232022
Subscription fees$66,405 $63,469 
Professional services8,435 7,112 
Other2,295 2,173 
Total revenues$77,135 $72,754 
Deferred Revenue
The changes in the Company’s deferred revenue as of March 31, 2023 and 2022 were as follows (in thousands):
Three Months Ended March 31,
20232022
Deferred revenue, beginning balance$18,086 $14,707 
Billing of transaction consideration94,131 87,340 
Revenue recognized(77,135)(72,754)
Deferred revenue, ending balance$35,082 $29,293 
Deferred revenue, current$34,090 $29,293 
Long-term deferred revenue992  
Total deferred revenue$35,082 $29,293 
10

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Assets Recognized from Costs to Obtain a Contract with a Customer
The following table represents the changes in contract cost assets (in thousands):
Three Months Ended March 31,
20232022
Beginning balance$6,539 $5,835 
Additions1,151 607 
Amortization(747)(554)
Ending balance$6,943 $5,888 
Contract cost assets, current$3,196 $2,572 
Contract cost assets, noncurrent3,747 3,316 
Total deferred contract cost assets$6,943 $5,888 
Accounts Receivable and Allowance for Credit Losses
Effective January 1, 2023, the Company adopted the requirements of ASU 2016-13-Credit Loses, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) using a modified retrospective method of adoption. The Standard replaces the existing incurred credit loss model with the current expected credit losses model for financial instruments, including accounts receivable.
The Company’s accounts receivable includes billed and unbilled receivables, net of an allowance for credit losses. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company recognizes an allowance for credit losses on accounts receivable in an amount equal to the current expected credit losses. The estimation of the allowance is based on an analysis of historical loss experience, current receivables aging, and management’s assessment of current conditions and estimated future conditions, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible.
The Company assesses collectability by pooling receivables where similar characteristics exist and evaluates receivables individually when specific customer balances no longer share those risk characteristics and are considered at risk or uncollectible. The expense associated with the allowance for expected credit losses is recognized in general and administrative expenses.
A rollforward of the Company’s allowance for expected credit losses balance for the three months ended March 31, 2023 is as follows:
Three Months Ended March 31, 2023
Allowance for doubtful accounts, December 31, 2022$165 
Impact of adopting ASU 2016-13 
Allowance for expected credit losses, January 1, 2023165 
Provision for expected credit losses532 
Write offs, net(33)
Allowance for expected credit losses, March 31, 2023$664 
11

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Note 4 – Balance Sheet Components
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Prepaid expenses$6,994 $6,069 
Contract cost assets – current3,196 2,938 
Other608 440 
Total prepaid expenses and other current assets$10,798 $9,447 
Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Computer equipment and software $7,987 $7,854 
Leasehold improvements2,732 2,732 
Office equipment and furniture986 978 
Total11,705 11,564 
Less: Accumulated depreciation(7,814)(7,319)
Property and equipment, net$3,891 $4,245 
Depreciation expense amounted to $0.5 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively. The Company disposed of office furniture that resulted in a loss of $0.1 million for the three months ended March 31, 2022. The losses are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. There were no disposals of property and equipment for the three months ended March 31, 2023.
Intangible Assets, Net
Intangible assets, net consisted of the following (in thousands):
As of March 31, 2023
Gross AmountAccumulated AmortizationNet Carrying Amount
Customer relationships$343,300 $(140,845)$202,455 
Developed technology96,400 (43,426)52,974 
Trademarks24,975 (10,920)14,055 
Non-competition agreements5,500 (1,008)4,492 
Capitalized software21,416 (9,980)11,436 
Total intangible assets, net$491,591 $(206,179)$285,412 
12

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
As of December 31, 2022
Gross AmountAccumulated AmortizationNet Carrying Amount
Customer relationships$343,300 $(132,298)$211,002 
Developed technology96,400 (40,360)56,040 
Trademarks24,975 (10,205)14,770 
Non-competition agreements5,500 (688)4,812 
Capitalized software19,443 (8,592)10,851 
Total intangible assets, net$489,618 $(192,143)$297,475 
The weighted average remaining useful lives for intangible assets at March 31, 2023 were as follows:
Weighted Average Remaining Useful Life
Customer relationships5 years
Developed technology4 years
Trademarks5 years
Non-competition agreements4 years
Capitalized software3 years
Amortization expense related to intangible assets was as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$4,454 $3,434 
General and administrative expense9,582 8,910 
Total amortization expense$14,036 $12,344 
The estimated future amortization of intangible assets as of March 31, 2023 was as follows (in thousands):
Years ending December 31,
2023 (remaining nine months)$41,133 
202453,415 
202547,535 
202642,510 
202742,052 
202824,901 
Thereafter33,866 
Total amortization expense$285,412 
13

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Accrued payroll and payroll-related expenses$8,791 $9,836 
Accrued costs of revenues5,408 3,141 
Sales tax liability from acquisitions4,572 4,572 
Accrued operating costs4,352 4,016 
Accrued bonuses4,315 5,947 
User conference1,971 755 
Lease liability - current1,139 1,223 
Income taxes payable889 939 
Other accrued expenses2,665 2,071 
Total accrued liabilities$34,102 $32,500 
Note 5 – Commitments and Contingencies
Legal Matters
The Company is, and from time to time may be, involved in legal proceedings and claims arising out of the Company’s operations in the ordinary course of business. Management is not currently aware of any legal proceedings or claims against it that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company.
Other Contractual Commitments
The Company’s contractual commitments primarily consist of third-party cloud infrastructure agreements and service subscription arrangements used to support operations at the enterprise level. Future minimum payments under the Company’s non-cancelable purchase commitments as of March 31, 2023 are as follows (in thousands):
Contractual Commitments
Years ending December 31,
2023 (remaining nine months)$375 
2024395 
20253,020 
Total$3,790 
14

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Note 6 – Long-Term Debt
Long-term debt consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
2021 Term loan
$430,650 $431,738 
Debt issuance costs
(4,618)(4,829)
Total debt, net
426,032 426,909 
Less: Current portion of long-term debt
2021 Term loan4,350 4,350 
Debt issuance costs
(844)(845)
Total current portion of long-term debt, net
3,506 3,505 
Total non-current portion of long-term debt, net
$422,526 $423,404 
Amortization of deferred financing fees was $0.2 million and $0.5 million for the three months ended March 31, 2023 and 2022 respectively. Total interest expense, excluding amortization of deferred financing fees, was $8.9 million and $3.9 million, for the three months ended March 31, 2023 and 2022, respectively.
2021 Credit Agreement
On November 10, 2021, the Company entered into a credit agreement (the “2021 Credit Agreement”), which provides for a term loan facility (the “2021 Term Loan”) in an aggregate principal amount of $435.0 million, and a revolving credit facility (the “2021 Revolving Credit Facility”) in an aggregate principal amount of $50.0 million, inclusive of a $10.0 million letter of credit sub-facility. The Company used the proceeds from the 2021 Term Loan to pay all outstanding amounts due under the Company’s previous 2018 First Lien plus certain fees and expenses. The 2021 Term Loan and 2021 Revolving Credit Facility mature on November 10, 2028 and November 10, 2026, respectively. The Company has not drawn on the 2021 Revolving Credit Facility as of March 31, 2023.
The obligations under the 2021 Credit Agreement are secured by a lien on substantially all tangible and intangible property of the Company, subject to customary exceptions, limitations, and exclusions from the collateral.
The 2021 Credit Agreement contains customary affirmative covenants, negative covenants and events of default, including covenants and restrictions that, among other things, require the Company to satisfy a financial covenant, and restricts or limits the ability of the Company to grant or incur liens, incur additional indebtedness, enter into joint ventures or partnerships, engage in mergers and acquisitions, engage in asset sales, and declare dividends on its capital stock, subject in each case to certain customary exceptions. A failure to comply with certain covenants could permit the lenders to declare the 2021 Term Loan, and any then outstanding borrowings on the 2021 Revolving Credit Facility, together with accrued interest and fees thereon, to be immediately due and payable. The Company was in compliance with all financial covenants of the 2021 Credit Agreement at March 31, 2023.
2021 Term Loan
Borrowings under the 2021 Term Loan bear interest at a variable rate, elected by the Company, equal to the Base Rate (as defined in the 2021 Credit Agreement) or the Adjusted Eurocurrency Rate (as defined in the 2021 Credit Agreement), plus, an initial margin based on the Company’s Consolidated First Lien Net Leverage Ratio (as defined by the 2021 Credit Agreement), which was 3.00% at March 31, 2023. Beginning in June 2022, the Company is required to make quarterly principal payments equal to 0.25% of the original principal, with the remainder due at maturity.
Debt issuance costs of $7.6 million were included as a reduction of the debt balance on the condensed consolidated balance sheets and are amortized into interest expense over the contractual life of the loans using the effective interest method. Included in the debt issuance costs were $4.8 million incurred in connection with the 2021 Term Loan, and $2.8 million carried forward from the Company’s previous 2018 First Lien. The Company recognized $0.2 million, and $0.5 million of amortization of debt issuance costs for the 2021 Term Loan during the three months ended March 31, 2023 and 2022, respectively. The effective interest rate on the 2021 Term Loan was 8.5% as of March 31, 2023.
15

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
2021 Revolving Credit Facility
Borrowings under the 2021 Revolving Credit Facility bear interest, at the election of the Company, at a rate equal to the Base Rate (as defined in the 2021 Credit Agreement) or the Adjusted Eurocurrency Rate (as defined in the 2021 Credit Agreement), plus, in each case, the Applicable Rate (as defined in the 2021 Credit Agreement), which shall vary based on the Company’s Consolidated First Lien Net Leverage Ratio.
In connection with the 2021 Revolving Credit Facility, the Company incurred $0.5 million in debt issuance costs. Expenses associated with the issuance of the revolving credit facility are presented in the accompanying condensed consolidated balance sheets in prepaid expenses and other current assets and other assets, and are amortized to interest expense over the life of the 2021 Revolving Credit Facility using the straight-line method.
The 2021 Revolving Credit Facility also requires a quarterly commitment fee based on the Company’s consolidated first lien net leverage ratio. As of March 31, 2023, the applicable rate was 0.5%, which was applied against the $50.0 million unused revolving credit facility balance.
Future Principal Payments
Future principal payments of long-term debt as of March 31, 2023 were as follows (in thousands):
Years ending December 31,
2023 (remaining nine months)$3,263 
20244,350 
20254,350 
20264,350 
20274,350 
Thereafter409,987 
Total$430,650 
Note 7 - Stockholders’ Equity
Stock Repurchase Program
In May 2022, the Company’s board of directors authorized a new stock repurchase program to acquire up to $75.0 million of the Company’s common stock, with no requirement to purchase any minimum number of shares. The manner, timing, and actual number of shares repurchased under the program will depend on a variety of factors, including price, working capital needs, general business and market conditions, regulatory requirements, and other investment opportunities. Shares may be repurchased through privately negotiated transactions, or open market purchases, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934. The repurchase program may be commenced, suspended, or terminated at any time by the Company at its discretion without prior notice.

The Company retires the repurchased shares, which automatically return to the status of authorized but unissued shares of common stock. The cost of the repurchased shares, including commissions, fees, and excise taxes are recorded as an adjustment to retained earnings on the Company’s condensed consolidated balance sheets and statements of stockholders’ equity. During the three months ended March 31, 2023, the Company repurchased 228,529 shares of its common stock for $3.5 million, including commissions, fees, and excise taxes. As of March 31, 2023, there was a total of $68.1 million remaining for repurchase under the stock repurchase program.
16

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Note 8 – Share-based Compensation
2021 Stock Option and Incentive Plan
The 2021 Stock Option and Incentive Plan (the “2021 Plan”) was adopted by the board of directors and approved by the Company’s stockholders following the Corporate Conversion and became effective as of July 26, 2021. The 2021 Plan replaced both the Company’s 2019 Equity Option Plan (the “2019 Plan”) and the Project Angel Parent, LLC Equity Plan (the “2018 Plan”). Outstanding options to purchase Class B Units granted under the 2019 Plan were converted into options to purchase shares of common stock, and all outstanding Carried Equity Units granted under the 2018 Plan were converted into restricted stock awards (“RSAs”), both of which have been granted under the 2021 Plan.
The Company had initially reserved 13,171,588 shares of its common stock for the issuance of awards under the 2021 Plan. The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase on January 1, 2022 and each January 1 thereafter, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s compensation committee. The number of shares reserved under the 2021 Plan is subject to adjustment in the event of a stock split, stock dividend, or other change in the Company’s capitalization.
The 2021 Plan provides flexibility to the Company’s compensation committee to use various equity-based incentive awards as compensation tools to motivate the Company’s workforce. The incentive awards that may be granted under the 2021 Plan include, but are not limited to, options to purchase common stock, stock appreciation rights, restricted shares of common stock, restricted stock units, and cash bonuses.
Stock Options
A summary of stock option activity during the three months ended March 31, 2023 is as follows (in thousands, except options, price per option, and term amounts):
Number of OptionsWeighted Average Exercise PriceWeighted Average Remaining Contract TermAggregate Intrinsic Value
Outstanding – January 1, 2023
4,739,783 $13.21 
7.61
$19,855 
Granted
  
Exercised(97,412)6.10 
Forfeited(143,087)21.78 
Outstanding – March 31, 2023
4,499,284 $13.09 
7.34
$28,349 
Vested and expected to vest in the future at March 31, 2023
4,499,284 13.09 
7.34
28,349 
Exercisable at March 31, 2023
2,951,792 $9.28 
6.67
$27,428 
The total fair value of options that vested during the three months ended March 31, 2023 and 2022 was $1.1 million and $1.5 million, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $0.9 million and $0.4 million, respectively.
The Company recognized $1.3 million and $1.4 million in share-based compensation expense related to time-based and performance-based stock options for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023 and 2022, performance-based options were probable of vesting and, therefore, were included as part of share-based compensation expense.
As of March 31, 2023, there was $14.1 million of unrecognized share-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.56 years.
17

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Restricted Stock Awards
The number of restricted stock awards (“RSAs”) that vested during the three months ended March 31, 2023 and 2022 was 59,558 and 484,401, respectively.

The liability balance as of March 31, 2023 and 2022, related to the unvested RSAs was $0.00 million and $0.01 million, respectively. As of March 31, 2023 and 2022, the number of unvested RSAs amounted to 4,051 and 183,741, respectively.
There were a total of 0 and 22,212 RSAs cancelled or forfeited during the three months ended March 31, 2023 and 2022, respectively.
The Company recognized $0.1 million and $0.1 million in share-based compensation expense related to the vesting of RSAs for the three months ended March 31, 2023 and 2022, respectively.
Restricted Stock Units
A summary of restricted stock unit (“RSU”) activity during the three months ended March 31, 2023, is as follows:
Number of RSUsWeighted Average Grant Date Fair Value
Non-vested – January 1, 2023
3,111,831 $19.27 
Granted
424,266 15.00 
Vested(65,770)25.73 
Forfeited(258,916)19.76 
Non-vested – March 31, 2023
3,211,411 $18.53 
As of March 31, 2023, 3,211,411 RSUs are expected to vest. The Company recognized $3.4 million and $2.2 million in share-based compensation expense related to RSUs for the three months ended March 31, 2023, and 2022, respectively.
As of March 31, 2023, there was $48.2 million of unrecognized share-based compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of 2.96 years.
Employee Stock Purchase Program
As of March 31, 2023, the Company has issued 127,700 shares of common stock pursuant to the 2021 Employee Stock Purchase Plan under its employee stock purchase program (“ESPP”). As of March 31, 2023, there was $0.1 million of unrecognized share-based compensation related to the ESPP that is expected to be recognized over the remaining term of the current offering period. The Company recognized $0.1 million and $0.1 million of share-based compensation expense related to the ESPP for the three months ended March 31, 2023 and 2022, respectively.
18

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Share-Based Compensation
Share-based compensation for share-based awards granted to participants has been recorded in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$853 $965 
General and administrative2,264 1,381 
Research and development (1)
1,783 1,077 
Sales and marketing290 385 
Restructuring related costs (2)
(299) 
Total share-based compensation expense $4,891 $3,808 
______________
(1)Net of $0.1 million and $0.1 million additions to capitalized software on the Company’s condensed consolidated balance sheets during the three months ended March 31, 2023 and 2022, respectively.
(2)Relates to unvested stock compensation that was forfeited as part of the Restructuring Plan. See Note 12, “Restructuring.”
Note 9 – Income Taxes
In accordance with applicable accounting guidance, the Company is required to use an estimated annual effective tax rate to compute its tax provision during an interim period. The Company’s provision for income taxes reflected an effective tax rate of 17% and 28% for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to R&D credits, state taxes, permanent unfavorable differences related to share-based compensation expense, certain employee remuneration under section 162(m) of the Internal Revenue Code, and other expected permanent differences. During the three months ended March 31, 2022, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to R&D credits, state taxes, permanent differences related to share-based compensation expense, and other expected permanent differences.
The Company has gross unrecognized tax benefits with respect to R&D credits of $3.1 million as of March 31, 2023 and $2.5 million as of December 31, 2022. Penalties and interest have been recorded on these liabilities as the credits have started to be utilized.
The Company assesses whether a valuation allowance should be recorded against its deferred tax assets based on the consideration of all available evidence, using a “more likely than not” realization standard. The four sources of taxable income that must be considered in determining whether deferred tax assets will be realized are: (l) future reversals of existing taxable temporary differences (i.e., offset of gross deferred tax assets against gross deferred tax liabilities); (2) taxable income in prior carryback years, if carryback is permitted under the applicable tax law; (3) tax planning strategies; and (4) future taxable income exclusive of reversing temporary differences and carryforwards. Based on the evaluation of the evidence and sources of taxable income, the Company has determined that no valuation allowance is necessary as of March 31, 2023.
19

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Note 10 – Related Party Transactions
The following table presents the impact of related party transactions on the Company’s condensed consolidated statements of operations (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$319 $472 
General and administrative248 207 
Research and development162 63 
Sales and marketing 22 
Total related party expenses$729 $764 
The following table presents the impact of related party transactions on the Company’s condensed consolidated balance sheets (in thousands):
As of
March 31, 2023
December 31, 2022
Prepaid assets$156 $37 
Total current assets$156 $37 
Accounts payable$152 $30 
Accrued liabilities529 456 
Total current liabilities$681 $486 
Note 11 – Net (Loss) Income Per Share
The following table presents the calculation of basic and diluted net (loss) income per share (in thousands, except share and per share data):
Three Months Ended March 31,
20232022
Basic and diluted net (loss) income per share
Numerator:
Net (loss) income attributable to common stockholders
$(5,666)$7,479 
Denominator:
Weighted average common stock outstanding:
Basic80,659,97879,974,071
Diluted80,659,97882,228,936
Net (loss) income per share:
Basic$(0.07)$0.09 
Diluted(0.07)0.09 
A reconciliation of the denominator used in the calculation of basic and diluted earnings per share is as follows:
20

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Three Months Ended March 31,
20232022
Weighted average shares outstanding for basic earnings per share80,659,97879,974,071
Effect of dilutive securities:
Options outstanding, unexercised
1,736,275
RSAs unvested488,291
RSUs unvested27,120
Purchase rights committed under the ESPP3,179
Weighted average shares outstanding for diluted earnings per share80,659,97882,228,936
The following outstanding potentially dilutive securities were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders because their impact would have been anti-dilutive for the periods presented:
As of March 31,
20232022
Options to purchase common stock outstanding, unexercised2,017,496 1,476,592 
Restricted stock units, unvested600,981 874,425 
Total2,618,477 2,351,017 
Note 12 – Restructuring Activities
Restructuring Plan
In February 2023, the Company’s board of directors authorized a restructuring plan (the “Restructuring Plan”) that was designed to consolidate the Company’s functions and investments to prioritize customer-centric areas of the Company’s organization, align teams with the Company’s highest business priorities, and improve efficiencies. The Restructuring Plan included a reduction of the Company’s current workforce by 9%.

The Company estimated that it would incur charges of $2.5 million to $3.5 million in connection with the Restructuring Plan, consisting primarily of cash expenditures and relating to employee severance payments, employee benefits, and employee transition costs. Restructuring charges of $2.9 million for severance and related costs, net of $0.3 million previously vested stock based compensation, was recognized during the three months ended March 31, 2023, and is reflected in restructuring related costs on the Company’s condensed consolidated statements of operations. Accrued severance and related costs as of March 31, 2023 were $0.6 million. The Company expects to incur the remaining estimated restructuring related costs during the second quarter of 2023.
Note 13 – Business Combinations
Acquisition of OpenClose
On November 4, 2022, the Company acquired all of the outstanding stock of Beanstalk Networks L.L.C. doing business as OpenClose (“OpenClose”) for cash consideration of $63.1 million. In connection with the acquisition, the Company incurred $1.9 million in acquisition related costs. The acquisition was funded by the Company’s available cash. OpenClose is based out of West Palm Beach, Florida, and provides mortgage lending technology, with a particular focus on supporting depository institutions. The acquisition is expected to improve the company’s existing lending platform and improve our offerings for depository institutions. The acquisition is accounted for using the acquisition method of accounting whereby the acquired assets and liabilities will be recorded at their respective fair values and added to those of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets.
As of March 31, 2023, the Company is still finalizing the provisional purchase price allocation related to final working capital adjustments and income tax effects.
21

MERIDIANLINK, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (CONTINUED)
Pro Forma Financial Information
The pro forma statements of operations data for the three months ended March 31, 2022 give effect to the OpenClose acquisition, described above, as if it had occurred at January 1, 2021. These amounts have been calculated after adjusting the operating results of OpenClose for the following primary items: (1) additional intangible amortization from the transaction, (2) acquisition-related expenses incurred, and (3) the related tax effects of the above adjustments. For the three months ended March 31, 2022, pro forma revenue was $76.2 million, and pro forma earnings reflect net income of $6.4 million.
The unaudited pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the acquisitions taken place as of January 1, 2021, or the results of our future operations. Furthermore, the pro forma results do not give effect to all cost savings or incremental costs that may occur as a result of the integration and consolidation of the completed acquisitions.
Acquisition of StreetShares
On April 1, 2022, the Company acquired all of the outstanding stock of StreetShares, Inc. (“StreetShares”) for cash consideration of $28.0 million, $30.0 million in escrow for a contingent earnout that expires April 1, 2023, subject to adjustment as defined in the purchase agreement, and $1.6 million in acquisition costs. The $30.0 million is considered contingent consideration and accounted for separate from the business combination accounting. The acquisition was funded by the Company’s available cash. StreetShares is based out of Reston, VA, and is a financial technology company that provides digital small business lending technology to banks and credit unions. The acquisition is accounted for using the acquisition method of accounting whereby the acquired assets and liabilities are recorded at their respective fair values and added to those of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. Results of operations of StreetShares have been included in the operations of the Company beginning with the closing date of the acquisition.
During the three months ended March 31, 2023, the Company completed the provisional purchase price allocation related to income tax effects, resulting in a reduction to the deferred tax asset and corresponding increase to goodwill in the amount of $0.2 million.
Pro forma information for the StreetShares acquisition is not provided because their historical operating results were not material to the Company’s consolidated results of operations.
Note 14 – Subsequent Events
Equity Grants
Pursuant to approval by the Company’s compensation committee and board of directors, in April 2023, the Company awarded $43.6 million service-based RSUs to its employees. Service-based RSUs generally vest over four years, subject to the participant’s continued service relationship with the Company through each such vesting date.
22

Special Note about Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans, and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
our future financial performance, including our expectations regarding our revenue, gross profit or gross margin, operating expenses, ability to generate cash flow, revenue mix, and ability to achieve and maintain future profitability;
our ability to execute on our strategies, plans, objectives, and goals;
our ability to compete with existing and new competitors in existing and new markets and offerings;
our ability to develop and protect our brand;
our ability to effectively manage privacy and information and data security;
the concentration of our customer base in the financial institution industry, and spending by financial institutions on cloud-based technology;
anticipated trends and growth rates in our business and in the markets in which we operate;
our ability to maintain and expand our customer base and our partner network;
our ability to sell our applications and expand internationally;
our ability to comply with laws and regulations;
our ability to anticipate market needs and successfully develop new and enhanced solutions to meet those needs;
the impact of the novel coronavirus, or COVID-19, pandemic and other global financial, economic, and political events on our industry, business, and results of operations;
our ability to successfully identify, acquire, and integrate complementary businesses and technologies, and our expectations regarding the expected impact of such acquisitions on our business;
our ability to hire and retain necessary qualified employees to grow our business and expand our operations;
the execution of restructuring plans, including expected or contemplated associated timing, benefits, and costs;
the evolution of technology affecting our applications, platform, and markets;
economic and industry trends, including the impact of rising inflation rates on our customers and consumers generally;
seasonal fluctuations in consumer borrowing trends and impact of changes in interest rates;
our ability to adequately protect our intellectual property; and
our ability to service our debt obligations.
We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.
The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future,

23

may file with the Securities and Exchange Commission, or SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
In this Quarterly Report on Form 10-Q, the terms “MeridianLink,” “we,” “us,” and “our” refer to MeridianLink, Inc. and its subsidiaries, unless the context indicates otherwise.

24

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, or our 2022 Annual Report on Form 10-K, filed with the SEC on March 9, 2023. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties described in the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q. These risks and uncertainties could cause actual results to differ materially from those projected in forward-looking statements contained in this report or implied by past results and trends. Our fiscal year ends on December 31. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and our interim results are not necessarily indicative of the results we expect for the full fiscal year or any other period.
Overview
We are a leading provider of cloud-based software solutions for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and credit reporting agencies, or CRAs. Financial institutions are undergoing digital transformation as they seek to transition business models, create new revenue streams, and increase customer engagement. We support our customers’ digital transformations by helping them create a superior consumer experience with our mission-critical loan origination system, or LOS, digital lending platform, data verification solutions, and data analytics. Our solutions allow our customers to meet their clients’ financial needs across the institution, which enables improved client acquisition and retention. Additionally, our solutions allow our customers to operate more efficiently by enabling automated loan decisioning and enhanced risk management.
The effective delivery and management of secure and advanced digital solutions in the complex and heavily regulated financial services industry requires significant resources, personnel, and expertise. We provide digital solutions that are designed to be highly configurable, scalable, and adaptable to the specific needs of our customers. We design and develop our solutions with an open platform approach intended to provide comprehensive integration among our solution offerings and our customers’ internal systems and third-party systems. Our multi-product platform, MeridianLink One, can be tailored to meet the needs of our customers as they digitally transform their organizations and adapt to changing business and consumer demands. Moreover, our expert consultants offer strategic guidance and customized solutions through our modular platform to help our customers more quickly reduce costs and increase revenue, efficiency, and satisfaction of their customers.

Our solutions are central to the financial institution’s technology ecosystem and help drive additional business volume for our customers both directly and indirectly through our Partner Marketplace. Our omni-channel borrowing experience seamlessly integrates all the touch points a borrower may have with the financial institution (remote via the web or an app, in person at a branch, or telephonically through an operator). In addition to our streamlined workflow, which has been refined over twenty years with input from across our customer base, our Partner Marketplace provides our customers optional integrations, the collective capabilities of which we believe further distinguish our solution from that of competitors.
We deliver our solutions to the substantial majority of our customers using a SaaS model under which our customers pay subscription fees for the use of our solutions as well as fees for transactions processed using our solutions. Our subscription fees consist of revenues from software solutions that are governed by pricing and terms contained in contracts between us and our customers. The initial term of our contracts is typically three years, but may range from one to seven years. Our customer contracts are typically not cancellable without penalty. Our contracts almost always contain an evergreen auto-renewal term that is often for a one-year extension after the initial term, but can extend the auto-renewal of the contract up to the length of the original term. Our subscription fee revenues include annual base fees, platform partner fees, and, depending on the product, fees per search or per loan application or per closed loan (with contractual minimums based on volume) that are charged on a monthly basis, which we refer to as volume-based fees. We earn additional revenues based on the volume of applications or closed loans processed above our customers’ contractual minimums.

25

As a result of this pricing approach, our revenues from our customers grow as our customers add additional transaction types, purchase more modules, utilize more of our partner integrations, or see increased transaction volume. We generally sell our solutions through our direct sales organization or channel partners and recognize our subscription fee revenues over the terms of the customer agreements.
Our revenues per customer vary from period to period based on the length and timing of customer implementations, sales of additional solutions to existing customers, changes in the number of transactions processed (including impacts from seasonality and cyclicality), and variations among existing customers and new customers with respect to the mix of purchased solutions and related pricing.
We seek to strengthen and grow our customer relationships by providing consistent, high-quality implementations and customer support services, which we believe drive higher customer retention and incremental sales opportunities within our existing customer base. We have invested in migrating our solutions onto the public cloud, which helps to extend our innovation and security posture. We believe that our increased focus on our go-to-market strategy and strategic partnerships will drive incremental opportunities for revenue and accelerate client cross-sell growth.
In addition, we believe there is untapped market potential in the loan origination and digital banking markets. We believe significant opportunity for additional customer acquisition and revenue growth exists as financial institutions continue to adopt online lending and account opening practices and require more efficient technologies. We provide these services to institutions of all sizes and complexities, but currently focus on the middle market. By focusing on better sales execution, providing and allocating resources where needed, and improving marketing efforts, we are confident in our ability to expand our customer base within our current target market.
We cater largely to financial institutions such as community banks and credit unions with assets under management between $100 million and $10 billion. In recent years, community banks have continued to compete with their typically larger non-community bank competitors, and the FDIC reported that, in 2019, net interest income accounted for over 78 percent of community bank net operating revenues. A large opportunity exists in expanding our target market to new customers with less than $100 million or greater than $10 billion in assets under management. In our down-market, smaller institutions commonly use spreadsheets or other inexpensive alternatives. These companies have a smaller volume of loans per month, but there is opportunity to alter our solutions to offer decreased pricing and functionality in order to lower implementation fees.
We have continuously invested in expanding and improving our solutions since they were first introduced more than two decades ago, and we intend to continue investing both organically and inorganically through acquisitions to expand our portfolio. We are focused on introducing new solutions and enhancing services and capabilities in areas including digital lending, data insights, and collections to further expand our reach into the consumer lending markets. In addition to developing our solutions organically, such as the combination of our capabilities to create our patented consumer debt optimization functionality, we may selectively pursue acquisitions, joint ventures, or other strategic transactions that provide additional capabilities or customers, or both. Acquisitions to date have included CRIF Lending Solutions, or CRIF, in June 2018, and Teledata Communications, Inc, or TCI, in November 2020. TCI is the creator of DecisionLender, a SaaS loan origination solution. We believe that with the addition of TCI, our position as a vendor of choice is enhanced among financial institutions seeking solutions to manage their needs from initiation of client relationships to facilitating the extension of credit to their clients. In December 2020, we acquired all of the assets of TazWorks, LLC, or TazWorks.. TazWorks provides software and data solutions to CRAs focused on the employment and tenant screening market, a market that is adjacent and complementary to our current solutions for credit-focused CRAs. In April 2021, we acquired Saylent, a data analytics and marketing solution that offers insights to financial institutions that help drive account and credit and debit card usage and enabled us to more rapidly bring to market our MeridianLink Engage product. In April 2022, we acquired StreetShares, Inc., or StreetShares,, a financial technology company that offers digital small business lending technology to banks and credit unions. The acquisition of StreetShares complements our existing lending platform and enhances our small business lending capabilities. In November 2022, we acquired Beanstalk Networks LLC doing business as OpenClose, or OpenClose, a leader in mortgage lending technology, with a particular focus on supporting depository institutions. This transaction is expected to improve our platform by providing additional advanced, more open, and more customer-friendly capabilities, particularly through our Point of Sale solution. In addition to improving our capabilities, this transaction is expected to present benefits of increased scale and help solidify our position in the market by allowing us to target additional sales to depository institutions.
We have designed our Partner Marketplace to act as the gateway for third parties to access our customers, which allows our customers to leverage the capabilities from these third parties to enable an accelerated loan process with improved

26

efficiency and reduced cost. We are able to capitalize on one-time service fees from our partners upon their integration into our Partner Marketplace and a revenue share from our partners as they derive revenues from our software solution. As we grow our business, we expect to add additional product partners and drive additional monetization opportunities. We also intend to cultivate and leverage existing and future partners to grow our market presence.
We believe that delivery of consistent, high-quality implementations and customer support services is a significant driver of purchasing and renewal decisions of our prospects and customers. To develop and maintain a reputation for high-quality service, we seek to build deep relationships with our customers through our customer support organization, which we staff with personnel who are motivated by our common mission of using technology to help our customers succeed and who are knowledgeable with respect to the regulated and complex nature of the financial services industry. As we grow and scale our business, we intend to continue to invest in and grow our internal services and support organization, as well as partner with high quality third-party organizations, to support our customers’ needs and maintain our reputation.
Global Considerations
Economic Uncertainty, Rising Inflation, and Increasing Interest Rates
We are also closely monitoring the recent volatility in capital markets and the increased economic uncertainty in the United States. These developments have led to higher inflation and increased uncertainty about business continuity. Additionally, interest rates, including for mortgages and consumer lending, have risen from historic lows and may increase further in the future. These factors may adversely affect our business and our results of operations. As our customers react to global economic conditions and the potential for a global recession, we may see reduced spending on our products and, therefore, may take additional precautionary measures to limit or delay expenditures and preserve capital and liquidity.
Inflation rates, particularly in the United States, have increased recently to multi-year highs. Increased inflation may result in decreased demand for mortgages and consumer lending, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may cause us to experience lower than expected volumes if there is a decrease in customer spending.
As economic conditions continue to change quickly and are subject to rapid and possibly material change, we will continue to actively monitor these factors and may take actions that alter our business operations as we may determine are in the best interests of our customers and stockholders.
Impact of the COVID-19 Pandemic
The COVID-19 pandemic has had widespread, rapidly-evolving, and unpredictable impacts on global societies, economies, financial markets, and business practices (including in California where our corporate headquarters are located). Our focus remains on promoting employee health and safety, serving our customers, complying with regulations, and ensuring business continuity. While the impacts of the COVID-19 pandemic have not caused a material adverse financial impact to our business to date, the future impacts remain uncertain. The extent to which the COVID-19 pandemic, including any variants of the virus that have emerged, may impact our business going forward will depend on numerous evolving factors that we cannot reliably predict, including factors that may adversely impact business spending on technology, and customers’ ability to pay for our products and services on an ongoing basis. See Part I, Item 1A. “Risk Factors” in our 2022 Annual Report on Form 10-K for further discussion of the impact and possible future impacts of the COVID-19 pandemic on our business.

Recent Developments
In February 2023, our board of directors authorized a restructuring plan, or the “Restructuring Plan”, that was designed to consolidate the Company’s functions and investments to prioritize customer-centric areas of the Company’s organization, align teams with the Company’s highest business priorities, and improve efficiencies. The Restructuring Plan included a reduction of our then-current workforce by approximately 9%.

We estimated that we would incur charges of $2.5 million to $3.5 million in connection with the Restructuring Plan, consisting primarily of cash expenditures and relating to employee severance payments, employee benefits, and employee

27

transition costs. The majority of these costs were incurred during the three months ended March 31, 2023, totaling $2.9 million, and up to another $0.6 million is expected to be incurred during the second quarter of 2023.

The estimates of the charges and expenditures that we expect to incur in connection with the Restructuring Plan, and timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual amounts may differ from the estimates discussed above.
We may not be able to fully realize the benefits initially anticipated from the Restructuring Plan, and the expected costs may be greater than expected. See Part II, Item 1A. “Risk Factors” herein for further discussion on the impact and possible future impacts of the Restructuring Plan on our business.
Key Operating Measures
In addition to the GAAP measures described below in “—Components of Operating Results,” we monitor operating measures to evaluate growth trends, plan investments, and measure the effectiveness of our sales and marketing efforts. For a complete listing and definitions of our key operating metrics, refer to “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Operating Metrics” in our 2022 Annual Report on Form 10-K. There have been no material changes to the definitions of our key performance metrics during the three months ended March 31, 2023, other than the ARR Net Retention Rate, as described below.
ARR Net Retention Rate
Our ARR Net Retention Rate provides insight into growth in the usage of our solutions, sales of new solutions, and services into revenue generating entities during the current year and attrition. Our ARR Net Retention Rate is calculated by taking the annual recurring revenue, or ARR, recorded in the latest twelve-month measurement period for the cohort of revenue-generating entities in place throughout the entire prior twelve-month measurement period, and dividing the result by the cohort’s ARR recorded in the twelve-month period that is immediately prior to the beginning of the current measurement period.
During the three months ended March 31, 2023, we refined our methodology for calculating ARR Net Retention Rate to include the impact from cross-sell revenue streams. Under the refined methodology, the ARR Net Retention rate was 100% and 109% for the years ended December 31, 2022 and 2021, respectively. For the three months ended March 31, 2023 and 2022, the ARR Net Retention rate was 101% and 98%, respectively.

Using our prior calculation methodology, the ARR Net Retention rate was 96% and 103% for the years ended December 31, 2022 and 2021, respectively, and 97% and 96% for the three months ended March 31, 2023 and 2022, respectively.

The most significant drivers of improvements in our ARR Net Retention Rate each year are the increases in adoption of additional solutions such as additional products, channels, loan types, or modules, the increase in volume transacted on our systems, and price increases. The most significant factors in the decrease in ARR Net Retention Rate are customer attrition and reduced volume transacted on our systems either due to decreased product usage or lower transaction volumes. Our use of ARR Net Retention Rate has limitations as an analytical tool, and investors should not consider it in isolation. Other companies in our industry may calculate revenue retention rate differently, which reduces its usefulness as a comparative measure.

28

Components of Operating Results
We have one primary business activity and operate in a single operating and reportable segment.
Revenues
Our revenues consist of three components: subscription fees, professional services, and other revenues.
Subscription Fee Revenues
Our subscription fees consist of revenues from software solutions that are governed by pricing and terms contained in contracts between us and our customers. Our subscription fee revenues include annual base fees, platform partner fees, and, depending on the solution, fees per search or per application or per closed loan (with contractual minimums based on volume) that are charged on a monthly basis, which we refer to as volume-based fees.
Our software solutions are primarily hosted in cloud-based hosting services and are generally available for use as hosted application arrangements under subscription fee agreements. Subscription fees from these applications are recognized over time on a ratable basis over the customer agreement term generally beginning on the date our solution is made available to the customer. Amounts that have been invoiced are recorded in accounts receivable and deferred revenues or revenues, depending on whether the revenue recognition criteria have been met. Revenue that is earned but not yet invoiced is recorded in accounts receivable. For the majority of our customers, additional fees for monthly usage above the levels included in the standard subscription fee are recognized as revenue in the month when the usage amounts are determined and reported.
Professional Services Revenues
We offer implementation, configuration, consulting, and training services for our software solutions and SaaS offerings. Revenues from professional services are recognized as control is transferred to the customer.
Other Revenues
We enter into referral and marketing agreements with various third parties, in which revenues are primarily generated from transactions initiated by the third parties’ customers. We may introduce our customers to a referral partner or offer additional services available from the referral partner via an integration with our solutions. We market our partners’ solutions to our customers as a way not only to generate revenue but also to ensure that our customers are leveraging the full benefit of our solution, which includes the capabilities offered through our partners. Revenues are recognized in the period the services are performed, provided that collection of the related receivable is reasonably assured.
Cost of Revenues
Cost of revenues consists primarily of salaries and other personnel-related costs, including employee benefits, bonuses, and share-based compensation for employees providing services to our customers. This includes the costs of our implementation, customer support, data center, and customer training personnel. Additional expenses include fees paid to third-party vendors in connection with delivering services to customers.
Cost of revenues also includes cloud-based hosting services, an allocation of general overhead costs, and the amortization of developed technology. We allocate general overhead expenses to all departments based on the number of employees in each department, which we consider to be a fair and representative means of allocation.
We capitalize certain software development costs related to programmers, software engineers, and quality control teams working on our software solutions. We commence amortization of capitalized costs for solutions that have reached general release. Capitalized software development costs are amortized to cost of revenues over their estimated economic lives.
We intend to continue to increase our investments in our implementation and customer support teams and technology infrastructure to serve our customers and support our growth. We expect cost of revenues to continue to grow in absolute dollars as we grow our business.

29

Gross Profit and Gross Margin
Gross profit is revenues less cost of revenues, and gross margin is gross profit as a percentage of revenues. Gross profit has been, and will continue to be, affected by various factors, including the mix of our subscription fees, professional service and other revenues, the costs associated with our personnel, third-party vendors, and cloud-based hosting services, and the extent to which we expand our implementation and customer support services. We expect that our gross margin will fluctuate from period to period depending on the interplay of these various factors. Our gross margin was 63.8% and 66.3% for the three months ended March 31, 2023 and 2022 respectively.
Operating Expenses
General and Administrative
General and administrative expenses consist primarily of allowance for credit losses, salaries and other personnel-related costs, including employee benefits, bonuses, and share-based compensation, of our administrative, finance and accounting, information systems, legal, and human resources employees. General and administrative expenses also include consulting and professional fees, insurance, franchise taxes, and travel.
General and administrative expenses include depreciation and amortization of property and equipment and amortization of acquired intangibles. Identifiable intangible assets with finite lives, such as customer relationships, trademarks, and non-competition agreements, are amortized over their estimated useful lives on either a straight-line or accelerated basis, depending on the nature of the intangible asset.
We continue to incur incremental expenses associated with the growth of our business and to meet increased compliance requirements associated with operating as a public company. These expenses include costs to comply with Section 404 of the Sarbanes-Oxley Act and other regulations governing public companies, increased costs of investor relations activities, and investments to drive scalability. As a result, we expect our general and administrative expenses to increase in absolute dollars, but to decrease as a percentage of revenues over the long term as we scale the business and continue to adjust to being a public reporting company.
Research and Development
Research and development expenses include salaries and other personnel-related costs, including employee benefits, bonuses, and share-based compensation. Research and development expenses also include third-party contractor expenses, software development costs, allocated overhead, and other related expenses incurred in developing new solutions and enhancing existing solutions.
Certain research and development costs that are related to our internal software development, which include salaries and other personnel-related costs attributed to certain programmers, software engineers, and quality control teams, are capitalized and are included in intangible assets, net on the condensed consolidated balance sheets.
We believe that continuing to improve and enhance our solutions is essential to maintaining our reputation for innovation and growing our customer base and revenues. We plan to continue investing in research and development by increasing our software development capacity. As a result, we expect our research and development expenses to increase in absolute dollars, over the long term as we scale the business, including through integration of our acquisitions.
Sales and Marketing
Sales and marketing expenses consist primarily of salaries and other personnel-related costs, including commissions, employee benefits, bonuses, and share-based compensation. Sales and marketing expenses also include expenses related to advertising, lead generation, promotional event programs, corporate communications, travel, outside consulting fees, and allocated overhead. Commissions related to software sales are generally capitalized and then amortized over the expected period of customer benefit.

30

Sales and marketing expenses are also impacted by the timing of significant marketing programs such as our annual client conference, which we typically hold during the second quarter. We plan to continue investing in sales and marketing by increasing our number of sales and marketing personnel and expanding our sales and marketing activities. As a result, we expect our sales and marketing expenses to increase in absolute dollars. We believe these investments will help us build brand awareness, add new customers, and expand sales to our existing customers as they continue to buy more solutions from us.
Total Other (Income) Expense, Net
Total other (income) expense, net consists primarily of interest expense, net. Interest expense consists of interest attributable to our credit facilities and amortization of lender-related fees and other direct incremental costs of securing financing, partially offset by interest income from our interest-bearing cash accounts.
Provision for Income Taxes
Our income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. We are subject to federal income taxes in the United States and numerous state jurisdictions. Significant judgments and estimates are required in the determination of the consolidated income tax expense.
We recognize deferred tax assets to the extent that these assets are more likely than not to be realized. If they are not, deferred tax assets are reduced by a valuation allowance. In making such a determination, all available positive and negative evidence is considered, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If it is subsequently determined that deferred tax assets would be more likely than not realized in the future, in excess of their net recorded amount, an adjustment would be made to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. After a review of the four sources of taxable income (as described above), and after consideration of our continuing cumulative income position, inclusive of impact from permanent differences, as of March 31, 2023, we have not recorded a valuation allowance on its deferred tax assets.
We have recorded an uncertain tax position with respect to our R&D credits. We have recorded an immaterial amount of penalties and interest as the credits have been fully utilized in certain jurisdictions, however almost all credits have no penalties or interest recorded as the credits have not yet been fully utilized, and therefore the uncertain tax position is recorded primarily as a reduction of the deferred tax asset related to these credits.

31

Results of Operations
Condensed Consolidated Statements of Operations
The following table sets forth our condensed consolidated statements of operations data for each of the periods indicated:
Three Months Ended March 31,
(in thousands, except share and unit and per share and per unit amounts)20232022
Revenues, net$77,135 $72,754 
Cost of revenues:
Subscription and services (1)
23,501 21,104 
Amortization of developed technology4,454 3,434 
Total cost of revenues27,955 24,538 
Gross profit49,180 48,216 
Operating expenses:
General and administrative (1)
22,555 18,187 
Research and development (1)
13,812 8,409 
Sales and marketing (1)
8,213 4,743 
Acquisition related costs— 2,283 
Restructuring related costs (1)
2,904 — 
Total operating expenses47,484 33,622 
Operating (loss) income1,696 14,594 
Other (income) expense, net:
Other income(470)(163)
Interest expense, net9,031 4,358 
Total other expense, net8,561 4,195 
(Loss) income before (benefit from) provision for income taxes(6,865)10,399 
(Benefit from) provision for income taxes(1,199)2,920 
Net (loss) income$(5,666)$7,479 
Net (loss) income per share:
Basic$(0.07)$0.09 
Diluted(0.07)0.09 
Weighted average common stock outstanding:
Basic80,659,978 79,974,071 
Diluted80,659,978 82,228,936 
______________
(1)Share-based compensation is as follows:
Three Months Ended March 31,
20232022
Cost of revenues$853 $965 
General and administrative2,264 1,381 
Research and development, net of amounts capitalized1,783 1,077 
Sales and marketing290 385 
Forfeitures included in restructuring related costs(299)— 
Total share-based compensation expense$4,891 $3,808 

32

Comparison of the Three Months Ended March 31, 2023 and 2022
Revenues, net
Three Months Ended March 31,Change
(in thousands)20232022$%
Revenues, net$77,135 $72,754 $4,381 %
Revenues increased $4.4 million, or 6% for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. For the three months ended March 31, 2023, revenue from our Lending Software Solutions accounted for 12% of the growth compared to the three months ended March 31, 2022, driven primarily from new and ramping customers as well as volume and revenue increases from existing customers. Lending Software Solutions growth was partially offset by a decline in Data Verification Software Solutions revenue, which accounted for (6)% of the growth, driven primarily by the decline in mortgage refinance application volumes. For both of our solutions, we receive incremental revenues if customers exceed their minimum commitments for monthly transactions, which typically is based off of number of applications or closed and funded loans for Lending Software Solutions and credit, tenant, or employment verification reports for our Data Verification Software Solutions.

Cost of Revenues and Gross Profit
Subscription and services
Three Months Ended March 31,Change
(in thousands)20232022$%
Subscription and services$23,501 $21,104 $2,397 11 %
Subscription and services cost of revenues increased $2.4 million, or 11%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase was partially due to $2.1 million in additional cloud-based data storage costs, as well as a $1.7 million increase due to higher compensation and benefits spend, largely from additional employee headcount. The increase was partially offset by a $1.8 million decrease in third-party costs driven by lower Data Verification Software Solutions application volumes.
Amortization of Developed Technology
Three Months Ended March 31,Change
(in thousands)20232022$%
Amortization of developed technology$4,454 $3,434 $1,020 30 %
Amortization of developed technology increased $1.0 million, or 30%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase was due to increased amortization for internally developed software and additional amortization on developed technology from the acquisitions of StreetShares and OpenClose, which occurred in the second quarter of 2022 and fourth quarter of 2022, respectively.

Gross Profit
Three Months Ended March 31,Change
(in thousands)20232022$%
Gross profit$49,180 $48,216 $964 %
Gross profit increased $1.0 million, or 2%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase was primarily due to an increase of revenues, partially offset by an increase in cost of

33

revenues due to an increase in cloud-based data storage costs and increased personnel-related expenses from increased employee headcount.
Operating Expenses
General and Administrative
Three Months Ended March 31,Change
(in thousands)20232022$%
General and administrative$22,555 $18,187 $4,368 24 %
General and administrative expenses increased $4.4 million, or 24%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. Share-based compensation increased $0.9 million due to more options and restricted stock units vesting in 2023 compared to 2022. Additionally, during the three months ended March 31, 2023, we increased our allowance for expected credit losses on our accounts receivable, resulting in a credit loss expense of $0.5 million. Amortization of intangible assets also increased, primarily related to additional amortization from the acquisitions of StreetShares and OpenClose. The remainder of the increase primarily relates to higher personnel-related expenses from increased employee headcount. Our Restructuring Plan was approved by the board in February 2023 and was mostly completed during the second half of March 2023. We anticipate personnel-related costs to reduce starting in the second quarter of 2023.
Research and Development
Three Months Ended March 31,Change
(in thousands)20232022$%
Research and development$13,812 $8,409 $5,403 64 %
Research and development expenses increased $5.4 million, or 64%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase was primarily due to additional personnel-related expenses from increased employee and contractor headcount on our research and development teams.
Sales and Marketing
Three Months Ended March 31,Change
(in thousands)20232022$%
Sales and marketing$8,213 $4,743 $3,470 73 %
Sales and marketing expenses increased $3.5 million, or 73%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022, primarily due to higher personnel-related expenses from increased headcount on our sales and marketing teams. In addition, capitalized commissions, net of amortization, increased $0.6 million for the three months ended March 31, 2023 compared to the same period in 2022.
Acquisition Related Costs
Three Months Ended March 31,Change
(in thousands)20232022$%
Acquisition related costs$— $2,283 $(2,283)(100)%
Acquisition related costs decreased for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The decrease was due to costs directly related to the acquisition of StreetShares during the three months ended March 31, 2022, as well as additional professional services costs incurred while pursuing other strategic opportunities that were not repeated during the same period in 2023. There have been no acquisitions and no acquisition related costs for the three months ended March 31, 2023.

34

Restructuring Related Costs
Three Months Ended March 31,Change
(in thousands)20232022$%
Restructuring related costs$2,904 $— $2,904 100 %
Restructuring related costs are costs related to the Restructuring Plan that went into effect during the three months ended March 31, 2023. Restructuring related costs incurred during the three months ended March 31, 2023 were $2.9 million, primarily related to cash payments for severance, net of non-cash stock compensation forfeitures, and other termination-related costs. The total estimated expense for the Restructuring Plan is estimated to be between $2.5 and $3.5 million, with the remainder of the expense expected to be recognized in the second quarter of 2023. There were no restructuring related costs during the three months ended March 31, 2022.
Total Other Expense, net
Three Months Ended March 31,Change
(in thousands)20232022$%
Total other expense, net$8,561 $4,195 $4,366 104 %
Total other expense, net increased $4.4 million, or 104%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase was due to higher interest rates on our variable rate term loan during the three months ended March 31, 2023.
Provision for Income Taxes
Three Months Ended March 31,Change
(in thousands)20232022$%
(Benefit from) Provision for income taxes$(1,199)$2,920 $(4,119)(141)%
Benefit from income taxes was $1.2 million for the three months ended March 31, 2023, compared to a provision for income taxes of $2.9 million for the three months ended March 31, 2022. The decrease in the (benefit from) provision for income taxes was primarily due to a decrease in earnings before income tax.
Liquidity and Capital Resources
Sources of Liquidity
We have financed our operations primarily through cash flows from operations, long-term debt, and, concurrent with the completion of our IPO on July 30, 2021, through proceeds from the issuance of our common stock. In connection with our IPO, we sold 10.0 million shares of our common stock at a price of $26.00 per share, before underwriting discounts and commissions, which generated net proceeds to us of $242.1 million, after deducting $17.9 million in underwriting discounts and commissions and offering costs.
As of March 31, 2023, our principal sources of liquidity were cash and cash equivalents of $77.8 million and unused capacity under our revolving line of credit of $50.0 million. As of March 31, 2023, $30.0 million was held in an escrow deposit account for a contingent earnout related to our StreetShares acquisition, which we expect to be released to us in full during the second quarter of 2023, after the end of the earnout period. Based upon our current levels of operations, we believe that our cash flows from operations along with our other sources of liquidity are adequate to meet our cash requirements for at least the next twelve months.
Our primary uses of cash are funding operations, acquisitions, capital expenditures, debt principal and interest payments, and stock repurchases. Our use of cash is impacted by the timing and extent of the required payments for each of these activities.

35

Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support research and development efforts, the continued expansion of sales and marketing activities, the introduction of new and enhanced solutions, the seasonality impacts on our business, the timing and extent of spending to support our growth strategy, the continued market acceptance of our solutions, the future acquisitions of solutions or businesses, and future stock repurchases. In the event that additional financing is required from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. We continue to monitor our financing requirements and may pursue refinancing opportunities to potentially reduce interest rates and extend maturities. If we are unable to raise additional capital when desired, our business, operating results, and financial condition would be adversely affected.
Operating Leases
We lease office space and server equipment under various operating lease agreements that expire through December 2026. We recognize the related rent expense on a straight-line basis over the term of each lease. Free rent and rental increases are recognized on a straight-line basis over the term of each lease.
One lease, which was with a related party, expired in December 2022, so there were no monthly payments during the three months ended March 31, 2023.. The monthly payments during the three months ended March 31, 2022, were $0.1 million.
Long-Term Debt
For a detailed description of our long-term debt, please see Note 6 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Cash Flows
The following table summarizes our cash flows for the periods presented (in thousands):
Three Months Ended March 31,Change
(in thousands)20232022$%
Net cash provided by (used in):
Operating activities$28,081 $34,863 $(6,782)(19)%
Investing activities(2,058)(1,941)(117)%
Financing activities(4,007)179 (4,186)(2,339)%
Net increase in cash, cash equivalents$22,016 $33,101 $(11,085)33 %
Cash Flows from Operating Activities
Our largest source of operating cash is cash collection from sales of subscriptions to our customers. Our primary uses of cash from operating activities are for personnel-related expenses, marketing expenses, and payments to third-party vendors.
Operating cash flow is derived by adjusting our net (loss) income for non-cash operating items, such as depreciation and amortization, amortization of debt issuance costs, share-based compensation expense, deferred income taxes, loss on disposal of fixed assets, and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations.
For the three months ended March 31, 2023, cash provided by operating activities was $28.1 million. Net loss was $5.7 million, adjusted by non-cash charges of $19.0 million and a decrease of $14.8 million related to operating assets and liabilities. The non-cash charges consist primarily of depreciation and amortization of $14.5 million, provision for expected credit losses of $0.5 million, share-based compensation of $4.9 million, and deferred income taxes of $1.2 million. Net cash outflows from changes in operating assets and liabilities of $14.8 million primarily consisted of increased accounts receivable of $5.0 million due to increased revenue and timing of cash receipts, increased prepaid expenses and other assets of $1.6 million, offset by increased accrued liabilities of $1.7 million, increased accounts payable of $2.7 million due to timing, and increased deferred revenue of $17.0 million.
For the three months ended March 31, 2022, cash provided by operating activities was $34.9 million. Net income was $7.5 million, adjusted by non-cash charges of $20.0 million and a decrease of $7.4 million related to operating assets and liabilities. The non-cash charges consist primarily of depreciation and amortization of $12.9 million, share-based

36

compensation of $3.8 million, and deferred income taxes of $2.7 million. Net cash inflows from changes in operating assets and liabilities of $7.2 million primarily consisted of increased deferred revenue of $14.6 million, partially offset by increased accounts receivable of $7.2 million and an increase in prepaid expenses and other assets of $0.5 million.
Cash Flows from Investing Activities
Net cash used in investing activities of $2.1 million for the three months ended March 31, 2023, $1.9 million for capitalized software additions, and $0.1 million for purchases of property and equipment.
Net cash used in investing activities of $1.9 million for the three months ended March 31, 2022, consisted of $1.5 million for capitalized software additions and $0.4 million for purchases of property and equipment.
Cash Flows from Financing Activities
Net cash used in financing activities of $4.0 million for the three months ended March 31, 2023, consisted of $1.1 million of principal payments of long-term debt, and $3.5 million cash paid to repurchase our common stock, partially offset by $0.6 million of proceeds from the exercise of stock options. Principal repayments on our term loan started in June 2022 and are payable quarterly.
Net cash provided by financing activities of $0.2 million for the three months ended March 31, 2022, consisted entirely of proceeds from the exercise of stock options.
Recent Accounting Pronouncements
See Note 2, “Significant Accounting Policies” to our unaudited condensed consolidated financial statements included in Part I, Item 1 included in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial condition, and cash flows.
Emerging Growth Company Status
We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial results may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We expect to use the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company.
Critical Accounting Policies and Significant Judgments and Estimates
There have been no material changes to our critical accounting policies and estimates since December 31, 2022, except for the updates resulting from the adoption of ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)” which are discussed in more detail within Note 2, “Significant Accounting Policies” and Note 3, “Revenue Recognition” in our unaudited condensed consolidated financial statements included in Part I, Item 1 included in this Quarterly Report on Form 10-Q.

For a full discussion of these estimates and policies, see “Critical Accounting Policies and Significant Judgments” within “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2022 Annual Report on Form 10-K.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no significant changes in our exposures to market risk since December 31, 2022. For a full discussion of our exposures to market risks, see “Quantitative and Qualitative Disclosures about Market Risk” within “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2022 Annual Report on Form 10-K.

37

Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q.
Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitation in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

38

PART II. OTHER INFORMATION
Item 1. Legal Proceedings
We are not currently a party to any litigation or claims that, if determined adversely to us, would have a material adverse effect on our business, operating results, financial condition, or cash flows. We are, from time to time, party to litigation and subject to claims in the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
Item 1A. Risk Factors
Investing in our common stock involves substantial risks. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, including the financial statements and the related notes, before deciding to invest in our common stock. Any of the risk factors we describe below could have a material adverse effect on our business, financial condition, results of operations, cash flow, and prospects. The market price of our common stock could decline if one or more of these risks or uncertainties develop into actual events, causing you to lose all or part of your investment. Other risks, events, and uncertainties that we do not currently anticipate or that we currently deem immaterial may also affect our business. Certain statements contained in the risk factors described below are forward-looking statements. See the section titled “Special Note Regarding Forward-Looking Statements” for more information.
Summary of Risk Factors
The following risk factor summary provides an overview of the inherent uncertainty investing in us presents. This summary does not contain all of the information that may be important to you, and you should read this risk factor summary together with the more detailed discussion of risks and uncertainties set forth following this section as well as elsewhere in this Quarterly Report on Form 10-Q. The risks and uncertainties to which our business is subject include, but are not limited to, the following:
Risks Related to Our Strategy and Industry
The mortgage lending market and the broader financial services industry in which our customers operate are subject to various economic factors (such as rising interest or inflation rates), the deterioration of which would directly affect our performance.
Failure to retain or attract customers, innovate our platform and its capabilities, address technological requirements, or increase brand recognition may limit both growth and profitability.
Opportunities to grow our business may be limited by inability to identify suitable partnerships, acquisitions, or new business opportunities, or to effectively integrate businesses we acquire.
Changing dynamics, such as pricing pressure, new entrants, and customer preferences, within our highly-fragmented and competitive landscape may adversely affect our operations.
Risks Related to Our Business and Operations
Any disruption in the performance or delivery of our software solutions, whether due to security compromises, third-party providers, or other unforeseeable circumstances, could affect brand perception, decrease demand, and subject us to substantial liability.
Integration or implementation challenges could affect the functionality of our software solutions and delay revenue recognition.
Challenges in measuring and tracking key operating metrics could affect our ability to consistently report results over time or develop long-term strategies.
The seasonal and cyclical nature of our business, including our usage and volume-based pricing and sales process, could result in volatility in our operating results.
Failure to retain or expand personnel, including management, sales, marketing, development, and support functions, to sustain our growth and infrastructure or failure to execute any restructuring plan, including realizing

39

the anticipated benefits of such plan, may result in operational disruptions, reduced sales opportunities, and increased expenses.
Our success is dependent on our ability to retain and attract product partners to drive further volume through our platform.
Risks Related to Legal and Regulatory Matters
Failures in data protection, privacy, and information security and intellectual property rights could critically impair our offerings and ability to conduct business.
Failure to comply with laws and regulations as a technology provider to our customers who operate in a highly regulated industry, as well as failure to create solutions that assist our customers to comply with their regulatory requirements, could disrupt our operations and result in significant expense to alter and update our solutions.
Changes in laws and regulations could affect our ability to compete, require us to change our pricing model, or result in additional charges booked to our balance sheet.
Risks Related to Finance and Accounting
Fluctuations in performance and our inability to accurately forecast results may affect our market perception.
Accounting treatments, such as revenue recognition or goodwill impairment, may cause fluctuations in earnings that do not fully reflect the underlying performance of our business.
High levels of indebtedness, as well as the terms of our existing debt, or our inability to effectively access capital markets may restrict our ability to compete, react to changes in our business, and fund future needs.
Changes in applicable tax laws, rules, or regulations could adversely affect our financial position.
Risks Related to Potential Conflicts of Interests and Related Parties
Thoma Bravo holds a controlling stake in our company, and their interests may conflict with ours and those of our other stockholders.
Risks Related to Our Common Stock and Governance Structure
Market conditions, issuances of additional or preferred stock, and payments of dividends may result in dilution or otherwise affect our stockholders’ return on investment.
The consummation, suspension, or termination of our capital allocation strategies, including any stock repurchases, may affect our stock price, stock volatility, or liquidity.
Delaware law and certain provisions in our charter and bylaws could restrict certain strategic activity or limit stockholder actions that may be beneficial or favorable to our stockholders.
Risks Related to Our Strategy and Industry
Mortgage lending volume is expected to be lower in 2023 than it was at the same point in 2020, 2021, or 2022 due to various economic factors, including increased mortgage interest rates, which could adversely affect our business.
Factors that adversely impact mortgage lending volumes include reduced consumer and investor demand for mortgages, more stringent underwriting guidelines, decreased liquidity in the secondary mortgage market, high levels of unemployment, high levels of consumer debt, lower consumer confidence, changes in tax and other regulatory policies, and other macroeconomic factors.
In addition, mortgage interest rates rose from historic lows in 2022, and many economists predict that mortgage interest rates will not fall meaningfully in 2023. Mortgage interest rates are influenced by a number of factors, particularly monetary policy. The Federal Reserve Bank has been raising the Federal funds rate to combat higher than expected inflation in the United States and began reducing its holdings of Fannie Mae and Freddie Mac mortgage-backed securities in the second quarter of 2022, each of which could cause mortgage interest rates to rise further. Further increases in

40

mortgage interest rates could reduce the volume of new mortgages originated, in particular the volume of mortgages refinanced.
The lower levels of residential mortgage loan market volume in 2022 as compared to 2020 and 2021 levels required us to increase either our share of loan volume, our revenues per loan effected through use of our solutions, or both, in order to maintain our financial performance. Any additional decrease in residential mortgage loan market volumes would exacerbate our need to increase either our share of loan volume, our revenues per loan effected through use of our solutions, or both. We cannot assure you that we will be successful in our efforts to increase either our share of loan volume, our revenues per loan effected through use of our solutions, or both, which could materially adversely affect our business.
In addition, increases in interest rates and supply chain shortages for goods subject to financing generally may also negatively impact consumer demand for loans other than mortgages. If demand for non-mortgage loans also decreases as a result of increased interest rates, our business and operating results could be materially adversely affected.
If we fail to increase the number of our customers or retain existing customers, our business may be harmed.
Our growth depends in large part on increasing the number of customers using our software solutions. To attract customers to our solutions, we must convince them that the utility of, and access to, our software solutions can assist them in their digital transformations, help create new revenue streams, and increase engagement with their customers. In particular, we must enhance the features and functionality of our software solutions and convince financial institutions of the benefits of our software solutions and encourage them to switch from competing loan origination, digital lending, and data analytics solutions or to forgo using more traditional processes and procedures, including (with respect to the loan origination business) paper, facsimile, courier, mail, and email processing.
Due to the fragmented nature of the consumer lending (including mortgage) and CRA industries, many industry participants may not be familiar with our software solutions and the benefits of our solutions. Any consolidation in our industry could also decrease our market advantage and may impact our competitive position. Some of our current and potential customers have developed, and may continue to develop, their own proprietary technologies and may one day become our competitors. In particular, some of our customers and potential customers have increasing market share in their respective markets that could be leveraged to introduce, directly or indirectly, alternative solutions to the use of our services in the short term with the potential to replace our solutions within their organizations in the long term. As our customers increase their spend with us, there may be internal pressure to evaluate and potentially create their own internal solutions as a cost-savings measure. We cannot assure you that we will be successful in attracting new customers or retaining existing customers, and increased competition from both competitors and any internal development efforts by our current customers could harm our business.
Additionally, with increased competition, existing customers may decide not to continue to use our software solutions in favor of other alternatives for financial or other reasons. Customer attrition could impact the performance of our business in the future. We have agreements in place with various product partners with respect to the integration between their businesses and our solutions, such as e-signing vendors, insurance providers, dealership integrators, credit card processors, home banking systems, and settlement service tools. Most of these contracts are not long term or are subject to termination rights. An unexpected termination, or a failure to renew, of a significant number of our agreements or relationships with these platform partners could have an adverse effect on our business as our customers may find our solutions less valuable without these integrations. If we lose existing platform partners due to terminations or failures to renew our agreements, we would also lose revenues associated with such platform partners, which could have a material adverse impact on our results of operations and financial condition.
In addition, our recent development efforts have been focused on our cloud-based offerings, and, as a result, we have not invested in upgrading certain legacy products or developing added functionality for them, and may not invest in certain products in the future, including legacy products acquired through past strategic transactions, such as the acquisition of CRIF in 2018. As a result, customers using these legacy products may determine that these legacy offerings no longer satisfy their needs. If we are unsuccessful in transitioning these customers to our newer, cloud-based offerings, these customers may cease doing business with us. Therefore, we must continue to demonstrate to our customers that using our solutions is the most effective and cost-efficient way to maximize their results, and if we are not successful, our business and results of operations could be materially and adversely impacted.

41

We may not accurately predict the long-term rate of customer subscription renewals or adoption of our software solutions, or any resulting impact on our revenues or operating results.
Our customers have no obligation to renew their subscriptions for our software solutions after the expiration of the initial or current subscription term, and our customers, if they choose to renew at all, may renew for shorter subscription terms, or on less favorable usage-based or volume-based pricing terms. Since we have only been tracking our retention rates since November of 2020, we have limited historical data with respect to rates of customer subscription renewals and cannot be certain of anticipated renewal rates. Our renewal rates may decline or fluctuate as a result of a number of factors, including our customers’ satisfaction with our pricing or our software solutions or their ability to continue their operations or spending levels. Strategic acquisitions can further complicate our ability to predict customer subscription renewals. If our customers do not renew their subscriptions for our software solutions on similar pricing terms, our revenues may decline and our business could suffer.
Additionally, as the markets for our solutions develop, or as new or existing competitors introduce new solutions or services that compete with ours, we may experience pricing pressure and be unable to renew our agreements with existing customers, or we may be unable to attract new customers based on the same subscription models that we have used historically or at fee levels that are consistent with our pricing models and operating budget. Moreover, large or influential customers may demand more favorable pricing or other contract terms from us. In addition, our pricing strategy for new solutions may prove to be unappealing to our potential customers, and our competitors could choose to bundle certain solutions and services competitive with ours. If any of these were to occur, we may in the future be required to change our pricing model, reduce our prices, or accept other unfavorable contract terms, any of which could adversely affect our revenues, gross margin, profitability, financial position, cash flow, or growth prospects.
If we cannot continue to innovate our platform and its capabilities or address evolving technological requirements, our software solutions could become obsolete or less competitive and our revenue growth rate may be reduced.
The market for our software solutions is characterized by rapid technological advancements, changes in customer requirements and technologies, frequent new solution introductions and enhancements, and changing regulatory requirements. The life cycles of our software solutions are difficult to estimate. Rapid technological changes and the introduction of new products and enhancements by new or existing competitors or large financial institutions could undermine our current market position. Other means of digital or virtual consumer lending and banking may be developed or adopted in the future, and our software solutions may not be compatible with these new technologies. In addition, the technological needs of, and services provided by, the banks, credit unions, mortgage lenders, specialty lending providers, and CRAs that we endeavor to serve may change if they or their competitors offer new services to account holders. Maintaining adequate research and development resources to meet the demands of the market is essential. The process of developing new technologies and software solutions is complex and expensive. The introduction of new products by our competitors, the market acceptance of competitive products based on new or alternative technologies, or the emergence of new technologies or products in the broader financial services industry could render our solutions obsolete or less effective.
The success of any enhanced or new software solution depends on several factors, including timely completion, adequate testing, and market release and acceptance of the solution. Any new software solutions that we develop or acquire may not be introduced in a timely or cost-effective manner, may contain defects, or may not achieve the broad market acceptance necessary to generate significant revenues. In addition, we must continuously develop, market, and sell new features and functionalities to our existing software solutions that respond to the changing needs of our customers and offer better functionality than competing offerings from other providers. If we are unable to anticipate customer requirements or work with our customers successfully on implementing new software solutions or features in a timely manner or enhance our existing software solutions to meet our customers’ requirements, our business, growth prospects, and operating results may be adversely affected.
If we fail to develop, maintain, and enhance our brands, our ability to expand our business, operating results, and financial condition could be adversely affected.
We believe that maintaining and enhancing the brands associated with our solutions is important to support the marketing and sale of our existing and future solutions to new customers and to increase adoption of our solutions by existing customers. Successfully maintaining and enhancing our brands will depend largely on the effectiveness of our marketing and demand generation efforts, our ability to provide reliable solutions that continue to meet the needs of our customers at competitive prices, our ability to maintain our customers’ trust, our ability to continue to develop new functionality and solutions, and our ability to successfully differentiate our solutions from competitive products and services. Our promotion

42

activities may not generate brand awareness or yield increased revenues, and even if they do, any increased revenues may not offset the expenses we incur in building our brand. If we fail to successfully promote and maintain our brands, our business, operating results, and financial condition could be adversely affected.
We have entered, and may in the future enter into, partnership agreements with third parties for reseller services, which may adversely affect our ability to generate revenues.
We have entered into and may seek to enter into additional collaborations or partnerships with third parties for reseller services. Should we seek to collaborate with a third party with respect to a prospective reseller program, we may not be able to locate a suitable partner or to enter into an agreement on commercially reasonable terms or at all. Even if we succeed in securing partners for reseller services, such as the arrangement we have entered into with Jack Henry & Associates, Inc., we have limited control over the time and resources that our partners may dedicate to such services. These partnerships pose a number of risks, including the following:
partners may terminate our reseller arrangement, may not have sufficient resources, or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus; or
partners may decide to pursue a competitive product developed outside of the collaboration arrangement.
As a result of the foregoing risks and others, partnership agreements may not lead to successful reseller programs. We also face competition in seeking out partners. If we are unable to secure new partnerships that achieve the partner’s objectives and meet our expectations, we may be unable to generate meaningful revenues.
We may acquire or invest in companies, or pursue business partnerships, which could prove difficult to integrate, divert our management’s attention, or dilute stockholder value, and we may be unable to realize the expected benefits of such acquisitions, investments, or partnerships.
From time to time, we consider potential strategic transactions, including acquisitions of, or investments in, businesses, technologies, services, products, and other assets. For example, in November 2022, we acquired OpenClose, a mortgage lending technology provider, with a particular focus on supporting depository institutions, and in April 2022, we acquired StreetShares, a financial technology company that provides digital small business lending technology to banks and credit unions. We may also enter into relationships with other businesses to expand our platform capabilities, which could involve preferred or exclusive licenses, additional channels of distribution, discount pricing, or investments in other companies. Negotiating these transactions can be time-consuming, difficult, and expensive, and our ability to close these transactions may be subject to approvals that are beyond our control. If an acquired business fails to meet our expectations, our operating results, business, and financial position may suffer. We may not be able to find and identify desirable acquisition targets, we may incorrectly estimate the value of an acquisition target, and we may not be successful in entering into an agreement with any particular target. We may not integrate an acquired company smoothly, successfully, or within our budgetary expectations and anticipated timetable. If we are successful in acquiring additional businesses, we may not achieve the anticipated benefits from the acquired business due to a number of factors, including:
our inability to integrate or benefit from developed technologies or services;
unanticipated costs or liabilities associated with the acquisition;
incurrence of acquisition-related costs;
difficulty, including unanticipated delays, costs, or inefficiencies associated with, integrating the operational and compliance policies and practices, technology, accounting systems, operations, and control environments of the acquired business and integrating the acquired business or its employees into our culture;
difficulties and additional expenses associated with supporting legacy products and infrastructure of the acquired business;
difficulty retaining or converting the customers of the acquired business to our software solutions and contract terms, including disparities in subscription terms;
additional costs for the support or professional services model of the acquired company;
diversion of management’s attention and other resources;
adverse effects to our existing business relationships with business partners and customers;

43

the issuance of additional equity securities that could dilute the ownership interests of our stockholders;
incurrence of debt on terms unfavorable to us or that we are unable to repay;
incurrence of substantial liabilities;
difficulties retaining key employees of the acquired business; and
adverse tax consequences, substantial depreciation, or deferred compensation charges.
Accordingly, we may fail to realize some or all of the anticipated benefits of the acquisition, such as increase in our scale, diversification, cash flows, and operational efficiency. In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.
The markets in which we participate are intensely competitive and highly fragmented, and pricing pressure, new technologies, or other competitive dynamics could adversely affect our growth, business, results of operations, and future prospects.
We have experienced growth in recent periods. In future periods, we may not be able to sustain net revenue growth consistent with recent history, or at all. We believe our net revenue growth depends on several factors, including, but not limited to, our ability to add new customers and to expand our existing customers’ usage of our solutions. The markets in which we compete, however, are highly competitive, fragmented, evolving, complex, and defined by rapidly changing technology and customer demands. We currently compete with providers of technology and products in the financial services industry, primarily point solution vendors that focus on building functionality that competes with specific components of our solutions. From time to time, we also compete with systems internally developed by financial institutions.
Many existing and potential competitors enjoy substantial competitive advantages, such as:
larger sales, development, support, and marketing budgets and resources;
the ability to bundle competitive offerings;
greater brand recognition and longer operating histories;
more extensive customer bases and broader customer relationships;
lower labor and development costs;
greater resources to make acquisitions;
larger and more mature intellectual property portfolios; and
substantially greater financial, technical, management, and other resources.
Further, one of our competitors may establish or strengthen a cooperative relationship with, or acquire one or more software application, data analytics, compliance, or network vendors. We may also face competition from new companies entering our markets, which may include large established businesses that decide to develop, market, or resell cloud-based banking technology, acquire one of our competitors, or form a strategic alliance with one of our competitors. In addition, new companies entering our markets may choose to offer cloud-based consumer lending and related products at little or no additional cost to the customer by bundling them with their existing products, including adjacent financial services technologies.
We expect competition to intensify in the future, and these competitive pressures in our markets or our failure to compete effectively may result in fewer customers, increased pricing pressure, reduced revenues and gross profit, increased sales and marketing expenses, and loss of market share. Any failure to meet and address these factors could materially and adversely affect our business, operating results, and financial condition.

44

If the market for cloud-based solutions develops more slowly than we expect or changes in a way that we fail to anticipate, our sales would suffer and our results of operations would be adversely affected.
We do not know whether our prospective customers will continue to adopt cloud-based financial products such as our software solutions or whether the market will change in ways we do not anticipate. Many potential customers have invested substantial personnel and financial resources in legacy software, and these institutions may be reluctant, unwilling, or unable to convert from their existing systems to our solutions. Furthermore, these potential customers may be reluctant, unwilling, or unable to use cloud-based financial solutions due to various concerns such as the security of their data and reliability of the delivery model. These concerns or other considerations may cause prospects to choose not to adopt cloud-based financial products such as ours or to adopt them more slowly than we anticipate, either of which would adversely affect us. Our future success also depends on our ability to sell additional solutions and functionality to our current and prospective customers. As we create new solutions and enhance our existing solutions to meet anticipated market demand, these solutions and enhancements may not be attractive to customers. In addition, promoting and selling new and enhanced functionality may require increasingly costly sales and marketing efforts, and if customers choose not to adopt this functionality our business and results of operations could suffer. If potential customers are unwilling or unable to transition from their legacy systems, or if the demand for our solutions does not meet our expectations, our results of operations and financial condition will be adversely affected.
We derive all of our revenues from customers in the financial services industry, and any downturn or consolidation or decrease in technology spend in the financial services industry could adversely affect our business.
All of our revenues are derived from customers in the financial services industry, an industry which has experienced significant pressure in recent years due to economic uncertainty, low interest rates, liquidity concerns, and increased regulation. In the past, financial institutions have experienced consolidation, distress, and failure. It is possible these conditions may reoccur.
Recently, concerns have arisen with respect to the financial condition of a number of banking organizations in the United States, in particular those with exposure to certain types of depositors and portfolios of investment securities in the face of rapid interest rate increases. In March 2023, after being closed by their respective state authorities, the Federal Deposit Insurance Corporation took control of Silicon Valley Bank and Signature Bank due to liquidity concerns, and a number of other financial institutions experienced turbulence and a precipitous decline in market value. It is possible these conditions may persist, deteriorate or reoccur, and may negatively impact our results of operations and financial condition.
If any of our customers merge with or are acquired by other entities, such as financial institutions that have internally developed technology products or that are not our customers or use our software solutions less, we may lose business. Additionally, changes in management of our customers could result in delays or cancellations of the implementation of our software solutions. Consolidation within the financial services industry could also lead to fewer, but larger customers, who could may have increased bargaining power, which could lead to lower prices or more favorable terms for our customers. Our business may also be materially and adversely affected by weak economic conditions in the financial services industry generally. Any downturn in the financial services industry may cause our customers to reduce or delay their spending on technology or cloud-based financial products or to seek to terminate or renegotiate their contracts with us.
Additionally, a prolonged economic slowdown may result in reduced consumer demands for loans and reduced application volume for credit, employment, tenant, or other forms of screening, which would negatively impact our revenues from existing customers due to the volume-based aspect of our customer agreements. Due to recent levels of inflation, the U.S. Federal Reserve has begun to increase interest rates, which could also reduce consumer demand for loans and materially and adversely impact our business. Moreover, even if the overall economy is robust, economic fluctuations caused by factors such as the U.S. Federal Reserve changing interest rates or otherwise managing market liquidity may cause potential new customers and existing customers to become less profitable and therefore forego or delay purchasing our software solutions or reduce the amount of spend with us, which would also materially and adversely affect our business.

45

Risks Related to Our Business and Operations
Uncertain or weakened economic conditions, including as a result of increasing interest rates, rising inflation, and the COVID-19 pandemic, may continue to heighten many of our known risks and has affected, continues to affect, and may adversely affect our industry, business, and results of operations.
Our overall performance depends on economic conditions, which are beyond our control and may be difficult or impossible to forecast. The United States and other key international economies have experienced significant economic and market downturns and periods of uncertainty, including recently in connection with increasing interest rates, rising inflation, and the COVID-19 pandemic, and are likely to experience additional cyclical downturns from time to time, in which economic activity is impacted by falling demand for a variety of goods and services, restricted credit, poor liquidity, inflation, fluctuations in interest rates, reduced corporate profitability, volatility in credit and equity markets, bankruptcies, and overall uncertainty. Macroeconomic developments can arise suddenly, as did the conditions associated with the COVID-19 pandemic and fluctuating rates of inflation, and the full impact can be difficult to predict. Adverse macroeconomic conditions, including inflation, slower growth or recession, changes to fiscal and monetary policy, tighter credit, higher or fluctuating interest rates, high unemployment, and currency fluctuations have in the past and may in the future adversely impact the rate of technology spending generally and could adversely affect our customers’ ability or willingness to purchase our software solutions, delay prospective customers’ purchasing decisions, reduce the value or duration of their subscriptions or affect renewal rates, or impact the demand for our customers’ services, any of which could adversely affect our results of operations. As a result, our operating results are sensitive to changes in macroeconomic conditions that impact our customers’ technology spending.
COVID-19 has impacted, and may continue to impact, our business operations, employees, customers, their clients, the industries in which our customers operate, partners, suppliers, and communities. We have taken certain measures, and will continue to implement applicable steps, to manage the evolving risks and uncertainties. We moved to a fully remote work-from-home work model in 2020 and plan to continue operating as remote-first. In 2022, we allowed travel for our employees based on business need and some on-site meetings, and, in May 2022, we conducted our first in-person user forum since the COVID-19 pandemic began, and we expect to hold in-person events in 2023, as well, including another user forum. In connection with in-person activity, we implemented safety precautions, including travel and in-person testing requirements.
While we have been operating effectively under our remote work model, and do not foresee it changing, we cannot be certain that a prolonged remote work model will continue to be effective or will not introduce new operational difficulties that could result in harm to our business. Our shift to remote work has caused us to assess our IT security measures, identify any vulnerabilities, and enhance protections against unauthorized access to our network and systems. We cannot guarantee these private work environments and electronic connections to our work environment have the same robust security measures deployed in our physical offices. While we have not yet experienced a network breach or intrusion as a result of moving to a remote work model, we are unable to unequivocally affirm that the protective measures we have taken will remain sufficient given the ever-changing threat landscape, and any such related security compromise that may occur could materially and adversely impact our business, results of operations, or reputation.
We continue to evaluate, and adjust, our hiring plans and investment spending accordingly. We are monitoring the potential effects of changed rate of spending on software solutions, purchasing decisions, delayed payments, and supply chain shortages on our business. To the extent economic volatility, including as a result of the COVID-19 pandemic, adversely affects our business, results of operations, financial condition, or liquidity, many of the other risks described in this “Risk Factors” section may also be heightened.
A breach or compromise of our security measures or those we rely on could result in unauthorized access to or other compromise of customers’ data or customers’ clients’ data, which may materially and adversely impact our reputation, business, and results of operations.
Certain elements of our business and software solutions, particularly our origination and analytics solutions, involve the processing and storage of personally identifiable information, or PII, such as banking information and PII of our customers’ clients. We may also have access to PII during various stages of the implementation process of our solutions or during the course of providing customer support. Furthermore, as we develop additional functionality, we may gain greater access to PII and process additional PII. While we maintain policies, procedures, and technological safeguards designed to protect the confidentiality, integrity, and availability of this information and our information technology systems, we cannot entirely eliminate the risk of improper, unlawful, or unauthorized access to, or disclosure, alteration, corruption,

46

unavailability, or loss of PII or other data that we process or maintain, other security events that impact the integrity or availability of PII or our systems and operations, or the related costs we may incur to mitigate the consequences from certain events such as the following:
third-party social engineering attempts to fraudulently induce our employees, partners, or customers to disclose sensitive information;
malicious intrusions and attacks by individuals or groups of hackers and sophisticated organizations, such as state-sponsored organizations or nation-states, to launch coordinated attacks, such as ransomware and distributed denial-of-service attacks;
cyberattacks on our internally built infrastructure on which many of our solutions operate, or on third-party cloud-computing platform providers;
vulnerabilities resulting from the configuration, implementation, enhancement, or update of our software solutions, as well as in the products or components across the broad ecosystem that our solutions operate in conjunction with and are dependent on;
vulnerabilities or breach of those third-party providers (cloud, software, data center, and other critical technology vendors) security measures or a failure in our third-party providers’ data security procedures, measures, and policies;
vulnerabilities existing within new technologies and infrastructures, including those from acquired companies;
attacks on, or vulnerabilities in, the many different underlying networks and services that power the Internet that our products depend on, most of which are not under our control or the control of our vendors, partners or customers; and
employee or contractor human errors or intentional insider threats that compromise our security systems.
Currently, we mitigate these risks, to the extent possible, by maintaining and enhancing business, privacy, and data governance policies, an information security program, and an incident response and disaster recovery program, as well as participating in third-party audits. Our board of directors formed a cybersecurity committee to delegate oversight of risks in this area, and our board of directors, cybersecurity committee, and executive leadership are briefed at least quarterly on our cybersecurity policies, practices, and efforts, and any cybersecurity events, as appropriate. When engaging third-party providers, we assess their policies and procedures relating to cybersecurity and privacy. In addition, we anticipate expending increasing expenses and other resources in an effort to identify, prevent, and respond to actual or potential security breaches. Although we have developed systems and processes designed to protect our customers’ clients’ sensitive data, we can provide no assurances that such measures will provide absolute security or that a material breach will not occur. Mitigation efforts may be impacted by factors such as:
changes to, and complexity of, techniques used to breach, obtain unauthorized access to, or sabotage IT systems and infrastructure, which generally are not identified until after an initial launch against a target, resulting in a reduced ability to anticipate or implement adequate preventive measures;
continued refinement, updating, and replacement of our internal systems and technology, particularly when adopting new technologies and new methods of sharing data and communicating internally and with customers and partners;
the acquisition of new companies and their solutions, requiring us to integrate, improve, and secure different or more complex IT environments and technologies;
authorization by our customers to third-party technology providers to access their clients’ data, which may lead to our customers’ inability to protect their data that is stored on our servers;
our limited control over our customers or third-party technology providers, or the processing of data by third-party technology providers, which may not allow us to maintain the integrity or security of such transmissions or processing; and
increased risk of security compromises associated with our employees working remotely, as they have since the beginning of the COVID-19 pandemic.
A security breach or compromise could result in operational disruptions, loss, compromise, unauthorized use of, or access to, alteration, or corruption of customer data or customers’ client data or data we rely on to provide our software solutions,

47

including our analytics initiatives and offerings, that impair our ability to provide our software solutions and meet our customers’ requirements. Such impairment would result in decreased revenues and otherwise materially negatively impact our financial results. Also, the occurrence, or perception of an occurrence, of any of these events could results in a loss of confidence in the security of our services, irreparable reputational damage, a decline in current and prospective customer use of our software solutions, business disruptions, increases in cybersecurity insurance premiums, and allocation of significant financial and operational resources in response, including repairing system damage, increasing security protection costs by deploying additional personnel and protection technologies, and defending against and resolving legal and regulatory claims and proceedings. The detection, prevention and remediation of known or potential security vulnerabilities, including those arising from third-party hardware or software, may result in additional financial burdens due to additional direct and indirect costs, such as additional infrastructure capacity spending to mitigate any system degradation and the reallocation of resources from development activities. Furthermore, data security breaches and compromises could expose us to legal, regulatory, and financial exposure and liability, notification requirements, third-party claims and lawsuits, indemnification, or other claims from customers and other third parties, regulatory investigations or proceedings, fines, or other actions or liabilities, which could materially and adversely affect our business and results of operations. In addition, some of our customers contractually require notification of data security breaches or compromises and include representations and warranties in their contracts with us that our software solutions comply with certain legal and technical standards related to data security and privacy and meets certain service levels. In certain of our contracts, a data security breach or compromise or operational disruption impacting us or one of our vendors, or system unavailability or damage due to other circumstances, may constitute a material breach and give rise to a customer’s right to terminate their contract with us or may cause us to be liable for certain monetary penalties, including as a result of a failure to meet service level agreements.
As of the date of this Quarterly Report on Form 10-Q, we have not experienced any material impact to the business or operations resulting from information or cybersecurity attacks; however, because of the frequently changing nature of attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for us to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm, as well as financial costs and regulatory action. We maintain cybersecurity insurance in the event of an information security or cyber incident, however, the coverage may not be sufficient to cover all financial losses. In these circumstances, it may be difficult or impossible to cure such a breach or compromise in order to prevent customers from potentially terminating their contracts with us. Furthermore, although our customer contracts typically include limitations on our potential liability, there can be no assurance that such limitations of liability would be adequate. We also cannot be sure that our existing general liability insurance coverage and coverage for errors or omissions will be available on acceptable terms or in sufficient amounts to cover one or more claims or that our insurers will not deny or attempt to deny coverage as to any future claim. The successful assertion of one or more claims against us, the inadequacy or denial of coverage under our insurance policies, litigation to pursue claims under our policies, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or coinsurance requirements, could materially and adversely affect our business and results of operations.
Defects, errors, or other performance problems in our software solutions could harm our reputation, result in significant costs to us, impair our ability to sell our software solutions, and subject us to substantial liability.
Our software solutions are complex and may contain defects, viruses, or errors when implemented or when new functionality is released. Such defects or disruptions could be the result of undetected vulnerabilities in third-party supplied software and technologies, bug fixes or upgrades, whether in connection with day-to-day operations or otherwise, or employee, contractor, or other third-party acts or inaction. Despite extensive testing, from time to time we have discovered, and may in the future discover, defects or errors in our software solutions. We may experience temporary system interruptions, either to our solutions as a whole, individual software solutions or groups thereof, or to some or all of our software hosting locations, for a variety of reasons, including network failures, power failures, software errors, or an overwhelming number of users trying to access our software solutions during periods of strong demand. Defects, errors, or other performance problems or disruptions in our software solutions or service could be costly for us, damage our customers’ businesses, result in loss of credibility with current or potential customers or partners, and harm our reputation, any of which could result in a material adverse effect on our business, operating results, and financial condition. In addition, our customers could seek to terminate their contracts, elect not to renew their subscriptions, delay or withhold payment, or make claims against us.
Because we are dependent on third parties for the implementation and maintenance of certain aspects of our systems and because some of the causes of system interruptions may be outside of our control, we may not be able to remedy such interruptions in a timely manner, if at all. As we rely heavily on our servers, computer, and communications systems and

48

the Internet to conduct our business, any of these actions could result in liability, lost business, increased insurance costs, difficulty in collecting accounts receivable, costly litigation, or adverse publicity. Errors, defects, or other problems could also result in reduced sales or a loss of, or delay in, the market acceptance of our software solutions.
If we are unable to effectively integrate our software solutions with other systems, products, or other technologies used by our customers and prospective customers, or if there are performance issues with such third-party systems, products, or other technologies, our software solutions will not operate effectively and our operations will be adversely affected.
The functionality of our software solutions depends on our ability to integrate with other third-party systems, products, and other technologies used by our customers. Certain providers of these third-party systems, products, or other technologies also offer products that are competitive with our software solutions. These products may have an advantage over ours if customers using their software are better able to integrate with their own software. In addition, these third-party providers may be able to bundle their competitive products with other applications used by our customers and prospective customers at favorable pricing.
In addition, some of our competitors may be able to disrupt the operations or compatibility of our solutions with their products or services or exert strong business influence on our ability to, and terms on which we, provide our solutions. For example, core banking system companies provide critical back-end services to financial institutions. If these core banking system companies seek to compete with us in the markets we target or make it more difficult for us to integrate our solutions with their offerings, our business and results of operations could be materially and adversely affected. We do not have formal arrangements with many of these third-party providers regarding our access to their APIs to enable these customer integrations.
Our business may be harmed if any of our third-party providers:
change the features or functionality of their applications and platforms in a manner adverse to us;
discontinue or limit our software solutions’ access to their systems or other technologies;
terminate or do not allow us to renew or replace our existing contractual relationships on the same or better terms;
modify their terms of service or other legal terms or policies, including fees charged to, or other restrictions on, us or our customers;
establish exclusive or more favorable relationships with one or more of our competitors, or acquire one or more of our competitors and offer competing services; or
otherwise have or develop their own competitive offerings.
Third-party services and products are constantly evolving. We may not be able to modify our solutions to assure compatibility with that of other third parties as they continue to develop or emerge in the future or make such modifications in a timely and cost-effective manner. Such changes could limit or prevent us from integrating our software solutions with these third-party systems, which could impair the functionality of, prohibit the use of, or limit our ability to sell our software solutions to customers. If we are not permitted or able to integrate with such third-party technologies as a result of changes to, or third parties restricting our access to, the technologies during the terms of existing customer agreements, we may not be able to meet our contractual obligations to customers who use such third-party software. Should any of our competitors modify their products or standards in a manner that degrades the functionality of our solutions or gives preferential treatment to our competitors or competitive products, whether to enhance their competitive position or for any other reason, the interoperability of our products with these products could decrease, and our business, results of operations, and financial condition would be harmed. In addition, if any third-party technology providers experience an outage, our software solutions integrated with such technology will not function properly or at all, and our customers may be dissatisfied with our software solutions. If the technology of such third-party providers has performance or other problems, such issues may reflect poorly on us, and the adoption and renewal of our software solutions and our business may be harmed. Although our customers may be able to switch to alternative technologies if a provider’s services were unreliable or if a provider were to limit such customer’s access and utilization of its data or the provider’s functionality, our business could nevertheless be harmed due to the risk that our customers could reduce their use of our software solutions.

49

As the number of customers that we serve increases, we may encounter implementation challenges, and we may have to delay revenue recognition for some complex engagements, which would harm our business and operating results.
We may face unexpected implementation challenges related to the complexity of our customers’ implementation and integration requirements. Our implementation expenses increase when customers have unexpected data, integrations, hardware, or software technology challenges or complex or unanticipated business requirements. In addition, certain of our customers require complex acceptance testing related to the implementation of our software solutions. Further, because we do not fully control our customers’ implementation schedules, implementation issues may occur if our customers do not allocate the internal resources necessary to meet implementation timelines or if there are unanticipated implementation delays. Any difficulties or delays in implementation processes could cause customers to delay or forego future purchases of our software solutions or require us to delay revenue recognition under the related customer agreement longer than expected, either of which would adversely affect our business, operating results, and financial condition.
If we fail to meet our service level commitments, we could be obligated to provide credits or refunds or face contract terminations, which could adversely affect our business, operating results, and financial condition.
Certain of our agreements with our customers contain service level commitments. If we are unable to meet the stated service level commitments or suffer extended periods of unavailability for our solutions, we may be contractually obligated to provide these parties with service credits or refunds. In addition, we could face contract terminations, in which case we would be subject to a loss of future revenues. Our revenues could be significantly affected if we suffer unexcused downtime under our agreements with our customers and partners. Further, any extended service outages could adversely affect our reputation, revenues, and operating results.
Certain of our key operating metrics are subject to inherent challenges in measurement, and real or perceived inaccuracies in such metrics may harm our reputation and negatively affect our business.
We track certain key operating metrics using internal tools, which have certain limitations. In addition, we rely on data received from third parties, including industry forecast reports, to track certain performance indicators. We have only a limited ability to verify data from both of these sources. Our methodologies for tracking metrics may also change over time, which could result in changes to the metrics we report. If we under count or over count performance due to the internal tools we use or issues with the data received from third parties, or if our internal tools contain errors, the data we report may not be accurate or comparable with prior periods. In addition, limitations, changes or errors with respect to how we measure data may affect our understanding of certain details of our business, which could affect our longer-term strategies.
If our performance metrics are not, or are not perceived to be, accurate representations of our financial or operational performance, if we discover material inaccuracies in our metrics, or if we can no longer calculate any of our key performance metrics with a sufficient degree of accuracy and cannot find an adequate replacement for the metric, our business, operating results, and financial condition could be adversely affected.
Our usage and volume-based pricing can cause revenue fluctuation and may adversely affect our business and operating results.
Our customer relationships are generally conducted in accordance with the terms of multi-year contracts that, among other things, may provide for minimum purchases and specified levels of pricing based on the volume of loans, applications, or searches conducted or processed during the applicable billing period. These contractual features are key determinants of profitability. Certain of our contracts provide for contractually scheduled price changes. From time to time, we also negotiate pricing or other changes with our existing customers that include, but are not limited to, extending or renewing a contract or adjusting minimum volumes. Our usage and volume-based pricing, which is seasonal and cyclical, can cause our revenues to fluctuate which could affect our business. Additionally, our usage and volume-based pricing can be negatively impacted by macroeconomic trends, which may disproportionately impact our revenues and operating results.
We depend on satisfied customers to succeed and, in certain instances, have aligned our financial goals with those of our customers. Our historical contracts are subject to de minimis minimum commitments with certain of our customers, who may be less willing or able to accommodate modifications to our contracts given their own business constraints. Such minimum commitment obligations may not be cost-effective or provide positive returns.

50

Our sales cycle can be unpredictable, time-consuming, and costly, which could harm our business and operating results.
Our sales process involves educating prospective customers and existing customers about the use, technical capabilities, and benefits of our software solutions. Prospective customers often undertake a prolonged evaluation process, which typically involves not only our software solutions but also those of our competitors, and typically lasts from six to nine months or longer. We may spend substantial time, effort, and money on our sales and marketing efforts without any assurance that our efforts will produce any sales. It is also difficult to predict the level and timing of sales opportunities that come from our referral partners. Events affecting our customers’ businesses may occur during the sales cycle that could affect the size or timing of a purchase, contributing to more unpredictability in our business and operating results. As a result of these factors, we may face greater costs, longer sales cycles, and less predictability in the future.
If we fail to effectively expand our sales and marketing capabilities and teams, including through partner relationships, we may not be able to increase our customer base and achieve broader market acceptance of our software solutions.
While we expect to continue to grow headcount in our sales and marketing teams over the long-term, in February 2023, we authorized a workforce reduction impacting approximately 9% of our workforce. We may be unable to effectively manage the organizational changes we are making in connection with the Restructuring Plan (as defined below), which could result in declines in quality or customer satisfaction, increases in costs, difficulties in obtaining new customers, difficulty in introducing new solutions to our existing customers, reputational harm, loss of customers, or operational difficulties in executing sales strategies, any of which could adversely affect our business performance and operating results.
Increasing our customer base and achieving broader market acceptance of our software solutions will depend on our ability to expand the abilities of our sales and marketing organizations to obtain new customers and sell additional solutions and services to existing customers. We believe there is significant competition for direct sales and marketing professionals with the skills and knowledge that we require, and we may be unable to hire or retain sufficient numbers of qualified individuals in the future. Our ability to achieve significant future revenue growth will depend on our success in recruiting, training, and retaining a sufficient number of direct sales professionals. New hires require significant training and time before they become fully productive and may not become as productive as quickly as we anticipate. As a result, the cost of hiring and carrying new representatives cannot be offset by the revenues they produce for a significant period of time. Our growth prospects will be harmed if our efforts to expand, train, and retain our direct sales team do not generate a corresponding significant increase in revenues. Additionally, if we fail to sufficiently invest in our marketing programs or they are unsuccessful in creating market awareness of our company and software solutions, our business may be harmed, and our sales opportunities may be limited.
In addition to our direct sales team, we also extend our sales distribution through formal and informal relationships with referral and reseller partners. While we are not substantially dependent upon referrals from any partner, our ability to achieve significant revenue growth in the future will depend upon continued referrals from our partners and growth of the network of our referral partners. These partners are under no contractual obligation to continue to refer business to us, nor do these partners have exclusive relationships with us and may choose to instead refer potential customers to our competitors. We cannot be certain that these partners will prioritize or provide adequate resources for promoting our software solutions or that we will be successful in maintaining, expanding, or developing our relationships with referral partners. Our competitors may be effective in providing incentives to third parties, including our partners, to favor their software products or prevent or reduce subscriptions to our software solutions, either by disrupting our relationship with existing customers or limiting our ability to win new customers. Establishing and retaining qualified partners and training them with respect to our software solutions requires significant time and resources. If we are unable to devote sufficient time and resources to establish and train these partners or if we are unable to maintain successful relationships with them, we may lose sales opportunities and our revenues could suffer.
Our product partners may change their dependence on our system for providing service to their customers, which could harm our business and operating results.
Our continued success will depend in part on our ability to retain a number of key product partners. In addition, we believe that our future success will depend in large part on our ability to attract product partners who utilize our system to service their customers, driving further volumes through our platform. Value associated with our platform is derived from the ability of our customers to access these product partners through our solutions. There can be no assurance that we will be successful in attracting and retaining such partners. The loss of certain key product partners or our inability to attract or

51

retain other product partners could have a material adverse effect on our business, operating results, and financial condition.
If we fail to offer high-quality customer support, or if our support is more expensive than anticipated, our business and reputation could suffer.
Our customers rely on our customer support services to resolve issues and realize the full benefits provided by our solutions. High-quality support is also important to maintain and drive further adoption by our existing customers. We primarily provide customer support over the phone, chat, and via web portal. If we do not help our customers quickly resolve issues and provide effective ongoing support or if our support personnel or methods of providing support are insufficient to meet the needs of our customers, our ability to retain customers, increase adoption by our existing customers, and acquire new customers could suffer, and our reputation with existing or potential customers could be harmed. If we are not able to meet the customer support needs of our customers during the hours that we currently provide support, we may need to increase our support coverage and provide additional support, which may reduce our profitability.
We may not achieve some or all of the expected benefits of our restructuring plans, and the restructuring may adversely affect our business.
We have undertaken, and may undertake in the future, restructuring, reorganization, or other strategic changes in order to adapt our business to serve customers more effectively, align teams with the Company’s highest business priorities, achieve operating efficiencies, and realign our cost structure, including the Restructuring Plan approved in February 2023. Implementation of any restructuring plan may be costly and disruptive to our business, and we may not be able to obtain the anticipated cost savings, operational improvements, and estimated workforce reductions within the projected timing or at all. Further, we may experience a loss of continuity, loss of accumulated knowledge and/or inefficiency, adverse effects on employee morale, and/or key or other retention issues during transitional periods. Restructuring can require a significant amount of time and focus, which may divert attention from operating and growing our business. For more information about our Restructuring Plan, see Note 12 to our Consolidated Financial Statements in Item 1.
We depend on key and highly skilled personnel to operate our business, and if we are unable to retain our current personnel or hire additional personnel, our ability to develop and successfully market our business could be harmed.
We believe our future success will depend in large part upon our ability to attract and retain highly skilled managerial, technical, finance, creative, and sales and marketing personnel. Moreover, we believe that our future success is highly dependent on the contributions of our executive officers. All of our officers and other employees are at-will employees, which means they may terminate their employment relationship with us at any time, and their knowledge of our business and industry would be extremely difficult to replace. In addition, the loss of any key employees or the inability to attract or retain qualified personnel could delay the development and introduction of, and harm our ability to sell, our software solutions and harm the market’s perception of us. The workforce reduction we implemented as part of our Restructuring Plan may also adversely impact our ability to attract, integrate, retain, and motivate highly qualified employees, and may harm our reputation with current or prospective employees. Qualified individuals are in high demand, and we may incur significant costs to attract them. We may be unable to attract and retain suitably qualified individuals who are capable of meeting our growing sales, operational, and managerial requirements, or may be required to pay increased compensation in order to do so. Furthermore, although we believe a remote-first work model will help us attract and retain talent across a broad geographic base, a remote work environment could, among other things, negatively impact company culture, employee morale, and productivity, inhibit our ability to hire and train new employees, and impede our ability to support customers at the levels they expect. If we are unable to attract and retain the qualified personnel we need to succeed, our business will suffer.
Volatility or lack of performance in our stock price may also affect our ability to attract and retain our key employees. Certain of our employees have become, or will soon become, vested in a substantial amount of stock options. Employees may be more likely to leave us if the shares they own or the shares underlying their vested options have significantly appreciated in value relative to the original purchase prices of the shares or the exercise prices of the vested options, or if the exercise prices of the options that they hold are significantly above the market price of our common stock. If we are unable to retain or find a suitable replacement for our named executive officers or other key employees, our business will be harmed.

52

Growth may place significant demands on our management and our infrastructure.
Our growth has placed, and may continue to place, significant demands on our management and our operational and financial infrastructure. As our operations grow in size, scope, and complexity, we will need to improve and upgrade our systems and infrastructure to offer an increasing number of customers enhanced software solutions, features, and functionality. The expansion of our systems and infrastructure will require us to commit substantial financial, operational, and technical resources in advance of an increase in the volume of business, with no assurance that the volume of business will increase. To support our growth, we must also continue to improve our management resources and our operational and financial controls and systems, and these improvements may increase our expenses more than anticipated and result in a more complex business. Continued growth could also strain our ability to maintain reliable service levels for our customers and recruit, train, and retain highly skilled personnel.
Managing our growth will require significant expenditures and allocation of valuable management resources. If we fail to achieve the necessary level of efficiency in our organization as it grows, our business would be harmed.
We depend on data centers operated by third parties and third-party Internet hosting providers, and any disruption in the operation of these facilities or access to the Internet could adversely affect our business.
While the majority of our customers have been migrated to cloud-based solutions like Microsoft Azure and Amazon Web Services, we continue to serve a small subset of our customers from two third-party data center hosting facilities located in Lone Mountain, Nevada and Atlanta, Georgia. The third-party owners and operators of these current and future facilities do not guarantee that our customers’ access to our software solutions will be uninterrupted, error-free, or secure. We may experience website disruptions, outages, and other performance problems at third-party data centers. These problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks (including ransomware attacks), fraud, spikes in customer usage, and denial of service issues. In some instances, we may not be able to identify the cause or causes of these performance problems within an acceptable period of time. Data center facilities are vulnerable to damage or interruption from human error, intentional bad acts, power loss, hardware failures, telecommunications failures, fires, wars, terrorist attacks, floods, earthquakes, hurricanes, tornadoes, or similar catastrophic events. They also could be subject to break-ins, computer viruses, sabotage, intentional acts of vandalism, and other misconduct. The occurrence of a natural disaster or an act of terrorism, a decision to close the facilities without adequate notice or terminate our hosting arrangement or other unanticipated problems could result in lengthy interruptions in the delivery of our software solutions, cause system interruptions, prevent our customers’ account holders from accessing their accounts online, cause reputational harm and loss, corruption, or unavailability of critical data, prevent us from supporting our software solutions, or cause us to incur additional expense in arranging for new facilities and support.
We also depend on third-party Internet-hosting providers and continuous and uninterrupted access to the Internet through third-party bandwidth providers to operate our business. As we continue to expand the number of our customers and available solutions, we may not be able to scale our technology to accommodate the increased capacity requirements, which may result in interruptions or delays in service. In addition, the failure of data centers, Internet service providers, or other third-party service providers to meet our capacity requirements could result in interruptions or delays in access to our solutions or impede our ability to grow our business and scale our operations. If our third-party infrastructure service agreements are terminated, if there is a service lapse, interruption of Internet service provider connectivity, or damage to data centers, or if we experience a service loss or disruption of one or more of our Internet-hosting or bandwidth providers for any reason, such as viruses, denial of service, ransomware, cybersecurity attacks or other attacks on their systems, human error, intentional bad acts, power loss, hardware failures, telecommunications failures, fires, wars, terrorist attacks, floods, earthquakes, hurricanes, tornadoes, or other catastrophic events, we could experience disruption in our ability to offer our software solutions and adverse perception of our software solutions’ reliability. We could also be required to retain the services of replacement providers, which could cause interruptions in access to our solutions as well as delays and additional expense in arranging new facilities and services and could also increase our operating costs and harm our business and reputation. Additionally, any need to change Internet-hosting service providers would require a significant amount of time and effort by our information technology department.

53

The recent transition of our software solutions to the public cloud could present significant risks and uncertainties unique to such a migration, which could adversely affect our business and operations.
We recently completed the transition of all our software solutions to the public cloud. This migration could introduce future risks associated with data and services migration that could affect our business continuity, result in loss, corruption, or compromise of data, and impact the provision of our software solutions. Further, the success in transitioning to the public cloud is dependent on our ability to effectively align, prioritize, and allocate our information technology, information security, product, and other resources to balance the needs of maintaining our existing infrastructure, while also innovating in future products and features and ensuring security and resiliency.
While we expect the transition to allow for greater scalability, security, and integration, if this planned transition impacts the reliability and availability of our software solutions, we may not realize our financial and strategic objectives. In addition, any unanticipated interruption, delay, or degradation in the performance and delivery of our solutions could negatively impact our customer relationships. Accordingly, any such delays, errors, or difficulties may result in operational challenges, security failures, increased costs, or reputational harm, any of which could materially adversely impact our profitability and operations.
Because our services are complex and incorporate a variety of hardware, proprietary software, and third-party software, our services may have errors or defects that could result in unanticipated downtime for our customers and harm to our reputation and our business. Cloud services frequently contain undetected errors when first introduced or when new versions or enhancements are released. We have from time to time found defects in, and experienced disruptions to, our services, and new defects or disruptions may occur in the future. Such defects could also create vulnerabilities that could inadvertently permit access to protected customer data.
We have a significant portion of our product development operations in India, which poses risks.
We have used, and intend to continue to use, unrelated third parties to provide us with technology development services, through individuals based in India. We have increased the amount of our product development work performed by contractors in India to expand our access to additional resources so we can meet the needs of our increased development efforts. However, we may not achieve the cost savings and other benefits we anticipate from these programs, and we may not be able to find sufficient numbers of developers with the necessary skill sets in India to meet our needs. While our experience to date with our India-based contractors has been positive, there is no assurance that this will continue. Specifically, there are a number of risks associated with this activity, including, but not limited to, the following:
communications and information flow may be less efficient and accurate as a consequence of the time and distance differences between our primary development organization and the foreign-based activities, resulting in delays in development or errors in the software developed;
in addition to the risk of misappropriation of intellectual property from departing personnel, there is a general risk of the potential for misappropriation of our intellectual property that might not be readily discoverable;
the ability to obtain fulsome rights to intellectual property arising from the work performed by India-based individuals may be more difficult than it is with respect to intellectual property arising from work performed for us by our U.S.-based employees;
the quality of the development efforts undertaken offshore may not meet our requirements, including due to experiential differences, resulting in potential product errors and/or delays;
currency exchange rates could fluctuate and adversely impact the cost advantages intended from maintaining these relationships; and
as would be the case with any of our third-party developers, if those based in India were to leave their employment or if the third-party development services agreement with us were terminated, we would lose some short-term development capacity, and while we believe we would still be able to continue maintaining and improving all of our service offerings, we would need to expend resources and management time to on-board additional development resources.
In addition, as a result of the foregoing arrangements, we have a heightened risk exposure to changes in the economic, security, and political conditions of India. India has also been affected by the pandemic and taken measures to try to contain it, at times resulting in disruptions to their work force and slowdowns in certain deliverables. Economic and political instability, military actions, and other unforeseen occurrences in India could impair our ability to develop and

54

introduce new software applications and functionality in a timely manner, which could put our products at a competitive disadvantage whereby we lose existing customers and/or fail to attract new customers.
Risks Related to Legal and Regulatory Matters
Any future litigation against us could damage our reputation and be costly and time-consuming to defend.
We have in the past and may become in the future subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by our customers in connection with commercial disputes or employment claims made by current or former employees. In other instances, our customers become involved in litigation where we are required to provide information pursuant to a court order, subpoena, or customer request. From time to time, we also may initiate litigation to enforce our rights, including with respect to payments that we are owed. Litigation could result in reputational damage and substantial costs and may divert management’s attention and resources, any of which may adversely impact our business, overall financial condition, and results of operations and affect the value of our common stock. While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise. We are not currently aware of any material pending or threatened litigation against us but can make no assurances the same will continue to be true in the future.
If we are unable to protect our intellectual property, our business could be adversely affected.
We rely on a combination of copyrights, trademarks, service marks, patents and trade secret laws, confidentiality obligations, and other contractual restrictions to establish and protect our intellectual property and other proprietary rights. Despite our efforts, these protections may be limited and may not adequately permit us to gain or keep any competitive advantage. Unauthorized third parties may try to copy or reverse engineer our solutions, technology, systems, methods, processes, or proprietary information. A third party may develop software solutions, adopt trade names or domain names, or acquire other intellectual property and proprietary rights similar to ours, thus diluting or diminishing the value of our intellectual property, proprietary rights, and overall brand. Our ability to assert our intellectual property rights against potential competitors or to settle current or future disputes could be limited by our agreements with third parties. Our patents may be invalidated or circumvented. A patent application may not be issued with the claim scope we seek, if at all. In addition, the laws of some countries do not provide the same level of intellectual property protection as U.S. laws and courts.
We may be required to spend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. We may also allow certain of our registered intellectual property rights, or our pending applications or registrations for intellectual property rights, to lapse or to become abandoned if we determine that obtaining or maintaining the applicable registered intellectual property rights is not worthwhile. Our inability to protect our intellectual property against unauthorized copying or use, as well as any costly litigation or diversion of our management’s attention and resources, could delay sales or the implementation of our software solutions, impair the functionality of our software solutions, delay introductions of new software solutions, result in our substituting less-advanced or more-costly technologies into our software solutions, or harm our reputation. In addition, should any of our protections fail, we may be required to license additional intellectual property from third parties to develop and market new software solutions, and we cannot ensure that we could license that intellectual property on commercially reasonable terms or at all.
We use open source software in our solutions, which could subject us to litigation or other actions, or otherwise negatively affect our ability to sell our solutions.
Our solutions incorporate software modules licensed to us by third-party authors under “open source” licenses. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide support, warranties, indemnification, or other contractual protections regarding infringement claims or the quality of the code. In addition, the public availability and unknown vulnerabilities of such software may make our solutions more susceptible to compromise. The terms of many open source licenses have not been interpreted by U.S. or foreign courts, and there is a risk that these licenses could be construed in a way that imposes unanticipated conditions or restrictions on our ability to provide or distribute our solutions.

55

We could become subject to lawsuits by parties claiming ownership of what we believe to be open source software. If we are held to have breached or failed to fully comply with all the terms and conditions of an open source software license, we could face infringement or other liability, or be required to seek costly licenses from third parties, to re-engineer our solutions, to discontinue or delay the provision of our offerings if re-engineering could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, financial condition, and results of operations. Although we monitor our use of open source software to avoid subjecting our solutions to unintended conditions, such use may require us to take remedial action that may divert resources away from our development efforts and could materially adversely affect our business.
Lawsuits by third parties against us or our customers for alleged infringement of the third parties’ proprietary rights or for other intellectual property-related claims relating to our solutions or business could result in significant expenses and harm our operating results.
Our industry is characterized by the existence of a large number of patents, copyrights, trademarks, trade secrets, and other intellectual property and proprietary rights, along with frequent litigation based on allegations of infringement or other violations of intellectual property rights. We have been, and, from time to time, expect to be involved in disputes related to patent and other intellectual property rights of third parties. To date, none of these disputes have resulted in material liabilities. Our business could be adversely affected by any significant disputes between us and our customers as to the applicability or scope of our indemnification obligations to them. There can be no assurances that any existing limitations of liability provisions in our contracts would be enforceable or adequate or would otherwise protect us from any such liabilities or damages with respect to any particular claim. If such claims are successful, or if we are required to indemnify or defend our customers from these or other claims, these matters could be disruptive to our business and management, result in material liabilities, and have an adverse effect on our business, operating results, and financial condition.
From time to time, we have received, and may continue to receive, threatening letters or notices or, in the future, may be the subject of claims that our software solutions and underlying technology infringe or otherwise violate the intellectual property rights of others, and we may be found to be infringing upon or otherwise violating such rights. We also face, from time to time, trade name or trademark or service mark infringement claims brought by owners of other registered or unregistered trademarks or service marks, including trademarks or service marks that may incorporate variations of our brand names. In addition, the risk of patent litigation has been amplified by the increase in the number of patent holding companies or other adverse patent owners that have no relevant product revenues, and therefore, our existing patent and any patents we may obtain in the future may provide little or no deterrence as we would not be able to assert them against such entities or individuals. Any claims or litigation could cause us to incur significant expenses and, if successfully asserted against us or our customers whom we indemnify, could subject our technologies to injunction preventing us from accessing such third-party intellectual property rights, require that we pay substantial damages or ongoing royalty payments, prevent us from offering our software solutions, or require that we comply with other unfavorable terms. Even if the claims do not result in litigation or are resolved in our favor, these claims and the time and resources necessary to resolve them could divert the resources of our management and harm our business and operating results. Any claims related to our intellectual property or customer confusion related to our solutions could damage our reputation and adversely affect our growth prospects.
Any use of our solutions by our customers in violation of legal or regulatory requirements could damage our reputation and subject us to additional liability.
If our customers or their clients use our solutions in violation of regulatory requirements and applicable laws, we could suffer damage to our reputation and could become subject to claims in connection with their use of our solutions. We rely on our customers’ contractual obligations that their use and their clients’ use of our solutions will comply with applicable laws. However, we do not audit our customers or their clients to confirm compliance. Even if claims asserted against us do not result in liability, we may incur costs in investigating and defending against such claims. If we are found liable in connection with our customers’ or their clients’ activities, we could incur liabilities and be required to redesign our solutions or otherwise expend resources to remedy any damages caused by such actions and to avoid future liability.

56

Privacy, information security, and data protection concerns, data collection and transfer restrictions, and related domestic regulations may limit the use and adoption of our software solutions and adversely affect our business and results of operations.
The regulatory framework governing privacy, information security, data protection, and the collection, processing, storage, and use of certain information, particularly financial and other personally identifiable information, is rapidly evolving. We expect that there will continue to be new proposed and adopted laws, regulations, and industry standards concerning privacy, data protection, and information security in the United States. For example, California enacted the California Consumer Privacy Act, or CCPA, which went into effect in January 2020 and, among other things, requires companies covered by the legislation to provide new disclosures to California consumers and afford such consumers new rights of access and deletion for personal information, as well as the right to opt-out of collection of their data and certain sales of personal information. Additionally, on November 3, 2020, the California Privacy Rights Act (“CPRA”), was approved by California voters. The CPRA amends and expands the CCPA and went into effect January 1, 2023. The CCPA and the CPRA has required us to modify and augment our practices and policies and incur substantial costs and expenses in an effort to comply or respond to further changes to laws or regulations.
We cannot yet fully determine the impact these or future laws, rules, and regulations may have on our business or operations. Any such laws, rules, and regulations may be inconsistent among different jurisdictions, subject to new or differing interpretations, or conflict with our current or future practices. Additionally, we may be bound by contractual requirements applicable to our collection, use, processing, and disclosure of various types of information, including financial and PII, and may be bound by, or voluntarily comply with, self-regulatory or other industry standards relating to these matters that may further change as laws, rules, and regulations evolve. Any failure or perceived failure by us, our third-party service providers, or any other third parties with which we do business, to comply with these laws, rules, and regulations, or with other obligations to which we or such third parties are or may become subject, may materially and adversely affect our business and results of operations, and result in reputational harm, governmental investigations and enforcement actions, litigation, claims, fines and penalties, or adverse publicity.
Additionally, if in the future we seek to sell our solutions outside of the United States, we would face similar or potentially more stringent laws and regulations relating to personal privacy, information security, and data protection and we cannot be certain we would be able to adequately address these laws and regulations as part of any international expansion without incurring substantial costs and expenses to comply.
Our customers are highly regulated and subject to a number of challenges and risks. Our failure to comply with laws and regulations applicable to us as a technology provider to financial institutions could adversely affect our business and results of operations, increase costs, and impose constraints on the way we conduct our business.
Our customers and prospective customers are highly regulated and are generally required to comply with stringent regulations in connection with performing business functions that our software solutions address. As a provider of technology to financial institutions, and as a result of obligations under some of our customer contracts, we are required to comply with certain provisions of the Gramm-Leach-Bliley Act, or GLBA, related to the privacy and security of certain consumer information, in addition to other contractual obligations that relate to our customers’ obligations under the GLBA and other laws and regulations to which they are subject, including, but not limited to, state privacy laws and regulations. We also may be subject to other laws and regulations, including those relating to privacy and data security, due to the software solutions we provide to financial institutions.
Matters subject to review and examination by federal and state regulatory agencies and external auditors include our internal information technology controls in connection with our performance of data processing services, the agreements giving rise to those processing activities, and the design of our software solutions. Any inability to satisfy these examinations and maintain compliance with applicable regulations could adversely affect our ability to conduct our business, including attracting and maintaining customers. If we have to make changes to our internal processes and software solutions as a result of these regulations, we could be required to invest substantial additional time and funds and divert time and resources from other initiatives to remedy any identified deficiency.

57

Our indirect, wholly-owned subsidiary, Professional Credit Reporting, Inc., functions as a consumer reporting agency and, as a result, is subject to rules and regulations applicable to consumer reporting agencies, such as the FCRA. In addition, with our acquisition of the assets of TazWorks and MeridianLink Wholesale Data, LLC, doing business as Trade House Data, we may have additional exposure to FCRA as a wholesale data furnisher of certain background screening pointer data. Other than these exposures to FCRA, we have adopted the position that we are not otherwise subject directly to the FCRA in our position as a provider of technology to financial institutions and CRAs. It is possible that this position may be challenged by regulatory authorities or others, however, which could result in regulatory investigations and other proceedings, claims, and other liability, and which could require us to redesign our solutions and otherwise substantially modify our operations, processes, and solutions. This could require dedication of substantial funds and other resources, and time of management and technical personnel, and could be highly disruptive to our operations. This could adversely affect our business and results of operations. The CRA industry is facing aggressive litigation efforts from plaintiffs attorneys against CRAs requiring substantial resources by us in response to subpoenas and additional technical software reporting requests. These efforts could affect us more significantly if additional customers are impacted or if MeridianLink is otherwise implicated in such litigation.
The evolving, complex, and often unpredictable regulatory environment in which our customers operate could result in our failure to provide compliant software solutions, which could result in customers not purchasing our software solutions or terminating their contracts with us or the imposition of fines or other liabilities for which we may be responsible. In addition, as a service provider to financial institutions, we may be subject to direct regulation and examination by federal and/or state agencies, and such agencies may attempt to further regulate our activities in the future which could adversely affect our business and results of operations.
The financial services industry is heavily regulated and changes in current legislation or new legislation could adversely affect our business.
The financial services industry in the United States, and, in particular, the consumer lending and mortgage industries, are heavily regulated. Our software solutions are designed to assist our customers with their compliance of consumer protection laws and institutionally mandated compliance policies and, therefore, must be updated to incorporate changes to such laws and policies. For example, we made certain changes to our software solutions to assist our customers with compliance with modifications to the Truth in Lending Act. Federal and state governments and agencies could enact legislation or other policies that could negatively impact the business of our customers and our product partners. Any changes to existing laws or regulations or adoption of new laws or regulations that increase restrictions on the consumer lending and mortgage industries may decrease usage and volumes transacted with our solutions or otherwise limit the ability of our customers and our product partners to operate their businesses, resulting in decreased usage of our software solutions. Updates that we have undertaken in the past have caused us to incur significant expense, and future updates to address such legal and regulatory developments will likely similarly cause us to incur significant expense.
While our customers are ultimately responsible for compliance with the laws and regulations that apply to the consumer lending and mortgage industries, a failure to design or to appropriately update our software solutions to reflect and comply with changes to existing laws or regulations or with new laws or regulations may contribute to violations by our customers of such laws and regulations. Any such violations could result in our customers to discontinue using our software solutions and cause us reputational harm, which would negatively impact our financial position and results of operations.
Failure to comply with anti-bribery, anti-corruption, and similar laws, could subject us to penalties and other adverse consequences.
Failure to comply with anti-bribery, anti-corruption, anti-money laundering, and similar laws could subject us to penalties and other adverse consequences. We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other federal, state, and local laws that address anti-bribery, anti-corruption, and anti-money laundering. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years and are interpreted broadly to generally prohibit companies, their employees, agents, representatives, business partners, and third-party intermediaries from authorizing, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector.
While we have policies and procedures to address compliance with such laws, we cannot ensure that none of our employees, agents, representatives, business partners, or third-party intermediaries will take actions in violation of our policies and applicable law, for which we may be ultimately held responsible.

58

Any allegations or violation of the FCPA or other applicable anti-bribery or anti-corruption laws or anti-money laundering laws could result in whistleblower complaints, sanctions, settlements, prosecution, enforcement actions, fines, damages, adverse media coverage, investigations, severe criminal or civil sanctions, or suspension or debarment from U.S. government contracts, all of which may have an adverse effect on our reputation, business, results of operations, and prospects. Responding to any investigation or action will likely result in a materially significant diversion of management’s attention and resources and significant defense costs and other professional fees. In addition, the U.S. government may seek to hold us liable for successor liability for FCPA violations committed by companies in which we invest or that we acquire. As a general matter, investigations and enforcement actions could harm our reputation, business, results of operations, and financial condition.
If one or more U.S. states or local jurisdictions successfully assert that we should have collected, or in the future should collect, additional sales or use taxes on our fees, we could be subject to additional liability with respect to past or future sales, and the results of our operations could be adversely affected.
An increasing number of states have considered or adopted laws that attempt to impose sales tax collection obligations on out-of-state sellers. We do not collect state and local sales and use taxes in all jurisdictions in which our customers are located, based on our belief that such taxes are not applicable. Jurisdictions in which we do not collect sales and use taxes may assert that such taxes are applicable and require us to calculate, collect, and remit taxes, interest, and penalties, as well as collect such taxes in the future. In addition, one or more states, the federal government, or other countries may seek to impose additional reporting, record-keeping, or indirect tax collection obligations on businesses like ours that offer subscription services. For example, on June 21, 2018, the Supreme Court held in South Dakota v. Wayfair, Inc. that states could impose sales tax collection obligations on out-of-state sellers even if those sellers lack any physical presence within the states imposing the sales taxes. In response to Wayfair, states may require us to collect and remit sales and use taxes where we have not collected and remitted sales and use taxes that occurred in prior tax years. The imposition by state governments or local governments of sales tax collection obligations on out-of-state sellers could also create additional administrative burdens for us, subject us to additional costs, put us at a competitive disadvantage if similar obligations are not imposed on our competitors, and decrease our future sales, which could have an adverse effect on our business, financial condition, and results of operations.
Risks Related to Finance and Accounting
Our quarterly results may fluctuate significantly and may not fully reflect the underlying performance of our business.
Our quarterly results of operations, including the levels of our revenues, gross margin, profitability, and cash flow may vary significantly in the future and, accordingly, period-to-period comparisons of our results of operations may not be meaningful. Thus, the results of any one quarter should not be relied upon as an indication of future performance. Our quarterly financial results may fluctuate as a result of a variety of factors, many of which are outside of our control, and may not fully or accurately reflect the underlying performance of our business. For example, while subscriptions with our customers often include multi-year terms that typically range from three to five years, a majority of our revenues from these subscriptions comes from usage or volume-based fees, such as application fees and per inquiry fees, as opposed to annual or monthly base fees. As such, if our customers terminate their agreements with us prior to their scheduled term, we may only recover a portion of our contractual base fees, and not any usage or volume-based fees. Fluctuation in quarterly results may negatively impact the value of our common stock. Factors that may cause fluctuations in our quarterly financial results include, without limitation, those listed below:
general economic, industry, and market conditions (particularly those affecting financial institutions), including fears of global economic downturn or recession, inflation and corresponding central bank countermeasures, and rising interest rates and their resulting effect on the mortgage market;
our ability to retain current customers or attract new customers;
the overall usage, volume, and type of transactions handled or processed using our software solutions, which may vary based on external factors such as macroeconomic conditions, including the impact of the COVID-19 pandemic, and seasonality;
the activation, delay in activation, or cancellation by customers;
the timing of recognition of professional services revenues;
the amount and timing of operating expenses, particularly increased expenses in connection with rising inflation, related to the maintenance and expansion of our business, operations, and infrastructure;

59

consolidations between or mergers or acquisitions of our customers, to the extent the combined entity or acquirer elects not to continue using our solutions or reduces subscriptions to it;
customer renewal, expansion, and retention rates;
increases or decreases in usage or pricing changes upon renewals of customer contracts;
network outages or security breaches;
changes in our pricing policies or those of our competitors;
seasonal variations in sales of our software solutions, which have historically been highest in the third quarter of our fiscal year;
the timing and success of introductions of new solutions or features and functionality by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers, or strategic partners;
unexpected expenses such as those related to litigation and other disputes; and
the timing of expenses related to the development or acquisition of technologies or businesses and potential future charges for impairment of goodwill or other intangibles from acquired companies.
Our forecasts, including forecasts related to acquired entities, are subject to significant risks, assumptions, estimates, and uncertainties, which may cause our revenues, market share, expenses, and profitability to differ materially from our expectations. For acquired entities, this could lead to an impairment charge.
Our forecasts, as well as our internal estimates and research, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. We operate in rapidly evolving, fragmented, and competitive industries, which make our results of operations difficult to predict. Additionally, we have a limited operating history at the current scale of our business, which makes it difficult to forecast our future results.
Forecasts are inherently imperfect predictors of actual results due to their reliance on historical data and a significant number of assumptions regarding factors such as the competition our business faces, our ability to attract and retain customers and partners, our ability to successfully implement our business strategy, future demand, subscription renewals, as well as industry and market trends. In addition, any issues with the quality or effectiveness of our data aggregation and validation procedures, as well as the quality and integrity of data inputs, could result in ineffective or inaccurate forecast outputs and reports. Forecasts based on historical data sets might not be accurate predictors of future outcomes, and their ability to appropriately predict future outcomes may degrade over time.
Given the challenges of predicting future behavior, management judgment is used at every stage of the forecasting process, from forecast design decisions regarding core underlying assumptions, to interpreting and applying final output. Further, when market conditions change quickly and unpredictably, there is an increased risk that the assumptions and data inputs for our forecasts are not representative of the most recent market conditions, which requires management judgment to make adjustments or overrides to our forecasts. In a rapidly changing environment, we may be unable to update existing forecasts expeditiously to properly account for the most recently available data and events.
If the forecasts of market growth, anticipated spending, or predictions regarding market size prove to be inaccurate, our business and growth prospects could be adversely affected. Even if all or some of the forecasted growth occurs, our business may not grow at a similar rate, or at all. If actual results differ from our estimates, analysts may negatively react and our stock price could be materially impacted. In the case of acquired entities, if our forecasts of market growth, anticipated spending, or predictions regarding market size prove to be inaccurate, an impairment charge could materialize.
Because we recognize certain subscription fee revenues over the term of the contract, downturns or upturns in our business may not be fully reflected in our results of operations until future periods.
We generally recognize revenues from subscription fees ratably over the terms of our customer contracts, which typically have an initial term of three years. As such, a portion of the subscription fee revenues we report each quarter are derived from the recognition of deferred revenues relating to subscriptions activated in previous quarters. Consequently, a reduction in customer subscriptions in any single quarter may only have a small impact on our revenues for that quarter. However, such a decline will negatively affect our revenues in future quarters. Accordingly, the effect of significant

60

downturns in sales or market acceptance of our software solutions, and changes to our attrition rate, may not be fully reflected in our results of operations until future periods.
If our goodwill and other intangibles become impaired, we may be required to record a significant charge to earnings.
We have a significant amount of goodwill and other intangibles. Our goodwill and other intangible asset balances as of March 31, 2023 were approximately $608.9 million and $285.4 million, respectively. We test goodwill at least annually, on October 1, or more frequently if circumstances indicate that goodwill may not be recoverable. Testing involves estimates and judgments by management. Such assets are considered to be impaired when the carrying value of an intangible asset exceeds its estimated fair value. We may be required to record a significant charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill or intangible assets is determined. While no impairment has been recorded in the consolidated financial statements included in this Quarterly Report on Form 10-Q, any future impairment of a significant portion of our goodwill could materially adversely affect our financial condition and results of operations.
Our debt agreements contain restrictions that limit our flexibility.
Our debt agreements contain, and any future indebtedness of ours would likely contain, a number of covenants that impose significant operating and financial restrictions on us, including restrictions on our and our subsidiaries’ ability, among other things, to:
incur additional indebtedness;
incur liens;
engage in mergers, consolidations, liquidations, or dissolutions;
pay dividends and distributions on, or redeem, repurchase, or retire our capital stock;
make investments, acquisitions, loans, or advances;
create negative pledge or restrictions on the payment of dividends or payment of other amounts owed from subsidiaries;
sell, transfer, or otherwise dispose of assets, including capital stock of subsidiaries;
make prepayments of material debt that is subordinated with respect to right of payment or liens, or is unsecured;
engage in certain transactions with affiliates;
modify certain documents governing material debt that is subordinated with respect to right of payment; and
change our lines of business.
As a result of these covenants, we will be limited in the manner in which we conduct our business, and we may be unable to engage in favorable business activities or finance future operations or capital needs.
We are highly leveraged and have substantial indebtedness, which reduces our capability to withstand adverse developments or business conditions.
We have incurred substantial amounts of indebtedness to finance our business operations, including our growth initiatives. Our level of indebtedness increases the possibility that we may be unable to generate cash sufficient to pay, when due, the principal of, interest on, or other amounts due in respect of our indebtedness. Additionally, actual or anticipated downgrades to our credit rating, including any announcement that our credit rating is under review, could impact our ability to borrow money and increase future lending costs.
Our overall leverage and the terms of our financing arrangements could also:
make it more difficult for us to satisfy obligations under our outstanding indebtedness, and any failure to comply with the obligations under any of our debt instruments, including restrictive covenants, could result in an event of default under any of the agreements governing our indebtedness;
limit our ability to obtain additional financing in the future for working capital, capital expenditures, or acquisitions;

61

limit our ability to refinance our indebtedness on terms acceptable to us or at all;
delay investments, restrict us from making strategic acquisitions, or cause us to make non-strategic divestitures;
require us to dedicate a significant portion of our cash flow from operations to paying the principal of and interest on our indebtedness, thereby limiting the availability of our cash flow to fund future capital expenditures, working capital, and other corporate purposes;
increase our vulnerability to adverse economic and industry conditions, which could place us at a competitive disadvantage or require us to dispose of assets to raise funds if needed for working capital;
limit our flexibility in planning for, or reacting to, changes in our business and our industry;
place us at a competitive disadvantage compared with competitors that have a less significant debt burden; and
expose us to increased market interest rates resulting in our variable-rate debt having higher debt service requirements.
We may not be able to secure sufficient additional financing on favorable terms, or at all, to meet our future capital needs.
We may require additional capital in the future to pursue business opportunities or acquisitions or respond to challenges and unforeseen circumstances. We may also decide to engage in equity or debt financings or enter into additional credit facilities for other reasons. We may not be able to secure additional debt or equity financing in a timely manner, on favorable terms, or at all. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods should we seek additional funding. Moreover, global capital markets have undergone periods of significant volatility and uncertainty in the past, and there can be no assurance that such financing alternatives will be available to us on favorable terms or at all, should we determine it necessary or advisable to seek additional capital.
The phase-out, replacement, or unavailability of the London Inter-Bank Offered Rate, or LIBOR, could affect interest rates under our revolving credit facility, as well as our ability to obtain future debt financing on favorable terms.
We are subject to interest rate risk on floating interest rate borrowings under our credit facilities. Borrowings under our credit facilities use LIBOR as a benchmark for establishing the interest rate. In July 2017, the Financial Conduct Authority (the regulatory authority over LIBOR) stated that it would phase out LIBOR as a benchmark after 2021 to allow for an orderly transition to an alternative reference rate, and have since initiated the phase-out of LIBOR. Our term loan and revolving credit facilities provide for alternative methods of calculating the interest rate payable on such facilities by moving through a waterfall of defined successor Secured Overnight Financing Rate, or SOFR, -based benchmark interest rates (or, if a SOFR-based benchmark rate is not available, such rate as agreed between us and the administrative agent of the credit facility), along with technical changes to reflect the adoption of any such new benchmark rate upon the occurrence of certain triggering events. It is not presently known whether SOFR or any other alternative reference rates that have been proposed will attain market acceptance as replacements of LIBOR. In addition, the overall financial markets may be disrupted as a result of the phase-out or replacement of LIBOR. Furthermore, the consequences of the transition from LIBOR could result in an increase in the cost of our borrowings on our variable rate debt, which could adversely impact our interest expense, results of operations and cash flows. Uncertainty as to the nature of such phase out and selection of an alternative reference rate, together with disruption in the financial markets, could have a material adverse effect on our financial condition, results of operations and cash flows, and may adversely affect our ability to obtain future debt financing on favorable terms.
Amendments to existing, or enactment of new unfavorable, tax laws, rules, or regulations could adversely affect our financial position.
Changes in applicable U.S. federal, state, and local income taxation laws, rules, or regulations, or their interpretation and application, including possible retroactive effect, could adversely affect our tax expense and profitability. In recent years, many such changes have been made, and changes are likely to continue to occur in the future. For example, many provisions of the Tax Cuts and Jobs Act of 2017, or TCJA, and the Inflation Reduction Act of 2022, or IRA, still require guidance through the issuance or finalization of regulations by the U.S. Treasury Department in order to fully assess their effects. There may be substantial delays before such regulations are promulgated or finalized as well as proposed technical corrections or other legislation, resulting in uncertainty as to their ultimate effects. Under the TJCA, research and development costs are no longer fully deductible and are required to be capitalized and amortized for U.S. tax purposes

62

effective January 1, 2022. The mandatory capitalization requirement increases our deferred tax assets and may have an impact on future cash tax liabilities. In August 2022, President Biden signed into law the IRA. The IRA includes a 15% corporate alternative minimum tax for companies with modified United States generally accepted accounting principles, or GAAP, net income in excess of $1 billion, a 1% excise tax on certain stock repurchases, and numerous environmental and green energy tax credits, each of which still require guidance and finalization of regulations by the U.S. Treasury Department. Currently, we are not subject to the corporate alternative minimum tax, have determined the 1% excise tax on certain stock repurchases to be immaterial to our business or stock repurchase program, and are evaluating the applicability and impact of the law’s additional tax provisions. Changes in our tax provisions or an increase in our tax liabilities, whether due to changes in applicable laws and regulations, the interpretation or application thereof, or a final determination of tax audits or litigation or agreements, could have an adverse effect on our financial position.
Risks Related to Potential Conflicts of Interests and Related Parties
We are a controlled company within the meaning of the NYSE rules and, as a result, qualify for and rely on exemptions from certain corporate governance requirements.
Thoma Bravo, as the ultimate general partner of the Thoma Bravo Discover Fund, L.P., Thoma Bravo Discover Fund A, L.P., Thoma Bravo Discover Fund II,L.P., Thoma Bravo Discover Fund II-A, L.P., and Thoma Bravo Discover Executive Fund II, L.P., or collectively, the Thoma Bravo Funds, and its related entities own a majority of the voting power of our outstanding common stock. As a result, we are, and expect we will continue to be, a controlled company within the meaning of the NYSE corporate governance standards. Under the NYSE rules, a company of which more than 50% of the voting power is held by another person or group of persons acting together is a controlled company and may elect not to comply with certain NYSE corporate governance requirements, including the requirements that:
a majority of the board of directors consist of independent directors as defined under the rules of the NYSE;
the nominating and governance committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and
the compensation committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities.
We have and, for so long as we remain a controlled company, expect to continue to use some or all of these exemptions. Additionally, our current executive officers, directors, and the Thoma Bravo Funds beneficially own approximately 68.7% of our issued and outstanding shares of common stock as of April 26, 2023. These stockholders may be able to determine all matters requiring stockholder approval including, but not limited to, elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. Accordingly, you may not have the same protections afforded to stockholders of companies that are subject to all of the NYSE corporate governance requirements.
Thoma Bravo has a controlling influence over matters requiring stockholder approval, which may have the effect of delaying or preventing changes of control, or limiting the ability of other stockholders to approve transactions they deem to be in their best interest.
As of April 26, 2023, Thoma Bravo and its related entities beneficially own, in the aggregate, approximately 50.2% of our issued and outstanding shares of common stock. As a result, Thoma Bravo could exert significant influence over our operations and business strategy and would have sufficient voting power to determine the outcome of all matters requiring stockholder approval. These matters may include:
the composition of our board of directors, which has the authority to direct our business and to appoint and remove our officers;
approving or rejecting a merger, consolidation, or other business combination;
raising future capital; and
amending our charter and bylaws, which govern the rights attached to our common stock.
Pursuant to our certificate of incorporate and bylaws, for so long as Thoma Bravo beneficially owns 30% or more of our outstanding shares of common stock, Thoma Bravo will have the right to designate a majority of our board of directors.

63

Accordingly, we expect the directors designated by Thoma Bravo to constitute a majority of each committee of our board of directors, other than the audit committee, and to chair each of the committees, other than the audit committee. At such time as we are not a “controlled company” under the NYSE corporate governance standards, however, our board of directors and committee membership will comply with all applicable requirements of those standards.
This concentration of ownership of our common stock could delay or prevent proxy contests, mergers, tender offers, open-market purchase programs, or other purchases of our common stock that might otherwise give you the opportunity to realize a premium over the then-prevailing market price of our common stock, and could, in turn, adversely affect our share price.
Thoma Bravo may pursue corporate opportunities independent of us that could present conflicts with our and our stockholders’ interests.
Thoma Bravo is in the business of making or advising on investments in companies and holds (and may from time to time in the future acquire) interests in or provides advice to businesses that may directly or indirectly compete with our business or be suppliers or customers of ours. Thoma Bravo may also pursue acquisitions that may be complementary to our business and, as a result, those acquisition opportunities may not be available to us.
Our charter provides that none of our officers or directors who are also an officer, director, employee, partner, managing director, principal, independent contractor, or other affiliate of Thoma Bravo will be liable to us or our stockholders for breach of any fiduciary duty by reason of the fact that any such individual pursues or acquires a corporate opportunity for its own account or the account of an affiliate, as applicable, instead of us, directs a corporate opportunity to any other person, instead of us, or does not communicate information regarding a corporate opportunity to us. Such provision will apply for so long as Thoma Bravo holds any of our securities.
Risks Related to Our Common Stock and Governance Structure
The trading price of our common stock could be volatile, and you could lose all or part of your investment.
Our IPO occurred in July 2021. As such, there has only been a public market for our common stock for a short period of time. An active trading market for our common stock may not be sustained. In addition, the trading prices of technology stocks have historically experienced high levels of volatility. If the market for technology stocks or the broader stock market experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition, or results of operations. The trading price of our common stock may fluctuate substantially.
Some of the factors that may cause the market price of our common stock to fluctuate, many of which may be beyond our control and may not be related to our operating performance, include:
changes in monetary policy by the Federal Reserve, including recent increases in interest rates and plans for future increases;
general economic conditions and trends, including changes in interest rates and consumer borrowing habits;
announcements of new products or technologies, commercial relationships, acquisitions, or other events by us or our competitors;
changes in how customers perceive the benefits of software solutions;
shifts in the mix of billings and revenues attributable to subscription fees, service fees, and product partner fees, from quarter to quarter;
departures of key personnel;
price and volume fluctuations in the overall stock market from time to time;
fluctuations in the trading volume of our shares or the size of our public float, including by stock repurchase;
sales of large blocks of our common stock, including by key personnel or the Thoma Bravo Funds;
actual or anticipated changes or fluctuations in our operating results;

64

unfavorable securities analysts’ research and reports published about us, our business, our market, or our competitors;
whether our operating results meet the expectations of securities analysts or investors, or changes in actual or future expectations of investors or securities analysts;
fluctuations in our quarterly or annual earnings results or those of other companies in our industry;
litigation involving us, our industry, or both;
regulatory developments;
actual or perceived security compromises or breaches;
major catastrophic events in domestic and foreign markets, including, for instance, the ongoing military conflict between Ukraine and Russia; and
the other factors described in these “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.
These fluctuations may limit or prevent investors from readily selling their shares of common stock, could cause investors to lose all or part of their investment in our common stock, and may otherwise negatively affect the liquidity of our common stock.
In addition, if the market for technology stocks or the stock market in general experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, operating results, or financial condition. The trading price of our common stock might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. In the past, following periods of volatility in the trading price of a company’s securities, securities class action litigation has often been brought against that company.
For as long as we are an emerging growth company, we will not be required to comply with certain requirements that apply to other public companies.
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we are an emerging growth company, unlike other public companies, we will not be required to, among other things: (i) provide an auditor’s attestation report on management’s assessment of the effectiveness of our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act; (ii) comply with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about the audit and the financial statements of the issuer; (iii) provide certain disclosures regarding executive compensation required of larger public companies; or (iv) hold nonbinding advisory votes on executive compensation and any golden parachute payments not previously approved. In addition, the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for adopting new or revised financial accounting standards. We intend to take advantage of the longer phase-in periods for the adoption of new or revised financial accounting standards permitted under the JOBS Act until we are no longer an emerging growth company. If we were to subsequently elect instead to comply with these public company effective dates, such election would be irrevocable pursuant to the JOBS Act.
We will remain an emerging growth company up until December 31, 2026, although we will lose that status sooner if we have more than $1.235 billion of revenues in a fiscal year, have more than $700 million in market value of our common stock held by non-affiliates, or issue more than $1.0 billion of non-convertible debt over a three-year period.
To the extent that we rely on any of the exemptions available to emerging growth companies, you will receive less information about our executive compensation and internal control over financial reporting than issuers that are not emerging growth companies. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock to be less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
Any issuance or sale of our capital stock may adversely affect the market price of our common stock and may dilute existing stockholders.
We may issue additional capital stock in the future that will result in dilution to all other stockholders. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in

65

complementary companies, products, or technologies and issue equity securities to pay for any such acquisition or investment. We plan to continue to issue common stock pursuant to our 2021 Stock Option and Incentive Plan, 2021 Employee Stock Purchase Plan, or other equity incentive plans that we may adopt in the future. Any such sales or issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.
In addition, our charter authorizes us to issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designations, preferences, limitations, and relative rights, including preferences over our common stock respecting dividends and distributions, as our board of directors may determine. For example, we might grant holders of preferred stock the right to elect some number of our directors in all events or on the happening of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences we might assign to holders of preferred stock could affect the residual value of our common stock. Designation and issuance of one or more classes or series of preferred stock could adversely affect the voting power or value of our common stock.
We do not intend to pay dividends on our common stock and, consequently, our stockholders’ return on investment will depend on appreciation in the price of our common stock.
We have never declared or paid any dividends on our common stock. We intend to retain any earnings to finance the operation and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. As a result, you may only receive a return on your investment in our common stock if the market price of our common stock increases.
We cannot guarantee that our stock repurchase program will be fully consummated or will enhance long-term stockholder value, and stock repurchases could increase the volatility of our stock prices and could diminish our cash reserves.
In May 2022, our board of directors approved a stock repurchase program under which we are authorized to purchase up to $75.0 million of our common stock from time to time. Our repurchase program does not have an expiration date and does not obligate us to repurchase any specific dollar amount or to acquire any specific number of shares, on any particular timetable or at all. There can be no assurance that we will repurchase stock at favorable prices. Further, our stock repurchases could affect our stock trading prices, increase their volatility, reduce our cash reserves, and may be suspended or terminated at any time, which may result in a lower market valuation of our common stock. We are currently evaluating the impacts of the IRA’s excise tax on our stock repurchase program, however do not currently expect the new law to have a material impact on our results of operations.
Delaware law and certain provisions in our charter and bylaws could delay, discourage, or prevent a change in control of our company.
Our status as a Delaware corporation and the existence of certain provisions of our charter and bylaws contain provisions that could delay, discourage, or prevent a change in control of our company that a stockholder may consider favorable. These provisions include:
a classified board of directors with three-year staggered terms;
after Thoma Bravo ceases to beneficially own at least 30% of the outstanding shares of our common stock, the removal of directors only for cause and subject to the affirmative vote of holders of at least 66 2/3% of our voting power;
the ability of our board of directors to both issue shares of preferred stock and determine the price and other terms of those shares without stockholder approval;
allowing Thoma Bravo to fill any vacancy on our board of directors for so long as affiliates of Thoma Bravo own 30% or more of our outstanding shares of common stock and, thereafter, allowing only our board of directors to fill vacancies on our board of directors;
after Thoma Bravo ceases to beneficially own at least a majority of the outstanding shares of our common stock, a prohibition on stockholder action by written consent;

66

after we cease to be a controlled company, the requirement that a special meeting of stockholders may be called only by our board of directors, the chairperson of our board of directors, our chief executive officer, or our president (in the absence of a chief executive officer);
after we cease to be a controlled company, the requirement for the affirmative vote of holders of at least 66 2/3% of our outstanding voting stock, voting together as a single class, to amend the provisions of our charter relating to the management of our business or the requirement for the affirmative vote of holders of at least 75% of our outstanding voting stock, voting together as a single class, to amend certain provisions of our bylaws;
the ability of our board of directors to amend our bylaws;
advance notice procedures for stockholders to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting; and
prohibition of cumulative voting in the election of our board of directors.
Our charter also provides us with protections similar to Section 203 of the Delaware General Corporation Law and prevents certain business combinations with a stockholder owning at least 15% of our outstanding voting stock, unless approved in a prescribed manner. Our charter also provides, however, that transactions with Thoma Bravo, including the Thoma Bravo Funds and any persons to whom any Thoma Bravo Fund sells its common stock, will be deemed to have been approved by our board of directors.
While these provisions may protect our stockholders from coercive or otherwise unfair takeover tactics, these provisions could also delay, discourage, or prevent a change in control transaction or changes in our board of directors that some stockholders may consider beneficial or prevent our stockholders from receiving a premium over the market price of our common stock that they might otherwise receive.
Our bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
Our bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a breach of fiduciary duty by one or more of our directors, officers or employees, (iii) any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or (iv) any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum selection clause may impose additional litigation costs on stockholders, discourage claims, or limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us. Although this provision may be beneficial in its consistency in the application of Delaware law, the Court of Chancery of the State of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. Alternatively, if the enforceability of the choice of forum provision contained in our bylaws is challenged and a court finds such provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. Our bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. This provision would not apply to any action brought to enforce a duty or liability created by the Exchange Act and the rules and regulations thereunder. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions.

67

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities by the Issuer
The following table summarizes the stock repurchase activity for the three months ended March 31, 2023:
PeriodTotal Number of Shares PurchasedAverage Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Programs
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
(in thousands) (1)
January 1 to January 31, 2023138,819 $14.88 376,460 $69,559 
February 1 to February 28, 202319,234 15.90 395,694 69,253 
March 1 to March 31, 202370,476 15.86 466,170 68,135 
Total228,529 — 466,170 $68,135 
______________
(1)In May 2022, our board of directors authorized a stock repurchase program to acquire up to $75.0 million of the Company’s common stock, with no fixed expiration date. Shares may be repurchased through privately negotiated transactions, or open market purchases, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.

68

Exhibit Index

Exhibit No.Exhibit TitleFormExhibitFiling Date
3.110-Q3.1September 7, 2021
3.2S-13.3April 30, 2021
4.1S-14.1April 30, 2021
4.2S-14.2April 30, 2021
31.1Filed herewith
31.2Filed herewith
32.1#Filed herewith
32.2#Filed herewith
101.INSInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).Filed herewith
101.SCHInline XBRL Taxonomy Extension Schema Document.Filed herewith
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.Filed herewith
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.Filed herewith
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.Filed herewith
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.Filed herewith
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).Filed herewith
_____________________
#    The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed “furnished” and not “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates them by reference.

69

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MERIDIANLINK, INC.
Dated: May 2, 2023
By:/s/ Nicolaas Vlok
Name:Nicolaas Vlok
Title:Chief Executive Officer (Principal Executive Officer)
Dated: May 2, 2023
By:/s/ Sean Blitchok
Name:Sean Blitchok
Title:Chief Financial Officer (Principal Financial and Accounting Officer)


70
EX-31.1 2 exhibit311toq12023form10-q.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Nicolaas Vlok, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of MeridianLink, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 2, 2023
/s/ Nicolaas Vlok                
Name: Nicolaas Vlok
Title: President and Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 exhibit312toq12023form10-q.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Sean Blitchok, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of MeridianLink, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 2, 2023

/s/ Sean Blitchok                
Name: Sean Blitchok
Title: Chief Financial Officer
(Principal Financial and Accounting Officer)


EX-32.1 4 exhibit321toq12023form10-q.htm EX-32.1 Document

Exhibit 32.1

Certification of Principal Executive Officer
Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report on Form 10-Q of MeridianLink, Inc. (the “Company”) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Nicolaas Vlok, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Nicolaas Vlok                    
Name: Nicolaas Vlok
Title: President and Chief Executive Officer
(Principal Executive Officer)
May 2, 2023

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.


EX-32.2 5 exhibit322toq12023form10-q.htm EX-32.2 Document

Exhibit 32.2

Certification of Principal Financial Officer
Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report on Form 10-Q of MeridianLink, Inc. (the “Company”) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Sean Blitchok, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Sean Blitchok                    
Name: Sean Blitchok
Title: Chief Financial Officer
(Principal Financial and Accounting Officer)
May 2, 2023

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.


EX-101.SCH 6 mlnk-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Net (Loss) Income Per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Restructuring Activities link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Net (Loss) Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Revenue Recognition - Disaggregation of Revenue by Solution Type (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Revenue Recognition - Disaggregation of Revenue by Major Source (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Revenue Recognition - Schedule of Changes in Contract Cost Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Revenue Recognition - Summary of Allowance for Expected Credit Losses Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Balance Sheet Components - Summary of Intangible Assets, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Balance Sheet Components - Summary of Estimated Useful Lives and Weighted Average Amortization Periods for Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Balance Sheet Components - Summary of amortization expense related to intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Balance Sheet Components - Summary of Estimated Future Amortization of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Purchase Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Long-Term Debt - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Long-Term Debt - Summary of Future Principal Payments of Long-term Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Share-Based Compensation - Schedule of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Share-Based Compensation - Summary of Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Net (Loss) Income Per Share - Summary of calculation of basic and diluted net income (loss) per share (Detail) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Net (Loss) Income Per Share - Summary of outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per common unit attributable to common unitholders (Detail) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Restructuring Activities (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Business Combinations (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mlnk-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mlnk-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mlnk-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net (loss) income Net income (loss) Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Party Transactions [Abstract] Provision for expected credit losses Accounts Receivable, Credit Loss Expense (Reversal) Lending Software Solutions Lending Software Solutions [Member] Lending Software Solutions [Member] Deferred tax assets, net Deferred Income Tax Assets, Net 2021 Term loan Total Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Data Verification Software Solutions Data Verification Software Solutions [Member] Data Verification Software Solutions [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding 2025 Long-Term Debt, Maturity, Year Two Revenue recognized Contract With Customer, Liability, Revenue Recognized, Including Opening Balance Contract With Customer, Liability, Revenue Recognized, Including Opening Balance Debt Instrument [Axis] Debt Instrument [Axis] Property plant and equipment gross Property, Plant and Equipment, Gross Total related party expenses Related Party Transaction, Expenses from Transactions with Related Party Revolving credit facility, principal amount Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Additions Capitalized Contract Cost Additions Capitalized contract cost additions. Accrued severance and related costs Restructuring Reserve Depreciation and amortization Other Depreciation and Amortization Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Issuance of common stock due to exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Interest expense Interest Expense, Debt, Excluding Amortization Concentration risk Concentration Risk Percentage Concentration risk percentage. RSAs cancelled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Share-Based Payment Arrangement [Abstract] Organization, Consolidation and Presentation of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table]. Additional paid-in capital Additional Paid in Capital, Common Stock Summary of prepaid expenses and other current assets Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block] Schedule of prepaid expenses and other current assets Shares that remained subject to future vesting (in shares) Conversion Of Stock, Shares Converted, Nonvested Conversion Of Stock, Shares Converted, Nonvested Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average common stock outstanding: Weighted Average Number of Shares Outstanding, Basic And Diluted [Abstract] Weighted Average Number of Shares Outstanding, Basic And Diluted Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Summary of future principal payments of long-term debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Secured Debt Secured Debt [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] Adjusted Eurocurrency Rate Adjusted Eurocurrency Rate [Member] Adjusted Eurocurrency Rate Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Unrecognized stock-based compensation expense, awards other than options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Beginning balance Ending balance Total deferred contract cost assets Capitalized Contract Cost, Net Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Purchase rights committed under the ESPP Employee Stock [Member] Weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Lease liability - current Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Restructuring and related cost, expected cost Restructuring and Related Cost, Expected Cost Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Capitalized computer software, gross Capitalized Computer Software, Gross Long-term debt, net of debt issuance costs Total non-current portion of long-term debt, net Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Purchase price allocation adjustment related to income tax effects for StreetShares acquisition Purchase accounting adjustments, goodwill Goodwill, Purchase Accounting Adjustments Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] StreetShares StreetShares [Member] StreetShares Capitalized software Capitalized Software [Member] Capitalized software [Member]. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Revolving Credit Facility Revolving Credit Facility [Member] Summary of property and equipment, net Property, Plant and Equipment [Table Text Block] Preferred sock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Beanstalk Networks, L.L.C. (OpenClose) Beanstalk Networks, L.L.C. [Member] Beanstalk Networks, L.L.C. Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restructuring Type [Axis] Restructuring Type [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Non-vested beginning balance (in dollars per share) Non-vested ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Segments [Axis] Segments [Axis] Long-Term Debt Debt Disclosure [Text Block] Cost of revenues: Cost of Revenue [Abstract] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued liabilities Increase (Decrease) in Accrued Liabilities Developed technology Developed Technology Rights [Member] 2026 Long-Term Debt, Maturity, Year Three Affiliated Entity Affiliated Entity [Member] Subsequent Event Subsequent Event [Member] Schedule of changes in the deferred revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Total assets Assets Write offs, net Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income taxes payable Sales and Excise Tax Payable, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Current portion of long-term debt, net of debt issuance costs Current portion of long term debt Long-Term Debt, Current Maturities Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Service-based RSUs awarded Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid Accounting Policies [Abstract] Stock repurchase program authorized amount Stock Repurchase Program, Authorized Amount Accrued payroll and payroll-related expenses Employee-related Liabilities, Current Line of Credit Line of Credit [Member] (Loss) income before (benefit from) provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Segments [Domain] Segments [Domain] Deferred income taxes Deferred Income Taxes and Tax Credits Net (Loss) Income Per Share Earnings Per Share [Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Initial recognition of operating lease liability Increase (Decrease) in Operating Lease Liability Related Party Transaction [Line Items] Related Party Transaction [Line Items] Fair value of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Domain] Award Type [Domain] Unrecognized stock-based compensation expense, weighted -average period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average remaining contractual term, exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring Plan [Domain] Restructuring Plan [Domain] Basic and diluted net (loss) income per share Reconciliation Of Earnings Per Share, Basic And Diluted [Abstract] Reconciliation Of Earnings Per Share, Basic And Diluted Summary of intangible assets, net and estimated useful lives and weighted average amortization periods Schedule of Finite-Lived Intangible Assets [Table Text Block] Vesting of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Cash consideration, gross Payments to Acquire Businesses, Gross Computer equipment and software Computer Equipment [Member] Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component Subsequent Events Subsequent Events [Text Block] Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Operating expenses: Operating Expenses [Abstract] Minimum Minimum [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Capitalized computer software, accumulated amortization Capitalized Computer Software, Accumulated Amortization Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Debt issuance costs Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Accounting Standards Update [Axis] Accounting Standards Update [Axis] Variable Rate Component Two Variable Rate Component Two [Member] Variable Rate Component Two Trading Symbol Trading Symbol Entity File Number Entity File Number 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Long-term deferred revenue Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units Restricted stock units (RSUs) Restricted Stock Units (RSUs) [Member] Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent 2021 Plan Two Thousand Twenty One Stock Option and Incentive Plan [Member] 2021 stock option and incentive plan. Vested and expected to vest in the future (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Business Combinations Business Combination Disclosure [Text Block] Subsequent Events [Abstract] Business acquisition, pro forma net income (loss) Business Acquisition, Pro Forma Net Income (Loss) Stockholders’ Equity Limited Liability Company (LLC) Members' Equity [Abstract] Income Taxes Income Tax Disclosure [Text Block] Credit Facility [Domain] Credit Facility [Domain] Amortization of intangible assets Amortization of Intangible Assets Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Other Service, Other [Member] Basic (in dollars per share) Earnings Per Share, Basic Billing of transaction consideration Contract With Customer, Liability, Additions Contract With Customer, Liability, Additions Organization, Consolidation and Presentation of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Sales and marketing Selling and Marketing Expense Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Prepaid expenses Prepaid Expense, Current Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Accrued costs of revenues Accrued Costs Of Revenues Accrued costs of revenues. Entity Interactive Data Current Entity Interactive Data Current Amortization Capitalized Contract Cost, Amortization Intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Restricted stock units, unvested Restricted Stock Units, Unvested [Member] Restricted Stock Units, Unvested Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Accumulated deficit Retained Earnings [Member] Unrecognized stock-based compensation expense related to stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Initial recognition of operating lease right-of-use asset Increase (Decrease) in Operating Lease Right-Of-Use Asset Increase (Decrease) in Operating Lease Right-Of-Use Asset Common Stock Common Stock [Member] Summary of stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Number of reportable segments Number of Reportable Segments Repurchases of common stock Payments for Repurchase of Common Stock Schedule of RSU activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Statement [Table] Statement [Table] Principal payments of long-term debt Repayments of Other Long-Term Debt Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Interest rate, effective Debt Instrument, Interest Rate, Effective Percentage Document Quarterly Report Document Quarterly Report Letter of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Trademarks Trademarks [Member] Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Operating and Reportable Segment Segment Reporting, Policy [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Summary of amortization expense related to intangible assets Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Subscription and services Cost of revenues Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Annual increase in shares authorized, percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved For Issuance, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved For Issuance, Percentage Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Non-vested beginning balance (in shares) Non-vested ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total other expense, net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Intangible assets, gross amount Finite-Lived Intangible Assets, Gross Percent of original principal Debt Instrument, Periodic Payment, Percent Of Principal Percentage of principal payments on Term loan. Right of use assets Operating Lease, Right-of-Use Asset Repurchase of stock Stock repurchased Stock Repurchased During Period, Value Capitalized Contract Cost [Roll Forward] Capitalized Contract Cost [Roll Forward] Capitalized Contract Cost Variable Rate Component One Variable Rate Component One [Member] Variable Rate Component One Vested and expected to vest in the future (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Summary of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating (loss) income Operating Income (Loss) Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Recent Accounting Pronouncements Adopted And Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Weighted average common stock outstanding: Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Professional services Professional Services [Member] Professional Services [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Repurchase of stock (in shares) Stock repurchased (in shares) Stock Repurchased During Period, Shares Debt issuance costs Debt Issuance Costs, Current, Net Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] (Benefit from) provision for income taxes Income Tax Expense (Benefit) Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional paid-in capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cumulative Effect, Period of Adoption, Adjusted Balance Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Net (loss) income per share: Earnings Per Share, Basic [Abstract] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Debt issuance costs, gross Debt Issuance Costs, Gross Base Rate Base Rate [Member] Common stock, $0.001 par value; 600,000,000 shares authorized, 80,636,894 and 80,644,452 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Restructuring related costs Restructuring Charges [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vesting of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Summary of Outstanding Potentially Dilutive Securities were Excluded from the Calculation of Diluted Net Loss Per Common Unit Attributable to Common Unitholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate intrinsic value, exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accrued bonuses Accrued Bonuses, Current Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net income (loss) attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Proceeds from exercise of stock options Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted average remaining contractual term, vested and expected to vest in the future Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current First Lien First Lien [Member] First Lien [Member] 2023 (remaining nine months) Purchase Obligation, to be Paid, Year One Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Schedule of changes in contract cost assets Capitalized Contract Cost [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Acquisition related costs Business Combination, Acquisition Related Costs Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Term loan Debt Instrument, Face Amount Contract cost assets – current Capitalized Contract Cost, Net, Current Business acquisition, pro forma revenue Business Acquisition, Pro Forma Revenue Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Weighted Average Remaining Contract Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Severance and related costs Employee Severance [Member] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Contract cost assets, noncurrent Capitalized Contract Cost, Net, Noncurrent Issuance of common stock through employee purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans 2024 Purchase Obligation, to be Paid, Year Two Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net The "Plan" The "Plan" [Member] The "Plan" Schedule of estimated future amortization of intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Office equipment and furniture Office Equipment [Member] Sales and marketing Selling and Marketing Expense [Member] Stock options Share-Based Payment Arrangement, Option [Member] Issuance of common stock due to exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total debt, net Long-Term Debt Other income Other Nonoperating Income (Expense) Restructuring Activities Restructuring and Related Activities Disclosure [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Total operating expenses Operating Expenses Maximum Maximum [Member] Options to purchase common stock outstanding, unexercised Options To Purchase Common Stock Outstanding, Unexercised [Member] Options To Purchase Common Stock Outstanding, Unexercised Accounts payable Increase (Decrease) in Accounts Payable, Trade Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Cash paid for income taxes Income Taxes Paid, Net Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Intangible assets, net Total amortization expense Finite-Lived Intangible Assets, Net Line of Credit Facility [Table] Line of Credit Facility [Table] Significant Accounting Policies Significant Accounting Policies [Text Block] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Future minimum payments under non-cancelable purchase commitments Contractual Obligation, Fiscal Year Maturity [Table Text Block] Excise taxes payable included in repurchases of common stock Excise Taxes Payable Included in Repurchases of Common Stock Excise Taxes Payable Included in Repurchases of Common Stock User conference Accrued User Conference Costs, Current Accrued User Conference Costs, Current Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Vesting of RSAs and RSUs Share Based Payment Arrangement, Vested Share Based Payment Arrangement, Vested Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Subscription fees Subscription Fees [Member] Subscription Fees [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 2023 (remaining nine months) Long-Term Debt, Maturity, Remainder of Fiscal Year Accounts payable Accounts Payable, Current Restructuring related costs Restructuring Charges Aggregate intrinsic value, vested and expected to vest in the future Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability 2027 Long-Term Debt, Maturity, Year Four Weighted Average Remaining Useful Life Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension Organization and Description of Business Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Class B Units Capital Unit, Class B [Member] Total share-based compensation expense Share-Based Payment Arrangement, Expense Accrued operating costs Accrued Operating Costs Accrued operating costs. Non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Commitments and contingencies (Note 5) Commitments and Contingencies Security Exchange Name Security Exchange Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred stock, $0.001 par value; 50,000,000 shares authorized; zero shares issued and outstanding at March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Restricted stock awards Restricted Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative expense General and Administrative Expense [Member] Revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Restructuring and Related Activities [Abstract] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Beginning Balance Allowance for doubtful accounts Ending Balance Accounts Receivable, Allowance for Credit Loss Numerator: Net Income (Loss) Available To Common Stockholders, Basic And Diluted [Abstract] Net Income (Loss) Available To Common Stockholders, Basic And Diluted Revenue Recognition Revenue from Contract with Customer [Text Block] Sales tax liability from acquisitions Sales and Excise Tax Payable Taxes paid related to net share settlement of RSUs Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Amortization of debt issuance costs Amortization of financing costs Amortization of Debt Issuance Costs Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Stock remaining for repurchase under repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount Effect of dilutive securities (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Net income (loss) attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in dollars per share) Earnings Per Share, Diluted Liability balance related to unvested RSAs Conversion Of Stock, Shares Converted, Nonvested, Value Conversion Of Stock, Shares Converted, Nonvested, Value Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Accounting Standards Update 2016-13 Accounting Standards Update 2016-13 [Member] Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Amortization of developed technology Cost, Amortization Other Other Assets, Current 2021 Term Loan 2021 Term Loan [Member] 2021 Term Loan Uncertain tax positions Unrecognized Tax Benefits Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Capitalized software costs Capitalized Computer Software, Additions Entity Ex Transition Period Entity Ex Transition Period Commitment fee rate Line of Credit Facility, Commitment Fee Percentage Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Summary of allowance for expected credit losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Other (income) expense, net: Nonoperating Income (Expense) [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Total cost of revenues Cost of Revenue Deferred revenue, beginning balance Deferred revenue, ending balance Deferred revenue, current Contract with Customer, Liability Share-based compensation expense capitalized to software additions Share-Based Payment Arrangement, Amount Capitalized Product and Service [Axis] Product and Service [Axis] Unused revolving credit facility balance Line of Credit Facility, Remaining Borrowing Capacity Interest expense, net Interest Expense Credit Facility [Axis] Credit Facility [Axis] Summary of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of long-term debt Schedule of Long-Term Debt Instruments [Table Text Block] Equity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number 2025 Purchase Obligation, to be Paid, Year Three 2021 Revolving Credit Facility 2021 Revolving Credit Facility [Member] 2021 Revolving Credit Facility Summary of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] 2023 (remaining nine months) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Non-competition agreements Noncompete Agreements [Member] Shares withheld related to net share settlement of restricted stock units (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Shares withheld related to net share settlement of restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Previously vested stock based compensation One-time Termination Benefits [Member] Other accrued expenses Other Accrued Liabilities, Current Capitalized computer software, net carrying amount Capitalized Computer Software, Net Accounting Standards Update [Domain] Accounting Standards Update [Domain] City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Total future minimum payments under non-cancelable purchase commitments Purchase Obligation Capitalized software additions Payments for Software Statement of Stockholders' Equity [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Capital Units by Class [Axis] Capital Units by Class [Axis] 2024 Long-Term Debt, Maturity, Year One Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Restricted stock awards, unvested Restricted Stock Awards, Unvested [Member] Restricted Stock Awards, Unvested Other long-term liabilities Other Liabilities, Noncurrent Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Escrow deposit Escrow Deposit 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Summary of Calculation of Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of revenues Cost of Sales [Member] Capital Unit, Class [Domain] Capital Unit, Class [Domain] Reduction in current workforce Restructuring and Related Cost, Number of Positions Eliminated, Period Percent EX-101.PRE 10 mlnk-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
3 Months Ended
Mar. 31, 2023
Apr. 26, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-40680  
Entity Registrant Name MeridianLink, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-4844620  
Entity Address, Address Line One 3560 Hyland Avenue  
Entity Address, Address Line Two Suite 200  
Entity Address, City or Town Costa Mesa  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92626  
City Area Code 714  
Local Phone Number 708-6950  
Title of 12(b) Security Common stock, par value $0.001 per share  
Trading Symbol MLNK  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   80,645,366
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Central Index Key 0001834494  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 77,796 $ 55,780
Accounts receivable, net 37,401 32,905
Prepaid expenses and other current assets 10,798 9,447
Escrow deposit 30,000 30,000
Total current assets 155,995 128,132
Property and equipment, net 3,891 4,245
Right of use assets 1,929 2,185
Intangible assets, net 285,412 297,475
Deferred tax assets, net 14,893 13,939
Goodwill 608,902 608,657
Other assets 4,784 4,524
Total assets 1,075,806 1,059,157
Current liabilities:    
Accounts payable 3,986 1,249
Accrued liabilities 34,102 32,500
Deferred revenue 34,090 16,945
Current portion of long-term debt, net of debt issuance costs 3,506 3,505
Total current liabilities 75,684 54,199
Long-term debt, net of debt issuance costs 422,526 423,404
Long-term deferred revenue 992 1,141
Other long-term liabilities 1,165 1,322
Total liabilities 500,367 480,066
Commitments and contingencies (Note 5)
Stockholders’ Equity    
Preferred stock, $0.001 par value; 50,000,000 shares authorized; zero shares issued and outstanding at March 31, 2023 and December 31, 2022 0 0
Common stock, $0.001 par value; 600,000,000 shares authorized, 80,636,894 and 80,644,452 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 132 128
Additional paid-in capital 626,905 621,396
Accumulated deficit (51,598) (42,433)
Total stockholders’ equity 575,439 579,091
Total liabilities and stockholders’ equity $ 1,075,806 $ 1,059,157
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 50,000,000 50,000,000
Preferred sock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 600,000,000 600,000,000
Common stock, shares issued (in shares) 80,636,894 80,644,452
Common stock, shares outstanding (in shares) 80,636,894 80,644,452
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenues, net $ 77,135 $ 72,754
Cost of revenues:    
Subscription and services 23,501 21,104
Amortization of developed technology 4,454 3,434
Total cost of revenues 27,955 24,538
Gross profit 49,180 48,216
Operating expenses:    
General and administrative 22,555 18,187
Research and development 13,812 8,409
Sales and marketing 8,213 4,743
Acquisition related costs 0 2,283
Restructuring related costs 2,904 0
Total operating expenses 47,484 33,622
Operating (loss) income 1,696 14,594
Other (income) expense, net:    
Other income (470) (163)
Interest expense, net 9,031 4,358
Total other expense, net 8,561 4,195
(Loss) income before (benefit from) provision for income taxes (6,865) 10,399
(Benefit from) provision for income taxes (1,199) 2,920
Net (loss) income $ (5,666) $ 7,479
Net (loss) income per share:    
Basic (in dollars per share) $ (0.07) $ 0.09
Diluted (in dollars per share) $ (0.07) $ 0.09
Weighted average common stock outstanding:    
Basic (in shares) 80,659,978 79,974,071
Diluted (in shares) 80,659,978 82,228,936
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Restricted stock awards
Common Stock
Common Stock
Restricted stock awards
Common Stock
Restricted stock units
Additional paid-in capital
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2021     79,734,984        
Beginning balance at Dec. 31, 2021 $ 556,278   $ 88     $ 596,542 $ (40,352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Vesting of restricted stock (in shares)       484,401 76,937    
Vesting of restricted stock 32     $ 32      
Issuance of common stock due to exercise of stock options (in shares)     28,909        
Issuance of common stock due to exercise of stock options 179         179  
Share-based compensation expense 3,887         3,887  
Net income (loss) 7,479           7,479
Ending balance (in shares) at Mar. 31, 2022     80,325,231        
Ending balance at Mar. 31, 2022 567,855   $ 120     600,608 (32,873)
Beginning balance (in shares) at Dec. 31, 2022     80,644,452        
Beginning balance at Dec. 31, 2022 $ 579,091   $ 128     621,396 (42,433)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Vesting of restricted stock (in shares)       59,558 65,770    
Vesting of restricted stock   $ 4   $ 4      
Issuance of common stock due to exercise of stock options (in shares) 97,412   97,412        
Issuance of common stock due to exercise of stock options $ 594         594  
Shares withheld related to net share settlement of restricted stock units (in shares)     (1,769)        
Shares withheld related to net share settlement of restricted stock units $ (24)         (24)  
Repurchase of stock (in shares) (228,529)   (228,529)        
Repurchase of stock $ (3,499)           (3,499)
Share-based compensation expense 4,939         4,939  
Net income (loss) (5,666)           (5,666)
Ending balance (in shares) at Mar. 31, 2023     80,636,894        
Ending balance at Mar. 31, 2023 $ 575,439   $ 132     $ 626,905 $ (51,598)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net (loss) income $ (5,666) $ 7,479
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 14,531 12,905
Provision for expected credit losses 532 0
Amortization of debt issuance costs 235 484
Share-based compensation expense 4,891 3,808
Loss on disposal of fixed assets 0 135
Deferred income taxes (1,198) 2,679
Changes in operating assets and liabilities, net of acquisitions:    
Accounts receivable (5,028) (7,248)
Prepaid expenses and other assets (1,636) (460)
Accounts payable 2,717 301
Accrued liabilities 1,706 194
Deferred revenue 16,997 14,586
Net cash provided by operating activities 28,081 34,863
Cash flows from investing activities:    
Capitalized software additions (1,924) (1,522)
Purchases of property and equipment (134) (419)
Net cash used in investing activities (2,058) (1,941)
Cash flows from financing activities:    
Repurchases of common stock (3,490) 0
Proceeds from exercise of stock options 594 179
Taxes paid related to net share settlement of RSUs (24) 0
Principal payments of long-term debt (1,087) 0
Net cash (used in) provided by financing activities (4,007) 179
Net increase in cash and cash equivalents 22,016 33,101
Cash and cash equivalents, beginning of period 55,780 113,645
Cash and cash equivalents, end of period 77,796 146,746
Supplemental disclosures of cash flow information:    
Cash paid for interest 9,019 3,869
Cash paid for income taxes 50 44
Non-cash investing and financing activities:    
Purchase price allocation adjustment related to income tax effects for StreetShares acquisition 245 0
Purchases of property and equipment included in accounts payable and accrued expenses 79 0
Share-based compensation expense capitalized to software additions 48 79
Excise taxes payable included in repurchases of common stock 9 0
Vesting of RSAs and RSUs 4 32
Initial recognition of operating lease liability 0 3,372
Initial recognition of operating lease right-of-use asset $ 0 $ 2,627
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Description of Business
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of BusinessMeridianLink, Inc., and its wholly-owned subsidiaries, (collectively the “Company”), provides secure, cloud-based digital solutions that transform the ways in which traditional and emerging financial services providers engage with account holders and end users. The Company sells its solutions to financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. The Company delivers its solutions to the substantial majority of its customers using a software-as-a-service (“SaaS”) model under which its customers pay subscription fees for the use of the Company’s solutions. The Company is controlled by its majority stockholder, which is represented by various investment funds of Thoma Bravo UGP, LLC and its affiliates (“Thoma Bravo”). The Company is headquartered in Costa Mesa, California.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
Basis of Presentation
The unaudited condensed consolidated financial statements of the Company have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or the consolidated balance sheets.

The interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations, stockholders’ equity, and cash flows for the three months ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of March 31, 2023, and its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three months ended March 31, 2023 and 2022, are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 9, 2023.
Operating and Reportable Segment
The Company operates and manages its business and financial information on a consolidated basis for the purposes of evaluating financial performance and the allocation of resources. The Company's management determined that it operates in one operating and reportable segment that is focused exclusively on providing cloud-based digital solutions in the United States. In reaching this conclusion, management considers the definition of the chief operating decision maker (“CODM”), how the business is defined by the CODM, the nature of the information provided to the CODM and how that information is used to make operating decisions, allocate resources, and assess performance. The Company's CODM is the chief executive officer. The results of operations provided to and analyzed by the CODM are at the consolidated level, and accordingly, key resource decisions and assessment of performance are performed at the consolidated level. The Company assesses its determination of operating segments at least annually.
Use of Estimates
The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses. Significant items subject to such estimates include revenue recognition including determining the nature and timing of satisfaction of performance obligations and variable consideration; allowance for credit losses; share-based compensation; the fair value of acquired intangibles; the capitalization of software development costs; the useful lives of long-lived intangible assets; impairment of goodwill and long-lived assets; and income taxes. In accordance with GAAP, management bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from those estimates.
Significant Accounting Policies
The Company’s significant accounting policies are discussed in Note 2, “Significant Accounting Policies” in the Company’s Annual Report. There have been no changes to the Company’s significant accounting policies described in the Company’s Annual Report that have had a material impact on its condensed consolidated financial statements and related notes, except for updates resulting from the adoption of ASU 2016-13, “Financial InstrumentsCredit Losses (Topic 326)” which is discussed in more detail within Note 3, “Revenue Recognition.”
Accounting Pronouncements Recently Adopted
The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies.
ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.”
Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted this guidance effective January 1, 2023, and the adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and disclosures.
Recent Accounting Pronouncements Not Yet Adopted
ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”
ASU 2020-04 provides optional guidance for a limited time to ease the potential accounting burden associated with transitioning away from reference rates, such as the London Inter-Bank Offered Rate (LIBOR), which regulators in the United Kingdom are currently phasing out. The expedients and exceptions provided by ASU 2020-04 are for the application of U.S. GAAP to contracts, hedging relationships, and other transactions affected by the rate reform. Companies can apply the ASU immediately, however, the guidance will only be available for a limited time. In December 2022, the FASB issued ASU 2022-06 which deferred the sunset date from December 31, 2022 to December 31, 2024, after which companies will no longer be permitted to apply the transition relief. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
The following table disaggregates the Company’s net revenues by solution type (in thousands):
Three Months Ended March 31,
20232022
Lending Software Solutions
$58,001 $49,167 
Data Verification Software Solutions
19,134 23,587 
Total$77,135 $72,754 
Lending Software Solutions accounted for 75%, and 68% of total revenues for the three months ended March 31, 2023 and 2022, respectively. Data Verification Software Solutions accounted for 25% and 32% of total revenues for the three months ended March 31, 2023 and 2022 respectively.
The following table disaggregates the Company’s net revenues by major source (in thousands):
Three Months Ended March 31,
20232022
Subscription fees$66,405 $63,469 
Professional services8,435 7,112 
Other2,295 2,173 
Total revenues$77,135 $72,754 
Deferred Revenue
The changes in the Company’s deferred revenue as of March 31, 2023 and 2022 were as follows (in thousands):
Three Months Ended March 31,
20232022
Deferred revenue, beginning balance$18,086 $14,707 
Billing of transaction consideration94,131 87,340 
Revenue recognized(77,135)(72,754)
Deferred revenue, ending balance$35,082 $29,293 
Deferred revenue, current$34,090 $29,293 
Long-term deferred revenue992 — 
Total deferred revenue$35,082 $29,293 
Assets Recognized from Costs to Obtain a Contract with a Customer
The following table represents the changes in contract cost assets (in thousands):
Three Months Ended March 31,
20232022
Beginning balance$6,539 $5,835 
Additions1,151 607 
Amortization(747)(554)
Ending balance$6,943 $5,888 
Contract cost assets, current$3,196 $2,572 
Contract cost assets, noncurrent3,747 3,316 
Total deferred contract cost assets$6,943 $5,888 
Accounts Receivable and Allowance for Credit Losses
Effective January 1, 2023, the Company adopted the requirements of ASU 2016-13-Credit Loses, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) using a modified retrospective method of adoption. The Standard replaces the existing incurred credit loss model with the current expected credit losses model for financial instruments, including accounts receivable.
The Company’s accounts receivable includes billed and unbilled receivables, net of an allowance for credit losses. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company recognizes an allowance for credit losses on accounts receivable in an amount equal to the current expected credit losses. The estimation of the allowance is based on an analysis of historical loss experience, current receivables aging, and management’s assessment of current conditions and estimated future conditions, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible.
The Company assesses collectability by pooling receivables where similar characteristics exist and evaluates receivables individually when specific customer balances no longer share those risk characteristics and are considered at risk or uncollectible. The expense associated with the allowance for expected credit losses is recognized in general and administrative expenses.
A rollforward of the Company’s allowance for expected credit losses balance for the three months ended March 31, 2023 is as follows:
Three Months Ended March 31, 2023
Allowance for doubtful accounts, December 31, 2022$165 
Impact of adopting ASU 2016-13— 
Allowance for expected credit losses, January 1, 2023165 
Provision for expected credit losses532 
Write offs, net(33)
Allowance for expected credit losses, March 31, 2023$664 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components Balance Sheet Components
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Prepaid expenses$6,994 $6,069 
Contract cost assets – current3,196 2,938 
Other608 440 
Total prepaid expenses and other current assets$10,798 $9,447 
Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Computer equipment and software $7,987 $7,854 
Leasehold improvements2,732 2,732 
Office equipment and furniture986 978 
Total11,705 11,564 
Less: Accumulated depreciation(7,814)(7,319)
Property and equipment, net$3,891 $4,245 
Depreciation expense amounted to $0.5 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively. The Company disposed of office furniture that resulted in a loss of $0.1 million for the three months ended March 31, 2022. The losses are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. There were no disposals of property and equipment for the three months ended March 31, 2023.
Intangible Assets, Net
Intangible assets, net consisted of the following (in thousands):
As of March 31, 2023
Gross AmountAccumulated AmortizationNet Carrying Amount
Customer relationships$343,300 $(140,845)$202,455 
Developed technology96,400 (43,426)52,974 
Trademarks24,975 (10,920)14,055 
Non-competition agreements5,500 (1,008)4,492 
Capitalized software21,416 (9,980)11,436 
Total intangible assets, net$491,591 $(206,179)$285,412 
As of December 31, 2022
Gross AmountAccumulated AmortizationNet Carrying Amount
Customer relationships$343,300 $(132,298)$211,002 
Developed technology96,400 (40,360)56,040 
Trademarks24,975 (10,205)14,770 
Non-competition agreements5,500 (688)4,812 
Capitalized software19,443 (8,592)10,851 
Total intangible assets, net$489,618 $(192,143)$297,475 
The weighted average remaining useful lives for intangible assets at March 31, 2023 were as follows:
Weighted Average Remaining Useful Life
Customer relationships5 years
Developed technology4 years
Trademarks5 years
Non-competition agreements4 years
Capitalized software3 years
Amortization expense related to intangible assets was as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$4,454 $3,434 
General and administrative expense9,582 8,910 
Total amortization expense$14,036 $12,344 
The estimated future amortization of intangible assets as of March 31, 2023 was as follows (in thousands):
Years ending December 31,
2023 (remaining nine months)$41,133 
202453,415 
202547,535 
202642,510 
202742,052 
202824,901 
Thereafter33,866 
Total amortization expense$285,412 
Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Accrued payroll and payroll-related expenses$8,791 $9,836 
Accrued costs of revenues5,408 3,141 
Sales tax liability from acquisitions4,572 4,572 
Accrued operating costs4,352 4,016 
Accrued bonuses4,315 5,947 
User conference1,971 755 
Lease liability - current1,139 1,223 
Income taxes payable889 939 
Other accrued expenses2,665 2,071 
Total accrued liabilities$34,102 $32,500 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Matters
The Company is, and from time to time may be, involved in legal proceedings and claims arising out of the Company’s operations in the ordinary course of business. Management is not currently aware of any legal proceedings or claims against it that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company.
Other Contractual Commitments
The Company’s contractual commitments primarily consist of third-party cloud infrastructure agreements and service subscription arrangements used to support operations at the enterprise level. Future minimum payments under the Company’s non-cancelable purchase commitments as of March 31, 2023 are as follows (in thousands):
Contractual Commitments
Years ending December 31,
2023 (remaining nine months)$375 
2024395 
20253,020 
Total$3,790 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt
3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Long-Term Debt Long-Term Debt
Long-term debt consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
2021 Term loan
$430,650 $431,738 
Debt issuance costs
(4,618)(4,829)
Total debt, net
426,032 426,909 
Less: Current portion of long-term debt
2021 Term loan4,350 4,350 
Debt issuance costs
(844)(845)
Total current portion of long-term debt, net
3,506 3,505 
Total non-current portion of long-term debt, net
$422,526 $423,404 
Amortization of deferred financing fees was $0.2 million and $0.5 million for the three months ended March 31, 2023 and 2022 respectively. Total interest expense, excluding amortization of deferred financing fees, was $8.9 million and $3.9 million, for the three months ended March 31, 2023 and 2022, respectively.
2021 Credit Agreement
On November 10, 2021, the Company entered into a credit agreement (the “2021 Credit Agreement”), which provides for a term loan facility (the “2021 Term Loan”) in an aggregate principal amount of $435.0 million, and a revolving credit facility (the “2021 Revolving Credit Facility”) in an aggregate principal amount of $50.0 million, inclusive of a $10.0 million letter of credit sub-facility. The Company used the proceeds from the 2021 Term Loan to pay all outstanding amounts due under the Company’s previous 2018 First Lien plus certain fees and expenses. The 2021 Term Loan and 2021 Revolving Credit Facility mature on November 10, 2028 and November 10, 2026, respectively. The Company has not drawn on the 2021 Revolving Credit Facility as of March 31, 2023.
The obligations under the 2021 Credit Agreement are secured by a lien on substantially all tangible and intangible property of the Company, subject to customary exceptions, limitations, and exclusions from the collateral.
The 2021 Credit Agreement contains customary affirmative covenants, negative covenants and events of default, including covenants and restrictions that, among other things, require the Company to satisfy a financial covenant, and restricts or limits the ability of the Company to grant or incur liens, incur additional indebtedness, enter into joint ventures or partnerships, engage in mergers and acquisitions, engage in asset sales, and declare dividends on its capital stock, subject in each case to certain customary exceptions. A failure to comply with certain covenants could permit the lenders to declare the 2021 Term Loan, and any then outstanding borrowings on the 2021 Revolving Credit Facility, together with accrued interest and fees thereon, to be immediately due and payable. The Company was in compliance with all financial covenants of the 2021 Credit Agreement at March 31, 2023.
2021 Term Loan
Borrowings under the 2021 Term Loan bear interest at a variable rate, elected by the Company, equal to the Base Rate (as defined in the 2021 Credit Agreement) or the Adjusted Eurocurrency Rate (as defined in the 2021 Credit Agreement), plus, an initial margin based on the Company’s Consolidated First Lien Net Leverage Ratio (as defined by the 2021 Credit Agreement), which was 3.00% at March 31, 2023. Beginning in June 2022, the Company is required to make quarterly principal payments equal to 0.25% of the original principal, with the remainder due at maturity.
Debt issuance costs of $7.6 million were included as a reduction of the debt balance on the condensed consolidated balance sheets and are amortized into interest expense over the contractual life of the loans using the effective interest method. Included in the debt issuance costs were $4.8 million incurred in connection with the 2021 Term Loan, and $2.8 million carried forward from the Company’s previous 2018 First Lien. The Company recognized $0.2 million, and $0.5 million of amortization of debt issuance costs for the 2021 Term Loan during the three months ended March 31, 2023 and 2022, respectively. The effective interest rate on the 2021 Term Loan was 8.5% as of March 31, 2023.
2021 Revolving Credit Facility
Borrowings under the 2021 Revolving Credit Facility bear interest, at the election of the Company, at a rate equal to the Base Rate (as defined in the 2021 Credit Agreement) or the Adjusted Eurocurrency Rate (as defined in the 2021 Credit Agreement), plus, in each case, the Applicable Rate (as defined in the 2021 Credit Agreement), which shall vary based on the Company’s Consolidated First Lien Net Leverage Ratio.
In connection with the 2021 Revolving Credit Facility, the Company incurred $0.5 million in debt issuance costs. Expenses associated with the issuance of the revolving credit facility are presented in the accompanying condensed consolidated balance sheets in prepaid expenses and other current assets and other assets, and are amortized to interest expense over the life of the 2021 Revolving Credit Facility using the straight-line method.
The 2021 Revolving Credit Facility also requires a quarterly commitment fee based on the Company’s consolidated first lien net leverage ratio. As of March 31, 2023, the applicable rate was 0.5%, which was applied against the $50.0 million unused revolving credit facility balance.
Future Principal Payments
Future principal payments of long-term debt as of March 31, 2023 were as follows (in thousands):
Years ending December 31,
2023 (remaining nine months)$3,263 
20244,350 
20254,350 
20264,350 
20274,350 
Thereafter409,987 
Total$430,650 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Stock Repurchase Program
In May 2022, the Company’s board of directors authorized a new stock repurchase program to acquire up to $75.0 million of the Company’s common stock, with no requirement to purchase any minimum number of shares. The manner, timing, and actual number of shares repurchased under the program will depend on a variety of factors, including price, working capital needs, general business and market conditions, regulatory requirements, and other investment opportunities. Shares may be repurchased through privately negotiated transactions, or open market purchases, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934. The repurchase program may be commenced, suspended, or terminated at any time by the Company at its discretion without prior notice.
The Company retires the repurchased shares, which automatically return to the status of authorized but unissued shares of common stock. The cost of the repurchased shares, including commissions, fees, and excise taxes are recorded as an adjustment to retained earnings on the Company’s condensed consolidated balance sheets and statements of stockholders’ equity. During the three months ended March 31, 2023, the Company repurchased 228,529 shares of its common stock for $3.5 million, including commissions, fees, and excise taxes. As of March 31, 2023, there was a total of $68.1 million remaining for repurchase under the stock repurchase program.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation
3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-based Compensation
2021 Stock Option and Incentive Plan
The 2021 Stock Option and Incentive Plan (the “2021 Plan”) was adopted by the board of directors and approved by the Company’s stockholders following the Corporate Conversion and became effective as of July 26, 2021. The 2021 Plan replaced both the Company’s 2019 Equity Option Plan (the “2019 Plan”) and the Project Angel Parent, LLC Equity Plan (the “2018 Plan”). Outstanding options to purchase Class B Units granted under the 2019 Plan were converted into options to purchase shares of common stock, and all outstanding Carried Equity Units granted under the 2018 Plan were converted into restricted stock awards (“RSAs”), both of which have been granted under the 2021 Plan.
The Company had initially reserved 13,171,588 shares of its common stock for the issuance of awards under the 2021 Plan. The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase on January 1, 2022 and each January 1 thereafter, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s compensation committee. The number of shares reserved under the 2021 Plan is subject to adjustment in the event of a stock split, stock dividend, or other change in the Company’s capitalization.
The 2021 Plan provides flexibility to the Company’s compensation committee to use various equity-based incentive awards as compensation tools to motivate the Company’s workforce. The incentive awards that may be granted under the 2021 Plan include, but are not limited to, options to purchase common stock, stock appreciation rights, restricted shares of common stock, restricted stock units, and cash bonuses.
Stock Options
A summary of stock option activity during the three months ended March 31, 2023 is as follows (in thousands, except options, price per option, and term amounts):
Number of OptionsWeighted Average Exercise PriceWeighted Average Remaining Contract TermAggregate Intrinsic Value
Outstanding – January 1, 2023
4,739,783 $13.21 
7.61
$19,855 
Granted
— — 
Exercised(97,412)6.10 
Forfeited(143,087)21.78 
Outstanding – March 31, 2023
4,499,284 $13.09 
7.34
$28,349 
Vested and expected to vest in the future at March 31, 2023
4,499,284 13.09 
7.34
28,349 
Exercisable at March 31, 2023
2,951,792 $9.28 
6.67
$27,428 
The total fair value of options that vested during the three months ended March 31, 2023 and 2022 was $1.1 million and $1.5 million, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $0.9 million and $0.4 million, respectively.
The Company recognized $1.3 million and $1.4 million in share-based compensation expense related to time-based and performance-based stock options for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023 and 2022, performance-based options were probable of vesting and, therefore, were included as part of share-based compensation expense.
As of March 31, 2023, there was $14.1 million of unrecognized share-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.56 years.
Restricted Stock Awards
The number of restricted stock awards (“RSAs”) that vested during the three months ended March 31, 2023 and 2022 was 59,558 and 484,401, respectively.

The liability balance as of March 31, 2023 and 2022, related to the unvested RSAs was $0.00 million and $0.01 million, respectively. As of March 31, 2023 and 2022, the number of unvested RSAs amounted to 4,051 and 183,741, respectively.
There were a total of 0 and 22,212 RSAs cancelled or forfeited during the three months ended March 31, 2023 and 2022, respectively.
The Company recognized $0.1 million and $0.1 million in share-based compensation expense related to the vesting of RSAs for the three months ended March 31, 2023 and 2022, respectively.
Restricted Stock Units
A summary of restricted stock unit (“RSU”) activity during the three months ended March 31, 2023, is as follows:
Number of RSUsWeighted Average Grant Date Fair Value
Non-vested – January 1, 2023
3,111,831 $19.27 
Granted
424,266 15.00 
Vested(65,770)25.73 
Forfeited(258,916)19.76 
Non-vested – March 31, 2023
3,211,411 $18.53 
As of March 31, 2023, 3,211,411 RSUs are expected to vest. The Company recognized $3.4 million and $2.2 million in share-based compensation expense related to RSUs for the three months ended March 31, 2023, and 2022, respectively.
As of March 31, 2023, there was $48.2 million of unrecognized share-based compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of 2.96 years.
Employee Stock Purchase Program
As of March 31, 2023, the Company has issued 127,700 shares of common stock pursuant to the 2021 Employee Stock Purchase Plan under its employee stock purchase program (“ESPP”). As of March 31, 2023, there was $0.1 million of unrecognized share-based compensation related to the ESPP that is expected to be recognized over the remaining term of the current offering period. The Company recognized $0.1 million and $0.1 million of share-based compensation expense related to the ESPP for the three months ended March 31, 2023 and 2022, respectively.
Share-Based Compensation
Share-based compensation for share-based awards granted to participants has been recorded in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$853 $965 
General and administrative2,264 1,381 
Research and development (1)
1,783 1,077 
Sales and marketing290 385 
Restructuring related costs (2)
(299)— 
Total share-based compensation expense $4,891 $3,808 
______________
(1)Net of $0.1 million and $0.1 million additions to capitalized software on the Company’s condensed consolidated balance sheets during the three months ended March 31, 2023 and 2022, respectively.
(2)Relates to unvested stock compensation that was forfeited as part of the Restructuring Plan. See Note 12, “Restructuring.”
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
In accordance with applicable accounting guidance, the Company is required to use an estimated annual effective tax rate to compute its tax provision during an interim period. The Company’s provision for income taxes reflected an effective tax rate of 17% and 28% for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to R&D credits, state taxes, permanent unfavorable differences related to share-based compensation expense, certain employee remuneration under section 162(m) of the Internal Revenue Code, and other expected permanent differences. During the three months ended March 31, 2022, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to R&D credits, state taxes, permanent differences related to share-based compensation expense, and other expected permanent differences.
The Company has gross unrecognized tax benefits with respect to R&D credits of $3.1 million as of March 31, 2023 and $2.5 million as of December 31, 2022. Penalties and interest have been recorded on these liabilities as the credits have started to be utilized.
The Company assesses whether a valuation allowance should be recorded against its deferred tax assets based on the consideration of all available evidence, using a “more likely than not” realization standard. The four sources of taxable income that must be considered in determining whether deferred tax assets will be realized are: (l) future reversals of existing taxable temporary differences (i.e., offset of gross deferred tax assets against gross deferred tax liabilities); (2) taxable income in prior carryback years, if carryback is permitted under the applicable tax law; (3) tax planning strategies; and (4) future taxable income exclusive of reversing temporary differences and carryforwards. Based on the evaluation of the evidence and sources of taxable income, the Company has determined that no valuation allowance is necessary as of March 31, 2023.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The following table presents the impact of related party transactions on the Company’s condensed consolidated statements of operations (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$319 $472 
General and administrative248 207 
Research and development162 63 
Sales and marketing— 22 
Total related party expenses$729 $764 
The following table presents the impact of related party transactions on the Company’s condensed consolidated balance sheets (in thousands):
As of
March 31, 2023
December 31, 2022
Prepaid assets$156 $37 
Total current assets$156 $37 
Accounts payable$152 $30 
Accrued liabilities529 456 
Total current liabilities$681 $486 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Net (Loss) Income Per Share
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net (Loss) Income Per Share Net (Loss) Income Per Share
The following table presents the calculation of basic and diluted net (loss) income per share (in thousands, except share and per share data):
Three Months Ended March 31,
20232022
Basic and diluted net (loss) income per share
Numerator:
Net (loss) income attributable to common stockholders
$(5,666)$7,479 
Denominator:
Weighted average common stock outstanding:
Basic80,659,97879,974,071
Diluted80,659,97882,228,936
Net (loss) income per share:
Basic$(0.07)$0.09 
Diluted(0.07)0.09 
A reconciliation of the denominator used in the calculation of basic and diluted earnings per share is as follows:
Three Months Ended March 31,
20232022
Weighted average shares outstanding for basic earnings per share80,659,97879,974,071
Effect of dilutive securities:
Options outstanding, unexercised
1,736,275
RSAs unvested488,291
RSUs unvested27,120
Purchase rights committed under the ESPP3,179
Weighted average shares outstanding for diluted earnings per share80,659,97882,228,936
The following outstanding potentially dilutive securities were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders because their impact would have been anti-dilutive for the periods presented:
As of March 31,
20232022
Options to purchase common stock outstanding, unexercised2,017,496 1,476,592 
Restricted stock units, unvested600,981 874,425 
Total2,618,477 2,351,017 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring Activities
3 Months Ended
Mar. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Activities Restructuring Activities
Restructuring Plan
In February 2023, the Company’s board of directors authorized a restructuring plan (the “Restructuring Plan”) that was designed to consolidate the Company’s functions and investments to prioritize customer-centric areas of the Company’s organization, align teams with the Company’s highest business priorities, and improve efficiencies. The Restructuring Plan included a reduction of the Company’s current workforce by 9%.
The Company estimated that it would incur charges of $2.5 million to $3.5 million in connection with the Restructuring Plan, consisting primarily of cash expenditures and relating to employee severance payments, employee benefits, and employee transition costs. Restructuring charges of $2.9 million for severance and related costs, net of $0.3 million previously vested stock based compensation, was recognized during the three months ended March 31, 2023, and is reflected in restructuring related costs on the Company’s condensed consolidated statements of operations. Accrued severance and related costs as of March 31, 2023 were $0.6 million. The Company expects to incur the remaining estimated restructuring related costs during the second quarter of 2023.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations
3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
Acquisition of OpenClose
On November 4, 2022, the Company acquired all of the outstanding stock of Beanstalk Networks L.L.C. doing business as OpenClose (“OpenClose”) for cash consideration of $63.1 million. In connection with the acquisition, the Company incurred $1.9 million in acquisition related costs. The acquisition was funded by the Company’s available cash. OpenClose is based out of West Palm Beach, Florida, and provides mortgage lending technology, with a particular focus on supporting depository institutions. The acquisition is expected to improve the company’s existing lending platform and improve our offerings for depository institutions. The acquisition is accounted for using the acquisition method of accounting whereby the acquired assets and liabilities will be recorded at their respective fair values and added to those of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets.
As of March 31, 2023, the Company is still finalizing the provisional purchase price allocation related to final working capital adjustments and income tax effects.
Pro Forma Financial Information
The pro forma statements of operations data for the three months ended March 31, 2022 give effect to the OpenClose acquisition, described above, as if it had occurred at January 1, 2021. These amounts have been calculated after adjusting the operating results of OpenClose for the following primary items: (1) additional intangible amortization from the transaction, (2) acquisition-related expenses incurred, and (3) the related tax effects of the above adjustments. For the three months ended March 31, 2022, pro forma revenue was $76.2 million, and pro forma earnings reflect net income of $6.4 million.
The unaudited pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the acquisitions taken place as of January 1, 2021, or the results of our future operations. Furthermore, the pro forma results do not give effect to all cost savings or incremental costs that may occur as a result of the integration and consolidation of the completed acquisitions.
Acquisition of StreetShares
On April 1, 2022, the Company acquired all of the outstanding stock of StreetShares, Inc. (“StreetShares”) for cash consideration of $28.0 million, $30.0 million in escrow for a contingent earnout that expires April 1, 2023, subject to adjustment as defined in the purchase agreement, and $1.6 million in acquisition costs. The $30.0 million is considered contingent consideration and accounted for separate from the business combination accounting. The acquisition was funded by the Company’s available cash. StreetShares is based out of Reston, VA, and is a financial technology company that provides digital small business lending technology to banks and credit unions. The acquisition is accounted for using the acquisition method of accounting whereby the acquired assets and liabilities are recorded at their respective fair values and added to those of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. Results of operations of StreetShares have been included in the operations of the Company beginning with the closing date of the acquisition.
During the three months ended March 31, 2023, the Company completed the provisional purchase price allocation related to income tax effects, resulting in a reduction to the deferred tax asset and corresponding increase to goodwill in the amount of $0.2 million.
Pro forma information for the StreetShares acquisition is not provided because their historical operating results were not material to the Company’s consolidated results of operations.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsEquity GrantsPursuant to approval by the Company’s compensation committee and board of directors, in April 2023, the Company awarded $43.6 million service-based RSUs to its employees. Service-based RSUs generally vest over four years, subject to the participant’s continued service relationship with the Company through each such vesting date.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The unaudited condensed consolidated financial statements of the Company have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or the consolidated balance sheets.

The interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations, stockholders’ equity, and cash flows for the three months ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of March 31, 2023, and its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three months ended March 31, 2023 and 2022, are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 9, 2023.
Operating and Reportable Segment
Operating and Reportable Segment
The Company operates and manages its business and financial information on a consolidated basis for the purposes of evaluating financial performance and the allocation of resources. The Company's management determined that it operates in one operating and reportable segment that is focused exclusively on providing cloud-based digital solutions in the United States. In reaching this conclusion, management considers the definition of the chief operating decision maker (“CODM”), how the business is defined by the CODM, the nature of the information provided to the CODM and how that information is used to make operating decisions, allocate resources, and assess performance. The Company's CODM is the chief executive officer. The results of operations provided to and analyzed by the CODM are at the consolidated level, and accordingly, key resource decisions and assessment of performance are performed at the consolidated level. The Company assesses its determination of operating segments at least annually.
Use of Estimates
Use of Estimates
The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses. Significant items subject to such estimates include revenue recognition including determining the nature and timing of satisfaction of performance obligations and variable consideration; allowance for credit losses; share-based compensation; the fair value of acquired intangibles; the capitalization of software development costs; the useful lives of long-lived intangible assets; impairment of goodwill and long-lived assets; and income taxes. In accordance with GAAP, management bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from those estimates.
Recent Accounting Pronouncements Adopted And Not Yet Adopted
Accounting Pronouncements Recently Adopted
The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies.
ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.”
Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted this guidance effective January 1, 2023, and the adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and disclosures.
Recent Accounting Pronouncements Not Yet Adopted
ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”
ASU 2020-04 provides optional guidance for a limited time to ease the potential accounting burden associated with transitioning away from reference rates, such as the London Inter-Bank Offered Rate (LIBOR), which regulators in the United Kingdom are currently phasing out. The expedients and exceptions provided by ASU 2020-04 are for the application of U.S. GAAP to contracts, hedging relationships, and other transactions affected by the rate reform. Companies can apply the ASU immediately, however, the guidance will only be available for a limited time. In December 2022, the FASB issued ASU 2022-06 which deferred the sunset date from December 31, 2022 to December 31, 2024, after which companies will no longer be permitted to apply the transition relief. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Summary of disaggregation of revenue
The following table disaggregates the Company’s net revenues by solution type (in thousands):
Three Months Ended March 31,
20232022
Lending Software Solutions
$58,001 $49,167 
Data Verification Software Solutions
19,134 23,587 
Total$77,135 $72,754 
The following table disaggregates the Company’s net revenues by major source (in thousands):
Three Months Ended March 31,
20232022
Subscription fees$66,405 $63,469 
Professional services8,435 7,112 
Other2,295 2,173 
Total revenues$77,135 $72,754 
Schedule of changes in the deferred revenue
The changes in the Company’s deferred revenue as of March 31, 2023 and 2022 were as follows (in thousands):
Three Months Ended March 31,
20232022
Deferred revenue, beginning balance$18,086 $14,707 
Billing of transaction consideration94,131 87,340 
Revenue recognized(77,135)(72,754)
Deferred revenue, ending balance$35,082 $29,293 
Deferred revenue, current$34,090 $29,293 
Long-term deferred revenue992 — 
Total deferred revenue$35,082 $29,293 
Schedule of changes in contract cost assets
The following table represents the changes in contract cost assets (in thousands):
Three Months Ended March 31,
20232022
Beginning balance$6,539 $5,835 
Additions1,151 607 
Amortization(747)(554)
Ending balance$6,943 $5,888 
Contract cost assets, current$3,196 $2,572 
Contract cost assets, noncurrent3,747 3,316 
Total deferred contract cost assets$6,943 $5,888 
Summary of allowance for expected credit losses
A rollforward of the Company’s allowance for expected credit losses balance for the three months ended March 31, 2023 is as follows:
Three Months Ended March 31, 2023
Allowance for doubtful accounts, December 31, 2022$165 
Impact of adopting ASU 2016-13— 
Allowance for expected credit losses, January 1, 2023165 
Provision for expected credit losses532 
Write offs, net(33)
Allowance for expected credit losses, March 31, 2023$664 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components (Tables)
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of prepaid expenses and other current assets
Prepaid expenses and other current assets consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Prepaid expenses$6,994 $6,069 
Contract cost assets – current3,196 2,938 
Other608 440 
Total prepaid expenses and other current assets$10,798 $9,447 
Summary of property and equipment, net
Property and equipment, net consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Computer equipment and software $7,987 $7,854 
Leasehold improvements2,732 2,732 
Office equipment and furniture986 978 
Total11,705 11,564 
Less: Accumulated depreciation(7,814)(7,319)
Property and equipment, net$3,891 $4,245 
Summary of intangible assets, net and estimated useful lives and weighted average amortization periods
Intangible assets, net consisted of the following (in thousands):
As of March 31, 2023
Gross AmountAccumulated AmortizationNet Carrying Amount
Customer relationships$343,300 $(140,845)$202,455 
Developed technology96,400 (43,426)52,974 
Trademarks24,975 (10,920)14,055 
Non-competition agreements5,500 (1,008)4,492 
Capitalized software21,416 (9,980)11,436 
Total intangible assets, net$491,591 $(206,179)$285,412 
As of December 31, 2022
Gross AmountAccumulated AmortizationNet Carrying Amount
Customer relationships$343,300 $(132,298)$211,002 
Developed technology96,400 (40,360)56,040 
Trademarks24,975 (10,205)14,770 
Non-competition agreements5,500 (688)4,812 
Capitalized software19,443 (8,592)10,851 
Total intangible assets, net$489,618 $(192,143)$297,475 
The weighted average remaining useful lives for intangible assets at March 31, 2023 were as follows:
Weighted Average Remaining Useful Life
Customer relationships5 years
Developed technology4 years
Trademarks5 years
Non-competition agreements4 years
Capitalized software3 years
Summary of amortization expense related to intangible assets
Amortization expense related to intangible assets was as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$4,454 $3,434 
General and administrative expense9,582 8,910 
Total amortization expense$14,036 $12,344 
Schedule of estimated future amortization of intangible assets
The estimated future amortization of intangible assets as of March 31, 2023 was as follows (in thousands):
Years ending December 31,
2023 (remaining nine months)$41,133 
202453,415 
202547,535 
202642,510 
202742,052 
202824,901 
Thereafter33,866 
Total amortization expense$285,412 
Summary of accrued liabilities
Accrued liabilities consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
Accrued payroll and payroll-related expenses$8,791 $9,836 
Accrued costs of revenues5,408 3,141 
Sales tax liability from acquisitions4,572 4,572 
Accrued operating costs4,352 4,016 
Accrued bonuses4,315 5,947 
User conference1,971 755 
Lease liability - current1,139 1,223 
Income taxes payable889 939 
Other accrued expenses2,665 2,071 
Total accrued liabilities$34,102 $32,500 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Future minimum payments under non-cancelable purchase commitments Future minimum payments under the Company’s non-cancelable purchase commitments as of March 31, 2023 are as follows (in thousands):
Contractual Commitments
Years ending December 31,
2023 (remaining nine months)$375 
2024395 
20253,020 
Total$3,790 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt (Tables)
3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of long-term debt
Long-term debt consisted of the following (in thousands):
As of
March 31, 2023
As of
December 31, 2022
2021 Term loan
$430,650 $431,738 
Debt issuance costs
(4,618)(4,829)
Total debt, net
426,032 426,909 
Less: Current portion of long-term debt
2021 Term loan4,350 4,350 
Debt issuance costs
(844)(845)
Total current portion of long-term debt, net
3,506 3,505 
Total non-current portion of long-term debt, net
$422,526 $423,404 
Summary of future principal payments of long-term debt
Future principal payments of long-term debt as of March 31, 2023 were as follows (in thousands):
Years ending December 31,
2023 (remaining nine months)$3,263 
20244,350 
20254,350 
20264,350 
20274,350 
Thereafter409,987 
Total$430,650 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of stock option activity
A summary of stock option activity during the three months ended March 31, 2023 is as follows (in thousands, except options, price per option, and term amounts):
Number of OptionsWeighted Average Exercise PriceWeighted Average Remaining Contract TermAggregate Intrinsic Value
Outstanding – January 1, 2023
4,739,783 $13.21 
7.61
$19,855 
Granted
— — 
Exercised(97,412)6.10 
Forfeited(143,087)21.78 
Outstanding – March 31, 2023
4,499,284 $13.09 
7.34
$28,349 
Vested and expected to vest in the future at March 31, 2023
4,499,284 13.09 
7.34
28,349 
Exercisable at March 31, 2023
2,951,792 $9.28 
6.67
$27,428 
Schedule of RSU activity
A summary of restricted stock unit (“RSU”) activity during the three months ended March 31, 2023, is as follows:
Number of RSUsWeighted Average Grant Date Fair Value
Non-vested – January 1, 2023
3,111,831 $19.27 
Granted
424,266 15.00 
Vested(65,770)25.73 
Forfeited(258,916)19.76 
Non-vested – March 31, 2023
3,211,411 $18.53 
Summary of stock-based compensation
Share-based compensation for share-based awards granted to participants has been recorded in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 as follows (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$853 $965 
General and administrative2,264 1,381 
Research and development (1)
1,783 1,077 
Sales and marketing290 385 
Restructuring related costs (2)
(299)— 
Total share-based compensation expense $4,891 $3,808 
______________
(1)Net of $0.1 million and $0.1 million additions to capitalized software on the Company’s condensed consolidated balance sheets during the three months ended March 31, 2023 and 2022, respectively.
(2)Relates to unvested stock compensation that was forfeited as part of the Restructuring Plan. See Note 12, “Restructuring.”
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The following table presents the impact of related party transactions on the Company’s condensed consolidated statements of operations (in thousands):
Three Months Ended March 31,
20232022
Cost of revenues$319 $472 
General and administrative248 207 
Research and development162 63 
Sales and marketing— 22 
Total related party expenses$729 $764 
The following table presents the impact of related party transactions on the Company’s condensed consolidated balance sheets (in thousands):
As of
March 31, 2023
December 31, 2022
Prepaid assets$156 $37 
Total current assets$156 $37 
Accounts payable$152 $30 
Accrued liabilities529 456 
Total current liabilities$681 $486 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Net (Loss) Income Per Share (Tables)
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Summary of Calculation of Basic and Diluted Net Income (Loss) Per Share
The following table presents the calculation of basic and diluted net (loss) income per share (in thousands, except share and per share data):
Three Months Ended March 31,
20232022
Basic and diluted net (loss) income per share
Numerator:
Net (loss) income attributable to common stockholders
$(5,666)$7,479 
Denominator:
Weighted average common stock outstanding:
Basic80,659,97879,974,071
Diluted80,659,97882,228,936
Net (loss) income per share:
Basic$(0.07)$0.09 
Diluted(0.07)0.09 
A reconciliation of the denominator used in the calculation of basic and diluted earnings per share is as follows:
Three Months Ended March 31,
20232022
Weighted average shares outstanding for basic earnings per share80,659,97879,974,071
Effect of dilutive securities:
Options outstanding, unexercised
1,736,275
RSAs unvested488,291
RSUs unvested27,120
Purchase rights committed under the ESPP3,179
Weighted average shares outstanding for diluted earnings per share80,659,97882,228,936
Summary of Outstanding Potentially Dilutive Securities were Excluded from the Calculation of Diluted Net Loss Per Common Unit Attributable to Common Unitholders
The following outstanding potentially dilutive securities were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders because their impact would have been anti-dilutive for the periods presented:
As of March 31,
20232022
Options to purchase common stock outstanding, unexercised2,017,496 1,476,592 
Restricted stock units, unvested600,981 874,425 
Total2,618,477 2,351,017 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies - Additional Information (Details)
3 Months Ended
Mar. 31, 2023
Segment
Accounting Policies [Abstract]  
Number of reportable segments 1
Number of operating segments 1
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Disaggregation of Revenue by Solution Type (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenues, net $ 77,135 $ 72,754
Lending Software Solutions    
Disaggregation of Revenue [Line Items]    
Revenues, net 58,001 49,167
Data Verification Software Solutions    
Disaggregation of Revenue [Line Items]    
Revenues, net $ 19,134 $ 23,587
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Additional Information (Details)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Lending Software Solutions    
Segment Reporting Information [Line Items]    
Concentration risk 75.00% 68.00%
Data Verification Software Solutions    
Segment Reporting Information [Line Items]    
Concentration risk 25.00% 32.00%
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Disaggregation of Revenue by Major Source (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenues, net $ 77,135 $ 72,754
Subscription fees    
Disaggregation of Revenue [Line Items]    
Revenues, net 66,405 63,469
Professional services    
Disaggregation of Revenue [Line Items]    
Revenues, net 8,435 7,112
Other    
Disaggregation of Revenue [Line Items]    
Revenues, net $ 2,295 $ 2,173
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Schedule of Changes in Deferred Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Contract With Customer, Liability [Roll Forward]      
Deferred revenue, beginning balance $ 18,086 $ 14,707  
Billing of transaction consideration 94,131 87,340  
Revenue recognized (77,135) (72,754)  
Deferred revenue, ending balance 35,082 29,293  
Deferred revenue, current 34,090 29,293  
Long-term deferred revenue 992 0 $ 1,141
Deferred revenue, current $ 35,082 $ 29,293 $ 18,086
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Schedule of Changes in Contract Cost Assets (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Capitalized Contract Cost [Roll Forward]      
Beginning balance $ 6,539 $ 5,835  
Additions 1,151 607  
Amortization (747) (554)  
Ending balance 6,943 5,888  
Contract cost assets – current 3,196 2,572 $ 2,938
Contract cost assets, noncurrent 3,747 3,316  
Total deferred contract cost assets $ 6,943 $ 5,888 $ 6,539
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Summary of Allowance for Expected Credit Losses Activity (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Beginning Balance $ (165)  
Allowance for doubtful accounts (664)  
Provision for expected credit losses 532 $ 0
Write offs, net (33)  
Ending Balance (664)  
Accounting Standards Update 2016-13 | Cumulative Effect, Period of Adoption, Adjustment    
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Beginning Balance 0  
Allowance for doubtful accounts    
Accounting Standards Update 2016-13 | Cumulative Effect, Period of Adoption, Adjusted Balance    
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Beginning Balance $ (165)  
Allowance for doubtful accounts    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Prepaid expenses $ 6,994 $ 6,069  
Contract cost assets – current 3,196 2,938 $ 2,572
Other 608 440  
Total prepaid expenses and other current assets $ 10,798 $ 9,447  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property plant and equipment gross $ 11,705 $ 11,564
Less: Accumulated depreciation (7,814) (7,319)
Property and equipment, net 3,891 4,245
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Property plant and equipment gross 7,987 7,854
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property plant and equipment gross 2,732 2,732
Office equipment and furniture    
Property, Plant and Equipment [Line Items]    
Property plant and equipment gross $ 986 $ 978
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Line Items]    
Depreciation   $ 600
Loss on disposal of fixed assets $ 0 135
Office equipment and furniture    
Organization, Consolidation and Presentation of Financial Statements [Line Items]    
Loss on disposal of fixed assets $ 0 $ 100
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of Intangible Assets, Net (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross amount $ 491,591 $ 489,618
Intangible assets, accumulated amortization (206,179) (192,143)
Total amortization expense 285,412 297,475
Capitalized computer software, gross 21,416 19,443
Capitalized computer software, accumulated amortization (9,980) (8,592)
Capitalized computer software, net carrying amount 11,436 10,851
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross amount 343,300 343,300
Intangible assets, accumulated amortization (140,845) (132,298)
Total amortization expense 202,455 211,002
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross amount 96,400 96,400
Intangible assets, accumulated amortization (43,426) (40,360)
Total amortization expense 52,974 56,040
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross amount 24,975 24,975
Intangible assets, accumulated amortization (10,920) (10,205)
Total amortization expense 14,055 14,770
Non-competition agreements    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross amount 5,500 5,500
Intangible assets, accumulated amortization (1,008) (688)
Total amortization expense $ 4,492 $ 4,812
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of Estimated Useful Lives and Weighted Average Amortization Periods for Intangible Assets (Detail)
3 Months Ended
Mar. 31, 2023
Customer relationships  
Finite-Lived Intangible Assets [Line Items]  
Weighted Average Remaining Useful Life 5 years
Developed technology  
Finite-Lived Intangible Assets [Line Items]  
Weighted Average Remaining Useful Life 4 years
Trademarks  
Finite-Lived Intangible Assets [Line Items]  
Weighted Average Remaining Useful Life 5 years
Non-competition agreements  
Finite-Lived Intangible Assets [Line Items]  
Weighted Average Remaining Useful Life 4 years
Capitalized software  
Finite-Lived Intangible Assets [Line Items]  
Weighted Average Remaining Useful Life 3 years
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of amortization expense related to intangible assets (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Amortization of intangible assets $ 14,036 $ 12,344
Cost of revenues    
Finite-Lived Intangible Assets [Line Items]    
Amortization of intangible assets 4,454 3,434
General and administrative expense    
Finite-Lived Intangible Assets [Line Items]    
Amortization of intangible assets $ 9,582 $ 8,910
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of Estimated Future Amortization of Intangible Assets (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
2023 (remaining nine months) $ 41,133  
2024 53,415  
2025 47,535  
2026 42,510  
2027 42,052  
2028 24,901  
Thereafter 33,866  
Total amortization expense $ 285,412 $ 297,475
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Summary of Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued payroll and payroll-related expenses $ 8,791 $ 9,836
Accrued costs of revenues 5,408 3,141
Sales tax liability from acquisitions 4,572 4,572
Accrued operating costs 4,352 4,016
Accrued bonuses 4,315 5,947
User conference 1,971 755
Lease liability - current 1,139 1,223
Income taxes payable 889 939
Other accrued expenses 2,665 2,071
Total accrued liabilities $ 34,102 $ 32,500
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Purchase Commitments (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2023 (remaining nine months) $ 375
2024 395
2025 3,020
Total future minimum payments under non-cancelable purchase commitments $ 3,790
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Summary of Long-term Debt (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
2021 Term loan $ 430,650 $ 431,738
Debt issuance costs (4,618) (4,829)
Total debt, net 426,032 426,909
Current portion of long term debt 3,506 3,505
Debt issuance costs (844) (845)
Total non-current portion of long-term debt, net 422,526 423,404
Secured Debt | 2021 Term Loan    
Debt Instrument [Line Items]    
Current portion of long term debt $ 4,350 $ 4,350
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Nov. 10, 2021
Debt Instrument [Line Items]      
Amortization of financing costs $ 235 $ 484  
Interest expense 8,900 3,900  
Debt issuance costs, gross 7,600    
2021 Term Loan      
Debt Instrument [Line Items]      
Amortization of financing costs $ 200 $ 500  
Percent of original principal 0.25%    
Debt issuance costs, gross     $ 4,800
Interest rate, effective 8.50%    
2021 Term Loan | Base Rate | Variable Rate Component One      
Debt Instrument [Line Items]      
Basis spread on variable rate 3.00%    
2021 Term Loan | Adjusted Eurocurrency Rate | Variable Rate Component Two      
Debt Instrument [Line Items]      
Basis spread on variable rate 3.00%    
2021 Term Loan | Secured Debt      
Debt Instrument [Line Items]      
Term loan     435,000
2021 Revolving Credit Facility | Revolving Credit Facility      
Debt Instrument [Line Items]      
Debt issuance costs, gross     500
Commitment fee rate 0.50%    
2021 Revolving Credit Facility | Letter of Credit      
Debt Instrument [Line Items]      
Revolving credit facility, principal amount     10,000
2021 Revolving Credit Facility | Line of Credit | Revolving Credit Facility      
Debt Instrument [Line Items]      
Revolving credit facility, principal amount     50,000
Unused revolving credit facility balance $ 50,000    
First Lien      
Debt Instrument [Line Items]      
Debt issuance costs, gross     $ 2,800
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Summary of Future Principal Payments of Long-term Debt (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
2023 (remaining nine months) $ 3,263  
2024 4,350  
2025 4,350  
2026 4,350  
2027 4,350  
Thereafter 409,987  
Total $ 430,650 $ 431,738
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
May 31, 2022
Equity [Abstract]    
Stock repurchase program authorized amount   $ 75,000,000
Stock repurchased (in shares) 228,529  
Stock repurchased $ 3,499,000  
Stock remaining for repurchase under repurchase program $ 68,100,000  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Jul. 26, 2021
Mar. 31, 2023
Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Fair value of options vested   $ 1,100 $ 1,500
Intrinsic value of options exercised   900 400
Total share-based compensation expense   4,891 3,808
Unrecognized stock-based compensation expense related to stock options   $ 14,100  
Issuance of common stock through employee purchase plan (in shares)   127,700  
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense   $ 1,783 1,077
Capitalized software costs   100 100
Class B Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Liability balance related to unvested RSAs   $ 0 $ 10
Shares that remained subject to future vesting (in shares)   4,051 183,741
RSAs cancelled or forfeited (in shares)   0 22,212
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense   $ 1,300 $ 1,400
Unrecognized stock-based compensation expense, weighted -average period for recognition   2 years 6 months 21 days  
Restricted stock awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense   $ 100 $ 100
Vested (in shares)   59,558 484,401
Restricted stock units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense   $ 3,400 $ 2,200
Unrecognized stock-based compensation expense, weighted -average period for recognition   2 years 11 months 15 days  
Vested (in shares)   65,770  
Unrecognized stock-based compensation expense, awards other than options   $ 48,200  
Purchase rights committed under the ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense   100 $ 100
Unrecognized stock-based compensation expense, awards other than options   $ 100  
2021 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Common stock, capital shares reserved for future issuance (in shares) 13,171,588    
Annual increase in shares authorized, percentage 5.00%    
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Number of Options    
Beginning balance (in shares) 4,739,783  
Granted (in shares) 0  
Exercised (in shares) (97,412)  
Forfeited (in shares) (143,087)  
Ending balance (in shares) 4,499,284 4,739,783
Vested and expected to vest in the future (in shares) 4,499,284  
Exercisable at end of period (in shares) 2,951,792  
Weighted Average Exercise Price    
Beginning balance (in dollars per share) $ 13.21  
Granted (in dollars per share) 0  
Exercised (in dollars per share) 6.10  
Forfeited (in dollars per share) 21.78  
Ending balance (in dollars per share) 13.09 $ 13.21
Vested and expected to vest in the future (in dollars per share) 13.09  
Exercisable at end of period (in dollars per share) $ 9.28  
Weighted Average Remaining Contract Term and Aggregate Intrinsic Value    
Weighted average remaining contractual term 7 years 4 months 2 days 7 years 7 months 9 days
Weighted average remaining contractual term, vested and expected to vest in the future 7 years 4 months 2 days  
Weighted average remaining contractual term, exercisable at end of period 6 years 8 months 1 day  
Aggregate intrinsic value $ 28,349 $ 19,855
Aggregate intrinsic value, vested and expected to vest in the future 28,349  
Aggregate intrinsic value, exercisable at end of period $ 27,428  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Schedule of RSU Activity (Details)
3 Months Ended
Mar. 31, 2023
$ / shares
shares
Number of RSUs  
Non-vested ending balance (in shares) 3,211,411
Restricted stock units (RSUs)  
Number of RSUs  
Non-vested beginning balance (in shares) 3,111,831
Granted (in shares) 424,266
Vested (in shares) (65,770)
Forfeited (in shares) (258,916)
Non-vested ending balance (in shares) 3,211,411
Weighted Average Grant Date Fair Value  
Non-vested beginning balance (in dollars per share) | $ / shares $ 19.27
Granted (in dollars per share) | $ / shares 15.00
Vested (in dollars per share) | $ / shares 25.73
Forfeited (in dollars per share) | $ / shares 19.76
Non-vested ending balance (in dollars per share) | $ / shares $ 18.53
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Summary of Stock-based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense $ 4,891 $ 3,808
Cost of revenues    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 853 965
General and administrative expense    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 2,264 1,381
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 1,783 1,077
Sales and marketing    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 290 385
Restructuring related costs    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense $ (299) $ 0
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Effective income tax rate reconciliation, percent 17.00% 28.00%  
Uncertain tax positions $ 3.1   $ 2.5
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]      
Cost of revenues $ 23,501 $ 21,104  
General and administrative 22,555 18,187  
Research and development 13,812 8,409  
Sales and marketing 8,213 4,743  
Prepaid expenses and other current assets 10,798   $ 9,447
Total current assets 155,995   128,132
Accounts payable 3,986   1,249
Accrued liabilities 34,102   32,500
Total current liabilities 75,684   54,199
Affiliated Entity      
Related Party Transaction [Line Items]      
Cost of revenues 319 472  
General and administrative 248 207  
Research and development 162 63  
Sales and marketing 0 22  
Total related party expenses 729 $ 764  
Prepaid expenses and other current assets 156   37
Total current assets 156   37
Accounts payable 152   30
Accrued liabilities 529   456
Total current liabilities $ 681   $ 486
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Net (Loss) Income Per Share - Summary of calculation of basic and diluted net income (loss) per share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net income (loss) attributable to common stockholders, basic $ (5,666) $ 7,479
Net income (loss) attributable to common stockholders, diluted $ (5,666) $ 7,479
Weighted average common stock outstanding:    
Basic (in shares) 80,659,978 79,974,071
Diluted (in shares) 80,659,978 82,228,936
Net (loss) income per share:    
Basic (in dollars per share) $ (0.07) $ 0.09
Diluted (in dollars per share) $ (0.07) $ 0.09
Restricted stock awards, unvested    
Weighted average common stock outstanding:    
Effect of dilutive securities (shares) 0 488,291
Restricted stock units, unvested    
Weighted average common stock outstanding:    
Effect of dilutive securities (shares) 0 27,120
Purchase rights committed under the ESPP    
Weighted average common stock outstanding:    
Effect of dilutive securities (shares) 0 3,179
Stock options    
Weighted average common stock outstanding:    
Effect of dilutive securities (shares) 0 1,736,275
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Net (Loss) Income Per Share - Summary of outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per common unit attributable to common unitholders (Detail) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 2,618,477 2,351,017
Options to purchase common stock outstanding, unexercised    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 2,017,496 1,476,592
Restricted stock units, unvested    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 600,981 874,425
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring Activities (Details) - USD ($)
$ in Thousands
3 Months Ended
Feb. 24, 2023
Mar. 31, 2023
Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]      
Restructuring related costs   $ 2,904 $ 0
The "Plan"      
Restructuring Cost and Reserve [Line Items]      
Reduction in current workforce 9.00%    
The "Plan" | Minimum      
Restructuring Cost and Reserve [Line Items]      
Restructuring and related cost, expected cost $ 2,500    
The "Plan" | Maximum      
Restructuring Cost and Reserve [Line Items]      
Restructuring and related cost, expected cost $ 3,500    
Severance and related costs      
Restructuring Cost and Reserve [Line Items]      
Restructuring related costs   2,900  
Accrued severance and related costs   600  
Previously vested stock based compensation      
Restructuring Cost and Reserve [Line Items]      
Restructuring related costs   $ 300  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Business Combinations (Details) - USD ($)
$ in Thousands
3 Months Ended
Nov. 04, 2022
Apr. 01, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Business Acquisition [Line Items]          
Acquisition related costs     $ 0 $ 2,283  
Escrow deposit     30,000   $ 30,000
Purchase accounting adjustments, goodwill     245 0  
Beanstalk Networks, L.L.C. (OpenClose)          
Business Acquisition [Line Items]          
Cash consideration, gross $ 63,100        
Acquisition related costs $ 1,900        
Business acquisition, pro forma revenue       76,200  
Business acquisition, pro forma net income (loss)       $ 6,400  
StreetShares          
Business Acquisition [Line Items]          
Cash consideration, gross   $ 28,000      
Acquisition related costs   1,600      
Escrow deposit   $ 30,000      
Purchase accounting adjustments, goodwill     $ 200    
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details) - Subsequent Event - Restricted stock units (RSUs)
$ in Millions
1 Months Ended
Apr. 30, 2023
USD ($)
Subsequent Event [Line Items]  
Service-based RSUs awarded $ 43.6
Vesting period 4 years
XML 70 mlnk-20230331_htm.xml IDEA: XBRL DOCUMENT 0001834494 2023-01-01 2023-03-31 0001834494 2023-04-26 0001834494 2023-03-31 0001834494 2022-12-31 0001834494 2022-01-01 2022-03-31 0001834494 us-gaap:CommonStockMember 2022-12-31 0001834494 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001834494 us-gaap:RetainedEarningsMember 2022-12-31 0001834494 us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001834494 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001834494 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001834494 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001834494 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001834494 us-gaap:CommonStockMember 2023-03-31 0001834494 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001834494 us-gaap:RetainedEarningsMember 2023-03-31 0001834494 us-gaap:CommonStockMember 2021-12-31 0001834494 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001834494 us-gaap:RetainedEarningsMember 2021-12-31 0001834494 2021-12-31 0001834494 us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001834494 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001834494 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001834494 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001834494 us-gaap:CommonStockMember 2022-03-31 0001834494 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001834494 us-gaap:RetainedEarningsMember 2022-03-31 0001834494 2022-03-31 0001834494 mlnk:LendingSoftwareSolutionsMember 2023-01-01 2023-03-31 0001834494 mlnk:LendingSoftwareSolutionsMember 2022-01-01 2022-03-31 0001834494 mlnk:DataVerificationSoftwareSolutionsMember 2023-01-01 2023-03-31 0001834494 mlnk:DataVerificationSoftwareSolutionsMember 2022-01-01 2022-03-31 0001834494 mlnk:LendingSoftwareSolutionsMember 2023-01-01 2023-03-31 0001834494 mlnk:LendingSoftwareSolutionsMember 2022-01-01 2022-03-31 0001834494 mlnk:DataVerificationSoftwareSolutionsMember 2023-01-01 2023-03-31 0001834494 mlnk:DataVerificationSoftwareSolutionsMember 2022-01-01 2022-03-31 0001834494 mlnk:SubscriptionFeesMember 2023-01-01 2023-03-31 0001834494 mlnk:SubscriptionFeesMember 2022-01-01 2022-03-31 0001834494 mlnk:ProfessionalServicesMember 2023-01-01 2023-03-31 0001834494 mlnk:ProfessionalServicesMember 2022-01-01 2022-03-31 0001834494 us-gaap:ServiceOtherMember 2023-01-01 2023-03-31 0001834494 us-gaap:ServiceOtherMember 2022-01-01 2022-03-31 0001834494 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2022-12-31 0001834494 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccountingStandardsUpdate201613Member 2022-12-31 0001834494 us-gaap:ComputerEquipmentMember 2023-03-31 0001834494 us-gaap:ComputerEquipmentMember 2022-12-31 0001834494 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001834494 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001834494 us-gaap:OfficeEquipmentMember 2023-03-31 0001834494 us-gaap:OfficeEquipmentMember 2022-12-31 0001834494 us-gaap:OfficeEquipmentMember 2022-01-01 2022-03-31 0001834494 us-gaap:OfficeEquipmentMember 2023-01-01 2023-03-31 0001834494 us-gaap:CustomerRelationshipsMember 2023-03-31 0001834494 us-gaap:DevelopedTechnologyRightsMember 2023-03-31 0001834494 us-gaap:TrademarksMember 2023-03-31 0001834494 us-gaap:NoncompeteAgreementsMember 2023-03-31 0001834494 us-gaap:CustomerRelationshipsMember 2022-12-31 0001834494 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001834494 us-gaap:TrademarksMember 2022-12-31 0001834494 us-gaap:NoncompeteAgreementsMember 2022-12-31 0001834494 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0001834494 us-gaap:DevelopedTechnologyRightsMember 2023-01-01 2023-03-31 0001834494 us-gaap:TrademarksMember 2023-01-01 2023-03-31 0001834494 us-gaap:NoncompeteAgreementsMember 2023-01-01 2023-03-31 0001834494 mlnk:CapitalizedSoftwareMember 2023-01-01 2023-03-31 0001834494 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001834494 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001834494 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001834494 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001834494 mlnk:A2021TermLoanMember us-gaap:SecuredDebtMember 2023-03-31 0001834494 mlnk:A2021TermLoanMember us-gaap:SecuredDebtMember 2022-12-31 0001834494 mlnk:A2021TermLoanMember us-gaap:SecuredDebtMember 2021-11-10 0001834494 us-gaap:RevolvingCreditFacilityMember mlnk:A2021RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-11-10 0001834494 us-gaap:LetterOfCreditMember mlnk:A2021RevolvingCreditFacilityMember 2021-11-10 0001834494 mlnk:A2021TermLoanMember mlnk:AdjustedEurocurrencyRateMember mlnk:VariableRateComponentTwoMember 2023-01-01 2023-03-31 0001834494 mlnk:A2021TermLoanMember us-gaap:BaseRateMember mlnk:VariableRateComponentOneMember 2023-01-01 2023-03-31 0001834494 mlnk:A2021TermLoanMember 2023-03-31 0001834494 mlnk:A2021TermLoanMember 2021-11-10 0001834494 mlnk:FirstLienMember 2021-11-10 0001834494 mlnk:A2021TermLoanMember 2023-01-01 2023-03-31 0001834494 mlnk:A2021TermLoanMember 2022-01-01 2022-03-31 0001834494 us-gaap:RevolvingCreditFacilityMember mlnk:A2021RevolvingCreditFacilityMember 2021-11-10 0001834494 us-gaap:RevolvingCreditFacilityMember mlnk:A2021RevolvingCreditFacilityMember 2023-01-01 2023-03-31 0001834494 us-gaap:RevolvingCreditFacilityMember mlnk:A2021RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-03-31 0001834494 2022-05-31 0001834494 mlnk:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2021-07-26 0001834494 mlnk:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2021-07-26 2021-07-26 0001834494 2022-01-01 2022-12-31 0001834494 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001834494 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001834494 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001834494 us-gaap:CapitalUnitClassBMember 2023-03-31 0001834494 us-gaap:CapitalUnitClassBMember 2022-03-31 0001834494 us-gaap:CapitalUnitClassBMember 2023-01-01 2023-03-31 0001834494 us-gaap:CapitalUnitClassBMember 2022-01-01 2022-03-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001834494 us-gaap:EmployeeStockMember 2023-03-31 0001834494 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001834494 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001834494 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001834494 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001834494 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001834494 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001834494 us-gaap:RestructuringChargesMember 2023-01-01 2023-03-31 0001834494 us-gaap:RestructuringChargesMember 2022-01-01 2022-03-31 0001834494 srt:AffiliatedEntityMember 2023-01-01 2023-03-31 0001834494 srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001834494 srt:AffiliatedEntityMember 2023-03-31 0001834494 srt:AffiliatedEntityMember 2022-12-31 0001834494 mlnk:RestrictedStockAwardsUnvestedMember 2023-01-01 2023-03-31 0001834494 mlnk:RestrictedStockAwardsUnvestedMember 2022-01-01 2022-03-31 0001834494 mlnk:RestrictedStockUnitsUnvestedMember 2023-01-01 2023-03-31 0001834494 mlnk:RestrictedStockUnitsUnvestedMember 2022-01-01 2022-03-31 0001834494 mlnk:OptionsToPurchaseCommonStockOutstandingUnexercisedMember 2023-01-01 2023-03-31 0001834494 mlnk:OptionsToPurchaseCommonStockOutstandingUnexercisedMember 2022-01-01 2022-03-31 0001834494 mlnk:RestrictedStockUnitsUnvestedMember 2023-01-01 2023-03-31 0001834494 mlnk:RestrictedStockUnitsUnvestedMember 2022-01-01 2022-03-31 0001834494 mlnk:ThePlanMember 2023-02-24 2023-02-24 0001834494 srt:MinimumMember mlnk:ThePlanMember 2023-02-24 0001834494 srt:MaximumMember mlnk:ThePlanMember 2023-02-24 0001834494 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-03-31 0001834494 us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-03-31 0001834494 us-gaap:EmployeeSeveranceMember 2023-03-31 0001834494 mlnk:BeanstalkNetworksLLCMember 2022-11-04 2022-11-04 0001834494 mlnk:BeanstalkNetworksLLCMember 2022-01-01 2022-03-31 0001834494 mlnk:StreetSharesMember 2022-04-01 2022-04-01 0001834494 mlnk:StreetSharesMember 2022-04-01 0001834494 mlnk:StreetSharesMember 2023-01-01 2023-03-31 0001834494 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-30 shares iso4217:USD iso4217:USD shares mlnk:Segment pure 2023 Q1 false 0001834494 --12-31 10-Q true 2023-03-31 false 001-40680 MeridianLink, Inc. DE 82-4844620 3560 Hyland Avenue Suite 200 Costa Mesa CA 92626 714 708-6950 Common stock, par value $0.001 per share MLNK NYSE Yes Yes Accelerated Filer false true false false 80645366 77796000 55780000 37401000 32905000 10798000 9447000 30000000 30000000 155995000 128132000 3891000 4245000 1929000 2185000 285412000 297475000 14893000 13939000 608902000 608657000 4784000 4524000 1075806000 1059157000 3986000 1249000 34102000 32500000 34090000 16945000 3506000 3505000 75684000 54199000 422526000 423404000 992000 1141000 1165000 1322000 500367000 480066000 0.001 0.001 50000000 50000000 0 0 0 0 0 0 0.001 0.001 600000000 600000000 80636894 80636894 80644452 80644452 132000 128000 626905000 621396000 -51598000 -42433000 575439000 579091000 1075806000 1059157000 77135000 72754000 23501000 21104000 4454000 3434000 27955000 24538000 49180000 48216000 22555000 18187000 13812000 8409000 8213000 4743000 0 2283000 2904000 0 47484000 33622000 1696000 14594000 470000 163000 9031000 4358000 -8561000 -4195000 -6865000 10399000 -1199000 2920000 -5666000 7479000 -0.07 0.09 -0.07 0.09 80659978 79974071 80659978 82228936 80644452 128000 621396000 -42433000 579091000 59558 4000 4000 65770 97412 594000 594000 1769 24000 24000 228529 3499000 3499000 4939000 4939000 -5666000 -5666000 80636894 132000 626905000 -51598000 575439000 79734984 88000 596542000 -40352000 556278000 484401 32000 32000 76937 28909 179000 179000 3887000 3887000 7479000 7479000 80325231 120000 600608000 -32873000 567855000 -5666000 7479000 14531000 12905000 532000 0 235000 484000 4891000 3808000 0 -135000 -1198000 2679000 5028000 7248000 1636000 460000 2717000 301000 1706000 194000 16997000 14586000 28081000 34863000 1924000 1522000 134000 419000 -2058000 -1941000 3490000 0 594000 179000 24000 0 1087000 0 -4007000 179000 22016000 33101000 55780000 113645000 77796000 146746000 9019000 3869000 50000 44000 245000 0 79000 0 48000 79000 9000 0 4000 32000 0 3372000 0 2627000 Organization and Description of BusinessMeridianLink, Inc., and its wholly-owned subsidiaries, (collectively the “Company”), provides secure, cloud-based digital solutions that transform the ways in which traditional and emerging financial services providers engage with account holders and end users. The Company sells its solutions to financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. The Company delivers its solutions to the substantial majority of its customers using a software-as-a-service (“SaaS”) model under which its customers pay subscription fees for the use of the Company’s solutions. The Company is controlled by its majority stockholder, which is represented by various investment funds of Thoma Bravo UGP, LLC and its affiliates (“Thoma Bravo”). The Company is headquartered in Costa Mesa, California. Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements of the Company have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or the consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations, stockholders’ equity, and cash flows for the three months ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of March 31, 2023, and its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three months ended March 31, 2023 and 2022, are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 9, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating and Reportable Segment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business and financial information on a consolidated basis for the purposes of evaluating financial performance and the allocation of resources. The Company's management determined that it operates in one operating and reportable segment that is focused exclusively on providing cloud-based digital solutions in the United States. In reaching this conclusion, management considers the definition of the chief operating decision maker (“CODM”), how the business is defined by the CODM, the nature of the information provided to the CODM and how that information is used to make operating decisions, allocate resources, and assess performance. The Company's CODM is the chief executive officer. The results of operations provided to and analyzed by the CODM are at the consolidated level, and accordingly, key resource decisions and assessment of performance are performed at the consolidated level. The Company assesses its determination of operating segments at least annually.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses. Significant items subject to such estimates include revenue recognition including determining the nature and timing of satisfaction of performance obligations and variable consideration; allowance for credit losses; share-based compensation; the fair value of acquired intangibles; the capitalization of software development costs; the useful lives of long-lived intangible assets; impairment of goodwill and long-lived assets; and income taxes. In accordance with GAAP, management bases its estimates on historical experience and on</span><span style="color:#332f2f;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various other assumptions that management believes are reasonable under the circumstances. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s significant accounting policies are discussed in Note 2, “Significant Accounting Policies” in the Company’s Annual Report. There have been no changes to the Company’s significant accounting policies described in the Company’s Annual Report that have had a material impact on its condensed consolidated financial statements and related notes, except for updates resulting from the adoption of ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326)” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is discussed in more detail within Note 3, “Revenue Recognition.”</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted this guidance effective January 1, 2023, and the adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and disclosures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional guidance for a limited time to ease the potential accounting burden associated with transitioning away from reference rates, such as the London Inter-Bank Offered Rate (LIBOR), which regulators in the United Kingdom are currently phasing out. The expedients and exceptions provided by ASU 2020-04 are for the application of U.S. GAAP to contracts, hedging relationships, and other transactions affected by the rate reform. Companies can apply the ASU immediately, however, the guidance will only be available for a limited time. In December 2022, the FASB issued ASU 2022-06 which deferred the sunset date from December 31, 2022 to December 31, 2024, after which companies will no longer be permitted to apply the transition relief. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements of the Company have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or the consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations, stockholders’ equity, and cash flows for the three months ended March 31, 2023 and 2022 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of March 31, 2023, and its consolidated results of operations and cash flows for the three months ended March 31, 2023 and 2022. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three months ended March 31, 2023 and 2022, are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 9, 2023.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating and Reportable Segment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business and financial information on a consolidated basis for the purposes of evaluating financial performance and the allocation of resources. The Company's management determined that it operates in one operating and reportable segment that is focused exclusively on providing cloud-based digital solutions in the United States. In reaching this conclusion, management considers the definition of the chief operating decision maker (“CODM”), how the business is defined by the CODM, the nature of the information provided to the CODM and how that information is used to make operating decisions, allocate resources, and assess performance. The Company's CODM is the chief executive officer. The results of operations provided to and analyzed by the CODM are at the consolidated level, and accordingly, key resource decisions and assessment of performance are performed at the consolidated level. The Company assesses its determination of operating segments at least annually.</span></div> 1 1 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses. Significant items subject to such estimates include revenue recognition including determining the nature and timing of satisfaction of performance obligations and variable consideration; allowance for credit losses; share-based compensation; the fair value of acquired intangibles; the capitalization of software development costs; the useful lives of long-lived intangible assets; impairment of goodwill and long-lived assets; and income taxes. In accordance with GAAP, management bases its estimates on historical experience and on</span><span style="color:#332f2f;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various other assumptions that management believes are reasonable under the circumstances. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from those estimates.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted this guidance effective January 1, 2023, and the adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements and disclosures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional guidance for a limited time to ease the potential accounting burden associated with transitioning away from reference rates, such as the London Inter-Bank Offered Rate (LIBOR), which regulators in the United Kingdom are currently phasing out. The expedients and exceptions provided by ASU 2020-04 are for the application of U.S. GAAP to contracts, hedging relationships, and other transactions affected by the rate reform. Companies can apply the ASU immediately, however, the guidance will only be available for a limited time. In December 2022, the FASB issued ASU 2022-06 which deferred the sunset date from December 31, 2022 to December 31, 2024, after which companies will no longer be permitted to apply the transition relief. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.</span></div> Revenue Recognition<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s net revenues by solution type (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lending Software Solutions </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Verification Software Solutions</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,754 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lending Software Solutions accounted for 75%, and 68% of total revenues for the three months ended March 31, 2023 and 2022, respectively. Data Verification Software Solutions accounted for 25% and 32% of total revenues for the three months ended March 31, 2023 and 2022 respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s net revenues by major source (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subscription fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,754 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the Company’s deferred revenue as of March 31, 2023 and 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billing of transaction consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,082 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,090 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,082 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets Recognized from Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in contract cost assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,943 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,888 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets, current</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets, noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred contract cost assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,888 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, the Company adopted the requirements of ASU 2016-13-Credit Loses, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) using a modified retrospective method of adoption. The Standard replaces the existing incurred credit loss model with the current expected credit losses model for financial instruments, including accounts receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable includes billed and unbilled receivables, net of an allowance for credit losses. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The Company recognizes an allowance for credit losses on accounts receivable in an amount equal to the current expected credit losses. The estimation of the allowance is based on an analysis of historical loss experience, current receivables aging, and management’s assessment of current conditions and estimated future conditions, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses collectability by pooling receivables where similar characteristics exist and evaluates receivables individually when specific customer balances no longer share those risk characteristics and are considered at risk or uncollectible. The expense associated with the allowance for expected credit losses is recognized in general and administrative expenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company’s allowance for expected credit losses balance for the three months ended March 31, 2023 is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for doubtful accounts, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of adopting ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for expected credit losses, January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write offs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for expected credit losses, March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s net revenues by solution type (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lending Software Solutions </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Verification Software Solutions</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,754 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s net revenues by major source (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subscription fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,754 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 58001000 49167000 19134000 23587000 77135000 72754000 0.75 0.68 0.25 0.32 66405000 63469000 8435000 7112000 2295000 2173000 77135000 72754000 <div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the Company’s deferred revenue as of March 31, 2023 and 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billing of transaction consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,082 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,090 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,082 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,293 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 18086000 14707000 94131000 87340000 77135000 72754000 35082000 29293000 34090000 29293000 992000 0 35082000 29293000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in contract cost assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,943 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,888 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets, current</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets, noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred contract cost assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,888 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 6539000 5835000 1151000 607000 747000 554000 6943000 5888000 3196000 2572000 3747000 3316000 6943000 5888000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company’s allowance for expected credit losses balance for the three months ended March 31, 2023 is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for doubtful accounts, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of adopting ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for expected credit losses, January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write offs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for expected credit losses, March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 165000 0 165000 532000 33000 664000 Balance Sheet Components<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets – current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,705 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,564 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,891 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense amounted to $0.5 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively. The Company disposed of office furniture that resulted in a loss of $0.1 million for the three months ended March 31, 2022. The losses are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. There were no disposals of property and equipment for the three months ended March 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,845)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-competition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,591 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206,179)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,298)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-competition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,618 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,143)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,475 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining useful lives for intangible assets at March 31, 2023 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-competition agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,036 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,344 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of intangible assets as of March 31, 2023 was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and payroll-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued costs of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax liability from acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">User conference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,069 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets – current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6994000 6069000 3196000 2938000 608000 440000 10798000 9447000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,705 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,564 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,891 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7987000 7854000 2732000 2732000 986000 978000 11705000 11564000 7814000 7319000 3891000 4245000 600000 -100000 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,845)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-competition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,591 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206,179)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,298)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-competition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,618 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,143)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,475 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining useful lives for intangible assets at March 31, 2023 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-competition agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div> 343300000 140845000 202455000 96400000 43426000 52974000 24975000 10920000 14055000 5500000 1008000 4492000 21416000 9980000 11436000 491591000 206179000 285412000 343300000 132298000 211002000 96400000 40360000 56040000 24975000 10205000 14770000 5500000 688000 4812000 19443000 8592000 10851000 489618000 192143000 297475000 P5Y P4Y P5Y P4Y P3Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,036 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,344 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 4454000 3434000 9582000 8910000 14036000 12344000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of intangible assets as of March 31, 2023 was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 41133000 53415000 47535000 42510000 42052000 24901000 33866000 285412000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and payroll-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued costs of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax liability from acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">User conference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8791000 9836000 5408000 3141000 4572000 4572000 4352000 4016000 4315000 5947000 1971000 755000 1139000 1223000 889000 939000 2665000 2071000 34102000 32500000 Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, and from time to time may be, involved in legal proceedings and claims arising out of the Company’s operations in the ordinary course of business. Management is not currently aware of any legal proceedings or claims against it that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contractual Commitments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contractual commitments primarily consist of third-party cloud infrastructure agreements and service subscription arrangements used to support operations at the enterprise level. Future minimum payments under the Company’s non-cancelable purchase commitments as of March 31, 2023 are as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Commitments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ending December 31, </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> Future minimum payments under the Company’s non-cancelable purchase commitments as of March 31, 2023 are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Commitments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ending December 31, </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 375000 395000 3020000 3790000 Long-Term Debt<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Term loan</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current portion of long-term debt, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current portion of long-term debt, net </span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,526 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,404 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of deferred financing fees was $0.2 million and $0.5 million for the three months ended March 31, 2023 and 2022 respectively. Total interest expense, excluding amortization of deferred financing fees, was $8.9 million and $3.9 million, for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Credit Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2021, the Company entered into a credit agreement (the “2021 Credit Agreement”), which provides for a term loan facility (the “2021 Term Loan”) in an aggregate principal amount of $435.0 million, and a revolving credit facility (the “2021 Revolving Credit Facility”) in an aggregate principal amount of $50.0 million, inclusive of a $10.0 million letter of credit sub-facility. The Company used the proceeds from the 2021 Term Loan to pay all outstanding amounts due under the Company’s previous 2018 First Lien plus certain fees and expenses. The 2021 Term Loan and 2021 Revolving Credit Facility mature on November 10, 2028 and November 10, 2026, respectively. The Company has not drawn on the 2021 Revolving Credit Facility as of March 31, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the 2021 Credit Agreement are secured by a lien on substantially all tangible and intangible property of the Company, subject to customary exceptions, limitations, and exclusions from the collateral.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement contains customary affirmative covenants, negative covenants and events of default, including covenants and restrictions that, among other things, require the Company to satisfy a financial covenant, and restricts or limits the ability of the Company to grant or incur liens, incur additional indebtedness, enter into joint ventures or partnerships, engage in mergers and acquisitions, engage in asset sales, and declare dividends on its capital stock, subject in each case to certain customary exceptions. A failure to comply with certain covenants could permit the lenders to declare the 2021 Term Loan, and any then outstanding borrowings on the 2021 Revolving Credit Facility, together with accrued interest and fees thereon, to be immediately due and payable. The Company was in compliance with all financial covenants of the 2021 Credit Agreement at March 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2021 Term Loan bear interest at a variable rate, elected by the Company, equal to the Base Rate (as defined in the 2021 Credit Agreement) or the Adjusted Eurocurrency Rate (as defined in the 2021 Credit Agreement), plus, an initial margin based on the Company’s Consolidated First Lien Net Leverage Ratio (as defined by the 2021 Credit Agreement), which was 3.00% at March 31, 2023. Beginning in June 2022, the Company is required to make quarterly principal payments equal to 0.25% of the original principal, with the remainder due at maturity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs of $7.6 million were included as a reduction of the debt balance on the condensed consolidated balance sheets and are amortized into interest expense over the contractual life of the loans using the effective interest method. Included in the debt issuance costs were $4.8 million incurred in connection with the 2021 Term Loan, and $2.8 million carried forward from the Company’s previous 2018 First Lien. The Company recognized $0.2 million, and $0.5 million of amortization of debt issuance costs for the 2021 Term Loan during the three months ended March 31, 2023 and 2022, respectively. The effective interest rate on the 2021 Term Loan was 8.5% as of March 31, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Revolving Credit Facility</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2021 Revolving Credit Facility bear interest, at the election of the Company, at a rate equal to the Base Rate (as defined in the 2021 Credit Agreement) or the Adjusted Eurocurrency Rate (as defined in the 2021 Credit Agreement), plus, in each case, the Applicable Rate (as defined in the 2021 Credit Agreement), which shall vary based on the Company’s Consolidated First Lien Net Leverage Ratio.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 Revolving Credit Facility, the Company incurred $0.5 million in debt issuance costs. Expenses associated with the issuance of the revolving credit facility are presented in the accompanying condensed consolidated balance sheets in prepaid expenses and other current assets and other assets, and are amortized to interest expense over the life of the 2021 Revolving Credit Facility using the straight-line method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility also requires a quarterly commitment fee based on the Company’s consolidated first lien net leverage ratio. As of March 31, 2023, the applicable rate was 0.5%, which was applied against the $50.0 million unused revolving credit facility balance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Principal Payments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments of long-term debt as of March 31, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Term loan</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current portion of long-term debt, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current portion of long-term debt, net </span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,526 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,404 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 430650000 431738000 4618000 4829000 426032000 426909000 4350000 4350000 844000 845000 3506000 3505000 422526000 423404000 200000 500000 8900000 3900000 435000000 50000000 10000000 0.0300 0.0300 0.0025 7600000 4800000 2800000 200000 500000 0.085 500000 0.005 50000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments of long-term debt as of March 31, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3263000 4350000 4350000 4350000 4350000 409987000 430650000 Stockholders’ Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company’s board of directors authorized a new stock repurchase program to acquire up to $75.0 million of the Company’s common stock, with no requirement to purchase any minimum number of shares. The manner, timing, and actual number of shares repurchased under the program will depend on a variety of factors, including price, working capital needs, general business and market conditions, regulatory requirements, and other investment opportunities. Shares may be repurchased through privately negotiated transactions, or open market purchases, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934. The repurchase program may be commenced, suspended, or terminated at any time by the Company at its discretion without prior notice.</span></div>The Company retires the repurchased shares, which automatically return to the status of authorized but unissued shares of common stock. The cost of the repurchased shares, including commissions, fees, and excise taxes are recorded as an adjustment to retained earnings on the Company’s condensed consolidated balance sheets and statements of stockholders’ equity. During the three months ended March 31, 2023, the Company repurchased 228,529 shares of its common stock for $3.5 million, including commissions, fees, and excise taxes. As of March 31, 2023, there was a total of $68.1 million remaining for repurchase under the stock repurchase program. 75000000 228529 3500000 68100000 Share-based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Stock Option and Incentive Plan (the “2021 Plan”) was adopted by the board of directors and approved by the Company’s stockholders following the Corporate Conversion and became effective as of July 26, 2021. The 2021 Plan replaced both the Company’s 2019 Equity Option Plan (the “2019 Plan”) and the Project Angel Parent, LLC Equity Plan (the “2018 Plan”). Outstanding options to purchase Class B Units granted under the 2019 Plan were converted into options to purchase shares of common stock, and all outstanding Carried Equity Units granted under the 2018 Plan were converted into restricted stock awards (“RSAs”), both of which have been granted under the 2021 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had initially reserved 13,171,588 shares of its common stock for the issuance of awards under the 2021 Plan. The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase on January 1, 2022 and each January 1 thereafter, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s compensation committee. The number of shares reserved under the 2021 Plan is subject to adjustment in the event of a stock split, stock dividend, or other change in the Company’s capitalization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Plan provides flexibility to the Company’s compensation committee to use various equity-based incentive awards as compensation tools to motivate the Company’s workforce. The incentive awards that may be granted under the 2021 Plan include, but are not limited to, options to purchase common stock, stock appreciation rights, restricted shares of common stock, restricted stock units, and cash bonuses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity during the three months ended March 31, 2023 is as follows (in thousands, except options, price per option, and term amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contract Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – January 1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.61</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.34</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest in the future at March 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.09 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.34</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,349 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,951,792 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,428 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options that vested during the three months ended March 31, 2023 and 2022 was</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million and $1.5 million, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $0.9 million and $0.4 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $1.3 million and $1.4 million in share-based compensation expense related to time-based and performance-based stock options for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023 and 2022, performance-based options were probable of vesting and, therefore, were included as part of share-based compensation expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was $14.1 million of unrecognized share-based compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.56 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of restricted stock awards (“RSAs”) that vested during the three months ended March 31, 2023 and 2022 was 59,558 and 484,401, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability balance as of March 31, 2023 and 2022, related to the unvested RSAs was $0.00 million and $0.01 million, respectively. As of March 31, 2023 and 2022, the number of unvested RSAs amounted to 4,051 and 183,741, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were a total of 0 and 22,212 RSAs cancelled or forfeited during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.1 million and $0.1 million in share-based compensation expense related to the vesting of RSAs for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit (“RSU”) activity during the three months ended March 31, 2023, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested – January 1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested – March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211,411 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, 3,211,411 RSUs are expected to vest. The Company recognized $3.4 million and $2.2 million in share-based compensation expense related to RSUs for the three months ended March 31, 2023, and 2022, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was $48.2 million of unrecognized share-based compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of 2.96 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Program</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has issued 127,700 shares of common stock pursuant to the 2021 Employee Stock Purchase Plan under its employee stock purchase program (“ESPP”). As of March 31, 2023, there was $0.1 million of unrecognized share-based compensation related to the ESPP that is expected to be recognized over the remaining term of the current offering period. The Company recognized $0.1 million and $0.1 million of share-based compensation expense related to the ESPP for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation for share-based awards granted to participants has been recorded in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,891 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">______________</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of $0.1 million and $0.1 million additions to capitalized software on the Company’s condensed consolidated balance sheets during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Relates to unvested stock compensation that was forfeited as part of the Restructuring Plan. See Note 12, “Restructuring.”</span></div> 13171588 0.05 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity during the three months ended March 31, 2023 is as follows (in thousands, except options, price per option, and term amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contract Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – January 1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.61</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.34</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest in the future at March 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.09 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.34</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,349 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,951,792 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,428 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4739783 13.21 P7Y7M9D 19855000 0 0 97412 6.10 143087 21.78 4499284 13.09 P7Y4M2D 28349000 4499284 13.09 P7Y4M2D 28349000 2951792 9.28 P6Y8M1D 27428000 1100000 1500000 900000 400000 1300000 1400000 14100000 P2Y6M21D 59558 484401 0 10000.00 4051 183741 0 22212 100000 100000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit (“RSU”) activity during the three months ended March 31, 2023, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested – January 1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested – March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211,411 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3111831 19.27 424266 15.00 65770 25.73 258916 19.76 3211411 18.53 3211411 3400000 2200000 48200000 P2Y11M15D 127700 100000 100000 100000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation for share-based awards granted to participants has been recorded in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,891 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">______________</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of $0.1 million and $0.1 million additions to capitalized software on the Company’s condensed consolidated balance sheets during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Relates to unvested stock compensation that was forfeited as part of the Restructuring Plan. See Note 12, “Restructuring.”</span></div> 853000 965000 2264000 1381000 1783000 1077000 290000 385000 -299000 0 4891000 3808000 100000 100000 Income Taxes <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with applicable accounting guidance, the Company is required to use an estimated annual effective tax rate to compute its tax provision during an interim period. The Company’s provision for income taxes reflected an effective tax rate of 17% and 28% for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to R&amp;D credits, state taxes, permanent unfavorable differences related to share-based compensation expense, certain employee remuneration under section 162(m) of the Internal Revenue Code, and other expected permanent differences. During the three months ended March 31, 2022, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to R&amp;D credits, state taxes, permanent differences related to share-based compensation expense, and other expected permanent differences. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has gross unrecognized tax benefits with respect to R&amp;D credits of $3.1 million as of March 31, 2023 and $2.5 million as of December 31, 2022. Penalties and interest have been recorded on these liabilities as the credits have started to be utilized.</span></div>The Company assesses whether a valuation allowance should be recorded against its deferred tax assets based on the consideration of all available evidence, using a “more likely than not” realization standard. The four sources of taxable income that must be considered in determining whether deferred tax assets will be realized are: (l) future reversals of existing taxable temporary differences (i.e., offset of gross deferred tax assets against gross deferred tax liabilities); (2) taxable income in prior carryback years, if carryback is permitted under the applicable tax law; (3) tax planning strategies; and (4) future taxable income exclusive of reversing temporary differences and carryforwards. Based on the evaluation of the evidence and sources of taxable income, the Company has determined that no valuation allowance is necessary as of March 31, 2023. 0.17 0.28 3100000 2500000 Related Party Transactions<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of related party transactions on the Company’s condensed consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related party expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of related party transactions on the Company’s condensed consolidated balance sheets (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of related party transactions on the Company’s condensed consolidated statements of operations (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related party expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the impact of related party transactions on the Company’s condensed consolidated balance sheets (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 319000 472000 248000 207000 162000 63000 0 22000 729000 764000 156000 37000 156000 37000 152000 30000 529000 456000 681000 486000 Net (Loss) Income Per Share<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net (loss) income per share (in thousands, except share and per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net (loss) income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,974,071</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,228,936</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the denominator used in the calculation of basic and diluted earnings per share is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,974,071</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, unexercised</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,275</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,291</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,120</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase rights committed under the ESPP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for diluted earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,228,936</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders because their impact would have been anti-dilutive for the periods presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock outstanding, unexercised</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units, unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351,017 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net (loss) income per share (in thousands, except share and per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net (loss) income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common stock outstanding:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,974,071</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,228,936</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the denominator used in the calculation of basic and diluted earnings per share is as follows: </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,974,071</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, unexercised</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,275</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,291</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,120</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase rights committed under the ESPP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for diluted earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,659,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,228,936</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -5666000 -5666000 7479000 7479000 80659978 79974071 80659978 82228936 -0.07 0.09 -0.07 0.09 80659978 79974071 0 1736275 0 488291 0 27120 0 3179 80659978 82228936 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders because their impact would have been anti-dilutive for the periods presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock outstanding, unexercised</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units, unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351,017 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2017496 1476592 600981 874425 2618477 2351017 Restructuring Activities<div style="margin-top:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company’s board of directors authorized a restructuring plan (the “Restructuring Plan”) that was designed to consolidate the Company’s functions and investments to prioritize customer-centric areas of the Company’s organization, align teams with the Company’s highest business priorities, and improve efficiencies. The Restructuring Plan included a reduction of the Company’s current workforce by 9%.</span></div>The Company estimated that it would incur charges of $2.5 million to $3.5 million in connection with the Restructuring Plan, consisting primarily of cash expenditures and relating to employee severance payments, employee benefits, and employee transition costs. Restructuring charges of $2.9 million for severance and related costs, net of $0.3 million previously vested stock based compensation, was recognized during the three months ended March 31, 2023, and is reflected in restructuring related costs on the Company’s condensed consolidated statements of operations. Accrued severance and related costs as of March 31, 2023 were $0.6 million. The Company expects to incur the remaining estimated restructuring related costs during the second quarter of 2023. 0.09 2500000 3500000 2900000 300000 600000 Business Combinations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of OpenClose</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2022, the Company acquired all of the outstanding stock of Beanstalk Networks L.L.C. doing business as OpenClose (“OpenClose”) for cash consideration of $63.1 million. In connection with the acquisition, the Company incurred $1.9 million in acquisition related costs. The acquisition was funded by the Company’s available cash. OpenClose is based out of West Palm Beach, Florida, and provides mortgage lending technology, with a particular focus on supporting depository institutions. The acquisition is expected to improve the company’s existing lending platform and improve our offerings for depository institutions. The acquisition is accounted for using the acquisition method of accounting whereby the acquired assets and liabilities will be recorded at their respective fair values and added to those of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company is still finalizing the provisional purchase price allocation related to final working capital adjustments and income tax effects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Financial Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma statements of operations data for the three months ended March 31, 2022 give effect to the OpenClose acquisition, described above, as if it had occurred at January 1, 2021. These amounts have been calculated after adjusting the operating results of OpenClose for the following primary items: (1) additional intangible amortization from the transaction, (2) acquisition-related expenses incurred, and (3) the related tax effects of the above adjustments. For the three months ended March 31, 2022, pro forma revenue was $76.2 million, and pro forma earnings reflect net income of $6.4 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the acquisitions taken place as of January 1, 2021, or the results of our future operations. Furthermore, the pro forma results do not give effect to all cost savings or incremental costs that may occur as a result of the integration and consolidation of the completed acquisitions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of StreetShares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the Company acquired all of the outstanding stock of StreetShares, Inc. (“StreetShares”) for cash consideration of $28.0 million, $30.0 million in escrow for a contingent earnout that expires April 1, 2023, subject to adjustment as defined in the purchase agreement, and $1.6 million in acquisition costs. The $30.0 million is considered contingent consideration and accounted for separate from the business combination accounting. The acquisition was funded by the Company’s available cash. StreetShares is based out of Reston, VA, and is a financial technology company that provides digital small business lending technology to banks and credit unions. The acquisition is accounted for using the acquisition method of accounting whereby the acquired assets and liabilities are recorded at their respective fair values and added to those of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. Results of operations of StreetShares have been included in the operations of the Company beginning with the closing date of the acquisition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company completed the provisional purchase price allocation related to income tax effects, resulting in a reduction to the deferred tax asset and corresponding increase to goodwill in the amount of $0.2 million. </span></div>Pro forma information for the StreetShares acquisition is not provided because their historical operating results were not material to the Company’s consolidated results of operations. 63100000 1900000 76200000 6400000 28000000 30000000 1600000 30000000 200000 Subsequent EventsEquity GrantsPursuant to approval by the Company’s compensation committee and board of directors, in April 2023, the Company awarded $43.6 million service-based RSUs to its employees. Service-based RSUs generally vest over four years, subject to the participant’s continued service relationship with the Company through each such vesting date. 43600000 P4Y EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�>6E.)M:68 M^&Y'Y'P'#57,);MRM2#\.?2W,F:/VZZ(;1.?PI@/1X'DN0T_TF_#SD(,=V%3!N.YP'7:-H@3,D.@]"6URGN$5/Y3'F/ MYK^2/O^?2?^?Y7Z].GN% [5PL"+K'">$L+ K(_\..W+02S18A8*,K: _VP=" M"5E[.TTG?-LH%2_..'6@2M[FZ3LR,78:PU]4(N$5K/MAQE>JC_9GM7 MHT9:Q0> @]C\NEMRF!W>&%?=U?ILWCU06(&5- X45@P=IV6>MW'V&#X>6U^ =02P,$% @ C(2B5M/'A?0@ M P E0< !D !X;"]W;W)K&ULQ97?3]LP$,?_ ME5.&T"9-I'5+VT%;JZ<-BL#*O&TE\3V MW7W\O?.O\=JZ6U\@!K@OM?&3I BA.DE3GQ582G]D*S1D65I7RD!=MTI]Y5#F M,:C4J>AT!FDIE4FFXS@V=].QK8-6!N<.?%V6TCVVE%R5:+RR!APN)\FL>W+69__H\%WAVN^T@3-96'O+G:_Y M).FP(-28!29(^MWA.6K-()+Q>\-,VBDY<+>]I7^*N5,N"^GQW.H?*@_%)!DE MD.-2UCI^22% M; )$U-U,%%5>R""G8V?7X-B;:-R(J<9H$J<,+\IU<&15%!>F5ZAEP!SFTH4' MN''2>!GKY<=I(#Y[I=F&==:PQ NL'EQ:$PH/'TV.^>/XE'2UXL16W)G8"[R4 M[@AZW?<@.J*WA]=KD^U%7N_5R<+/V<('1[U?S^7=8/O/8_G#M^,1'=XZB&SM$V,IQAJ>:M5'@$^ MT*^,,Q"6;A\G&\Q;Q1Q;>VER_^Z$Q#G$1UL.:,-D1;MC^"-H6K\1>(>F1@\' MY/"!OOVA@,]HB*^!D"!S.E^*=P%?%"#Z(P(,X8K2C5CVR0FB;<7RH#L0,.C! MM=0$92/=:K<8N%(Q1W$*-/V-#<1_7!V\KSAQEC(4+&4XZ/^76B^DEB9#B/?' MTPK/XA+\4]0+S+!.[PI3M7 M98EN%1\$K@_):&[-=K1]0H !D !X;"]W;W)K&ULE59M;]LV$/XK M!W4H$D"+)=F69-B05I_]^1TJ6;50QTB\2 M7^X>/O=&WFPGU9,N$ V\E*+2 5+A7HNBR9^G�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�>!STR@L9=S1_97KIDQ5&M\'S W5($N4UNQI7PKD]E*?,S0*U0$;6\SQ7" M:#N]/6V!Z-<#,[!M(2!^F,%QP<>=2Y1$D;, M_M2<,]0Y!B6IHA]BAH\^9XZ9ORZF^VQ]MICNESR/,,-@L&0%DJ6Y]N'+E,@\ M.R1?H@ U6SFN4O76#Z$F-WXTT'8QAS;HYNQ^)R#>Q\*)<-9J/33\U& M@YGH"'/HC4RC4X_X8IU86:\ZFWYN'LQA%:2GN;.R'*!8P# MYOG?SD),5/__<]"'1QGVF#;V3)^MV-?.H="03):TUM8FKW>O(PI-.LW@G.8] MT_?6%.*KQG?&_[?^=S2M[O<4O)C(=K'\NRR:]7[5 $%J$TW[!4 M\F?+U9Z3Q.4D3^S/MT.HCW3KNS8)F 6G^Y9=B,?>KB>#SR(U^77Z^,/, WY M"TF_VW]?NLR?5?;'\\CJ]+,B MB2SC WB^&ULE51-4]LP$/TK.Z;#B<:)DP*% M)#.!TH\#,QDRM(=.#[*]L55DR4CKA/S[KN3$#5/(T(NLE7:?WI/\=KPV]L&5 MB 1/E=)N$I5$]44J5'SSM+82A"'MHA=;5'DH:A2<=+OG\:5D#J: MCL/:W$['IB$E-03!GQ5> MHU(>B&D\;C&C[DA?N#_?H7\.VEE+*AQ>&_5#YE1.HO,(P7G_5<*DFU!$GBW!P66GP2) MZ=B:-5B?S6A^$J2&:B8GM7^4!5G>E5Q'TT63.GQL4!/$D8ALXM"N,IL='@]/^Y0&NHX[K MZ!#ZV][C/R%N'AM)&_AB!0?SQKJ&)T &1%U;LQ(*T@U0B7!MJEKHS?'1>3(X MNW20<#<:]D[;RZJD4A[7WZ#,\+WW5@YWBWOGJ4E^):QJ93:(K@>+?Y,*U&B%4AM8 MH2,P*[2P-(V%#0K/QC7I;V;FP3R36EB2F60VM*=/D]0-(VY)<)M10:TK9&PO=V]R:W-H M965T+EP>SX^<536L\+_JG5.@R>!5DR=^Z:/KPK7QY, M2"%E5!%)@L1_-^J5,H8$08W?L\R#[DC:.'QNI;]EVV'+7 ;URIE_Z3*N7AX\ M.Q"E6LC&Q$NW_KO*]CPA>84S@?\5Z[3V%"<638BNRIOQN=(V_2]OLQ\&&YY- M'M@PS1NFK'S'=*_"C]&-Q+<\2J#GH9:%>GF # G*WZB#\Y]_.CZ=G.W1]G&G[>-]TL\O M9-!!N(7X3+)ME 3K74K^ 3'BMY42C95-J:,J1>$0,1O24X!K2DE?+[25MM#2 MB(!M"KD965+$YE>NJJ6]$RMYH\1<*2O@@EIZ;(-X6B&+PC?8.V\5D+W[M>5/ MOH1\A12(J^';VFL<6QN$9ZFL\M*8.WJO:M)*)_%?+*M^19JQ^%FE/( M'OW\ MT[/I='+VM]GL,S\>G_TR%C-CL#,J7V3%Y]+0X4%(6PH@P ;)Q!$&)BFCD8,R MG]K[!LO&XI7R$2Q(VCHO:ASN2B$K,F(HPZO"R!"0=.11K"0Q.D1EB[MD.5E3 M--[#O:V8>A"K,04KJ(&@0K:*EL(ZH18+<%[K=D3!>=(8(D!5[!IPNL][H "? M-XQS=H5@6@E\7O*5KAZ"QL86(?D4I&NQZO)UU)ZS:_LFGGKU1GCCBNN5,Z7R M@:)W_/1,J-\;'>]&'*E"AI58H+8$=B:=$5=>*5$E[E'$/5NJ\$8\3 7PV<-^ MO)4%WS%Y9S8\#/\@*Y6Q#_=P0EA+^?!]H:0NBA55LE$+=U=K2XD+=U72HG[2 M4K@$L);E5Q2.SIL2F$#],ED,(8N2"C!N/#E+1G:#50!_0&'N_+B0VF\@;RO7 MS=<_W3(4Y![U7"83"E/3L4_?O!2V]3VD.JE M#H5QH2<E-W:,. RZO%J M\_S.D/VD\AK:57.(R]Z90DQA&O(:#E&(S1H+P1;0&6IY5Z5QX=89%)Q)6 ^->$P_&>)N9)U\0\V=M]?$HP!/\0 MJ).B. KUW1D2N2"X! ^HV'6O\E#"@>T 80 MT840@1!(=>RMTJ2E:G,]N\3W+@G9)6DCJ8X1 X+4+7 5D#%(>4>ER]WHDO:# M\9KRD,:>$@2XU)'PZ$R3B&17YS46[ZC'D<6*]L>59EIG\=F>23]P:K<0:[$8M)MQTZAU$;:=4'.14^M'"D MYP E=G; >2 M:Y0,,5<:<[>/MTX[WCK=RS)? N/D38BZ(ICOXJD?D\!&IB9QH[DB-[/EG'\_ M4&U2>2'GHCE.U85&'H0)[3)B-&BWGVB!_6U@_M,+9S+_RX0Z/*$*]JKD* MMJ*HIW7+S!WI74J]!)5$0UVRLVXTQ2U)FP#7AT4:]+;1ZN9&+P=MYPU:(F;1 MEKCXW1DG]IIW\#2'EA^4C$X1=IVA!0#H,X%27&%NWM9UV%0J5)J'.5 \>$B[ MU#@KI'6%K(EZ];<.*<$MXIKRJ:2,<75FU!#S#O 16C&$Y285)./L\M!P3]1+ MSP$\$QJ T[Y-V:5SY5J;-# ,-K:KN5VWL :]J[S-E+\]OA/T-NB>?)"2N(\D M;$&!B([F=,-H\%JUY1$OR>6N";F!O ?/H72,YHIL)9^@_ 1G.58-\B=/N-H7 M385\L5Q?/_9[O5HV1GK4OERV[^FYG1Q47);[5$\-+W#E/!R&H@'=_(CN(*D_ M:WFZX/:PU,@R+T*? = D-Z[H)WHU]O'8TX['GNYEH4LT>UM7?=Y9/!>916:E MXUN5&L2-@)115<0 MNHJ>&Y#W" P"BY;W$]KIB[;T7]%730V;"L;U='(\%8]H0VX=WG^ZN**7;?N0 M*CSD\Z5QJIA()#Y#W<;4+O/54"*;/#BE2YRJ-DS9C'ZKUC3A@*$T9?[@+HL M6$I?9@CS?4%" ,4E7=U082\9>"2Z;D!$!>M68ZJA%B*Y0A..9U=?R+#3PV,, MTMFNMUUY>&=#] V[G(>$Z=FKQ$\?F)_$H]]<#=DGT]-?GHN/2!M09$L#FRMI MF-@E=IR=)RXE@QY6V<$M7>;F;US,AM0HUBMEJ7G5W*',.5O9)>1M6L.1X*L4 MD U=AY6C7%624Y>-3GS3%;C.+12X]F3*R'TL'#RQ:^GR8B M,7JA-B#0^Z))[88D\U HRD/CW#5%H1O9!UX0E2N52?-Z@BK=4A0*:*,B-,(B M:7-AOW]'TF,A9?.@F6G1/M2+YQ(Z,5V!>A6]"W6&O:P!!@P/="OBFN6*1JZF M CW3V\-\L]E?<*5 T[4K33'24[7O1WBUE4_< :.H@UMNP=U;F!25 N&6SKCE MX"*6,KFU8JLQS'K]^VKA+S3192'1'[;D'8*@(9;=/)X>1Q1SB7JLV<2W(S/M*] M0R:79X^?@5S>RH+ZPXU6]PW[BH.U6\(&Z:31'AJVC#/0I!UR((M=B^5=1!C5 M@F[N.5JZ8AR ZQ*QUP[$'NF 4O/&P^74LUW.)OV)4!TW,\@7LM#P@/#'E'%TB'%])>BT],-&4R]=&'=Q>?+C&ZKE<:FU(S0GW#UGC] M*XXL<18U./G7 ?!K#9+D7K:)"9V4WJ7N8HW)7M5;ZYB)) M;V=7%ZA!H>FA/3VA@9)EFX%4]COWT7"3=M?(DOD J'/$OL: MQ:I;QQTV7L]Y-H;"N?'H73'H.#RUN8OQ=K?4XV%P\<3U(Q/'8HNE:%**/\X< M[G9/,$ '#@ &0 'AL+W=O#8+"=N.*+I;$3P\GIBBWP&LW7U:6BKV%KI> 5"LVE (7S ML\$T.#[/K+P3^,9QK7?&8".92?G#?GPJS@:^!80EYL9:8/2ZQ0LL2VN(8/R[ ML3EH75K%W?'6^F\N=HIEQC1>R/([+\SR;# :0(%S5I?F2JY_QTT\B;67RU*[ M)ZP;V9B$\UH;66V4"4'%1?-F=YL\["B,_&<4PHU"Z' WCAS*#\RPR:F2:U!6 MFJS9@0O5:1,X+FQ1KHVBOYSTS.0*;U'4"%>8RX7@+E,'-VQ6HCX\'1KR8.6& M^<;:>6,M?,9:!%^D,$L-'T6!Q6/](2%KX85;>.=AK\$O3!U!%'@0^F'48R]J MPXV@7XC,,A.- CJ(AL<&F;WH&59 M.WSF?H5PP&FPE+5FHM"'QW"S5(B/& -4[WS9%MP^0OB,HK @KN7.P%:09V$< W5'S.\R8U'6H!R48QA)&7C#*XD8:59"'+:#:Q M@]#+DAC^GQ14[!])35#6*G]U!J[KF0< MM>V5%(PM(L]);N3%%!(%%H3P)\%5$'KA.*%GD$6;R%NT3U/0P]FDY6S2SUG: M1HJ:4D<4S9=,+,B1RP+:YHE*4WEGHK4Y'^- MRHDT;-"O+>.'/:\>S'#!A;#TFK&2"6+(6PB(T:/4#F(O\S,XYV5I)0@?=26A M6;.=Y41D7J!J2#Z.J7 !C#(OBGW8=CG5-/6?Y/*@*>TA#5QI#SO0;-;9 Y0H M(2@A#<(QL2;J4,EK^A;&RL:>/_8?9#]+L7AO4%5/DST>A^!*$9YL*/A$Y*GO M'BJF+173UU QWVX#N=2&RJS1Z"XJ]AI_>1=5Z/X+T_2/7P!Y+=?..YB5>DDT MMCW3&]$BGQ8%W[1#+T@"2(EKTTHJPW\VG#K(XHSXDEBR?-RG1NJ-XZBQ-1H] M[*0[R!^1PPO&EM*AEV3A,])"BJU"Y)%K>D9!ND^0SASMP^GA2M9R)7OI5LML M_5S8= 8&O%O1@=(B(3C<0"D)0R=?>AUT\V4*BMA";FC#*MR*[VA>+\'35LJ* M6"/&T:9J:(-=M.%ZI\6]A&?31S@*6<_,O"[IG)W+6MB*?L DYIS> MSK:WG&ESN'\0;ZY(Y)-6M882YZ3J'V6T.ZKFVM%\&+ER1_V9-'26=<,EW=10 M60'Z/Y?2;#^L@_;N-_D/4$L#!!0 ( (R$HE8'+^^YP@8 %H3 9 M>&PO=V]R:W-H965TJRZ=[B8V^' MYVP(^PVAE[MCY*7\5EAQ?JK5CFBW&M37HA+- M4I)K'P%O5+U5C6RL(2?(TXN.T'NGUZ(I_Q$N+"AT M;HRJRD)T4=(4Y$I+ QMT$VI%OB\;V*@4%;G&I*R]??Z\N#56(ZC^&K-0)P ? M%\ EVFNS%4MY-MLZ7OI.SLZ__HHEP3<3ZO%!/3Y%_?RZRR\G.:AO15D0^1%) M;*3QZBF[D1JQI344(<(8:BX_LH352V-EX<3$ K)2%0"B;-;D MI&PPHUJ#S6;^FEP8MP9!L-P,4=!/?BN7LKX%]7X^)$\D>$$2FN?$\(#?*(@Z>;5>P90%-\PR# MG'*>D@D'QX.#X^<[&/"L[;T70'YHRZV+3DH::<=<.DGWF$N/]>QF@:Q.X5)XZZ,5!@N6SKMA).VT+"/@ $#Q GD('Q MN7M'+)^3*8.]0&1E.<.;TY#'4\&0#,&0/#<82F!6LRX!VWWT=4R]',:6M9>] M-7+55J1"+>S"=N<+%_Z(.ZE1AXFHE;8]/!*H4JIB%!^FY7H[+LQ_#9D?M#*& M7-2JA0\/?7)Q*/4OKI8)K>\=W7[Q&U],$51:5GZ5V91;EZ 1CV@4!!B=,![0 MC,=SC,&-\CA&=-ZA<]F"@Y7+3:,JM;XG>4(Y=IQ@)P^3.8D!%2DG-UH4Z)G0 M3Y&08R8&Q8#F83 GC-, U'Y1S1#](:.<)>0D1PXXROB,DCYRCX0 XBU',/O(.PF#A+(T]TIF,6B% M1Q/Q?[9V%-(PS[P@S.D=?L;: 8T2:!P#R1T4CUH[#&)O[30-GF'M)/.VSM@1 M6S,'VA$YR6"\<.ZP/(O99VV=Y31AF5P87/8/W X-?.P8_E2MYS$LQN9="FW%O M\/[G@?GWZR?LO=\U:N6H^SF!ANF ANEST? 1C/6%NM/3Z:.>VG4,XR:YC1?, MBR_E2W;PW(/SGN#@S096?-13?^K^OFBBGX'>&DYK6M_Y $1B[HL.CSCY03:( MATA@^Q#AUXR . MW3CS0!DPAT$XP:]ZH81[E M)NR) P6.&9R1:X%S-K'BXR#O/5EI5<- Z!Z-AU( *(W3L'_NZ;I&$[Z""AT' M3J/8K0G8 ^];U;1.-OQ#H,0TQQD$)4 [@ZP0!>[PSU ]&4G1G_A.^D".E\-Y MQ@5=CF>(V'S; .6E$QF$80UW4T"R+"2NYPM;@58HCDNYN&PO=V]R:W-H965TW%WUP3^OK/KQ*12B*J^V'N9.7/.S,Y,5MH\V0K1P8L4RDZCRKEZ',>VJ% R M>ZIK5'2ST$8R1UNSC&UMD)7!28HX39)A+!E743X)9WR5SK)[_Y4DZCQ!-"@87S"(Q^SWB%0G@@HO%[C1EU(;WC]GJ# M?A.TDY8YLWBEQ7=>NFH:G450XH(UPMWKU6=4U/;"[0'D]B1[&\1URL<6P%OF3F%K'<":9)F>_"R3G@6\++_ M$G[-;2&T;0S"S\NY=89>SZ]=66B#]'<'\1TUMC4K]87*Q M1T*_D]#?AY[?-,X3I%?!92.A9J^MG(92;D!I];%@JD#A:PAU8XJ*GB\4;\)W M"=H;@_3QGAPEO9&%_9?N &SH!= 92^JKN[ * Y=++2@:4+O MDRO"UXVE"MKC<2BB+U7#!&P7^ M[C%\@&PT\"9]R,[#8@#929(F\*@=A:#[D]%Y KMJ&6_UI$2S#)/'DL)&N;8] MN]-NN%VV/?UFWDY&RL&2*PL"%^2:G(X&$9AVVK0;I^O0X7/M:%Z$944#&HTW MH/N%UFZS\0&ZD9__ 5!+ P04 " ",A*)6&">&VD4# ," &0 'AL M+W=OTB"'1>828&XO Z/,= M+Y%S"T0TO@V8WKBD#7QH[]'?N-PIEPW3>"GYQ[HPU5!@R3INWLG=?SCD MXPCFDFO7PJ[W35,/\DX;V0S!Q*"I1?]E/X9]>! P"Q\)B(: R/'N%W(LKYAA MZZ62.U#6F]"LX5)UT42N%K8HMT;1;$UQ9GTMQ?;E':H&KG!CX.2.;3CJR3(P M!&Y=@GP NNB!HD> 8G@KA:DTO!8%%K_'!T1J9!;MF5U$1P'?,G4*\=2'*(SB M(WCQF&GL\.)'\%Q^5[7.N=2=0OA\OM%&D2J^'$JVQTH.8]F3LM MRW'ET5'0 MJ+ZCMW[Q;)J%KXXP34:FR3'T]2V=O*+C"+($;NMC;'T*XG^(Z5&LPTRO?P.% M7-(9TP8+NZ"I$$K)Z;#68@LGM: 1V6DF"CU9P+FV/E2:O!IK,PQ>88[-!M5^ M/++-%)RVN&0"GD,2AWZ6ALZ:^F?QK!==K77'1(Y$1!L-)XF?36<3^YU%\PG< M2<.X8^J#H&LJB3(_C"/WG8=SN$:M%W#9*87"0"N5.^Y_[=V?=!(_)BI]>Y#& M+$DFMDWW%/)_+='SB_TTS%R;#H%"BI=/#*:MB2(_C3)GQ7X2)G!$4NDHJ?2X MI/H[UZY:=L;*OU6UR.N6V+7L)]VR1C]-;D?7.2RW-T]?$=@A@>V0PFFFUZ7^ M2Y6?D"D-* HKV3]U&,.)0OL\V4EJ$!IW44UHAV,_RF+KE Q"(#.]-[-[\VPP M[RKBPDHB#$DX]^>SLZ'&]^H^5*[@P0W=H-JZ=TB3TCIA^LMZ'!V?NO/^AK]W M[]])VIMM+31P+"DT/#VCBJC^[>D[1K;NOM](0Z^',RMZKE%9!YHOI33[CEU@ M_ %8_P)02P,$% @ C(2B5B\/RFMQ!0 00T !D !X;"]W;W)K&ULG5=M;]LV$/XK![C ]MW,W M:GHN6U,6-=XHT&U5"?5TA:5<7PS\P6;BMEBN#$^,IN>-6.(,S:?F1M%HM$7) MBPIK7<@:%"XN!I?^Z57$Z^V"SP6N]]Y\"Z_&'CL$):8&480]'C M:RQ+!B(W_NXQ!]LMV7#W?8/^UL9.L36C\8D.UUN1<47-29D;1UX+LS'2V$@I?7U%<.5S+BG*MA3VN MX9V8EZA/SD>&MN'%HZR'O.H@@P.0(;R7M5EI^*7.,7]N/R+WMCX&&Q^O@J. M[X5R(?0="+P@/((7;F,.+5[X S'?B">BF(%+I42]1/O^Q^5<&T5\^7-?\!WV M>#\VU]"I;D2&%P,J$HWJ 0?35R_\R#L[XOEXZ_GX&/ITUI4.R 40,[)[D,U7 M;A?F:9^_1Q'W^WNYJ=&#&T'>JJ)>@EDA_2E$J+J<(^<<*&/9:ILR*#0(#0M9 MD@1H&!8UV"S*%N$CZW1AIQAFU1,R(,@<<)Q"I]1,S*?+SXVI),T M,!(>:!ILDA 6K6D5@C"'L7>0>]P^&!:0/9:!DTY\)TX#= LL<0>757KN=7[;.>.VT>'_P"U-\?W2)0>:G1V/HJU M4+F&97^"5%2-4*;(BH8F-*PHHW-$;FLRJ3CK?;EEDCA0=_"UEF61BXY9]."[ M27,\U)$IT:D>[_MC&LQ%3B_!024F5;VS*+NW]W>URPC7DO3!4O\!ZQ8UI2V9 ML."E$0DMR BIE8R_?H4_$ ML0+J.UXQ0;*>@P2-.3 MK<3>24-^Z4,I9 6DDZIRSFV7J)^LF_&9/L2!N2A%31>9[?7T MSUW F^0[+%?9N"%O79@A:P]ID4][;S1Q=YW;R^.^BA_MM+45JJ5MWOE\J GH.MSM[/;W MP677%G]=WOVXH/-8TE4.)2[(U'-CDGW5->S=P,C&-LES::CEMJ\K^HV#BA?0 M]X6D*/H!;[#]U33]%U!+ P04 " ",A*)68WDJEC$# "/!P &0 'AL M+W=O%GN@I;%%A")5DHJ3O]\92E:=UC&PIUXDDC/S^.:1,YSNK'OP M!6* IU(;/TN*$*K+-/59@:7TY[9"0Y:-=:4,-'7;U%<.91Z#2IV*7F^4EE*9 M9#Z-:TLWG]HZ:&5PZ<#792G=\S5JNYLE_62_<*>V1>"%=#ZMY!;O,7RMEHYF M:8>2JQ*-5]: P\TL6?0OKX?L'QW^5KCS!V/@3-;6/O#DKWR6])@0:LP"(TCZ M/>(-:LU 1.-[BYET6W+@X7B/_F?,G7)92X\W5G]3>2AFR22!'#>RUN'.[KY@ MF\\%XV56^_B%7>,[^)A 5OM@RS:8&)3*-'_YU.IP$##IO1(@V@ 1>3<;19:? M9)#SJ;,[<.Q-:#R(J<9H(J<,'\I]<&15%!?F=ZAEP!R6TH5G6#EIO(QZ>7BW MDFN-_OTT#;01NZ=9"WK=@(I70 =P:TTH//QA AE522&!N;B62Q6YA$,QJ>S8]\:2LWE^^V8B^N,K#YFE>V$\Q=#( M6ZWR". #_PQPK)/3B#:5DP/ M^B,!HP'<2RJ/:*1^]H"!E8HYBBN@[5&PO=V]R:W-H965TU(.S-1T^X\K/;!@9M@%3!KFZ;S[_?:$$HZ M-,I+ K;O\3GWBSO?"_FD4D0-+WE6J(63:EW.!@,5IY@S=25*+&AG*V3.-+W* MW4"5$EEBC?)L$'A>.,@9+YSEW*ZMY'(N*IWQ E<25)7G3/Z\P4SL%X[O'!;N M^2[59F&PG)=LAVO4C^5*TMN@14EXCH7BH@")VX5S[<]NQN:\/? WQ[WJ/(-1 MLA'BR;Q\21:.9PAAAK$V"(S^GO$6L\P $8W_&DRGO=(8=I\/Z']8[:1EPQ3> MBNP'3W2Z<"8.)+AE5:;OQ?Y/;/18@K'(E/V%?7/6]466Y6>FV7(NQ1ZD.4UHYL%*M=9$CA3G5Y^H[A? M_"64NH0O12QRA!5*6*=,(EP\L$V&ZG(^T'23.3^(&]2;&C5X!W4(7T6A4P5W M18+)L?V &+8T@P/-F^ DX%+%3';7_ M7&^4EI0E__;IK>%&_7"F7'#W[H?3I!=M22'9U"7Z[K M@@&QA5N6Q57&;$+3ZPU3/ 96)/"99Y7&!$P\FT V86T5]LDZ??%#BK 5&14N M^0JTR0:P^@JM0--F?$QGT]))&CJ%2:_,\N UJY+HJ#J]>$$@HE)DH%S EQA+ MW>P9C->3"67VY0P>4HEXE%E >1&G;6*8GZ#CE'-8?*MRE$P+.;.^.S[&M)9\ M4]7*M0!:S$DJ567\E(HL0:G@-[@8NV$87M)3Y(ZB*7S&0E"IUJ _;%\@$NR9 M[MGA$090FU2:J))_9PWQB>>&XZD[C280F;^1ZT5^&]_.[B1P@V#B3H=A#_-6 MX &6:'I77F18TO^T!6Q6[=HUM=E8%#'/>!M3$^;D51!4BHQLY,X(/Q[*[-7? M7 %335:ILV/ZBQJ E]0QMSXX>.'2> 'G\!WHV'H!M$8[M?7BHX\H]*=_=%DX@93GW8? M>W:#R/4##U85Z:8/#$BC5=E$X=HX;5SCS*L5HJ_*'U3 M5^>TL7,ZU09C1N5KKN 2>$XZ- U-599 2LE#^TAC$O']O>5J$LR(1KE(:??ZWK']12XGD\]=!I218VBT!U/ [BG8I$\-@ZH MK2L*H')?RRCT/'UHOOP?4$L#!!0 ( (R$HE8W,BLE1@( M $0% 9 >&PO=V]R:W-H965T*1-2W:BS!/>]K %O!+ MOU'F%(XL%>M :"8%45!GP6JZ7,^MO3/XRN"@3_;$1E)(^60/]U461%80<"C1 M,E"S[.$6.+=$1L;/@3,875K@Z?[(_M'%;F(IJ(9;R;^Q"MLL>!>0"FJZX_@H M#Y]@B,<)+"77[DL.WG9Q$Y!RIU%V ]@HZ)CP*WT>\G "B.,+@'@ Q$ZW=^14 MWE&D>:KD@2AK;=CLQH7JT$8<$_:G;%&95V9PF&]9(UC-2BJ0K,I2[@0RT9"- MY*QDH,E;LJHJ9A-(.;D7O@IL.E_= 5+&]>LT1*/#LH7EX'/M?<87?";D00IL M-?D@*JC^QH=&_QA$? QB'5\E?*!J0I+I&Q)'<4*VT)BJP2N\R9B3[JM"H3#'].!>XYYN=Y[,-MM0]+2$+3 =I4'L(\I^,/^9^OI@B:9C0A$-MH-'DQOA5 MOF?] 67O^J20:+K.;5LSYD!9 _->2XG'@W4P#L[\-U!+ P04 " ",A*)6 MC\@2J_T" ."P &0 'AL+W=O69[CM.Q0L=70 3B<@ M,F^X;/W\.WW][? M-RH474O(Q9\FWTK>5C.O?N4O18%#&%KJG1; EV %GS^Y'>=KD^@CD6U9T*HM M:!UB7]>=.$<49)/2$MXQ>B1'(MN2W:EE=SZH*CO'M.!(9%L6=&L+NN^K MRA+>WJBW=L]QW)VJ_#^JU7<[W>:J[-6Y]0[FIC_OZ $XB4E8GM#KZO,@ZUL/ MYTAD6P;T:P/Z'U2?_6-:<"2R+0MFX1(H9 LJR]]OO5HW=5>FE=E9'^EFSW0L+S1EIZA^K@FA F40 M*TKGHJO>&UXV7^5$LL+T+W,F53=DAJEJ6('K +4?,R;7$_V N@4._@%02P,$ M% @ C(2B5G#5[ANZ @ 2PD !D !X;"]W;W)K&ULM59=;YLP%/TK%I.F3=I" OE:1I":=%,KM5*5:-W#M <7+F#5V,PV MH?OWLPUA242B3F(OX(][C^\YOO9U4''Q+#, A5YRRN32R90J%JXKHPQR+ >\ M *9G$BYRK'17I*XL!.#8.N74]8;#J9MCPIPPL&,/(@QXJ2AA\""0+/,CQ7IN[*W! M(X%*'K218?+$^;/IW,9+9V@" @J1,@A8_W:P!DH-D [C5X/IM$L:Q\/V'OVK MY:ZY/&$):TZ_DUAE2V?NH!@27%*UX=4--'PF!B_B5-HOJFK;R<1!42D5SQMG M'4%.6/W'+XT.!PZCX^"=.HS/./B-@V^)UI%96M=8X3 0O$+"6<T[#: M6&_-AC"SBULE]"S1?BK

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

-8?20$3;8T.P6BP^0"X99K>]9!:G[\Y&XU^IG:$#XR'PBNC0V/;\$W! MH_O_?'LH'I13"U4I_S2)NN\51*)66M7J&E6\:9ZWD'=RX;H6+QOC'FF:C]*KM)MS%"-U&%X?7SVT0S^SOA-$LEZJ :U,T-6B_C:.% MJ@74;JTV+A):UC")/IH'L&(J5]#>5/@O-^7V!GT@0^&R9RJNQ-"ZE)<@RNLVG3'9HD@3PG(4U[(N5II M%:Z5VHO+HC"-]F'B$],0TT*!0Y#O" #=@)A!80)N>QZ!?2# /O"" MO4Z"G5;"LUAOC Y_@<,6CZFI>\S]GM2U\NU%KGL"P]O2#B_HG;&-2;\P"^;6 MZ-7Q'=@ZO" +CZDHH<3,1IE[4]RO356"=7^)3]^;D*Q@-LHC,;-(YFMIX?A* M;B? .O3DY,Y+$5,*B9D=0#$F)9"$?25"Y 7B M"&-2'DF8/=+/# 8'FU)*PJR4?1H>&&S**PFS5_:;KP/%F)1;$F:W$/IK.3$F MI9B$63'T9(F7G@DEFX19-D.3Y;&X5DZN5A96N"!"J2=E5L\PYF59=E_QH*>4 M>M(#J.=7-/OE)>RJ7JENI0L@S';A\3L1Y.R3\ILGSV835U+ M^R0,QJ0LE#);:&_*L67%F)2%4F8+D9C]0:8/[*X:J0SN/-CHRR4,9L(2J: MGQMJJJW_LTH"67<2Z%]Z]\WKLPH"67<=;?]F#L) M4DY)*.>NPA&8H7N,24DH9Y80&7<2Z&A MS91!"^64A7)N"^UNJPPC4@;*.P.-NHO=Q7D)RW#CY9?0O0OMA:R*J17MQW97 M.LO;?:1E4U4?0]M7?6MD^?I3L=>?N5W\!%!+ P04 " ",A*)6678!^/4! M X(P &@ 'AL+U]R96QS+W=OZ)0A&51G ;-JJRQY>V_^F2-??>4 M]VW9=<=QN^O'V<=A?QR7S;:4_E]*XVJ;#^UXU?7Y>+JR[H9#6T[+89/Z=O7: M;G+2^7R1AI\SFON[GS-GSY]]_I^)W7J]6^6';O5VR,?RR^#TW@VOXS;GTLR> MVV&3R[))'_O+Z3&=#W)UFMS,'E^6S?#X(DVJ':00I/6##(*L?I!#D-BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z M&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U M;T>]G4!O1[V=0&]'O9U ;Y]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3 MZ!VH=Q#H':AW$.@=J'<0Z!VH=Q#H':AW$.@=DX^5!'H'ZAT$>@?J'01Z!^H= M!'H'ZAU_J?=8/O=YO/1\K_$[]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L# M!!0 ( (R$HE87R,P;VP$ -$B 3 6T-O;G1E;G1?5'EP97-=+GAM M;,W:74^#,!0&X+^R<&M&UZ_Y$>>->JM>^ .+HS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1K MLR(F9K,Y*VP7J8O3V-?(KBYO:&DV39S<[M+K4-MND7EJ0C:YWD_LLQ:9<:ZI M"Q/3.-MVY9>4Z5M"GE8. MW7W6_*^+FGR8'R\,VV: MQ78-"_&EH9"/E_BF1[MG"=3AHHHMDV^+WHRGAS3#M/^RH_. M'\J,!::9#]ZZD$[,T^%Q[T?2KYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV M?CV<1V##[?@]_GS&'_4/[$. ]"%!^E @?6B0/N8@?9R"]'$&TL&UL4$L! A0#% M @ C(2B5@Z9)A !!@ G2 !@ ("!#0@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C(2B5M-!"MG; P H @ !@ M ("!TBT 'AL+W=O,Q !X;"]W;W)KF_HQ@' E$P & M @(%$/@ >&PO=V]R:W-H965T&UL4$L! A0#% M @ C(2B5I631VGR!@ W1$ !D ("!DD4 'AL+W=O&UL4$L! A0#% @ C(2B5BGC8&PO=V]R:W-H965T&UL4$L! A0#% @ C(2B5M/'A?0@ P E0< !D M ("!"&P 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ C(2B5K=O,9&PO=V]R:W-H965T&UL4$L! A0#% @ MC(2B5K/'IV3S! !PX !D ("!4HT 'AL+W=O&PO=V]R:W-H965T2J6,0, (\' 9 " @7:E !X;"]W;W)K&UL4$L! A0#% @ C(2B5A\$R)2"! I@L !D M ("!WJ@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ C(2B5G#5[ANZ @ 2PD !D ("!2+, 'AL M+W=O:3@# M !^#0 &0 @($YM@ >&PO=V]R:W-H965T&UL4$L! A0#% @ C(2B M5D \ (EZ P /0P !D ("!:+T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C(2B5M[5#/-T P O X M !D ("!:\@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C(2B5I]@_))$ P Z@T !D M ("!3-0 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ C(2B5A^L&LVG P /0L !D ("!?]X 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ C(2B5G5) M3DDH!@ NRP !D ("!;>@ 'AL+W=O&PO=V]R:W-H965T&PO M=V]R:W-H965T0, M (<, 9 " @80! 0!X;"]W;W)K&UL4$L! A0#% @ C(2B5GXFO-W_ P 410 !D ("! M- 4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ C(2B5L">1M6K! L18 !D ("!J1$! 'AL+W=O&PO=V]R:W-H965T7!E&UL4$L%!@ !# $, 3!( ' +@S 0 $! end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 134 286 1 false 56 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://med.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://med.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://med.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://med.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Description of Business Sheet http://med.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 0000008 - Disclosure - Significant Accounting Policies Sheet http://med.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Revenue Recognition Sheet http://med.com/role/RevenueRecognition Revenue Recognition Notes 9 false false R10.htm 0000010 - Disclosure - Balance Sheet Components Sheet http://med.com/role/BalanceSheetComponents Balance Sheet Components Notes 10 false false R11.htm 0000011 - Disclosure - Commitments and Contingencies Sheet http://med.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 0000012 - Disclosure - Long-Term Debt Sheet http://med.com/role/LongTermDebt Long-Term Debt Notes 12 false false R13.htm 0000013 - Disclosure - Stockholders' Equity Sheet http://med.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 0000014 - Disclosure - Share-Based Compensation Sheet http://med.com/role/ShareBasedCompensation Share-Based Compensation Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://med.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Related Party Transactions Sheet http://med.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 0000017 - Disclosure - Net (Loss) Income Per Share Sheet http://med.com/role/NetLossIncomePerShare Net (Loss) Income Per Share Notes 17 false false R18.htm 0000018 - Disclosure - Restructuring Activities Sheet http://med.com/role/RestructuringActivities Restructuring Activities Notes 18 false false R19.htm 0000019 - Disclosure - Business Combinations Sheet http://med.com/role/BusinessCombinations Business Combinations Notes 19 false false R20.htm 0000020 - Disclosure - Subsequent Events Sheet http://med.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 0000021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://med.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://med.com/role/SignificantAccountingPolicies 21 false false R22.htm 0000022 - Disclosure - Revenue Recognition (Tables) Sheet http://med.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://med.com/role/RevenueRecognition 22 false false R23.htm 0000023 - Disclosure - Balance Sheet Components (Tables) Sheet http://med.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://med.com/role/BalanceSheetComponents 23 false false R24.htm 0000024 - Disclosure - Commitments and Contingencies (Tables) Sheet http://med.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://med.com/role/CommitmentsandContingencies 24 false false R25.htm 0000025 - Disclosure - Long-Term Debt (Tables) Sheet http://med.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://med.com/role/LongTermDebt 25 false false R26.htm 0000026 - Disclosure - Share-Based Compensation (Tables) Sheet http://med.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://med.com/role/ShareBasedCompensation 26 false false R27.htm 0000027 - Disclosure - Related Party Transactions (Tables) Sheet http://med.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://med.com/role/RelatedPartyTransactions 27 false false R28.htm 0000028 - Disclosure - Net (Loss) Income Per Share (Tables) Sheet http://med.com/role/NetLossIncomePerShareTables Net (Loss) Income Per Share (Tables) Tables http://med.com/role/NetLossIncomePerShare 28 false false R29.htm 0000029 - Disclosure - Significant Accounting Policies - Additional Information (Details) Sheet http://med.com/role/SignificantAccountingPoliciesAdditionalInformationDetails Significant Accounting Policies - Additional Information (Details) Details 29 false false R30.htm 0000030 - Disclosure - Revenue Recognition - Disaggregation of Revenue by Solution Type (Details) Sheet http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails Revenue Recognition - Disaggregation of Revenue by Solution Type (Details) Details 30 false false R31.htm 0000031 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://med.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 31 false false R32.htm 0000032 - Disclosure - Revenue Recognition - Disaggregation of Revenue by Major Source (Details) Sheet http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails Revenue Recognition - Disaggregation of Revenue by Major Source (Details) Details 32 false false R33.htm 0000033 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue (Details) Sheet http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails Revenue Recognition - Schedule of Changes in Deferred Revenue (Details) Details 33 false false R34.htm 0000034 - Disclosure - Revenue Recognition - Schedule of Changes in Contract Cost Assets (Details) Sheet http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails Revenue Recognition - Schedule of Changes in Contract Cost Assets (Details) Details 34 false false R35.htm 0000035 - Disclosure - Revenue Recognition - Summary of Allowance for Expected Credit Losses Activity (Details) Sheet http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails Revenue Recognition - Summary of Allowance for Expected Credit Losses Activity (Details) Details 35 false false R36.htm 0000036 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) Sheet http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) Details 36 false false R37.htm 0000037 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail) Sheet http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail Balance Sheet Components - Summary of Property and Equipment, Net (Detail) Details 37 false false R38.htm 0000038 - Disclosure - Balance Sheet Components - Additional Information (Detail) Sheet http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail Balance Sheet Components - Additional Information (Detail) Details 38 false false R39.htm 0000039 - Disclosure - Balance Sheet Components - Summary of Intangible Assets, Net (Detail) Sheet http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail Balance Sheet Components - Summary of Intangible Assets, Net (Detail) Details 39 false false R40.htm 0000040 - Disclosure - Balance Sheet Components - Summary of Estimated Useful Lives and Weighted Average Amortization Periods for Intangible Assets (Detail) Sheet http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail Balance Sheet Components - Summary of Estimated Useful Lives and Weighted Average Amortization Periods for Intangible Assets (Detail) Details 40 false false R41.htm 0000041 - Disclosure - Balance Sheet Components - Summary of amortization expense related to intangible assets (Details) Sheet http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails Balance Sheet Components - Summary of amortization expense related to intangible assets (Details) Details 41 false false R42.htm 0000042 - Disclosure - Balance Sheet Components - Summary of Estimated Future Amortization of Intangible Assets (Detail) Sheet http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail Balance Sheet Components - Summary of Estimated Future Amortization of Intangible Assets (Detail) Details 42 false false R43.htm 0000043 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail) Sheet http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail Balance Sheet Components - Summary of Accrued Liabilities (Detail) Details 43 false false R44.htm 0000044 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Purchase Commitments (Details) Sheet http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Purchase Commitments (Details) Details 44 false false R45.htm 0000045 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Detail) Sheet http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail Long-Term Debt - Summary of Long-term Debt (Detail) Details 45 false false R46.htm 0000046 - Disclosure - Long-Term Debt - Additional Information (Detail) Sheet http://med.com/role/LongTermDebtAdditionalInformationDetail Long-Term Debt - Additional Information (Detail) Details 46 false false R47.htm 0000047 - Disclosure - Long-Term Debt - Summary of Future Principal Payments of Long-term Debt (Detail) Sheet http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail Long-Term Debt - Summary of Future Principal Payments of Long-term Debt (Detail) Details 47 false false R48.htm 0000048 - Disclosure - Stockholders' Equity (Details) Sheet http://med.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://med.com/role/StockholdersEquity 48 false false R49.htm 0000049 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://med.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 49 false false R50.htm 0000050 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails Share-Based Compensation - Summary of Stock Option Activity (Details) Details 50 false false R51.htm 0000051 - Disclosure - Share-Based Compensation - Schedule of RSU Activity (Details) Sheet http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails Share-Based Compensation - Schedule of RSU Activity (Details) Details 51 false false R52.htm 0000052 - Disclosure - Share-Based Compensation - Summary of Stock-based Compensation (Details) Sheet http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails Share-Based Compensation - Summary of Stock-based Compensation (Details) Details 52 false false R53.htm 0000053 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://med.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 53 false false R54.htm 0000054 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 54 false false R55.htm 0000055 - Disclosure - Net (Loss) Income Per Share - Summary of calculation of basic and diluted net income (loss) per share (Detail) Sheet http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail Net (Loss) Income Per Share - Summary of calculation of basic and diluted net income (loss) per share (Detail) Details http://med.com/role/NetLossIncomePerShareTables 55 false false R56.htm 0000056 - Disclosure - Net (Loss) Income Per Share - Summary of outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per common unit attributable to common unitholders (Detail) Sheet http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail Net (Loss) Income Per Share - Summary of outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per common unit attributable to common unitholders (Detail) Details http://med.com/role/NetLossIncomePerShareTables 56 false false R57.htm 0000057 - Disclosure - Restructuring Activities (Details) Sheet http://med.com/role/RestructuringActivitiesDetails Restructuring Activities (Details) Details http://med.com/role/RestructuringActivities 57 false false R58.htm 0000058 - Disclosure - Business Combinations (Details) Sheet http://med.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://med.com/role/BusinessCombinations 58 false false R59.htm 0000059 - Disclosure - Subsequent Events (Details) Sheet http://med.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://med.com/role/SubsequentEvents 59 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlnk-20230331.htm 4 mlnk-20230331.htm exhibit311toq12023form10-q.htm exhibit312toq12023form10-q.htm exhibit321toq12023form10-q.htm exhibit322toq12023form10-q.htm mlnk-20230331.xsd mlnk-20230331_cal.xml mlnk-20230331_def.xml mlnk-20230331_lab.xml mlnk-20230331_pre.xml http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mlnk-20230331.htm": { "axisCustom": 1, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 582, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 134, "dts": { "calculationLink": { "local": [ "mlnk-20230331_cal.xml" ] }, "definitionLink": { "local": [ "mlnk-20230331_def.xml" ] }, "inline": { "local": [ "mlnk-20230331.htm" ] }, "labelLink": { "local": [ "mlnk-20230331_lab.xml" ] }, "presentationLink": { "local": [ "mlnk-20230331_pre.xml" ] }, "schema": { "local": [ "mlnk-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 461, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 16, "keyStandard": 270, "memberCustom": 18, "memberStandard": 35, "nsprefix": "mlnk", "nsuri": "http://med.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://med.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Balance Sheet Components", "menuCat": "Notes", "order": "10", "role": "http://med.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "11", "role": "http://med.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Long-Term Debt", "menuCat": "Notes", "order": "12", "role": "http://med.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "13", "role": "http://med.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "14", "role": "http://med.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "15", "role": "http://med.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "16", "role": "http://med.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Net (Loss) Income Per Share", "menuCat": "Notes", "order": "17", "role": "http://med.com/role/NetLossIncomePerShare", "shortName": "Net (Loss) Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Restructuring Activities", "menuCat": "Notes", "order": "18", "role": "http://med.com/role/RestructuringActivities", "shortName": "Restructuring Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Business Combinations", "menuCat": "Notes", "order": "19", "role": "http://med.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://med.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://med.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://med.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "22", "role": "http://med.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "mlnk:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "23", "role": "http://med.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "mlnk:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://med.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Long-Term Debt (Tables)", "menuCat": "Tables", "order": "25", "role": "http://med.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Share-Based Compensation (Tables)", "menuCat": "Tables", "order": "26", "role": "http://med.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Related Party Transactions (Tables)", "menuCat": "Tables", "order": "27", "role": "http://med.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Net (Loss) Income Per Share (Tables)", "menuCat": "Tables", "order": "28", "role": "http://med.com/role/NetLossIncomePerShareTables", "shortName": "Net (Loss) Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "29", "role": "http://med.com/role/SignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Revenue Recognition - Disaggregation of Revenue by Solution Type (Details)", "menuCat": "Details", "order": "30", "role": "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue by Solution Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i7dfcdf43a0f64095b7489d8045b1fe77_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i71c20c4dc7e44882afabea9bc4e21985_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "mlnk:ConcentrationRiskPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Revenue Recognition - Additional Information (Details)", "menuCat": "Details", "order": "31", "role": "http://med.com/role/RevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i71c20c4dc7e44882afabea9bc4e21985_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "mlnk:ConcentrationRiskPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Revenue Recognition - Disaggregation of Revenue by Major Source (Details)", "menuCat": "Details", "order": "32", "role": "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue by Major Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i7500b01e64664f1ba8c2d56248461e47_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i92e8178454c24fe5bbcee3fcd22b3c8b_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue (Details)", "menuCat": "Details", "order": "33", "role": "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails", "shortName": "Revenue Recognition - Schedule of Changes in Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i45bfd4e0ec324859b22f9b1a9d5ef640_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:CapitalizedContractCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i92e8178454c24fe5bbcee3fcd22b3c8b_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CapitalizedContractCostNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Revenue Recognition - Schedule of Changes in Contract Cost Assets (Details)", "menuCat": "Details", "order": "34", "role": "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails", "shortName": "Revenue Recognition - Schedule of Changes in Contract Cost Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:CapitalizedContractCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i45bfd4e0ec324859b22f9b1a9d5ef640_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CapitalizedContractCostNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i92e8178454c24fe5bbcee3fcd22b3c8b_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Revenue Recognition - Summary of Allowance for Expected Credit Losses Activity (Details)", "menuCat": "Details", "order": "35", "role": "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails", "shortName": "Revenue Recognition - Summary of Allowance for Expected Credit Losses Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i92e8178454c24fe5bbcee3fcd22b3c8b_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mlnk:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)", "menuCat": "Details", "order": "36", "role": "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail", "shortName": "Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mlnk:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)", "menuCat": "Details", "order": "37", "role": "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail", "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ia5b400bea13d425aa427bbfc1eca208e_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Balance Sheet Components - Additional Information (Detail)", "menuCat": "Details", "order": "38", "role": "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail", "shortName": "Balance Sheet Components - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ia5b400bea13d425aa427bbfc1eca208e_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Balance Sheet Components - Summary of Intangible Assets, Net (Detail)", "menuCat": "Details", "order": "39", "role": "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail", "shortName": "Balance Sheet Components - Summary of Intangible Assets, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://med.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i8a7940c1ddcd4f2ebdd52656a414cc06_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Balance Sheet Components - Summary of Estimated Useful Lives and Weighted Average Amortization Periods for Intangible Assets (Detail)", "menuCat": "Details", "order": "40", "role": "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "shortName": "Balance Sheet Components - Summary of Estimated Useful Lives and Weighted Average Amortization Periods for Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i8a7940c1ddcd4f2ebdd52656a414cc06_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Balance Sheet Components - Summary of amortization expense related to intangible assets (Details)", "menuCat": "Details", "order": "41", "role": "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails", "shortName": "Balance Sheet Components - Summary of amortization expense related to intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Balance Sheet Components - Summary of Estimated Future Amortization of Intangible Assets (Detail)", "menuCat": "Details", "order": "42", "role": "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail", "shortName": "Balance Sheet Components - Summary of Estimated Future Amortization of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail)", "menuCat": "Details", "order": "43", "role": "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail", "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Purchase Commitments (Details)", "menuCat": "Details", "order": "44", "role": "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails", "shortName": "Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Purchase Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Detail)", "menuCat": "Details", "order": "45", "role": "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail", "shortName": "Long-Term Debt - Summary of Long-term Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Long-Term Debt - Additional Information (Detail)", "menuCat": "Details", "order": "46", "role": "http://med.com/role/LongTermDebtAdditionalInformationDetail", "shortName": "Long-Term Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Long-Term Debt - Summary of Future Principal Payments of Long-term Debt (Detail)", "menuCat": "Details", "order": "47", "role": "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail", "shortName": "Long-Term Debt - Summary of Future Principal Payments of Long-term Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i45455b7a668145c6901660c9ca848b5c_I20220531", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "48", "role": "http://med.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i45455b7a668145c6901660c9ca848b5c_I20220531", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "49", "role": "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ia97545f604b9435b8a298fa502eb59e2_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ia97545f604b9435b8a298fa502eb59e2_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i92e8178454c24fe5bbcee3fcd22b3c8b_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)", "menuCat": "Details", "order": "50", "role": "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails", "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Share-Based Compensation - Schedule of RSU Activity (Details)", "menuCat": "Details", "order": "51", "role": "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails", "shortName": "Share-Based Compensation - Schedule of RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib708f20c51b746c4b7d9a31c74979bd0_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Share-Based Compensation - Summary of Stock-based Compensation (Details)", "menuCat": "Details", "order": "52", "role": "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails", "shortName": "Share-Based Compensation - Summary of Stock-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i17c7a9d2df944f7eb5599e7f6cea9a17_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Income Taxes - Additional Information (Details)", "menuCat": "Details", "order": "53", "role": "http://med.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Related Party Transactions - Additional Information (Details)", "menuCat": "Details", "order": "54", "role": "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i3ca5228f57674e8aa80fdd03cbb0b5a5_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Net (Loss) Income Per Share - Summary of calculation of basic and diluted net income (loss) per share (Detail)", "menuCat": "Details", "order": "55", "role": "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "shortName": "Net (Loss) Income Per Share - Summary of calculation of basic and diluted net income (loss) per share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Net (Loss) Income Per Share - Summary of outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per common unit attributable to common unitholders (Detail)", "menuCat": "Details", "order": "56", "role": "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail", "shortName": "Net (Loss) Income Per Share - Summary of outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per common unit attributable to common unitholders (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Restructuring Activities (Details)", "menuCat": "Details", "order": "57", "role": "http://med.com/role/RestructuringActivitiesDetails", "shortName": "Restructuring Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i0ed994759eca488fa3317859bb3f37e1_D20230224-20230224", "decimals": "2", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Business Combinations (Details)", "menuCat": "Details", "order": "58", "role": "http://med.com/role/BusinessCombinationsDetails", "shortName": "Business Combinations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "i7475c355d1864ecdb41694ae3a1c60bc_D20221104-20221104", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ia2261dfd6a9d485e89fa905c9a526278_D20230401-20230430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "59", "role": "http://med.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ia2261dfd6a9d485e89fa905c9a526278_D20230401-20230430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://med.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "7", "role": "http://med.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://med.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "9", "role": "http://med.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mlnk-20230331.htm", "contextRef": "ib0fea0dab75e4446822b28d841e8e6af_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 56, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://med.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mlnk_A2021RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Revolving Credit Facility", "label": "2021 Revolving Credit Facility [Member]", "terseLabel": "2021 Revolving Credit Facility" } } }, "localname": "A2021RevolvingCreditFacilityMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_A2021TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Term Loan", "label": "2021 Term Loan [Member]", "terseLabel": "2021 Term Loan" } } }, "localname": "A2021TermLoanMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "domainItemType" }, "mlnk_AccruedCostsOfRevenues": { "auth_ref": [], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued costs of revenues.", "label": "Accrued Costs Of Revenues", "terseLabel": "Accrued costs of revenues" } } }, "localname": "AccruedCostsOfRevenues", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "mlnk_AccruedOperatingCosts": { "auth_ref": [], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued operating costs.", "label": "Accrued Operating Costs", "terseLabel": "Accrued operating costs" } } }, "localname": "AccruedOperatingCosts", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "mlnk_AccruedUserConferenceCostsCurrent": { "auth_ref": [], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued User Conference Costs, Current", "label": "Accrued User Conference Costs, Current", "terseLabel": "User conference" } } }, "localname": "AccruedUserConferenceCostsCurrent", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "mlnk_AdjustedEurocurrencyRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted Eurocurrency Rate", "label": "Adjusted Eurocurrency Rate [Member]", "terseLabel": "Adjusted Eurocurrency Rate" } } }, "localname": "AdjustedEurocurrencyRateMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_BeanstalkNetworksLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beanstalk Networks, L.L.C.", "label": "Beanstalk Networks, L.L.C. [Member]", "terseLabel": "Beanstalk Networks, L.L.C. (OpenClose)" } } }, "localname": "BeanstalkNetworksLLCMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "mlnk_CapitalizedContractCostAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized contract cost additions.", "label": "Capitalized Contract Cost Additions", "terseLabel": "Additions" } } }, "localname": "CapitalizedContractCostAdditions", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mlnk_CapitalizedContractCostRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalized Contract Cost", "label": "Capitalized Contract Cost [Roll Forward]", "terseLabel": "Capitalized Contract Cost [Roll Forward]" } } }, "localname": "CapitalizedContractCostRollForward", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails" ], "xbrltype": "stringItemType" }, "mlnk_CapitalizedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalized software [Member].", "label": "Capitalized Software [Member]", "terseLabel": "Capitalized software" } } }, "localname": "CapitalizedSoftwareMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "mlnk_ConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk percentage.", "label": "Concentration Risk Percentage", "terseLabel": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "mlnk_ContractWithCustomerLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Additions", "label": "Contract With Customer, Liability, Additions", "terseLabel": "Billing of transaction consideration" } } }, "localname": "ContractWithCustomerLiabilityAdditions", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "mlnk_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Revenue Recognized, Including Opening Balance", "label": "Contract With Customer, Liability, Revenue Recognized, Including Opening Balance", "negatedLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "mlnk_ContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability", "label": "Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ContractWithCustomerLiabilityRollForward", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "mlnk_ConversionOfStockSharesConvertedNonvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Of Stock, Shares Converted, Nonvested", "label": "Conversion Of Stock, Shares Converted, Nonvested", "terseLabel": "Shares that remained subject to future vesting (in shares)" } } }, "localname": "ConversionOfStockSharesConvertedNonvested", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "mlnk_ConversionOfStockSharesConvertedNonvestedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion Of Stock, Shares Converted, Nonvested, Value", "label": "Conversion Of Stock, Shares Converted, Nonvested, Value", "terseLabel": "Liability balance related to unvested RSAs" } } }, "localname": "ConversionOfStockSharesConvertedNonvestedValue", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "mlnk_DataVerificationSoftwareSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Data Verification Software Solutions [Member]", "label": "Data Verification Software Solutions [Member]", "terseLabel": "Data Verification Software Solutions" } } }, "localname": "DataVerificationSoftwareSolutionsMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "domainItemType" }, "mlnk_DebtInstrumentPeriodicPaymentPercentOfPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal payments on Term loan.", "label": "Debt Instrument, Periodic Payment, Percent Of Principal", "terseLabel": "Percent of original principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentOfPrincipal", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mlnk_ExciseTaxesPayableIncludedInRepurchasesOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excise Taxes Payable Included in Repurchases of Common Stock", "label": "Excise Taxes Payable Included in Repurchases of Common Stock", "terseLabel": "Excise taxes payable included in repurchases of common stock" } } }, "localname": "ExciseTaxesPayableIncludedInRepurchasesOfCommonStock", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mlnk_FirstLienMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Lien [Member]", "label": "First Lien [Member]", "terseLabel": "First Lien" } } }, "localname": "FirstLienMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease Right-Of-Use Asset", "label": "Increase (Decrease) in Operating Lease Right-Of-Use Asset", "terseLabel": "Initial recognition of operating lease right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mlnk_LendingSoftwareSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lending Software Solutions [Member]", "label": "Lending Software Solutions [Member]", "terseLabel": "Lending Software Solutions" } } }, "localname": "LendingSoftwareSolutionsMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "domainItemType" }, "mlnk_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, After Year Four", "label": "Long-Term Debt, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "mlnk_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Income (Loss) Available To Common Stockholders, Basic And Diluted", "label": "Net Income (Loss) Available To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "stringItemType" }, "mlnk_OptionsToPurchaseCommonStockOutstandingUnexercisedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options To Purchase Common Stock Outstanding, Unexercised", "label": "Options To Purchase Common Stock Outstanding, Unexercised [Member]", "terseLabel": "Options to purchase common stock outstanding, unexercised" } } }, "localname": "OptionsToPurchaseCommonStockOutstandingUnexercisedMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "domainItemType" }, "mlnk_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "mlnk_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table].", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "mlnk_ProfessionalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional Services [Member]", "label": "Professional Services [Member]", "terseLabel": "Professional services" } } }, "localname": "ProfessionalServicesMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "mlnk_ReconciliationOfEarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation Of Earnings Per Share, Basic And Diluted", "label": "Reconciliation Of Earnings Per Share, Basic And Diluted [Abstract]", "verboseLabel": "Basic and diluted net (loss) income per share" } } }, "localname": "ReconciliationOfEarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "stringItemType" }, "mlnk_RestrictedStockAwardsUnvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Awards, Unvested", "label": "Restricted Stock Awards, Unvested [Member]", "terseLabel": "Restricted stock awards, unvested" } } }, "localname": "RestrictedStockAwardsUnvestedMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "domainItemType" }, "mlnk_RestrictedStockUnitsUnvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units, Unvested", "label": "Restricted Stock Units, Unvested [Member]", "terseLabel": "Restricted stock units, unvested" } } }, "localname": "RestrictedStockUnitsUnvestedMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "domainItemType" }, "mlnk_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and other current assets", "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]", "terseLabel": "Summary of prepaid expenses and other current assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "mlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedForIssuancePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved For Issuance, Percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Annual Increase In Shares Reserved For Issuance, Percentage", "terseLabel": "Annual increase in shares authorized, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesReservedForIssuancePercentage", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mlnk_ShareBasedPaymentArrangementVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share Based Payment Arrangement, Vested", "label": "Share Based Payment Arrangement, Vested", "terseLabel": "Vesting of RSAs and RSUs" } } }, "localname": "ShareBasedPaymentArrangementVested", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mlnk_StreetSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "StreetShares", "label": "StreetShares [Member]", "terseLabel": "StreetShares" } } }, "localname": "StreetSharesMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "mlnk_SubscriptionFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Fees [Member]", "label": "Subscription Fees [Member]", "terseLabel": "Subscription fees" } } }, "localname": "SubscriptionFeesMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "mlnk_ThePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The \"Plan\"", "label": "The \"Plan\" [Member]", "terseLabel": "The \"Plan\"" } } }, "localname": "ThePlanMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "mlnk_TwoThousandTwentyOneStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 stock option and incentive plan.", "label": "Two Thousand Twenty One Stock Option and Incentive Plan [Member]", "terseLabel": "2021 Plan" } } }, "localname": "TwoThousandTwentyOneStockOptionAndIncentivePlanMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_VariableRateComponentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component", "label": "Variable Rate Component [Axis]", "terseLabel": "Variable Rate Component [Axis]" } } }, "localname": "VariableRateComponentAxis", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "mlnk_VariableRateComponentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component", "label": "Variable Rate Component [Domain]", "terseLabel": "Variable Rate Component [Domain]" } } }, "localname": "VariableRateComponentDomain", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_VariableRateComponentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component One", "label": "Variable Rate Component One [Member]", "terseLabel": "Variable Rate Component One" } } }, "localname": "VariableRateComponentOneMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_VariableRateComponentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component Two", "label": "Variable Rate Component Two [Member]", "terseLabel": "Variable Rate Component Two" } } }, "localname": "VariableRateComponentTwoMember", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mlnk_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number of Shares Outstanding, Basic And Diluted", "label": "Weighted Average Number of Shares Outstanding, Basic And Diluted [Abstract]", "verboseLabel": "Weighted average common stock outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract", "nsuri": "http://med.com/20230331", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "stringItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r552", "r557", "r635", "r674", "r675", "r676" ], "lang": { "en-us": { "role": { "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.", "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Future minimum payments under non-cancelable purchase commitments" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r597", "r612", "r613", "r617", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r673" ], "lang": { "en-us": { "role": { "documentation": "Represents amount after cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r138", "r181", "r188", "r194", "r264", "r416", "r417", "r418", "r431", "r432", "r459", "r462", "r464", "r465", "r498" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r138", "r181", "r188", "r194", "r264", "r416", "r417", "r418", "r431", "r432", "r459", "r462", "r464", "r465", "r498" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r138", "r181", "r188", "r194", "r264", "r416", "r417", "r418", "r431", "r432", "r459", "r462", "r464", "r465", "r498" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r307", "r308", "r309", "r310", "r380", "r511", "r537", "r553", "r554", "r573", "r583", "r589", "r630", "r679", "r680", "r681", "r682", "r683", "r684" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r307", "r308", "r309", "r310", "r380", "r511", "r537", "r553", "r554", "r573", "r583", "r589", "r630", "r679", "r680", "r681", "r682", "r683", "r684" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r251", "r513", "r574", "r588", "r625", "r626", "r633", "r686" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r251", "r513", "r574", "r588", "r625", "r626", "r633", "r686" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r307", "r308", "r309", "r310", "r378", "r380", "r406", "r407", "r408", "r510", "r511", "r537", "r553", "r554", "r573", "r583", "r589", "r623", "r630", "r680", "r681", "r682", "r683", "r684" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r307", "r308", "r309", "r310", "r378", "r380", "r406", "r407", "r408", "r510", "r511", "r537", "r553", "r554", "r573", "r583", "r589", "r623", "r630", "r680", "r681", "r682", "r683", "r684" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "Accounting Standards Update 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r587" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Summary of allowance for expected credit losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r254", "r255" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail", "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r67", "r147" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r5" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r416", "r417", "r418", "r609", "r610", "r611", "r669" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r182", "r183", "r184", "r185", "r194", "r257", "r258", "r261", "r262", "r263", "r264", "r265", "r266", "r416", "r417", "r418", "r429", "r430", "r431", "r432", "r444", "r445", "r446", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r484", "r485", "r489", "r490", "r491", "r492", "r495", "r496", "r497", "r498", "r499", "r500", "r515", "r516", "r517", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld related to net share settlement of restricted stock units" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r92", "r93", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r153", "r256", "r267", "r268", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedPeriodEndLabel": "Ending Balance", "negatedPeriodStartLabel": "Beginning Balance", "negatedTerseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write offs, net" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r24", "r342", "r487", "r605" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs", "verboseLabel": "Amortization of financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows", "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r40", "r58", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r113", "r124", "r151", "r174", "r232", "r243", "r249", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r449", "r453", "r468", "r587", "r628", "r629", "r677" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r143", "r156", "r174", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r449", "r453", "r468", "r587", "r628", "r629", "r677" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails", "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r442", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r97", "r98", "r442", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r440", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Business acquisition, pro forma net income (loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r440", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Business acquisition, pro forma revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r96" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails", "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r103", "r443" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r44", "r45", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B of capital units, which are a type of ownership interest in a corporation.", "label": "Capital Unit, Class B [Member]", "terseLabel": "Class B Units" } } }, "localname": "CapitalUnitClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalUnitClassDomain": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Description of the type or class of capital units or capital shares.", "label": "Capital Unit, Class [Domain]", "terseLabel": "Capital Unit, Class [Domain]" } } }, "localname": "CapitalUnitClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalUnitsByClassAxis": { "auth_ref": [ "r132", "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of the entity's capital units.", "label": "Capital Units by Class [Axis]", "terseLabel": "Capital Units by Class [Axis]" } } }, "localname": "CapitalUnitsByClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "auth_ref": [ "r687" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail": { "order": 1.0, "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.", "label": "Capitalized Computer Software, Accumulated Amortization", "negatedLabel": "Capitalized computer software, accumulated amortization" } } }, "localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized software costs" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r687" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail": { "order": 2.0, "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Capitalized computer software, gross" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r555" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "totalLabel": "Capitalized computer software, net carrying amount" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "negatedLabel": "Amortization" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r274" ], "calculation": { "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Net", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total deferred contract cost assets" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetCurrent": { "auth_ref": [ "r274" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 }, "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalizedContractCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Capitalized Contract Cost, Net, Current", "terseLabel": "Contract cost assets \u2013 current" } } }, "localname": "CapitalizedContractCostNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail", "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r274" ], "calculation": { "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_CapitalizedContractCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Capitalized Contract Cost, Net, Noncurrent", "terseLabel": "Contract cost assets, noncurrent" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinContractCostAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostTableTextBlock": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Table Text Block]", "terseLabel": "Schedule of changes in contract cost assets" } } }, "localname": "CapitalizedContractCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r42", "r145", "r558" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r37", "r42", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r37", "r104" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r119", "r129" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r71", "r305", "r306", "r550", "r627" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r609", "r610", "r669" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r75" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r587" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 600,000,000 shares authorized, 80,636,894 and 80,644,452 shares issued and outstanding at March\u00a031, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of changes in the deferred revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r363", "r364", "r375" ], "calculation": { "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, ending balance", "periodStartLabel": "Deferred revenue, beginning balance", "totalLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r363", "r364", "r375" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails": { "order": 2.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "periodEndLabel": "Deferred revenue, current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r363", "r364", "r375" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RevenueRecognitionScheduleofChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r601", "r602" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0 }, "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails": { "order": 1.0, "parentTag": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Subscription and services", "verboseLabel": "Cost of revenues" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r603" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Amortization", "terseLabel": "Amortization of developed technology" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r26", "r174", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r468", "r628" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "totalLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenues:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r74", "r172", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r336", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r0", "r1", "r2", "r114", "r115", "r123", "r177", "r320", "r321", "r322", "r323", "r324", "r326", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r488", "r568", "r569", "r570", "r571", "r572", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r2", "r115", "r123", "r346" ], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total", "verboseLabel": "2021 Term loan" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r106", "r108", "r320", "r488", "r569", "r570" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Term loan" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r16", "r106", "r348", "r488" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest rate, effective" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r17", "r177", "r320", "r321", "r322", "r323", "r324", "r326", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r488", "r568", "r569", "r570", "r571", "r572", "r606" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsCurrentNet": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Current, Net", "negatedLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsCurrentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs, gross" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r107", "r631" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r41" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r40", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r374", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r383", "r412", "r413", "r415", "r419", "r584" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r163", "r186", "r187", "r188", "r189", "r190", "r195", "r198", "r207", "r208", "r209", "r213", "r465", "r466", "r532", "r535", "r560" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net (loss) income per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r163", "r186", "r187", "r188", "r189", "r190", "r198", "r207", "r208", "r209", "r213", "r465", "r466", "r532", "r535", "r560" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r210", "r211", "r212", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net (Loss) Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate reconciliation, percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and payroll-related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Share-based compensation expense capitalized to software additions" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, weighted -average period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r662" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense, awards other than options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r662" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance and related costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Purchase rights committed under the ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r75", "r138", "r159", "r160", "r161", "r178", "r179", "r180", "r183", "r191", "r193", "r215", "r264", "r362", "r416", "r417", "r418", "r431", "r432", "r464", "r477", "r478", "r479", "r480", "r481", "r482", "r500", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r117", "r551" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails", "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension", "terseLabel": "Weighted Average Remaining Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r149", "r288" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 7.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r63" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2023 (remaining nine months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Summary of amortization expense related to intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r63" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2028" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r63" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r63" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r63" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r286", "r287", "r288", "r289", "r514", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r61", "r518" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets, gross amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail", "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r61", "r514" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Total amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedFutureAmortizationofIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail", "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r40" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail", "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails": { "order": 4.0, "parentTag": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r148", "r276", "r531", "r563", "r587", "r620", "r622" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r95", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Purchase accounting adjustments, goodwill", "verboseLabel": "Purchase price allocation adjustment related to income tax effects for StreetShares acquisition" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails", "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r25", "r174", "r232", "r242", "r248", "r250", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r468", "r562", "r628" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r22", "r112", "r120", "r131", "r232", "r242", "r248", "r250", "r533", "r562" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before (benefit from) provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r290", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r175", "r425", "r427", "r428", "r433", "r435", "r437", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r176", "r192", "r193", "r230", "r423", "r434", "r436", "r536" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "(Benefit from) provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r39" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r39" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r39" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r512", "r604" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r604", "r672" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Initial recognition of operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r39" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r199", "r200", "r201", "r209", "r382" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive securities (shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r107", "r121", "r162", "r226", "r486" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "verboseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r31", "r341", "r571", "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r166", "r169", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r174", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r450", "r453", "r454", "r468", "r561", "r628", "r677", "r678" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r116", "r127", "r587", "r607", "r616", "r671" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r144", "r174", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r450", "r453", "r454", "r468", "r587", "r628", "r677", "r678" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedLiabilityCompanyLLCMembersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Limited Liability Company (LLC) Members' Equity [Abstract]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "LimitedLiabilityCompanyLLCMembersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee rate" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Revolving credit facility, principal amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Unused revolving credit facility balance" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r11", "r606" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r2", "r115", "r125", "r333", "r347", "r569", "r570" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Total debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt, net of debt issuance costs", "verboseLabel": "Current portion of long term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r72", "r177", "r338" ], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r72", "r177", "r338" ], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r72", "r177", "r338" ], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r72", "r177", "r338" ], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r608" ], "calculation": { "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023 (remaining nine months)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtSummaryofFuturePrincipalPaymentsofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r152" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of debt issuance costs", "verboseLabel": "Total non-current portion of long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r17", "r73" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r216", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r168" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r168" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r38", "r41" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r186", "r187", "r188", "r189", "r195", "r196", "r206", "r209", "r232", "r242", "r248", "r250", "r562" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income (loss) attributable to common stockholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r197", "r202", "r203", "r204", "r205", "r206", "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income (loss) attributable to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements Adopted And Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-competition agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (income) expense, net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment and furniture" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail", "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r564", "r565", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "Previously vested stock based compensation" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r232", "r242", "r248", "r250", "r562" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating (loss) income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r494" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r493" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r155", "r587" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r150" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r27", "r40", "r65" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r35" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r33" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedLabel": "Capitalized software additions" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r165" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Taxes paid related to net share settlement of RSUs" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r32", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration, gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r33" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r349" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r349" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred sock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r587" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized; zero shares issued and outstanding at March\u00a031, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r598" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail", "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r154", "r272", "r273", "r559" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPrepaidExpensesandOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r34", "r90" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r142", "r157", "r158", "r167", "r174", "r182", "r192", "r193", "r232", "r242", "r248", "r250", "r259", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r448", "r451", "r452", "r466", "r468", "r533", "r562", "r585", "r586", "r600", "r628" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net (loss) income", "totalLabel": "Net (loss) income", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows", "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail", "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r66", "r146" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property plant and equipment gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r68", "r128", "r534", "r587" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail", "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsAdditionalInformationDetail", "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r164", "r269" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for expected credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows", "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "calculation": { "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "totalLabel": "Total future minimum payments under non-cancelable purchase commitments" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year One", "terseLabel": "2023 (remaining nine months)" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "PurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CommitmentsandContingenciesFutureMinimumPaymentsUnderNonCancelablePurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r379", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r109" ], "calculation": { "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "totalLabel": "Total related party expenses" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r379", "r503", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r676" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r501", "r502", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r36" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Principal payments of long-term debt" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r94", "r135", "r685" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails": { "order": 2.0, "parentTag": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units (RSUs)", "verboseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails", "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r292", "r294", "r297", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Activities" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r293", "r296", "r300", "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and related cost, expected cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Reduction in current workforce" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r40", "r298", "r300", "r624" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring related costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring related costs" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r293", "r294", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r294", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Accrued severance and related costs" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r80", "r126", "r544", "r549", "r587" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r138", "r178", "r179", "r180", "r183", "r191", "r193", "r264", "r416", "r417", "r418", "r431", "r432", "r464", "r540", "r542" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r223", "r224", "r241", "r246", "r247", "r251", "r252", "r253", "r373", "r374", "r513" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails", "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebySolutionTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Income taxes payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "auth_ref": [ "r118", "r130" ], "calculation": { "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax.", "label": "Sales and Excise Tax Payable", "terseLabel": "Sales tax liability from acquisitions" } } }, "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/NetLossIncomePerShareSummaryofoutstandingpotentiallydilutivesecuritieswereexcludedfromthecalculationofdilutednetlosspercommonunitattributabletocommonunitholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Outstanding Potentially Dilutive Securities were Excluded from the Calculation of Diluted Net Loss Per Common Unit Attributable to Common Unitholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r97", "r98", "r442" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r17", "r76", "r77", "r78", "r79", "r105", "r106", "r108", "r122", "r569", "r571", "r608" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Calculation of Basic and Diluted Net Income (Loss) Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/NetLossIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r88", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails", "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "auth_ref": [ "r556", "r618" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]" } } }, "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r59", "r60", "r514" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail", "http://med.com/role/BalanceSheetComponentsSummaryofamortizationexpenserelatedtointangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of intangible assets, net and estimated useful lives and weighted average amortization periods" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Summary of future principal payments of long-term debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of RSU activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofPropertyandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Related Party Transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r293", "r294", "r295", "r296", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r53", "r54", "r55", "r57" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r82", "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail", "http://med.com/role/LongTermDebtSummaryofLongtermDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r253", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r296", "r302", "r563", "r686" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r235", "r236", "r237", "r238", "r239", "r240", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Operating and Reportable Segment" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails": { "order": 3.0, "parentTag": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceOtherMember": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.", "label": "Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionDisaggregationofRevenuebyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r39" ], "calculation": { "http://med.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Non-vested ending balance (in shares)", "periodStartLabel": "Non-vested beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of RSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Non-vested ending balance (in dollars per share)", "periodStartLabel": "Non-vested beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid to settle liability for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid", "terseLabel": "Service-based RSUs awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)", "terseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "terseLabel": "RSAs cancelled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contract Term and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, vested and expected to vest in the future" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest in the future (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest in the future (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail", "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://med.com/role/ShareBasedCompensationScheduleofRSUActivityDetails", "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average remaining contractual term, exercisable at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, vested and expected to vest in the future" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld related to net share settlement of restricted stock units (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r141", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r253", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r291", "r296", "r302", "r563", "r686" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r75", "r138", "r159", "r160", "r161", "r178", "r179", "r180", "r183", "r191", "r193", "r215", "r264", "r362", "r416", "r417", "r418", "r431", "r432", "r464", "r477", "r478", "r479", "r480", "r481", "r482", "r500", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r178", "r179", "r180", "r215", "r513" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r3", "r4", "r75", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock through employee purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r75", "r80" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r3", "r4", "r75", "r80", "r392" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock due to exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/ShareBasedCompensationSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r3", "r4", "r75", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r21", "r75", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock due to exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock remaining for repurchase under repurchase program" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r3", "r4", "r75", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of stock (in shares)", "terseLabel": "Stock repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r3", "r4", "r75", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of stock", "terseLabel": "Stock repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://med.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r56", "r587", "r607", "r616", "r671" ], "calculation": { "http://med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedBalanceSheets", "http://med.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r173", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r455" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r483", "r508" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r483", "r508" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r483", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r483", "r508" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r507", "r509" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/BalanceSheetComponentsSummaryofEstimatedUsefulLivesandWeightedAverageAmortizationPeriodsforIntangibleAssetsDetail", "http://med.com/role/BalanceSheetComponentsSummaryofIntangibleAssetsNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r182", "r183", "r184", "r185", "r194", "r257", "r258", "r261", "r262", "r263", "r264", "r265", "r266", "r416", "r417", "r418", "r429", "r430", "r431", "r432", "r444", "r445", "r446", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r484", "r485", "r489", "r490", "r491", "r492", "r495", "r496", "r497", "r498", "r499", "r500", "r515", "r516", "r517", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RevenueRecognitionSummaryofAllowanceforExpectedCreditLossesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r293", "r294", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/RestructuringActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r420", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r50", "r51", "r52", "r217", "r218", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/LongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r197", "r209" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r195", "r209" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:", "verboseLabel": "Weighted average common stock outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://med.com/role/CondensedConsolidatedStatementsofOperations", "http://med.com/role/NetLossIncomePerShareSummaryofcalculationofbasicanddilutednetincomelosspershareDetail" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=25866437&loc=d3e10246-115837", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r591": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r592": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r593": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r594": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r595": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r596": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 78 0001834494-23-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001834494-23-000060-xbrl.zip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end

[B&]UG=ONL6J+-;I(HUBK]=Q=I8;HV%C_/AV5K_13J&SLYIL9_5E MI.L2^ D&EPML.8/K M@097EPTN%[^?)GSX"'_B#D/_D;*X'7$Z)B=7@^^D6;+<7[$,4 M@V>%#-<("N)L+S=&8\9X$;97D]U$9WMMT?;JWMOV^A#- _@C_,G97LZ4< NV M\POF;"\W1D/'> &V5[?M_]1@6>6,K^T97]W'#GSY1]YO[! F"TQ>EFPU^:7CSE#5\E\&Z2B8BVS_\TTLE@JTLMOI=)WQYFP1MV"- M6S!GO+DQ&CK&BS#>NLYX>Z'&VV-'SISQUK#;[6P1MV#.>'-CO,@Q?GSCS>_X M[?-/EPV65NO-MZ==+C2,D#L&_\W[G[=?/GKG\RP'4T9X[Y)Q@;7QWAX:()'Z MYU#]B,Q#I!_!>ODZ3%Y< 7& M3RH\! P*D8 %Y:0>P\Q'/>_U1OBW3ODX;>T6S)DW;HP7.\;+,&\NS_ZKP=*J MN>;-U^ FF2>SI??^)A?S#,,LE^.IF 7:WG%VAE.;;L$:LF#.SG!C-'2,EV%G MG)U^;+"TVBD[XRR(QT7,R:./T?R/$9+N.JO#*5&W8 U;,&=UN#$:.L;+L#K> MO?_08&FU4U;'.S&)YI$S.IP.=0O6Z 5S1H<;HZ%CO RCX^/IVP9+JYTR.CX& M(Q$[>\.I3[=@C5TP9V^X,1HZQLNP-RZ^O&^PM-HI>^,B%1ELL,NM."WJ%JS9 M"^;,#C=&0\=X"69'O\&2JEDFQUD"4_$N@JMU/2U[V!T6V?3PO_[D#SLGJ_];-Z=G7ZFO M4T$40AI2(O- FP3C*2L4J3,R#W'D2*4@)HF73X/<"\;C9 ;OLH2_1IGW:Q&D M<*OBI?=%+)(T]\ +_@#*"?3-_J_491DBSU'HH7SHPCL5Z3S*X#GT=_^$1L=6 M3O4YW@KU&6@Y1*=8))D@7G -87&DP"G>WXRGP1STY.DX;WN7Q7A:?:_K*([I M 2,]E3S!OT3S<0)#I\2^-%IZJ9C 7<0^TV@.W\ WA,F +,F\ N$Z& Q#C(LT MRB.8#P%AI"NS:'GB9BP6A*:!GPF,%.2\=A4BIPR).'&F,2R?-9T,OS@KS:F] MW\3)=13F4S@5N.GVKT9)GB>S-QWSDV"4)7&1 MK__)+$BOHOD^R,LWW7Z=9)5B].?_'*4'/Z^=;PF&)2MF,.QR[5A/?8F'QQ4X M$^M_\1VB\&^O(C'J#$:#T>%AKW?<[W4'1^/.\%ATNX$_/@J[1\&_NOW^*_6K MJ?8I%V#.[8]2$?RQ'TS@%=\$\76PS%X=E%<9EMC>TCMV0^YCKT,*<\V23;:$ M; -+MAGTSK//1:+L_'3WWOD=D(ZH>%'"G,$3X3AF-3@WU6/]]"?XL/8$7Y[_ M_=/IU]^^O+]%[13T6EB H"4T@)"U5\HZBQ5"!IL''\#C4/6-Q#2()RB$ M<2 Z2OP%&CD5!2H)&C H\FF2PEN'ZZ6T)3S]+D>5Z)!I<9S"^&@,Q,$B$V_4 M'T["*%O$P?)-1"[>/OWHI'SW44I4;5H\C/RQ$2#M#@L1&6603Y8?M^DC97"7 M/NL?MX^'ZS_NM/VUG]TV[*#=]P>//FK?;\.MWFC8.T(N=SHCPY6O;AA7X(UY M>@U'V__+^R_G[\Y//WT\__3?+;90SS^=M3<(AOK]6Z*A]W#=OO>K&^[;?3?C M.60@[<@[-$#?(/\G;T>7F )[&^.J[=+I>[M\LT& 8)?>Z" [\#Y%\+0 ],L_ MX^2/NIOTB%=A%];D4S 3F^RSU'JD%,%A O\C"CV:.^;N;:-2!TZA.HSJ-NJI1+P4\ M]VT-I4V2JTZA/IE$;N/M.HVY!HZXB5^_5P5ICAN!T/$Z*>0[O=XN"7'-D[5U;<]NV$G[/K\#1 MRTEGRLBWW#QQ.K(==SRCV!Y?DIZG#D2"$FJ*4 '0MOKK#Q8@)4J\ )3E1BW5 MA\8BL8O=_18+[!(D/OWR-([0 ^&"LOBHL_MFIX-([+. QL.CSMWMF?>A\\OG M5Z\^_Q1R-D;?&;^G#]CS/FNB M$S:9_?)/?1(Q_VWN_O'^P$ M0?#^Y^'AWDY(=@=$-0NP[QV0=P?>QP%^YWUX_^Y=L+_ODP/_0#-]$H?"'Y$Q M1DJQ6!P^B:/.2,K)8;?[^/CXYG'_#>/#[M[.SF[WMZ_]&]VTD[:-:'R_T/II MP*.L_7X7;@^P(%ES];]Y\S$)WOALW 4M=_;W=[-&P(+6,*6QD#CV9TP#R3TY MG1!13J-N=^$V]+/C[>QZ>PL]!7)&EN_F;=?<[" L):>#1)(SQL>G),1)I$B2 M^,\$1S2D)%#P1P0 7FB0NRTQ'Q)Y@<=$3+!/J@WP^15" <=3QB7*"Y0A%@, MM(2"2R#;ZR #79_Y6&I_A)8B4Z;0ODLB*>"7![_>/(F@TW7O-1'>$.-)HY[S M-*;W]$H3"7)^N/OQX\?N$SA6N02E+J/;>_"GM[OG[>\VZ+;*]]S[5K^\C&X= M,LP'53,9,KIGRE ZGJI\P4:I?PM',98(E5(DAP&7_6?R][=TJ<-JDA7'(+9[I%>Y:2I15@96(/:4]6^4!9KK;0SH$XP6)T%K''9P_-.2,KD.]6 1+X(]U!B^"[Y$,)X+&1-B P]K"VI\",F$D[4CSQ;I/BB'&. *V/=(K!NZ#"F MH9K]8]GS?9;$DL;#*^7.OLI&+"C5TUKA^; ,3XX?FC-$&<<6H7)-'DB*S6I6A=%/8H= 5$=IA6)W&8H<-SU)+/!K$1Y]%@]O"3Q) M&D@+ M-K1;?6[8XD'M CX!!BTS<.$=9(079W2_,L^U.+VY&F)-CK-."\42M MX;'#!%M!9#7^0<'XP,C3G%">58L .(^56$:X' MO@6#BF)U?B%9#9C@_)\6F3YFV0@R)^)4N#+ M@T,B6VANL_A>(86=LT"&1YNL75<*6TE8F4\O7"FDAS[=E-QZ:=XAR/:+7:9]M KR8OBA;XN&0DZ&6 MC(5IB\'TAD6)GIL4K1OJSV1N@WZ_4' HRZ!TDURGL*TG:S>8HJQCI$VR=0%@ M^HR!WI"9%>)"[:(@@B0@+3T98I<>"JO$7$LY)D#9>%7UWSE;L"\676M,GHC'* M>IU1;9&OP =J)%PE'B=,R)X01(HU@E_-W(I_H;C3"/^L8P0](]/UU@<,3,EX MC/F4A;TH8H]0SU3SXY>G"?%5-GJBQ@S5^91:AIO'D=.5_6'5CJR^4:@X5?B& M$0!<8R8"4C*@3 ADI$!&C.SYZ[25CE)>*I]A>,7)!-, +!I_$\[S$-XMNA7 [- M%R'I&!Y0W D2)E&?/NC9^#N!SWV1H/= .!Z2WIAQF;XO=T4X98%0PV@9UG6X MR@O(8_.Q ^=W03)Q42HOR@N,4HGU&K7@J%L?+?@$SAF/ MF-4:-T_5)*,S^^$&6>T+=&CULD))T\W+\K*@5!B42H,D0W-Y$&YO_NL:5:&2-?55_C9'R%I[K171P0?L'B$S!Q M!-L#KA+NC[ @.4YN4\^+=FUUFX9[Z;PL9*1"H4PJI,5"2BYO+AC*)%O@VL;I M*+^_;C;8X:),+SH%#UGK?CN/2E>L== M:Y5T5OB*G[(I><6^E5-B^8;GU<-KSRWM.SMG6OP-**:O\IWI+8(V]Z>F@7/G(@L5-$,7H51MHL2 M9=J82*JIE,W%1.4B0.FTSGZ9/JT^4BA9U;VQM1#-19JB$0\*\^]6^]7L]P"R1<$X0'"4V85)I27$43;4IX6DW\1.NGR(\$D[( MDQ\E 0G@"#$Y(@N^,?>)U!M4;V,6)TJ-[#@K*"&KF7AV/T+ MM3YGM\_IB')*HDQ+-%<3@9XH4]2<^*9471XY^?$"^NIA8C1#H!K*ZPR/HG/W M4K7;.)XJ/AOE.N'6$EO]I^3UX_)/3[5R_BS[HI3CAI$:2BLHQ:V*99^D:B4B MRU^;G)P%YW8>3O1VNUM]ME60F -2LGL#0WK4\?4K M(ATDE$-(*O6[P;]REDR..J8EE63<0>:$+'-%S77*5?CT7-T![O.C] K62[== MI.>SQ$-X74E46J.BM5T[PA M5:7:C?DT,(B3YK-C6X$'].:@?%8XO%Q^I:57]DJ+_K+$+7F2QQ'S[RLM\3RF M349!0[O(K!<'RWQY\JDP)2"%(0ADQBV,WVLR2;>*B,OP1"\;=1&NTB*K,=O< M>+"WL[<+#W7[#,=?R7A >%YU(VT:#,J:OB#$ 1MC&COH<$:YD'U*+/(7FFV" M[-\PIR##-99DME7N,B;UJMBH-D&S/M$IX T+Y2.DP.EG+D2]9C:J3="L%_RA M5@8D^))PYNOXYT\!"$(ECF!IDW^3^II%T1GC"I"@2CL7RK5K M:*XH<93'N&C'XO1H^DOS?$<7+X2YK)"Y@#\ HF\X2FJ7B(W8;.IJ*5WXOB'QD_%[T^R?U([2.8A-&Y^TCNQVQ!';KWCZJ M.U,5\?.;#V+(1Z#<]D"N(MMLOB*S3;!#Z>RG]%EASLQ1;8)F\X?2:;+1XQP^ M,0%_?M,QI7JE[D"ZL:O04RSQ-R4&?#1-/X9OMFAP)M\$C,WX$K4 M*MV_,9]GC(6 #%YN*.0W]G[%4"V7TUXH"?\?P?R,);S2! Z4FSI7Z]12+2E8 M] !5)MW7&?9UT1"#II;"3,*JX%WU+%[6])RH:K8(-P1H4"N1A0)6$$*7.5T_4 MX5E8=@CR&2&6U5]5ZXT(^_,1G2U*ZY6I(=@$?9:^?G&1@&AJ/M(#)K?:/(:] M3BJ'/#4[-WJIKE5:/YOMCRXMW8Y<4N[1QJ72^>/'YX?&F_S_*O>"2+.Y#3:Z]1XPU7+=LEQ.G6XH:QCAUL#X1X^"TJ7#J?; 1JN- MC&03QH7>E$;ATYP:@KN8PG<.3!Y5/])=*#=!P[1L?Z?6LFIXA@2>.Q%=Q$\? MW=L*_G64FUI/N.(L) )6H2K:J$4\]6V!NXYB$V!<=MJSFJ>6DFZ&CSV(H MW:03QA?,85.5R'91-PRY*[/[T8%6C39(_TP7UU3<.^2^M30;D:K6[ZQS>,+L M3/^WX:>W+ I_1,;X\ZO_ U!+ P04 " "-A*)6.>8Q4T\= "6&@$ %0 M &UL;FLM,C R,S S,S%?8V%L+GAM;.5=67,;.9)^GU_A];YNMG$?'=.SX7/" M$>ZQPW;O[#XQ<"2LBJ986I*2[?GUFZ H6;(NBD2)9>]$CRQ1I:H/R*_R0@+Y MU__\7?[ER_6>YNII[[Y^L?GM^Z:*[[D*Z M+7_RW[^_^9 .\#! -ULLPRS5!RRZ7Q>K#]_T*2Q7^G^![+H_KO'^]?GS_R$/,OJ3]\4C]_\KR?99PM M,-,WBW[:Y2K=9V%:@7\X0%PN"/[J=LNO1_C;XT5W>#3%L\\.YEA^>TQS\B=4 M.3-Y"N+?-[CKDV] 4YBFX^EJ7M[0S^M[5WAM,..7)=)?G,[-V4.G?;ITT;1* MII^?_>4T1)RN/IT<+^!3"$>3-UV(W;1;=KAX.LL?EGWZ\Z"?9GJ)7O[O<;?\ M.D&NT0>&P!D64,PC1)8-1(U.>^9,B.'RS-71+6AX*_F6L(@K(:\?2,(6X@E. MEXNS3^HDB]4$;XKI=)J;C'F"P1?L6J=M4H[Q1+FZ1*7KKY0ZRN>+(X/#U?WA&Z)AV=_ M7_7;@$Q8]FVF_%2D-)1=9?Z\/SSLEE7;U]'1.[8DJT#6H0*BAS,O50%9K 1E M40*I,0B> M>6 Q*VTMEAQX8VK^N9X3\&1BQHP"&) (*H9(/$8PLY-O%8B!(@1"8$HFY M@HJ7!R;"_,<5*!<91(,6F-%)H7+>%]=X M8-? &),AW%'ZWY-ZUTEO:@+[V044EIF<8O3 ,YE?Y7*B&"0HR%Y((5PF!>P' ML'L7,8S)V#66^T[3W4SH3W/NZMC#]%WH\NO9\W#4+GX ML,XZYA=8NM0M)\%&$XM-P),B7,$X\)Y;$(B1*X:<-%=CJMR-:A.JJ!^3*HU% MTDZK+!:X7#P_)K,V6TY*,"+(X(#&0M8L.DYV+0J0WG(;$;/#UO'3)0 [&\:P M.*@1"/U39782IJN89/D\S.=?:=I/U7<6MJ@0!/"(-6SU#J(GZYVYU%)D+#*U M3H1L!&Q,KM/VO+AB/9O+I!WY4^J/"MH:D@=9YBZW?A%CQC\J_:D:.9!)IQ@IS\(S+F+[\<(H7%N@00E@:K4#/P449PSB2&DHQ$P<;4V #6F!RM=@QI+8]F1'FYH"GY M_ */^@49;V%*X(XG\$E02$"A'\6!-@(CWX]\/)]RD8TI<0G F%RG=L+??HZ; MB?EBOMMH1?_+"H(-!$!BA.");(:K(F+).G#S4$L,.XWD3#84@0CI-8)C0=>8 MA +94CPP$9CP2N10Q' #NH?>VL/2R;VD?S31YP?OL"X_$<_ M2V<*,R4C+><@E(Z@M X0E0L0, 3MM8WD;K66^[5(QN35-)/][G/>,%,X6\Y# M6OZS6QX\/UXL^T.Y/*Y&>1*0YDD<$+S8G &;-M'1+= MC&9,'D\K8C2:^\;9H8DV,A;F-1$/Z=G9,OHN%A"2*4Q."VE:)TQ.G]PVNT62 M=5Z( I@D>:*6G$@OE(>,GNM4G%-ZF&&,T-'90K)78O>M)[=AL-X?X7SY]=TT MS)84&]8$TU&M0_@'+B?2.*U88>"$L?3&V S1HP6/S LGZ#5,K5/O,&PP/=U&M^6/Q:X&NPDL>*L);4LG12@6)+@%)G6Q+VF MR#$QVUR'W0IH3'Y- SJTF_QF?'C5S6C8;[H3S*]GRS#[U,7I*9Y%Y2A%78K0 M&"C&>E)8QD&((H)(13">=2$;VY@0MR,:DT/3@!$-I[\9)5ZL"SA>SQ+YW!_# MEV]XDA19(E? 662@R-N"F"@\RR%I*W+)A;=>^KH9S294T#\.%1I->S,:_+WO M\^=N.IT4%K47/I B$@X4#XX"+$Y1ELHR\A!D"JT#FK-G;R)B\^.(>*LI;1NS MKDGU+612%'&%&"-(3.2%6"8ARE1 UEJ,I&P210T1KGX/9!-1VQ]'U+M/]A#) M^?/E!J,H%-8)K*Y5%-ER<+9(8,)(BKU+SO:A4]K;+TR_"U_KFNCYV(HIO&@' M&C7-<784_D>=*<9*W,3BI>"MMSAR.'+AI17J'J6]9GS _QGS-"$W( M*B(6,#:1V90FT=MF-62+F;1O3%&W5FTW@AE38-N># T$\##9_//QIEIUC!I8 M76)0HF3P1G.0V6=7-+/2M8YK-L$UIGBW,4N:BV60Y;\S("J(9*VW@-%&&JE! M"KRL %&LLCPB(^4VX-K?/>BPA^Q]"SKL.NG?2?^O3[Z?HC?T90"?0'+$L4Y M(4H(GCQ?D;PURNH<56LU>^'QNU>(G^#L&%_1NW"=]GKY)4V/ZV[[ZN;3?YEB M]HE/DBN6!=A<%[!1JKKK(5'DGH-GA2*)U'J-> N88W)-M^7+U>+Q8:75T$%9 M+-^6-=R)==DK*0)8'\CD\ CDWB9Q@4 817 @1M!4REY!EDJV7VJZ V'FK*$ZG]1V:Y=_# M_$^\<.L),H$TC@B^UAR2+:^%AR4!XT%)6Q@WMK7+=#.:,2FXW9AP9=-P&PDT MW$:U0+I-W;WP@MZW:;]:WSR#E'SDF5'()U@F!:M8J9EKB@!%0"8QQ2S:[Z"Z M!="8PO"VO&@GAV;4>':\Z&9D:Y_WA[&;G4YS^M_C;K':#_@>5QN[JJI>3)@A MYUY91H < \5X 2>* ^,9XS9'Z;'UILS-T8TI*F]+FH$DU&X-"FW0QI3R-Z6*RUE MT=+Z+.?':7D\IV$^/PCS3S3*E)..7&0H*873@\DB$P9<3%)$YV(QK5\VY2W+Z>+C5:9UCN-OCU]UW%\D\I9ZJV;'=/L?DLS M/\/2S_&\K@D7+[^0[T T(I=S_O4U"7]5(U&3=OTJN'T]6^*<;,S$H#8B1PY9 MU\,DL!0(/"6P-DDKC"VZ^<0,.)PQ*=(MV??]NS06X3=[*\^!KI7#,_)Z5]E( MXS@AX("L*'*70J VBKPW!:K8T83AV'B%2BCTLU-:;3;K ^4G_>:ER 9![O6>">R];>Y.WY.>W'4VM/%R=8(CSDR[AXD,_S4\/^_FR^]=* MS!-KH]$I9XC:>Y*>)>?'921G/F,T4FM6VA\*N@FR,2G-[9EQ_0)%4ZDTYO]W MV,Z7SU[@T1Q3M\)'WT]Q)8O99=Q1EZ)\W=XGJBYPM?!'ZP)1B)05(^>J>=IW M=]1CR@T/S+3AI-F,A>04])<=_[-$DS4AQE#32R9K4+7BQ*MD(1L7.=>99]E: M5=T(IDE-]LU#)>FB=#Y"4C7I6L@/BDI%,-GG)%364K:N)K@=T9BT<1N&7%NX MW48B#9W24Y?X?#5',@I8Z5T4UD50H19>(7E)VK$2J.9"8EWI?0>P&WA A-Z2:K# M^WH(=BG@?")?'ITOTEM)SM5^W);]NKICI50;2>ZE3KD>(_IJVG\>IDSYV]V' MK%*^80R-BI3K 9KT@'?S_J2CNSW[^L>B[KP]5R-/T[([61]5PZ)@RDL07,EZ M.+6&Z%(D-8+H0T+M0NL$T.;H&O@7\WH6P0L\_??U[.INGDD.CENIZO$4I>Y6 MY13_)4^>3Q2I<$E*MODAKYO@&I-='(A/U^1)VXIKD-4L&01&'2#'6@ABR.X& M1N/EUG,:X0X86357HG^?TX<= MH>(^Q#F.+;"U#.#06 R9 M)J#YDM5FR.YY!L[ J=:'8=$ ,FN9DOW.!U^?OG^F+Z\]A7\2,"2FL@#/R!=7 M'!F$5%USHZ7@AC-C6ZNF[9#>\R">GX)O#R#3 ?EWZ]$*$\Q9LYSIK3 JTKSX M"(Y[!9;;@%HKTKNMP[%[0MR$<>[G,I-#"G% IEWM1#,1R(-CM>S+U",[F(U$ M?W('HT85HI4^-R\#\"D]0E2'^TX11@%;- W7L0B^:%67_>K>YQR4;WWTV_5(-N++3Y:;;B"3MD==7JQMNU+2 MICR&2#"XK=L^=*R]B;,&J3DZY4)H?UC!79@VXLQ/EKIN*J=V:_C7#_X\=7IA M\$%Z9A@B)%TH BA,03 &(6=IO"HFDBI\F,7!:]#MG&H+7U>+L>M]X!_[C^%+ M=4]KPU=ZT*M^?L,[+Q2Y&-Y9*%+4357!01 Z UI;E)#!4-#>.@VW)=9[+B+N MQ4_%,[ M';(H49 '8D+KM_!N5.,JD7Q89C625<-C H[6R-Z6T_9!%XX?G!@7DW.\0"KU MF-):,A94DI!B9E(%80IOW:GT5D#W7*3\*9C33D(M5YH28EZ5I:VX^_9H58[V M\@O.4T>S,(D^9UU" .8-Q3[($+SFI ]3%C;X))QL78=])Z@?8*&RN=9I*JBA MW0N3>@+-;V=>1(J[K1U;MD8_.F6YNC:V7 /_:KLX7F M>&-7I F*'*P*!;BJ*\I,<@C<4RP1C(]!%K(=S==O-T;W([B*NY+K)H/>6'9# M.(!CN+Y;Q+]3PS^@4Q]_('%ZY\A_.NSU?3G^LMDR^_D%<[ M^X3O*79Z60JF)1FOHDRM@7&AU(.KZ3NOF047>62:*TN3UIAQ#SO"@4SA=>FD MD&O56>U+GT-U! SQCSD)5EAE;$Z)F]9;'KNXI_'_GHI(S62GI M%>N!$5&#C]9#\"A+J=-06JGYZ[B'V)GVOK BO>8^D^SU1FR M'](!YN,I]N7Y:DX6W>RLIFI]\0MV)/MM(:&_V[FPD='PT";OYB<.;?4V'&LKPQ>. MNF68=O]:;2,_?W!MF5R8+-DH!)$9,4.33Q2+=! QYV(P>9.;M]6Y$ /-0"/;=_GQESW$@^D@O& H_T*G A3#3-5\+NAK5[ M7<;%1YR-E2EZ+VS@X 5;M5:/X+F1H(M*/DBC3?,>"=<"&9.]:\V1JX47NTKB M 2V=B05EBH:B#Y[KPJ8!'Z6I.ZJ"9SZAU@L@.DDL)(^>.1C_$YH!;M.1^D^5#4V-'&>S%_3DM@PD7*F"( MR0-Z/+<];T@G9^-Q-O-K;B@PJBYWDCEBP0C2F%)[PI)[G!,I#"T2F16EG6T= MK=R&9^>3DU(Z/CQ>%>%O0Y?( B=3BHZB!A.- MYZ45]E%5U34CWY5#F/8AZ9:5T-?#6;7/FNC"K'(,P>9JMXUGX&5)8'UDV1JA MI6K-OML1CK8,LT]=G.*IW1_2>-[\K.$,YX;C&R(1?GAT MO,3S LQ*,Q6T"U$0%Q37M?S=D[X0D2*R6,_)R:1/!DT-7T'4--J[?/<+FO;2 M3E),HNXB,4!.J0*5;6TGSPJ@4$%Y\B]%^Y8D]T8Y*F/8D%2WQH+MY3=,5N$R MSE,M&X5F2),+=8/*:3L(IV( IU6QAJ&(S1L0WX5I3,9O/Q2ZOVB:$>95-Z,9 M>=.=U JM*Q9@PF4LVM> 5CE1FVA[<-)SL"[8:K"=2ZTWJMZ.:,#QKJ40N*2! M(?A8MQ-P[>98B6N9^ERPPU MAR(5X8Q10TPH@/$0$W?%E-2Z#.?^*$>UW6<_K&HAOSU$(B\7R^ZP@GYUO#PF M_^,"]*MN_& QRC8HAHM>=IZ31G'-'42.,CJ=,Y'*62(R)Y_0140@S:9*8/2! M;^W3[\V<7I3!.A'_'@]#1[,\K\=Z+X@"_X-A/M',6EE/97:Y]DP5RH(/@=PK MEJ.7UO(<6V]*;P#[!S+*]V'=?=3G$ )^$+M]%?@_Z/W_^!FG)_A[/UL>+"9! MF212J*MZL9X"1AYY8(%,3A0^V*P*-P_H^&Z >$Q1U&CXN)-8]T3%^LJ\HFLG MR%P*R120B;/:ZD!#\,74IJ;<2<==K*>K[9&"9TC'M/([&NIM)<8]4NXC40@G M%A4*1[YNR4BJ6F)MX1L3:$=J.G#GK6O=0'!+J&,Z-F94I+N_(/?)NL_]Q E1 M'/H(ECL'*H0 $8VD'WF,R6D5<^OJE:V CJDYQK@8=T\A[M.P]L?S"5J%26L- M.25[FL4-L9!3FM$X98/4V'KY=SND]^RD\?^'U=YZ<$;D2'Q^KX45X3>;37^?Y!O>X'N(5%XM=7B8-G &Q\U M7,IOL]$URNM=?=A9W:=(S"0E%*14#]C@G+@GI(-L!*DGRV/. U2R70^F64OQ M-_5XB"N;5X.7O(A:Q>7H#:- 1H&OIXI@S(QI"IX]:WX&^:V(QI2#:\.0&]N$ M[RZ1Q@7H-P[76(HQHF)DAVL=%V<**,Q%8*%XF0T/PK8^#^MV1&/*C W$DG82 M:==D]13.LWYVO/@&Q3N)AF<'2,.J17XM<"&5/*:AA. M[#[_.U.A>A%G./Y8X/QY/RM(,!*N>KF>;\0H46@7$J1:[:*8CK6E:P'-12HZ M:9<Q18\H9M97Z %/=3!.\)/^R_XJX/KW_FA$C8R((YT [44Z=>!^" M ,ELLHH5;W+KQ98[08TIVS.,AF@KEW:MDL)TU;?WY9=Z%/;'\&7=O>E<4$:$8.K^!*,Q$E?1-;<.)NR90^L$R[A&U._T+THB.VEU51;G$?3*X9/ MLO0^2,9!"9[ D1L$1A>NO[KE MZDSW,%MMVR=HY ;3B$\K W_O9MWA\>'9P>]_U&(EHN;SFFF<5L:^6SM2R[-URPW MA#:F).R.++FR8W4 X;3;XWP]N ^8^EE>U5VZ4J0JL8"4#,G.4O@6K.80+3<" MLY&I>:1T)Z@Q)6,?ABU;"F1HGGP\Z.:GJ#*%:#*J!#EJ0J6LAE"WU43.E<,8 M4V[?C/ .3&-*SSX,2[83QQ NU,4^=N>+K:=.P;MY1R["49B>N05]J51NU-O_WJV6,Z/ZW.?A_G\:STX_["V,Y\([J.5PD/$2C_) M,OA"CGNQ)HFH1+2Z]3KL;7AV55 7!?![H'E?!2@7^RN>R^'U[+SZQWG/'#<, MY&HKKM,"O$H*+,M*9E5-;NMEQJV CLD]:L:J[Y7:\")L9@[O ?7ZW2Q2.)^4 M,B!/][ 85WMD($1I,H92HC6M#VK>%?.8G*XQ<'!WP>Z#CM<$'BG99+@,8')* MH(2LW>:]!1[H>%WS89.$5@DM=0T%';!'HSD>-J4R@.2\&F.UA^M^L:EW>A?GRZ\=YF"U"JG=:/,UY MU2&FLK7T\\/U89<[=+W9XCD[];K9=5R-$A,FAZ].D&NK,]*[E(L#A3R#BV315>*HK9'U],S&D[8[ZC$E1AZ2M5?[ MACVH_)NY<.]Q05H]U;ZC+_ $I_WJ+-?UE$V"EER3/@2E2DV1"PU>*0'.,68L M9]GDUH>ZW IH3"F0?;*MG=3:57KA=%J=CUG^/TI'A;).4A90:Y] MBI0W!;Q$"TZQ9'W1/F'K_,;-:,:4O-@GA1K)JQE__HXSG(=I58KYL)MUY-72 M%)[@&:@7[])DA*UH64>,$YI"3W3*AD2CKG0^8'(#.1R/SW M__OGV>B'+SB=#2?CO_TH_L)__ '':9*'XX]_^_&W#[\P_^/__8]_^[=__U^, M_>?S=Z]_^'F2SL]P//_AQ11ACOF'/X;S3S_\*^/L]Q_*='+VP[\FT]^'7X"Q M_UC\T8O)YZ_3X<=/\Q\DE^KF3Z=_A>QC\FG/_[XXR]_QNGH+Y/IQY\DY^JGB]_^+]%CQTW_^X_7[] G/@ W'LSF,T[<7T.OS_/(/KZ(Q/RU_2+\Z M&_YUMOC[UY,$\X5Z[AW"#QM_H_Z+7?P:JQ\Q(9D2?_ESEG_\CW_[X8>EY&": MII,1OL/RP^K;W]Z]NHUT.)[_E(=G/ZU^YR<8C0CQX@GSKY_Q;S_.AF>?1WCQ MV: -,:Y[^N&8+Y_%,A8X M'\T;(K[][*9X)V>^X5G!<@;R(\P_R7-#G[ M:8'JQ62<::28Z9O99#3,=5E]/Z>O=9V=3:(1:KE#.JF'B;8[,+ MSA:8Q07+5J\@MDGY$X[FLXM/JDKE0IV;42RUMO^X7HT3;>TS_!F7_WTUOBVZ M=Y/1Z)?)] ^8YH%+DF=O'R"0]>S6;G MF'\^GQ(QW^)T.,E+OK[#V7PZ3(NMFG[M61W_WZ>3V6P .B4PH3 )IA![2V$0 MB;TN!VY$1O16=,&5G9$^ 3YUJ[W;G%,=<>Z?,#K'S:!SB %D0.:B!P*=!?.6 M2Y:,-4GD7$I6_5#N;J!/DG$-=7>;<+K316[QPS>?JXIF+__$:1J2FS* (*60 M2(AIHV::Y$7+L.79&6\S.1M. M$,R,S/-46$$1-,E(90L]+FK?6=989[=)9MNX;V]AF&GX'^#/?PWGGZID"#I] ML/CIY;_ZWPV7P3IWN&H1NT^3+:%+J.*W*)E-CJ"CMS1KI]479=M MXH[^SZZ)Z1Y$N@/@/F[N]:7'VQ3T37;5=_CY?)H^56RWC8&!\#FY#"0*[TQ= MD@,#JP1+48EH>%:H.G%'[T3UN G56"NW>1.ZY,UB>Q_4Z(I!F9F/'LDMX% !Z]BZ)$V"U!/ES6[ZV1-7/3@Z/B5A?+#Y%G."^'#J.[:K\8OX/-P M#J,%O^/-=?(=DJAFPSF^Q^F78<+EJ-YAFGQY*%A2-31L-S&,, MS,LDC-&60VQM\G<]IL?-V9-BQ!K*'WP6\'8Z*9@@7=PA'\#T\^++6\K4(,;Z8N-V+ 64,M-?5/ZY1T<.%QQDZZDWALE MD);'(FCORR[2JAD#^>%9DA\NC!#.H3?0.K&C1RID"!+\RCL+1#]6_8-E#-I*=D.\O@V MN*(7X*S20@C#"F;#=-"9^91HY%$H!1"(]JU/?.X$]!@HT$[B'5.S%:H(4922)/.19Z8]GGC^]=OOO(6O];/%"+X-8YS?CF#\*YSA:A)L,Z:.O(0NQG,< M)^, FJS+##@%'7>1:=[%V*3+(M,(F%5 IE<.M.)J6Z=X"=+Z8H1K?N#[8'A[ MCT=TXK3=1;6=F%'7DEA7.SP8*81"S;(UM,.#I__;"IPMWAG+D07@-%R?>;5%$C/9Q&2A M>.%:YQG<">@[BQHJ;.,:].\_W1#O:_KGCK>/W^$7'-?,^LLCXY^',_CX<8H? M%Q*N)X<>>!04(PMIL$B;P& 8'OONPM>/ZJ]YS^>0,IR__3*/S>B;\ M;#9#^O_\ ?X<&*NM\H7$X)"6^$1>=O""_DE.MX@Y.>';1S)VAMG_VMJ4/[?7 MR6X5U<%>O$$>R[ :,=#LH7LVVQ932=CP47./*)*DAM%RWX_O>QPFGME#II*-R&#M\5/#.R+5>(9BO;E;Z+ M7!LJNWHY@]>XR#)\/RES="2UO]'7Z>3.>THEQY MP3>WA(O,DPZ)&0Z++2BR6$"1+DH**5OG56MW;1M391:FU] GS^0C?E#M$\/SKZH=+W\I;K;2,P(0*Y%M%K5E,4$@.,4:33,JI M^='F[C![NP30%77Z4M&Q8QJWTF.>G\](<+/9:D3+/%C!C>"*IDCQM0I9S8<" MY0)#KBP7H@JX=8CY3D!'2R+JF@V;+A@66"X<]BW =)4R=!7(D2\4 M'*ZHFQ0X6,J=JUYI#:HD9-9G F7 U1J%E@6D_VD4R:%\>"K?]N) QQK?1;@] MQT1TL@X-:E9"EK2RIBJI(_^ _YI,WT_.R6WJ M)W-DS0M[21RY;Z W B;&.XPI2^UMT4EYB!8D=]ZI@@&%WB5O9,VK.TX;$5!, M<+3>R%"C<3$@"UQPYD)TN5CO'&]]$> 4TT8R&%!2>9:DKM4UA" Q!$X[M4@D MF2(QM*[D^3C21G;A3XNTD5T4U7?:"!;E*@KFM8E,<]K48_% LE B ->R-*^/ M\2#21@[A2#.!'SO$LO$ U46EBI"*)6V(T;^/)6UD M)Z7>ES:RBW![2QS8!M032AO924=;91#L(^#>M!\X3ZB*9 71,DV,9B%'SXHL M,0=P.I9REZ7!1!/H7Q LWS]J4C+": 3A:RI01]18Q M,B&]],+H%.-VH9'USS^5E(&=)#]I*[;6(9%:@(V,S<5I]L4P+[)6)"=8F;8C MQ5T=)E&6&Z!AND1 (6F7MM+FYG<\>(TV$E\GP>H%FC?S3SA=(4K&!1T*40R] M8EIJRX*2GG$>C0:;N79;)>SN%+&^B>(AJ[R1;#?>A^\FPO7^_.P,IE\GY=EH M-/FC-G4M$W(V/V.]Z/5BBGE9@!%GS])\^&4X_]HTW+7WVUO&OMJ(X&8@3"?I MN<\NRZ"Y]M&H;#G(G'0F3P_6!,+VQG'86O#+<$SO&HX_$A0N<8[?JD72JN"Y*4VT%>,!]#+*6F44A,VTG6K H 5G"I*7C*471^E;]=LCZ MYU3'*MZ+4#OIIP.[;DN4*'RMDHT,,7*FAPHLVGW\9-%] M&5:#>\U;!E+K+*,CHT[;Q+1.@GE.AC>'>NW=2-JM?>-1WX7GL<^89KKHH)_B M=I+XUW0XQS>ES$@.A3M'#@#Z!=SB&!AC&&@GN,Y:)-6\-.!N$!\[F[K46 ?] M$[?=+E06.B7#,%<_DV3 ?,',+'=H(-M,R_2#7(B_987N8/JMRM I$4R.B45E M'2/?*9'%1U]L%$I+;X1J;D'OC[:O8\7>#>B>%'CL@\C+6?&M8PF-Z5?\8S4E M:JN=Z61,WR;\ELJH $RV3M&,=31MDZO165K7P'#)LY0FR X;TMP/\/BYX-V2 M9G.[F<;*Z\!$KU5PWI1G>;((]*\"A-M@ZBA3?!V>(Q6'[$Z-DXYTT!<_!%>H MO"JLR%Q;?)EJS4C/E _@R:T$CJT=MOYX<5_QQ>/28A?1=^'17P[V?6WZ0V;T M[+?/&>8HN;!"K4 6VNDUN4X,HR3+FGQXYG/A3#DH.NID"6SK#6D;8/U[)8?K M\.;FTEP!#:.']13KQ?G9^0CFPR_XLA1,\V7+M&\R6$P+2X9?#@&9]X8SC6+A M"3F&)>:DLK8\MBC'LPV6)V*<=**:AL6RM\&W.@W=!F'#%*WM4/6?K]5>FSM0 MY0!5-$[FVA)I+B!$IHU81EL[]JG(P*O,I$XR8BV$H[;*_SUALMR1YG4*7-E% M SUSY)M-=[%#.RPY*\VB<20*&7@]D4A,^"A('([6W*W.DP_=GV[@ZC&.)_KE/@5Y\MTFWT2 MGPYZW_ZI3NV&>3.YB<=Z3A>=P$Q>C_:BD!O%E8FZ0"XX..C-!Q\!+YY=*Y_/ MGUUYP;>XN,S<9*T#,[PF7PKGZQ4:\NY4"NL@O2FFY M9F/^&3]/,0U7A6"Y&NB1R M;%_0[BX\CXY$S83?12>WRYC=1I3+"%V2Q2J!!$S4F]"E% :UO:#.O) -*VFE M;5YO9TML?:4(=$R33E1Q*L?_&X?T_.MEVR\O> B:1Z:4MZSZ1BS*2&MDY)@E ME%":G[%L >OXT?26=-AV:=I3+7UN78MN-TLO>QN('9WN;P'O.(?]S56[+74. MU,N1*&1D@J!K@?IY,LR$^8B?A^DE44H5E0*3'M/T&1M[6RY5MH5 MS4WKK*$[X#P^2K22?0'Q4.EW>G][[7Q^/O:%70[I3CKI>T/MK8>D WSS-4XB$77Y3FVF;G M>;8^9ZL,^2L8-IUGW/6Z ZINO)E^A/$J9/=B,IY-1L,,JW#>VRG.:J'^9:FH M52(3C"XK[U[)_E?:TZA\9CE59U\6QWS*B4$"A5$D88NY3Z4-\1Q<;.Y*@'-0 MLG'<1L^$$HEI): V4D.6:'9Y7FR0O/5]K*OO[V_].A8A;E6>VU?Z'9@\?R>! MU>R\-^/W<"L \2VF34LY]T7+VI%8,XV23#2B-@M*R0S.@O*M#RJV0_;TV-.! MQEH7K3I(2JM:?5E)#9DF0^; M,B*_,VHF#,I*RTE"+%=2:3#L70=8B@=:E];W2$XQ5'X4E>X2P=]'6D>*/ MVT#\'L(^4+5[!"+WT E0FI9 X5RP8GAF-T#%0D:P"!6"%"H#.-.;( PI0[:2RK0)4 MN\A[HR?70T;N*]JDQQ^']:+6;(;S69?9N)O?U5DF[I;#NQ&U*L99;KTJSF92 MG?%)&:G1&RY3+-G=EX6[^:T'%Q0E8[S# ? MK61&6 $F\R2WNY"XPTS?!M>AR]H=[UBF@1(JC-+1/!.F-EYTEM%4TS1N"*1. MS>E+?^,^4B9NM \\# !#\A0B> )N+6A MM8UU-Z*G19I=5=!!5NT+^#RK,M5\=82U3[VID&R '1,4H6 M%'W!9(6T2CF96H?.[\/T"$G25 T=%$F\ ]^FE2][U%K)S"#P>H3NZ^4^1*:Q M:.%%KE+ICSA/9Y/J6%4=%$B\ W%=(:.'' MJ6A>38#H78& C@>5&2]4Z M=>EN1$^+-+NJX#9!3-,*DIL$L2K/(I(E>):9F.K5NIIKE6)@B8:O@Q$\-R^* MO3VZ'BM$=DN7CA1R*L=J=PSJ^;(5Z8L1S)9%QJ!PC,EGACDE6C&A]ETLD2D9 M74!CH8@>3>B;\(Y_):0M0;:WK0]25+^>V#>@O\+918!W&[@=G;+M"/4X)VZ= MJ7Y[BC73VPG0+4<=04I"G,*B1K9GM.$K%D(]:4+. [1V\TZ"9O>73E:=B-_A:.%!S#X-/U]DNRMG=' )2 RTBNMB"PO&$3YAR8/UH()O7;/[ M#C@G9:L?KLJ;9GLC/700UOX9O^!H\AGS!TR?QI/1Y./7=\./GRXO16CO>5!1 M,5EJ+T-0P ($S3)DT#!K71+R&J27,2&ZU@>EF]$\;E8TTL+&$'0/"2(O9_/A M68UQ_C;#X1C_@-&;Z"(81=%G4#,=QNXWX\8.E#]@<'? M??1V G1S=6=7X%B$FNZ6A6)0A&80B[0.G6M?:ODD:-;PB*%/ENVBKIZ/&"0* M!2$$EH+(]@80/./&0))@L]#?CQ@:4J6E/OHX8@C@N38)6%*!_,Y H")FSY"^(W31^-SZ M%NK#.V(XA! '2;S?(P:$9(WVM)7ZNK-FD"SH[%CB-?28!)>J=;G$AWS$< @K M&FFA89;[HCC$E138B]37BVU..@?<2QHB.8W:<$E6EY-,$6T5.IT1;QP_;2CF MLO$5CU/A#<6Z,>N\A_,DN')2@']^)K,>I[A(HI]/AI>R@ROG!;,.#HSV0='9 MB=#!(KEQY",M6H.R*!V%%MI S,I9'DV]?8#7LYT0O"8,\.8:;L# M^@Z,48Q&J(LNLOCY.*5 <*9LS2/P7+ HI&2T4/@ M40BU7>>U'49]-Z*36EWW8\>M;B_M5'#^ \P .2W8BP*0;173@_6^ MC)OMP'7T5'(G<".<_#1 M3(W;T>, '?1.% PI2T/0DG>!G!::& #%,(L"K==:*-OZNM<1"'+/D<5Q^+&+ MZ#MIM#&;ORFU:.U%M"*)F LWB251VSA*R9F/(C'CA0:1;8JQ?8N-&R#ZMVT; M*NE66XU#)-Q%=6D7\ M>O/#"$0Z2)EII7PMO6Q+V Z_3H<3C$ORU=CW5 71:9<*L7JF)F0CA9&K3V+@4;N%1EK5H' YBU1-T!Y+!PX M7,X=F*A7%]5!X,5(M(6A*U#O?U:37 *3T9:B:\M>TSK=ZNK['X>B]Y9H!Z?7 M5[&\."?Z+9IU6TR%#.2BQT&$AE+OH%K:59K6 M5(H54T.@M2FC84DB)RRAU $GAC)D492$U+PK['HDCX,##:3<02&T.K8WY05Q MHL#6ZM\$IJ]CLT[T MWD3"IW(P=M6AONPF$<$8J[QF/I)[HM%D%CWGK#@D;DOK$5H7:%F'XUA'88TT MO&:].$C2';D#5S&MXG#;H.KHK&L]HN,<2692=D=8^0\-%.E[.-R2F1;?/*:OT2X9Y- MOR\>["+GAOI?W+IX1BH0-7[Q>@+CB_IN20H5:%_SF6-M-U);QM$7[WG,)2N, M\<8VL.$:RYJ''SOHLZ_8)PUEUFE3O*OQJ&+9,LFF04W/7H M-AD%6X._D5$@= X%M,J5V%["(K5"-G4,L Q@@JFUAK3SP1S%( 3%9;*9*<1:YI@$XF,@ M0]\'SW7.WJANDS@W8WLVW60RT*CP_06OJ[^F>@_;\K;Z9!L MJL\P&D@-.@MCF2$1D'LHB-A9:N9%29%\C.ST=L4<=GSQPZ9$YZ+N(%EB71K/ MLIDFD=-EK0U#E++>$\B,["7)7(I*I!2L5NT+0VT \[!YT5;6MTE@V^XF%S9T M7;9>EH*IWB%9,1<^XD 5+]#(V@I<.%K((K"0A6 14W$HL"C5/J%N!X"/A2Q= MZ>0V@5P7QNR+R=G9<+XPNO$JU$2&DT<>&01ER%=7B04PF4DP9#>A!,N;9^-N M#^]QD*5-,PCC5!'Z9DGGYC)DD(PO"@P M<7N5WOFN1Z/A=A)M/6E_&4YG9-/B!?FP1*]R%DQ(3@R4M::2B< 46;,%N$I! MWYO;L^[!CT&5A\BJHZO9M^X1)!"U#V>I56X2TP*0@:#]I604W'LM039WT![$ M/:M#+.^#)=V#]B_:]&R!ZJG>L]I)8]O=L=E'W#U>NK/"<73 .*]W4BU/#$+T M9$G0#ZR0Z$47U[-/^9Y5!QS81KKWK';2SKWWK'81;0>)D5>WMQ4B4YP!232.1E1KQM#XM+8L!TP%'9F0 MN;6R;Z-X%-H^4+A=5/^\9L'#1>%\LM%[2 M;Z-X7-;=@5+N(!OM.J*+2L5;8.K(LEN'YSAVW:&ZNE/U!PBZ\\F_PJ8(@8HR M,,-K=I-1O/:R0I:,R*$ )&5;EWWM3_GWV'-]Z'X7^7:@\[OC1!BLCSE'IJ#& M&Z X%DM ABE+2(:##*TS/4XL/'>XSB9=";P+:P_G9.+<,$D4%Q@@TR:G,-?+ M@9E!TH9QHX)4W"LI6E]Y68?C$>C^8/%VL !<37%>U@6IJ"92-MJ!QKG7-C)L8'I>U=Y"$.ZBL=Q7/A1.S!:*.++W;:(YCYQVFI3M4 M?H"(.Y[N%X4WCI-O"^EWV/?=:WS723; M@:Z?PVR!YJ(OL>;.69N8"-8P';AGX RPJ),%B[$6#VRLY^L(^M_!#]7)I)E MFQ^;Y_\ZG\TQOSR?3I95.]/7*] \)E"0 BLR5*-"I-J>1C"5 YDI7D6O;V2_ M;#HRO_,]#U:CK678^I#\ZC O&X$NEBBCLHR9/$Z9O*PMQ@/S]28:>A I*30V MVZTTN_$5C\/Z:BC&AI>V-J-:D7D;7.LML5W4? Q#JZ5"[M7Q =+L92I?)(8( M6JY"K5R 43/-4V'11UIQK""[HSAIMKREV;N6-UA6QU#R+D+L1;EOQA=;B)'< MFVRPW@6U3(.N( V9"5::F)*&5,K^^KU\3W_;<%MEW*OA_239VM9:"^W#'Y-+ M.R'RXIQAA1V@,LVMZ,C^VBY,OW/%HE[R?)C3.Y11FR]Y]@ MBM7:SQ4EK7G+QH]M"Y+M_I+]2Y,=.* ;1H7U%C_9 MK#'F2(:FCBE T#*T/N8^'/7AS3[/SB;C]_-)^OT%?![.8;1XX>P=SG#Z!?,O MD^DOY_/S*;Z:S<[KC?>!-K32:@4LU[,);1Q-?>2%!1>3 I=^;?[8ZB7:JQ]7:ZM[">CU(4Z0?O1K?&N3%\*[#F#=-BD -KE"C! -G M2?#.9.9UK&54?')!.96;U[+I8UQ/VF!U7?UYKF?TZF?\_G+_#-/DX'OX/C;IZ%*OY-;"9*\]S MJ-T"D.3H#8O%'*E/CRX=5$7L;) K(VLR77U4?T\, MZFT<#'W67(Z!.J@?N3>PG[YW^?# M^==OM]YG;^:?#@B5;L#1.J6F;LMC@EE&FY<<$\G()6'H8*7I3I !F3$XU M5049)-KVD/!*(1T/PFP5;]SMO4^&>UWKI&%]S-V@#IS-R2?P+ L+Y)LF17+) MA7$%.J683;EYS_)0YGPGS>&:Z* 6YMY"HA$LU\];ZRM9&P6']01H]FRB:UDL$X(Y1NG13#,5/GCQK#E,.OJ[6 MG2=[^:3E']VT3P9ABT M6C.A#C^>K/MB/37%_//Y=#C^N#3 ESOEI5CJ+[T]GZ9/-)*W(ZC!GDC N"M, MR=H_,CM3:]QHAH5S TESE9L?PNP']'JT26.FVJW,[G.'T_ M*7,2#%[DDG(D:ZZL-8PZ M^/3M??J$^7R$;\I6"_SJ[&?A+]R,WBT:ORSOIJ#U.1@O:78$$IM-Y%SZVK6LJ49*[41KO5">O7]Q[IR=@)LF#322@?):A=85EG_VZ#IJ$C =23'*1"P MOV8VJ/@ L7:O;!TE"@F><>5J#,PIYKUW+/B 65IAO>IJ03AB08"N=+R+-%M? M4?OPQ^3#I\GY#,;YPQ^T;WQ],\8K)_7/QOG5N&;'UG9DH\N2\"+36*4$5AR( MVH^[,%K4-%-.&)09,<7MHM%[O;Y_ _H0A4UZE78'99\6]M5EP5H1@U5RD1U= M;W?9Y!D4,MN%3L5FIR6YAJW3SZX"^&X,'*Z78V3SSC;FZ5\.8YQO;GY;C*DC MFZ*+\1S',CF )KN>'O2EXZZN7K0>FP[:V5PDD_3?6J[7D1D""SE$QGE 6[P2 MP%OOSQO!G&"DLW-=;SHM.DA1'5AU[W VGP[3?)68>U%/OD@MH^[)FG>21 M:2R![%I:M$.2) T7%L<+YJ/T007'9=[E_?F=-(.5WT(5@>)"Y(_/SKBQ',9@OKT'F.M"IF%D2I M7K2V+'H=F78-4+Y')UKJJEL*+3"M)LHVJ+IJ9K$6T9':6;10 MVF8B'"KQ+KI:K$=G7"S:@F:!DZNI)0#S'FD=]=IG97GQH?6-K3YY<%]GB_YH ML(N@>U#_\PO#2*#6O'"6R0JB[:VFVM5]%(M!!%K^8O,H]P8H1VALT$!3]RA_ M'S%WX ._&J?)&1DX,%]86*]7>^*"ZZ!,<2I&5K);E!0DUGNBOE?(2\H8?&AM MA]X!Y[M=T5IG'=RTWP!M-7^V =>1B7$GL.-8&LW4N!T]#M!!![O.W2 ]E\)D MD(R CE9M:=C*I$) 1$J3(-T3>[GQ?#Q?3[C6E7E]F/&MERHWQ'VOYP?5:=,T@8RWI!0F6V3SK.'>!G>"!T9'9&G_$VH/BATCBVSO@?Z='C&_ MK%XYR$+8H$5D7&FR;V4 %B('EK3V!8L1WK:.3_+8HYY(!Q"L@_/N[L:Y*OQR MM1 ;Y)BB !9=KM=BM&+1Q,30!UY2LEHW;Q7;X_"^3Z>C3*?#:-;!*4]_QJP) M+AZ%I+TQF46R 0T1@:%IO<;E'T-_OL\/LUYW"6' M'W H[7Y!9"TRH"*#RB92IPN.>4M>9H;"<^;:V9M50TYX,N\X^.^3^30GM*@*RAH2>.6!>5I<0,> 01(K5M?$SZ-D7^?QJ'DJ=K6W&]+U.W$YUXG:B M21\%M_;1\4/A;PE18 T)69XLS6E'3B5(SI0*F*-PX)K?-7TXO-VI3MS)T787 MU?9>KPD#]SR1>&(HY BA\_2= X;2@;?6Y,1;\^XIU&O:2><[U6O:16''N'9V M?G8&TZ^390>]>//'[2^@;?>^YE?1]ACFC4MI#K3"Y+FO,1,4V2<;3%)69*T= MF+CI4MIV;SZMZVDT)H"8-%/)DG<5A6119\,@&EJ6(3CRL![W];35FZZV^+H* M9'6U=)"RHK7">.9"DN2&DKE/S]*,%HT2-/B<0NNHZG;('GYJSRX M%]>X.O$[C9!<"<>9-!F7E>X!>2W]5C X2R.&YH'^[Y&I-KP]/B-.)3)U5S$) MGIV(T4HFHLHT'I]8!*EKOHU("FI)U=8=NIY,G9^=N+)#G9]==-9[^99MP'VO M\[.S&G>JX[*/#GHG2B1O;5'[.P8>ZJF#9[X42;YB2%YI!-"MKT,_K#H_W?%C M%]%W4760EL@WY3V,<+9R[*T*F8Q$6BGK)4NMDF*A.,&R5,5QFWV1K>VL6R!. MK8;/3DJZ67#P( EW8)[_'<$T>J!(8I&W(#:G%O[YCV.K.80V"Q M:+ Y>:F:E_UY@)7 #J%*:RUTD=V+(_K11T+X#YC^CG/Z_CH^ZU")0DN>TK42 MFJF=NL&1)" JE1V":E[)^#Y,CXDB3>7?0<+HXCSA/,T7S=U?D#/W\7)'3+9X M\LLD@P*^5G..1%JNF+>"+"OKN'&EB].?M6@>$R<:R7QCZF&+ YQW.*HAS;